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“… candidates for statistical surgery are completely at the surgeon‟s mercy … 
Statistical operations are hard to explain to people. Such operations are rolls of the dice, 
a gamble that operating carries fewer risks than the disease.” 
 
 
When the Air Hits Your Brain 
Frank T Vertosick Jr, 1996 
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ABSTRACT 
 
Introduction 
Key trials and a Cochrane systematic review in asymptomatic carotid stenosis have 
highlighted the need to identify a high-risk subgroup of patients with carotid stenosis who 
may benefit from intervention. Traditionally, this risk stratification has considered structural 
imaging and clinical factors. However, using only these approaches, still a significant number 
of patients are missed. Biological attributes are acknowledged as key determinants of 
thrombo-embolic events. Functional and hybrid structural-functional imaging, and circulating 
biomarkers allow exploration of plaque biology non-invasively, in vivo. The importance of 
innate immunity in atherosclerosis is now established, with a recent interest in macrophage 
phenotypic polarisation in atherosclerosis supported by in vitro and experimental data, with 
the hypothesis of an M1 macrophage predominance associated with unstable plaques. The 
emergence of systems biology has been seen to facilitate understanding of biological 
pathways and generate hypotheses, although the utility of this approach for the examination of 
human atherosclerosis tissue has not been fully explored. 
 
Aims 
(i) To employ functional imaging to probe carotid atherosclerosis in vivo; (ii) to assess the 
plaque microenvironment in determination of the balance of macrophage populations in 
unstable compared with stable atherosclerosis; (iii) to investigate whether late phase (LP-) 
contrast enhanced ultrasound (CEUS) reflects plaque biological features; (iv) to examine the 
utility of systems biology techniques in distinguishing symptomatic from asymptomatic 
carotid atherosclerosis tissue, and in hypothesis generation; and (v) to evaluate a putative 
biomarker for carotid atherosclerosis and plaque vulnerability. 
 
Methods 
Patients with carotid stenosis, both symptomatic and asymptomatic, have undergone 
systematic collection of data, fresh carotid endarterectomy (CEA) specimens, and plasma. 
Thirty-two patients with 36 carotid stenoses underwent 
11
C-PK11195 PET/CT. Thirty-seven 
patients had dynamic (D-) and LP-CEUS carotid imaging. CEA specimens were assessed by 
immunohistochemical techniques, as well as atheroma cell culture with supernatant multi-
analyte profiling (MAP). MAP data was subject to Ingenuity Pathway Analysis. CEA 
specimens were further examined using systems biology methodologies: transcriptomics with 
Affymetrix Human Exon 1.0 ST arrays; proteomics and lipidomics by liquid chromatography 
(LC) coupled to tandem triple quadrupole mass spectrometry (MS); and metabolite profiling 
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by nuclear magnetic resonance and LC-MS. Furthermore, venous and arterial plasma was 
quantified for the lysozyme, a putative biomarker in carotid atherosclerosis. 
 
Results 
11
C-PK11195 PET allowed the non-invasive quantification of intraplaque inflammation in 
patients with carotid stenoses and, when combined with CTA, provided an integrated 
assessment of plaque structure, composition and biological activity. 
11
C-PK11195 PET/CT 
distinguished between recently symptomatic vulnerable plaques and asymptomatic plaques 
with a high positive predictive value. D-CEUS and LP-CEUS (at a cut-off of zero) was able 
to distinguish symptomatic and asymptomatic plaques. Atheroma cell culture and supernatant 
MAP revealed that symptomatic human atherosclerotic carotid disease is associated with a 
cytokine and chemokine pattern consistent with the predominance of pro-inflammatory M1-
type macrophage polarisation. Furthermore, IFNγ signatures are observed, including the novel 
finding of CCL20 with its significant elevation in symptomatic atherosclerosis. MAP of 
supernatants from patients who had undergone ipsilateral carotid LP-CEUS revealed 
significantly higher levels of IL6, MMP1 and MMP3, as well as greater CD68 and CD31 
immunopositivity, in those with high (0) compared with low (<0) LP-CEUS signal. This 
suggests that LP-CEUS was able to reflect plaque biology. Transcriptomic analysis was able 
to clearly separate stenosing plaque and intimal thickening, as well as unstable and stable 
atherosclerosis, finding differential expression and alternative splicing of interferon regulatory 
factor 5 between stenosing plaque and intimal thickening. Proteomic analysis of the salt 
extract fraction from carotid atherosclerotic plaques identified 2,470 proteins implicated in 33 
bio-molecular functions and having their origins previously described in 14 different cellular 
compartments. There were 159 proteins which, based upon the number of assigned spectra, 
were significantly different between symptomatic and asymptomatic atherosclerosis. Through 
lipidomic analysis, 150 lipid species from 9 different classes were identified, of which 24 
were exclusive to atherosclerotic plaques. A comparison of 28 carotid endarterectomy 
specimens revealed differential lipid signatures of symptomatic compared with asymptomatic 
lesions, as well as stable and unstable plaque areas. Similarly, LC-MS metabolite profiling of 
organic plaque extract was able to separate symptomatic from asymptomatic atherosclerosis. 
Arterial and venous plasma lysozyme levels were seen to distinguish individuals with carotid 
atherosclerosis from matched control subjects. Furthermore, arterial plasma lysozyme levels 
were significantly higher in patients with symptomatic than asymptomatic carotid stenosis. 
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Conclusions 
These findings support the use of hybrid structural-functional imaging, and the utility and use 
of a systems biology approach in identifying significantly different and biologically relevant 
variations in atherosclerosis tissue, and in hypothesis generation for further study. The data 
presented concurs with recent reports in the literature linking the lipidic/organic component of 
atherosclerosis with the generation of a pro-inflammatory plaque microenvironment prone to 
lesion development, instability and the complications thereof. The importance of innate 
immunity has been highlighted with the demonstration of a predominance of M1 macrophage 
polarisation and evidence of Th17/IL17 signalling in unstable atherosclerosis. It is hoped that 
this work will contribute to the ongoing refinement of multi-factorial risk stratification in 
carotid atherosclerosis. 
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1.1 ATHEROSCLEROSIS 
1.1.1 Variation across Vascular Beds, Clinical Context and Species 
Atherothrombotic vascular disease is the leading cause of mortality worldwide, accounting for 
a fifth of all deaths (Lopez et al. 2006). The manifestations of the disease are often sudden 
and dramatic, including myocardial infarction and sudden death (Oalmann et al. 1980). 
Atherosclerosis is a systemic condition affecting arteries throughout the body. Similar 
mechanisms apply in the formation of atheromatous plaques in arteries supplying all major 
organ systems. These include: 
 
 Coronary arterial disease, leading to ischaemic heart disease, myocardial infarction, 
cardiomyopathy and cardiac failure; 
 Renovascular disease, leading to hypertension and renal impairment; 
 Peripheral arterial disease, leading to intermittent claudication and critical limb 
ischaemia; 
 Mesenteric arterial disease, leading to gut claudication and acute ischaemic bowel; 
and 
 Cerebrovascular disease, leading to transient ischaemic attacks (TIAs), amaurosis 
fugax and cerebrovascular accidents (CVAs, strokes). 
 
Although similar mechanisms have been described in the formation of these atheromatous 
lesions throughout the arterial tree, the process by which the arterial disease in the carotid 
artery causes focal neurological symptomatology is somewhat different to the mechanisms by 
which end organ dysfunction is precipitated in the other listed organ systems. In the non-
cerebral arterial tree, it is an acute plaque event leading to platelet aggregation, thrombosis 
and vessel occlusion which is responsible for organ dysfunction. 
 
In addition to the differences seen in the various vascular beds, atheroma studies in humans 
show that plaque rupture may occur without the formation of an occlusive thrombus, 
highlighting the importance of understanding why some plaque disruptions (even mild 
disruptions or erosions) result in occlusive thrombus, whilst extensive disruption (i.e. plaque 
rupture) can occur with little consequence (Schwartz et al. 2007). 
 
Furthermore, much work on atherosclerosis has been undertaken in murine models. However, 
the relevance of the natural history of atheromata in these models to the final events seen in 
human lesions is not yet known (Schwartz et al. 2007). 
 
Chapter 1 
 28 
1.2 CEREBROVASCULAR DISEASE 
The World Health Organisation defines stroke as ‗a syndrome characterised by rapidly 
developing symptoms and signs of focal (at times global) loss of cerebral function lasting for 
24 hours or longer or leading to death with no apparent cause other than that which is vascular 
in origin‘. 
 
1.2.1 The Burden and Health Economic Impact of Stroke 
Stroke is the third most common cause of death and the single greatest cause of adult 
disability in the developed world (2009) with, according to the Office for National Statistics, 
150,000 individuals suffering a stroke in the UK per annum. Following a stroke, 20 to 30% of 
patients die within one month, approximately one third are left with a long-term disability, 
and 12% requiring institutional care at one year. Stroke has a greater disability impact than 
any other chronic disease, with over 300,000 people living with moderate to severe 
disabilities owing to stroke (Adamson et al. 2004). 
 
Data from the National Audit Office shows that stroke represents a huge economic burden 
and each year costs the NHS approximately £2.8 billion and industry £1.8 billion in lost 
productivity and disability. Furthermore, these costs are predicted to continue to rise. 
 
Approximately 15% of patients who have a stroke will have had a pre-warning in the form of 
a transient ischaemic attack (TIA), which is defined as an acute neurological event that 
resolves completely within 24 hours from onset. For events affecting the (internal) carotid 
artery territory, the transient neurological symptoms include contra-lateral hemiparesis, 
hemiparasthaesia, transient monocular blindness (amaurosis fugax), hemi-neglect and cortical 
dysfunction (aphasia, agraphia and apraxia). 
 
Approximately 80-90% of all strokes are ischaemic in nature and atherosclerosis affecting the 
major extracranial (internal and common carotid arteries) and intracranial (anterior, middle 
and posterior cerebral arteries) blood vessels is causal in approximately 30% of cases, with 
the ratio of extracranial to intracranial lesions being greater than 2:1. In a further 30% of 
cases, embolus originating from the heart is implicated and in the remaining 40% the cause is 
unknown. 
 
In the setting of the cerebral circulation, there is redundancy in the vascular supply owing to 
the anastomotic ring of the Circle of Willis, which is fed by the two internal carotid arteries 
and the two vertebral arteries (Figure 1). Occlusion of one of these four feeding vessels 
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should not result in critical cerebral ischaemia. As such, one or more of the vessels feeding 
the Circle of Willis have been found to be occluded on imaging without clinical consequence, 
and without radiological evidence of infarction on tomographic imaging. 
 
 
Figure 1 Intra- and extra-cranial arterial circulation 
A schematic representation of the supra-aortic extra-cranial arterial anatomy (A) and Circle 
of Willis (B) highlighting the anterior circulation, derived from the internal carotid arteries 
(ICA), and the posterior circulation derived from the vertebral arteries. The anastomotic ring 
is completed by the anterior communicating and paired posterior communicating arteries, 
which are shown as dashed lines in B. CCA, common carotid artery; ECA, external carotid 
artery. 
 
On the basis of anatomic or angiographic studies, several Circle of Willis variations exist in 
more than 50% of the human population (Macchi et al. 1996; Hoksbergen et al. 2000; 
Merkkola et al. 2006; Papantchev et al. 2007). Insufficient cross-perfusion could be expected 
mainly in cases with multiple variations, which were found in 30% of the patients in Macchi's 
series (Macchi et al. 1996) and in 23% of the patients in Hoksbergen's series (Hoksbergen et 
al. 2000; Urbanski et al. 2008). In such situations, occlusion of one carotid artery may result 
in critical focal cerebral ischaemia, and the consequences thereof. 
 
There are occasions where there is an overall reduction in the blood flow into the Circle of 
Willis by virtue of significant stenosis or occlusion to a number of these inflow arteries. This 
leads to non-focal ‗low flow‘ neurological episodes. This situation is uncommon. 
 
More common and significant is the embolisation of plaque material from stenosed internal 
carotid arteries into the end organ branches of the Circle, particularly the middle cerebral 
artery, which is responsible for clinically important focal neurological syndromes. 
 
Anterior Communicating Artery 
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Vertebral Arteries 
Middle Cerebral Artery 
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Therefore, it is important to learn lessons from the mechanisms which are responsible for 
atherosclerosis throughout the body‘s arterial tree. We can, to a certain extent, extrapolate 
what is seen in the non-cerebral vascular tree to the situation which arises in carotid artery 
stenosis. However, this needs to be done so with a degree of caution. Carotid arterial disease 
is a unique situation and, where possible, research to be applied to atherosclerotic carotid 
stenosis should be studied in carotid atherosclerosis and applied directly, as opposed to 
inferred wholly from what is seen in plaques from elsewhere in the body. 
 
1.2.2 A Brief History of Carotid Endarterectomy 
The first open carotid revascularisation procedure reported was performed in 1954 by Harry 
Hubery Grayson (―Felix‖) Eastcott at St Mary‘s Hospital, London (Eastcott et al. 1954). The 
indication for surgery in this landmark case was, what was described as, crescendo transient 
ischaemic attack, and involved the resection of the diseased arterial segment and vascular 
reconstruction by direct anastomosis. The first carotid endarterectomy (CEA) was reported by 
Michael DeBakey, the first of 1,155 cases undertaken over 11 years from 1954 (Debakey et 
al. 1965). However, some controversy exists over the claim of the first carotid 
endarterectomy, with reports that this was achieved – but not published – by Stanley 
Crawford (Crawford et al. 1966; Robertson 1998). 
 
1.2.3 Intervention for Symptomatic Carotid Stenosis 
Discussions regarding intervention for carotid stenosis have centred largely on symptomatic 
status. Intervention, in the form of CEA, for symptomatic carotid stenosis has been supported 
by two major trials: the European Carotid Surgery Trial (ECST) (ESCT 1998) and the North 
American Symptomatic Carotid Endarterectomy Trial (NASCET) (NASCET 1991), both of 
which showed a long term significant reduction in stroke and death rates with CEA. 
Furthermore, in the context of symptomatic disease, benefit was related to the degree of 
stenosis. At two years, NASCET demonstrated an absolute risk reduction with CEA of 8.4% 
and 15.0% for 50-69% and 70-99% stenosis, respectively (NASCET 1991). ECST, likewise, 
showed that risk was reduced by 5.7% and 21.2% at 5 years (ESCT 1998; Rothwell et al. 
2003b). The evidence has been re-evaluated by an expert working party of the European 
Society for Vascular Surgery (ESVS), with intervention stated to be indicated in symptomatic 
patients with stenosis greater than 70% (Liapis et al. 2009). The caveat is now in place that 
CEA is recommended for individuals with stenosis of greater than 50% where the peri-
operative risk of stroke and death is less than 6%, and surgery should be undertaken within 2 
weeks of symptoms (Naylor 2007; Liapis et al. 2009). 
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1.2.4 The Great and Ongoing Debate: Revascularisation for Asymptomatic Carotid 
Stenosis 
Two key trials investigating CEA in asymptomatic carotid disease have been completed. The 
Asymptomatic Carotid Atherosclerosis Study (ACAS) randomised 1,662 patients with 
asymptomatic carotid stenosis of 60-99% to either CEA or medical therapy. ACAS found that 
CEA afforded a significant reduction in TIA and stroke, but not major stoke and death 
(ACAS 1995). The benefit of CEA was not seen in women. The Asymptomatic Carotid 
Surgery Trial (ACST) randomised almost twice as many patients as ACAS (3,120 patients), 
also with asymptomatic 60-99% carotid stenosis, to either immediate or deferred CEA. ACST 
reported a significant reduction in all strokes at 5 years of 6.4% versus 11.8% in the 
immediate versus deferred CEA groups, respectively (Halliday et al. 2004). This represented 
a 5.4% net benefit with CEA which, when subgroup analysis based upon gender was 
undertaken, revealed a non-significant 4.1% absolute risk reduction in women and a 
significant 8.2% benefit in men. Three years was required to counterbalance the operative risk 
in women (Halliday et al. 2004). The ESVS recommends surgical intervention in males aged 
less than 75 years with an asymptomatic stenosis of 70-99% where the peri-operative stroke 
and death risk is less than 3%. The benefit conferred by intervention in women with 
asymptomatic carotid stenosis is less clear, therefore CEA is recommended in younger, fit 
females (Liapis et al. 2009). Alongside this, there has been an improvement in best medical 
therapy (BMT) which should reduce the benefit derived from CEA. However, surgery is 
becoming safer with peri-operative stroke and death rates in CEA falling, implying that the 
benefit from surgery could be maintained – further work is necessary to confirm or refute 
these hypotheses. 
 
The controversy surrounding the management of asymptomatic carotid stenosis is such that it 
has been the subject of a recent heated transatlantic debate which was published in both the 
Journal of Vascular Surgery (Schneider and Naylor 2010a), and the European Journal for 
Vascular and Endovascular Surgery (Schneider and Naylor 2010b). There was a similar 
recent debate presented in the British Medical Journal (Roffi 2010; Spence 2010). In these 
debates, some experts have called for CEA in all individuals with asymptomatic carotid 
stenosis, whilst others have recommended that none have revascularisation and be treated 
with BMT alone. 
 
The need for risk stratification in the appropriate case selection for intervention in 
asymptomatic carotid stenosis has been called for (Davies et al. 2010a; Rockman and Riles 
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2010). It is important to consider at all stages in the decision making process that 
asymptomatic carotid intervention is a prophylactic undertaking. 
 
1.3 STROKE RISK STRATIFICATION 
Risk stratification, here, describes efforts to identify those (predominantly) asymptomatic 
carotid plaques which are more likely to produce emboli and hence cause stroke. 
Traditionally, stroke risk stratification has centred on the degree of internal carotid artery 
luminal narrowing and the presence of recent focal neurological symptoms pertaining to the 
ipsilateral cerebral hemisphere. ACST (Halliday et al. 2004; Halliday et al. 2010) highlighted 
the need to identify a subgroup of asymptomatic individuals that would benefit from 
intervention. The identification of high-risk plaques that will cause acute cardiovascular 
events is an unmet clinical need, and has inspired an intense research effort in the field of 
imaging and biological markers (Libby et al. 2002; Koenig and Khuseyinova 2007). This has 
been in the hope that non-invasive preventative screening tools may be developed. 
 
To date, risk stratification has considered age, life expectancy and quality of life, but has 
otherwise focused on structural plaque features. The main structural predictor is degree of 
luminal stenosis as reported by the landmark European (ECST 1991) and North American 
(NASCET 1991) trials, but it is important to remember that these studied symptomatic 
individuals. Luminal stenosis was assessed in these trials using conventional angiography, 
however duplex ultrasonography is the main imaging modality used to estimate stenosis by 
velocity criteria (Oates et al. 2009). 
 
The Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) study confirmed, in 
asymptomatic individuals, a relationship between the degree of stenosis, as assessed by 
duplex ultrasound, and cerebral hemisphere ischemic events (relative risk 1.6) (Nicolaides et 
al. 2005). This study also showed that a combination of duplex-assessed stenosis, 
contralateral hemisphere transient ischemic attack and renal impairment (creatinine >85 
μmol/L) defined a high-risk asymptomatic subgroup. Plaque echogenicity on duplex 
ultrasound, has been linked with histological features of instability (Gray-Weale et al. 1988; 
Sztajzel et al. 2005). There has been conflicting evidence for the role of plaque echolucency 
in the context of asymptomatic carotid stenosis (Polak et al. 1998; Gronholdt et al. 2001; 
Mathiesen et al. 2001), and hazard ratios have not been sufficient to warrant translation into 
clinical practice (Shalhoub and Davies 2010). 
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A cost-effective method of identifying those at high risk of stroke would provide substantial 
benefits to patients, surgeons, neurologists and the taxpayer. Improving the predictive test(s) 
of those at risk this hopes to offer: 
 
1. A personalised risk estimate to facilitate decision making with regard to surgery, 
empowering both patients and clinicians; 
2. A reduction in unnecessary numbers of CEAs; 
3. A surgical cost and bed day reduction; 
4. A new surrogate endpoint for studies of plaque stabilising therapies; and 
5. Determining intervention criteria for future interventional trials, including those 
investigating carotid artery stenting. 
 
As per point 5, risk stratification of carotid atherosclerosis will not only facilitate the decision 
making process with regards whether to intervene on asymptomatic stenoses, but may also 
help with the choice of intervention, i.e. case selection for carotid artery stenting (CAS). The 
importance of the latter comes with the publication of results of recent randomised controlled 
trials which have failed to show non-inferiority of CAS as compared with carotid 
endarterectomy (CEA), for example the Endarterectomy Versus Angioplasty in Patients with 
Severe Symptomatic Carotid Stenosis (EVA-3S) trial (Mas et al. 2008). Furthermore, having 
the capacity to risk stratify atherosclerosis in vivo may permit the monitoring of response to 
plaque stabilising therapies. 
 
It is likely that risk stratification will be multifactorial and rely on a combination of the 
following: 
 
 Clinical parameters 
 Imaging 
o Structural 
o Functional 
 Biomarkers 
 
A ‗high risk‘ asymptomatic group may to be defined by an ‗overlap‘ region in the imaging 
signal, molecular or biomarker levels from plaques or patients with plaques that are 
symptomatic and those that are asymptomatic. 
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It is also important to consider what level of risk to benefit a patient is willing to accept and 
consider patients‘ perception of risk. Acknowledging this, with regards the management of 
particularly asymptomatic carotid stenosis, coupled with a recognition of the importance of 
patient choice and involvement in the decision-making process when it comes to their care, 
our group has conducted and published work on patient preference in asymptomatic carotid 
disease (Jayasooriya et al. 2011). 
 
1.3.1 The „Obsession‟ with Degree of Luminal Stenosis 
Relying solely on the degree of carotid stenosis during the decision-making process for 
intervention is inadequate as: (1) there is a lack of reliable correlation between the non-
invasive imaging currently in widespread use and the invasive catheter angiography employed 
in the large studies upon which degree of stenosis criteria were established; (2) there are 
inherent errors in estimating degree of stenosis by invasive catheter angiography; and (3) – 
and perhaps most importantly – this disregards the fact that stroke risk is also dependent on 
plaque stability and, in the case of symptomatic stenosis, the number of ischaemic events 
(Ahmed et al. 2010; Archie 2010). This challenge has been recognised for some time in the 
context of the coronary arterial territory (Topol and Nissen 1995). 
 
Following a study of CEA for symptomatic but ‗haemodynamically insignificant‘ carotid 
stenosis, relying only – or even largely – on the degree of luminal narrowing when referring 
patients with even symptomatic carotid stenosis for carotid intervention has been considered 
by some as inadequate: it overvalues hypoperfusion and undervalues embolisation as the 
mechanism of ischaemic events (Ahmed et al. 2010). Indeed, we are not treating the lumen, 
we are treating the plaque. 
 
The ACST (Halliday et al. 2004; Halliday et al. 2010), a recent Cochrane review (Chambers 
and Donnan 2005) and others (Inzitari et al. 2000) have demonstrated the number needed to 
treat (NNT) for asymptomatic carotid stenosis as being more than 16 (and even up to 32) to 
prevent a single stroke. This is considerably higher than in symptomatic patients, where it is 6 
to 13 (Rothwell et al. 2003a). One reason for this difference in NNT is that the use of carotid 
luminal stenosis is a poor risk predictor in asymptomatic patients (Nicolaides et al. 2005). 
Hence it is estimated that up to 94% of asymptomatic surgery could be avoided (Naylor et al. 
2009). 
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1.4 PLAQUE BIOLOGICAL ATTRIBUTES AND STABILITY 
Recently, biological attributes of atherosclerotic plaque have been acknowledged as key 
determinants of future thrombo-embolic events. These biological attributes are responsible for 
a number of closely inter-related processes that are felt to be causally linked to plaque 
vulnerability and include (Figure 2): 
 
 Inflammation (inflammatory cell recruitment and activation) (Discussed in depth in 
Section 1.5) 
 Matrix degradation 
 Angiogenesis 
 Intra-plaque haemorrhage 
 Apoptosis 
 Autophagy 
 Hypoxia 
 
 
Figure 2 Summary of biological attributes contributing to atheromatous plaque 
instability 
A diagrammatic representation of the numerous important inter-related factors responsible 
for plaque vulnerability (Narula and Strauss 2007). 
 
1.4.1 Angiogenesis 
Associations between human plaque vulnerability and angiogenic activity were originally 
noted in the late 1980s (Alpern-Elran et al. 1989). Subsequently it was found that plaques 
bearing hallmarks of vulnerability, including inflammation, haemorrhage, lipid accumulation 
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and thin fibrous caps, are also associated with increasing neovascularisation (de Boer et al. 
1999; McCarthy et al. 1999a; Moreno et al. 2004). Neovascularisation appears to be an early 
feature of atherosclerosis, predating macrophage infiltration (Fleiner et al. 2004), and as the 
plaque progresses so too does intimal neovascularisation (Chen et al. 1999). 
 
The majority of studies show carotid plaques retrieved at endarterectomy have many more 
microvessels and transcripts known to promote neovascularisation when they originate from 
symptomatic, compared to asymptomatic patients (McCarthy et al. 1999a; Mofidi et al. 2001; 
Tureyen et al. 2006; Dunmore et al. 2007). Statins have been shown to reduce this intra-
plaque angiogenesis (Koutouzis et al. 2007). Symptomatic plaques, in addition, have been 
shown to contain abnormal, immature or ‗incompetent‘ vessels that may precipitate plaque 
instability through their acting as sites of vascular leakage and so inflammation (McCarthy et 
al. 1999a; McCarthy et al. 1999b; Dunmore et al. 2007), or involvement in intra-plaque 
haemorrhage. 
 
1.4.2 Intra-Plaque Haemorrhage 
Intra-plaque haemorrhage, as identified by staining for the red blood cell membrane protein 
glycophorin A, has been described by Virmani et al as an important feature of unstable 
atherosclerotic lesions. Furthermore, effective clearance of extracellular haemoglobin is 
thought to attenuate oxidative haem toxicity, presumed to contribute to plaque instability. In 
unstable plaques intraplaque haemorrhage (by glycophorin A immunohistochemistry) has 
been shown to be positively associated with haemoglobin scavenger receptor (CD163) 
expression and lipid peroxidation in macrophages (by 4-hydroxy-2-noneal) (Crea and 
Andreotti 2009; Yunoki et al. 2009). 
 
1.4.3 Matrix Degradation  
A number of studies have directly implicated MMPs as having an integral role in these 
processes. For example, studies utilising multianalyte profiling platforms with cell cultures 
from human carotid endarterectomy plaques have shown that MMPs-1, 2, 3, 9 and 14 are 
produced by these cells (Monaco et al. 2004). MMPs have also been linked with smooth 
muscle cell (SMC) migration and accumulation in the intima (Southgate et al. 1996), which is 
known to be a key step in the formation of atherosclerotic plaques (Bendeck et al. 1994; 
Zempo et al. 1994). In a rodent model of balloon-injured carotid arteries, viral transfection of 
baboon TIMP-1 limited SMC migration both in vivo and in vitro, this effect being reversed by 
antibodies against TIMP-1 (Forough et al. 1996), further implicating MMP action in 
atherosclerosis. 
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1.4.4 The Language of Atherosclerotic Risk and Vulnerability 
The term ―plaque rupture‖ in human pathology is not controversial and describes a structural 
defect in the plaque fibrous cap, with exposure of the thrombogenic necrotic core to blood. 
This phenomenon is not commonly seen in atheroma-prone mice having not progressed to 
such a stage (Schwartz et al. 2007), hence adding complexity in relation to the terminology of 
risk in atherosclerosis. Murine plaques have a superficial xanthoma (including laterally) 
which penetrates the relatively thin fibrous cap, and plaque ‗disruption‘ may occur due to cell 
death in the lateral xanthoma (Schwartz et al. 2007). 
 
A need for agreement on nomenclature when referring to high risk, vulnerable and 
thrombosis-prone (these terms being synonyms) atheromatous plaques has been recognised 
and an agreement on the use of this terminology has been published (Schaar et al. 2004). This 
document employs terms as per the definitions in that Special Article. 
 
1.5 INFLAMMATION AND ATHEROSCLEROSIS 
Progress has been made in refining our understanding of the process of inflammation which 
underlies atherosclerosis since the early descriptions by Rudolf Virchow during the 19
th
 
century (Mayerl et al. 2006; Methe and Weis 2007) and subsequently Russell Ross in the late 
1990s (Ross 1999; Haque et al. 2008; Ridker et al. 2008; Full et al. 2009). Local rheological 
factors, such as low and oscillatory (with vortices) blood-to-wall shear stress dictate the 
location of atherosclerotic plaques to characteristic points along the vasculature (Cheng et al. 
2006; Caro 2009). The development of an atherosclerotic plaque begins with the recruitment 
of blood-borne inflammatory cells at sites of lipid deposition (Glass and Witztum 2001) or 
injury, where they produce pro-inflammatory cytokines and chemokines, growth factors, 
extracellular matrix degradation enzymes, and pro-angiogenic mediators (Ross 1999; Hansson 
2005). It is worth noting that cytokines are signalling molecules involved in communication 
between cells. Chemokines are a subgroup of cytokines that are chemotactic, i.e. chemotactic 
cytokines. There is considerable interaction between immune cells via cytokines, and the key 
interactions have been summarised in Figure 3. 
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Figure 3 Summary of known interaction between immune cells, through cytokines 
A diagrammatic representation of the cells of origin and target cells of key cytokines. This 
also highlights the cross-communication between innate and adaptive divisions of the immune 
system. 
 
Atherosclerosis shares features with diseases caused by chronic inflammation (Full et al. 
2009). Inflammation is intrinsically linked with disease activity, as the numbers of monocyte-
macrophages infiltrating the plaque (Davies et al. 1993) and their location at plaque rupture-
sensitive sites (such as the fibrous cap and areas of erosion (van der Wal et al. 1994; Virmani 
et al. 2003)) is related to plaque vulnerability. Moreover, lymphocyte abundance and their 
activation markers relate to plaque activity (van der Wal et al. 1994). Macrophage 
differentiation is acknowledged as critical for the development of atherosclerosis (Gleissner et 
al. 2010). The intimate relationship between atherosclerosis and inflammation is further 
exemplified by the involvement of cytokines and chemokines at all stages of the process of 
atherosclerosis (Tedgui and Mallat 2006). The extent of the inflammatory infiltrates and their 
strategic location within the protective fibrous cap is associated with plaque rupture and/or 
TNFα 
TNFβ 
IL10 
IL12 
IL1 
IL6 
IL10 
IL12 
IL15 
TNFα 
 
IFNα 
 
IFNβ 
 
TNFα 
 
TNFα 
 
IL1 
IL8 
TNFα 
 
IL1 
IL8 
IL5 
B Cell 
T Cell 
Macrophage 
Mast Cell 
Basophil 
Neutrophil 
Eosinophil 
IL1 
IFNα 
 
IFNβ 
 
TNFα 
 
TNFβ 
 
IL1 
IL6 
IL8 
IL12 
IL15 
IL18 
 
IL10 IFNα 
 
IFNγ 
TNFα 
 
IL1 
IL3 
IL4 
IL13 
IFNα 
 
IFNβ 
 
IL10 IFNγ 
 
TNFα 
 
TNFβ 
 
TNFα 
 
IL1 
IL3 
IL4 
IFNγ 
 
TNFα 
 
TNFβ 
 
IL8 
IL3 IL10 
 
IL9 
IL1 
IL3 
IL4 
IL8 
IL3 
IL4 
IL5 
IL4 
IL5 
IL10 
IL4 
IL4 
IL4 
IL1 
IL6 
IL10 
IL12 
IFNα 
 
IFNβ 
 
TNFα 
 
TNFβ 
 
IL1 
IL2 
IL4 
IL10 
IL13 
IL14 
 
IL6 IFNα 
 
IFNβ 
 
IFNγ 
 
IL2 
IL4 
IL6 
IL9 
IL16 
IL17 
 
IL8 IFNα 
 
IFNβ 
 
IFNγ 
 
IL10 
IL4 
Chapter 1 
 39 
thrombosis (Mauriello et al.). Adventitial inflammation has also been described (Grabner et 
al. 2009), and is linked with an expansion of the adventitial vasa vasorum in unstable 
atherosclerosis (Dunmore et al. 2007). The inflammatory nature of atherosclerosis is 
supported by the association between circulating plasma inflammatory markers, particularly 
C-reactive protein, with cardiovascular outcomes, even in the absence of dyslipidaemia 
(Ridker et al. 2008). Further evidence for a link between systemic inflammation and 
cardiovascular disease is the increased incidence of cardiovascular events in chronic 
inflammatory conditions, such as inflammatory arthritis and systemic lupus erythematosus 
(Haque et al. 2008; Full et al. 2009). The expanding knowledge base regarding inflammation 
in atherosclerosis has resulted in a keen interest in targeted therapeutics and functional 
imaging tools for the high-risk atherosclerotic plaque (Narula and Strauss 2007). 
 
1.5.1 Innate Immunity – A Key Player in Atherosclerosis 
How is inflammation established and maintained within an atherosclerotic plaque? 
Inflammation in physiological conditions is a self-limiting ancient protective mechanism that 
defends the host from invading pathogens. It relies on two arms: innate immunity and 
adaptive immunity, with these systems involved in all stages of atherosclerosis, from 
initiation and progression all the way through to complications (Packard et al. 2009). Innate 
immunity is activated immediately upon encounter with the pathogen and is executed 
primarily by myeloid cells with the participation of some ―innate‖ lymphocyte sub-
populations. Adaptive immunity is a second line of defence that is based upon the generation 
of antigen-specific recognition apparatus at cellular (T cell receptor) and humoral (antibody) 
levels. 
 
In the past decade it has become apparent that the innate arm of the immune inflammatory 
response is not merely a concoction of non-specific responses and phagocytosis. Rather it is 
the main orchestrator of the subsequent adaptive responses and is able to sense pathogen 
associated molecular patterns (PAMPs) with a specificity which was previously unsuspected. 
In inflammatory conditions, including atherosclerosis, the immune inflammatory apparatus is 
chronically activated, either due to the persistence of pro-inflammatory stimuli or due to the 
failure of regulatory mechanisms that should facilitate resolution. Significant progress has 
been made in the field linking innate immune sensors to the recognition of cholesterol 
(Duewell et al. 2010) and modified lipoproteins (Miller et al. 2003; Miller et al. 2005; Stewart 
et al. 2010b). Thus diverse innate immune signalling pathways have been seen to cooperate to 
induce and maintain inflammation upon exposure to exogenous and, importantly, endogenous 
molecular patterns (Cole et al. 2010; Duewell et al. 2010). 
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The most abundant cell types within the atherosclerotic plaque are innate immune cells, such 
as monocyte-macrophages, dendritic cells (DCs) and mast cells. Monocytes-macrophages 
came to the forefront of research owing to new awareness that they may represent a more 
heterogeneous and phenotypically plastic population than previously anticipated. 
 
1.5.2 Macrophage Heterogeneity in Atherosclerosis 
More than a century after Élie Metchinkov was awarded the Nobel Prize for discovering the 
function of the macrophage, there is still considerable interest in the cell type which (in 1908) 
he credited with influencing development, ensuring homeostasis, and protecting the host from 
infection through a process he described as ‗innate immunity‘ (Nathan 2008). 
 
Macrophages are a heterogeneous population of cells that adapt in response to a variety of 
micro-environmental signals; their phenotype is very much a function of environmental cues 
(Van Ginderachter et al. 2006; Waldo et al. 2008). In a nomenclature mirroring Th1 and Th2 
polarisation, macrophages are usually defined as M1 or M2 (Martinez et al. 2006). 
Characteristic cytokine and chemokine signatures pertaining to human monocyte-to-
macrophage differentiation and M1/M2 macrophage polarisation (Table 1) have been 
described (Martinez et al. 2006; Mantovani et al. 2009). 
 
M1 > M2 M2 > M1 
CXCL11 Insulin-like growth factor 1 
CCL19 CCL23 
CXCL10 CCL18 
Tumour necrosis factor ligand superfamily, member 2 CCL13 
CCL15 Bone morphogenic protein 2 
Interleukin 12B Hepatocyte growth factor 
Interleukin 15 Fibroblast growth factor 13 
Tumour necrosis factor ligand superfamily, member 10 CXCL1 
Interleukin 6 Transforming growth factor  receptor II 
CCL20 CXCR4 
Visfatin Mannose receptor C type 1 (CD206) 
Endothelial cell growth factor  
CCL1  
CCL17  
CCL22  
CCL13  
Transforming growth factor 2  
CCR7  
Interleukin 2 receptor  chain  
Interleukin 15 receptor  chain  
Interleukin 7 receptor  
Table 1 Cytokines and chemokine gene expression in human macrophage 
polarisation 
Cytokine and chemokine genes, and those of receptors (in italics), known to be differentially 
transcribed in human M1 and M2 macrophage in vitro polarisation (Adapted from (Martinez 
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et al. 2006) and (Waldo et al. 2008)). CCL2 was upregulated in M-CSF differentiated 
macrophages in one study (Waldo et al. 2008), whilst relatively increased by GM-CSF in 
another (Martinez et al. 2006). 
 
Classically activated (M1) macrophages were the first to be characterised (Gordon 2003; 
Gordon 2007). M1 macrophages are pro-inflammatory and participate in tissue destruction. 
Alternatively activated (M2) macrophages contribute to wound healing and regulation of 
inflammatory processes (Mosser and Edwards 2008). 
 
Macrophage phenotypic polarisation may have a role in the fate of an atherosclerotic plaque. 
The plaque is an environment with a strong skew towards Th1 lymphocytic responses, 
resulting in high levels of IFNγ (Hansson 2008; Mallat et al. 2009) which could in theory 
privilege M1-type macrophage polarisation. However, studies thus far have demonstrated 
macrophage heterogeneity within atherosclerosis, supporting that both M1 and M2 
macrophages are present in human and murine atherosclerotic lesions. In an ApoE
-/-
 murine 
model of atherosclerosis, early lesions were seen to be infiltrated by M2 (arginase I
+
) 
macrophages (Khallou-Laschet et al. 2010). As lesions progressed a phenotypic switch was 
observed, with an eventual predominance of M1 (arginase II
+
) macrophages. Upon exposure 
to the oxidised phospholipid 1-palmitoyl-2-arachidonoyl-sn-3-phosphorylcholine (oxPAPC), 
murine macrophages adopted a previously undescribed phenotype (Figure 4) (Kadl et al. 
2010). A reduction in the expression of genes characteristic of both M1 and M2, coupled with 
an up-regulation of a unique gene signature that includes haemoxygenase 1, was observed. 
This population, termed Mox macrophages, are nuclear factor erythroid 2-like 2 (Nrf2)-
dependent and have been shown to comprise approximately 30% of all macrophages in 
advanced atherosclerotic lesions of LDLR
-/- 
mice (Kadl et al. 2010). A variety of subtypes 
have been described which are considered to fall under the umbrella of alternatively activated 
M2 macrophages (Mantovani et al. 2004; Mosser and Edwards 2008). An example of this 
occurs with administration of IL33 (which is functionally atheroprotective (Miller et al. 
2008)) to genetically obese diabetic (ob/ob) mice, resulting in increased production of Th2 
cytokines and polarisation of adipose tissue macrophages to a CD206
+
 M2 phenotype (Miller 
et al. 2010). 
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M1 M2
iNOS, IL1  IL1, TNF, IL12 
NOS2, CXCL1 CXCL2, CXCL9
CXCL10,CXCL11 
Ym1, FIZZ1, ARG1, CCL22, CCL17
IL1ra, IL1R2, IL10, SR, GR
MOX
Host defense Healing
Redox / Antioxidant Activity
 
Figure 4 The relationship between M1, M2 and MOX macrophage phenotypes 
Macrophages have classically been described as M1 and M2. These two phenotypes differ 
substantially with respect to the expression of macrophage associated genes. More recently, 
Kadl et al have described a new subset termed MOX macrophages (Kadl et al. 2010). These 
are induced by an environment rich in structurally defined oxidation products such as 
oxidised 1-palmitoyl-2-arachidonoyl-sn-3-phosphorylcholine (oxPAPC) and can be induced 
from an M1 or M2 phenotype. ARE, antioxidant responsive elements; ARG1, arginase 1; 
CCL, chemokine ligand; COX2, cyclo-oxygenase 2; CXCL, chemokine CXC motif ligand; 
FIZZ1, found in inflammatory zone 1; GR, galactose receptor; HO1, heme-oxygenase 1; IL, 
interleukin; IL1ra; interleukin 1 receptor antagonist; ILR2, interleukin 1 receptor type II, 
decoy receptor; iNOS, inducible nitric oxide synthase; NRF2, nuclear factor erythroid 2-like 
2; SR, scavenger receptor; Ym1, chitinase 3-like 3 lectin. 
 
In human lesions different macrophage phenotypes exist, and do so in different plaque 
locations. M2 (CD68
+
 CD206
+
) macrophages were seen to reside in areas more stable zones 
of the plaque distant from the lipid core, with their M1 (CD68
+
 CCL2
+
) counterparts 
displaying a distinct tissue localisation pattern (Bouhlel et al. 2007). Subsequent work has 
confirmed this, finding CD68
+
 CD206
+
 cells far from the lipid core (Chinetti-Gbaguidi et al. 
2011). CD68
+
 CD206
+
 macrophages were also seen to contain smaller lipid droplets 
compared to CD68
+
 CD206
-
 (Chinetti-Gbaguidi et al. 2011). A subset of M2 macrophages has 
recently been detected in association with intraplaque haemorrhage in coronary atheromata 
(Boyle et al. 2009). These macrophages express high levels of CD163 (a scavenger receptor 
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that binds to haemoglobin-haptoglobin (HbHp) complexes). They also express low levels of 
MHC Class II and display low release of the reactive oxidative species hydrogen peroxide. 
Expression of CD163 by peripheral blood monocytes was not shown to be different between 
the CD14
+
 CD16
+
 and CD14
++
 CD16
-
 subsets. However, when monocytes were differentiated 
into macrophages in the presence of HbHp complexes for 8 days, they matured into a 
CD163
high
 HLA-DR
low
 phenotype similar to the haemorrhage-associated macrophages within 
coronary plaques (Boyle et al. 2009).  Differentiation into this macrophage subtype was 
dependent on the expression of CD163 and IL10 during in vitro blockade experiments. 
Interestingly, this polarisation was prevented by the incubation with specific inhibitors of 
endolysosomal acidification, such as chloroquine which is known to interfere with endosomal 
TLR signalling (Boyle et al. 2009).  
 
1.5.3 Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in 
Macrophage Phenotype 
Lesion development and stability are not only determined by the influx and differentiation of 
inflammatory cell subsets, but also their ability to act on vascular extracellular matrix. 
Importantly, the macrophage subtypes display a differential expression of matrix 
metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) (Chase et al. 
2002). In particular, a subset of lesional foam cell macrophages characterised by a high 
expression of MMP14 (membrane type 1 MMP) and a low expression of TIMP3 were highly 
invasive and catabolic (Johnson et al. 2008). Moreover, such expression pattern of MMP14 
and TIMP 3 was associated with markers of M1 polarisation (Johnson et al. 2008), whilst 
expression of MMP12 was associated with an M2-typical down-regulation of arginase I 
(Thomas et al. 2007). Thus MMP expression by macrophage subsets is also heterogeneous, 
further highlighting the different functionalities of these cells. 
 
The heterogeneity of macrophage phenotypes in the various studies is an important feature of 
our current view of atherosclerosis. Studies assessing multiple markers in human and murine 
lesions are needed to map such degree of heterogeneity. How is such heterogeneity 
generated? It is likely to be the result of recruitment of different monocytes subsets, or stimuli 
provided by the plaque microenvironment. Gordon and Martinez have proposed a four-stage 
paradigm of macrophage activation (Figure 5), where differentiation through exposure to 
growth factors is the first stage (Gordon and Martinez 2010). This stage is followed by 
priming (through cytokines, particularly IFNγ and IL4), activation (by TLR or similar), and 
finally resolution and repair (mediated by IL10, transforming growth factor (TGF)-β, 
nucleotides, glucocorticoids or lipotoxins) (Gordon and Martinez 2010). This review will 
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explore the potential mechanisms leading to macrophage activation and polarisation in 
atherosclerosis. 
 
 
Figure 5 Multi-step paradigm of macrophage activation 
Adapted from (Gordon and Martinez 2010). GM-CSF, granulocyte macrophage colony 
stimulating factor; M-CSF, macrophage colony stimulating factor; IFN, interferon; IL, 
interleukin; NLR, NOD-like receptor; TGF, transforming growth factor; TLR, toll-like 
receptor. 
 
1.5.4 Recruitment of Monocyte Subsets to Atherosclerotic Plaques 
In both mice and humans, monocytes comprise 5 to 10% of peripheral blood leukocytes (Cole 
et al. 2010). Two major circulating monocyte subsets have been described in humans and 
mice alike, the distinction made on the basis of size, granularity, and the differential 
expression of chemokine receptors and adhesion molecules (Geissmann et al. 2003). The two 
mouse monocyte sub-populations are represented approximately equally in murine blood; 
they are distinguished based upon their expression of CCR2, CX3CR1  and Ly6C (Fleming et 
al. 1993)) (Strauss-Ayali et al. 2007). CCR2
+
 CX3CR1
low
 Ly6C
+
 monocytes are termed 
‗inflammatory‘ monocytes, and CCR2- CX3CR1
high
 Ly6C
-
 are referred to as ‗resident‘ 
monocytes (Geissmann et al. 2003; Mosser and Edwards 2008; Gautier et al. 2009).  
 
Similarly to mouse monocytes, human monocytes can be separated into two groups based 
upon cell surface CD14 – a toll-like receptor (TLR) co-receptor sensing exogenous molecular 
patterns such as lipopolysaccharide (LPS) – and CD16 – a member of the family of Fc 
(Fragment, crystallisable) receptors FcγRIII. In humans, about 90% of monocytes are CD14++ 
CD16
-
 and termed ‗classical‘ monocytes (Gautier et al. 2009; Steinman and Idoyaga). CD14+ 
CD16
+
 monocytes, which constitute the remaining minority, are referred to as ‗non-classical‘ 
(Passlick et al. 1989; Ziegler-Heitbrock et al. 1993; Weber et al. 2000; Ancuta et al. 2003) 
(Table 2). 
Differentiation 
 
M-CSF ↔ GM-CSF 
Priming 
 
IFNγ ↔ IL4 
Activation 
 
Innate Immune Signalling 
(TLR, NLR, inflammasome) 
Resolution / 
Deactivation 
IL10, TGFβ, lipoxins, 
nucleotides, glucocorticoids 
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Table 2 A comparison of human and murine monocyte subsets 
The differences in surface receptor phenotypes are highlighted. The approximate abundance 
in peripheral blood is shown in brackets, however this may not reflect the proportions in 
other sites such as the spleen. 
 
To date, monocyte phenotype data has centred largely on the murine system (Gordon 2003). 
Similarities between mice and humans may be accounted for, at least in part, by the 
expression of surface receptors. For instance, chemokine receptors CCR1 and CCR2 are 
highly expressed on both CD16
-
 human and Ly6C
+
 murine monocytes, and CX3CR1 is 
increased on CD16
+
 human and Ly6C
-
 mouse monocytes (Palframan et al. 2001; Geissmann 
et al. 2003; Gordon and Taylor 2005; Tacke et al. 2007). More than 130 of these gene 
expression differences were conserved between mouse and human monocyte subsets, with 
many of these differences also confirmed at the protein level (Ingersoll et al.). A notable 
difference among these was the high expression of peroxisome proliferator-activated receptor 
γ (PPARγ, discussed in greater detail below) in Ly6C- mouse monocytes, but not the proposed 
CD16
+
 counterpart. (Ingersoll et al.). 
 
Two groups independently reported in 2007 that the Ly6C
+
 inflammatory monocyte subset 
increases its representation dramatically in the peripheral blood of the hypercholesterolemic 
apolipoprotein E (ApoE) deficient mouse on a high-fat diet (Swirski et al. 2007; Tacke et al. 
2007). Conversely, hypercholesterolemia did not affect Ly6C
-
 monocytes and also 
discouraged the conversion of Ly6C
+
 into Ly6C
- 
monocytes. Other mechanisms proposed for 
this increase in Ly6C
+
 monocytes during hypercholesterolemia include increased proliferation 
and reduced apoptosis (Swirski et al. 2009). Ly6C
+
 monocytes are recruited to activated 
endothelium and are thought to represent the majority of infiltrating macrophages within 
atherosclerotic plaques (Swirski et al. 2007). Conversely, Ly6C
-
 enter the atherosclerotic 
plaque in lower numbers and preferentially express CD11c upon entry (Tacke et al. 2007). 
This differential recruitment based upon Ly6C expression may condition the macrophage 
phenotype within the plaque, with reports that Ly6C
+
 monocytes differentiate into cells that 
resemble M1 macrophages and that cells derived from Ly6C
-
 monocytes exhibit M2 
 Human Mouse 
Classical / 
Inflammatory 
CD14
++
 CD16
-
 
(Ziegler-Heitbrock 2007; Yona and 
Jung) (>90%) 
Ly6C
+
 CCR2
+
 CD62L
+
 CX3CR1
low
 
(Geissmann et al. 2003; Ingersoll et 
al.) (~50%) 
Non-Classical / 
Resident 
CD14
+
 CD16
+ 
(Ziegler-Heitbrock 2007; Yona and 
Jung) (<10%) 
Ly6C
-
 CCR2
-
 CD62L
-
 CX3CR1
high
 
(Geissmann et al. 2003; Ingersoll et 
al.) (~50%) 
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characteristics (Nahrendorf et al. 2007; Auffray et al. 2009; Geissmann et al. 2010a; 
Geissmann et al. 2010b). 
 
Chemokine receptors are necessary for monocytes to traverse the endothelium (Tacke et al. 
2007; Saederup et al. 2008) (Tedgui and Mallat 2006). CX3CR1
-/-
 (fractalkine receptor) 
(Combadiere et al. 2003; Lesnik et al. 2003), CX3CL1
-/-
 (fractalkine) (Teupser et al. 2004) and 
CCR2
-/-
 (Boring et al. 1998; Dawson et al. 1999) mice (in the context of low density 
lipoprotein receptor (LDLR) or ApoE deficiency) exhibited a reduction in – but not 
elimination of – atherosclerosis. Furthermore, deficiency of CCR5 (the receptor for CCL5, a 
chemokine also known as RANTES) in ApoE
-/-
 mice does not appear to be protective in the 
early stages of atherosclerosis (Kuziel et al. 2003). Subsequently, in a wire injury study also 
using the ApoE
-/-
 mouse model, the authors found a significant reduction in the area neo-
intima formation with concurrent CCR5 deficiency, but not with concurrent absence of the 
alternative CCL5 receptor CCR1 (Zernecke et al. 2006). More recently, a multiple knockout 
model has reaffirmed the thinking that CCL2 (MCP1), CCR5 and CX3CR1 play independent 
and additive roles in atherogenesis (Combadiere et al. 2008). Combined inhibition of CCL2, 
CCR5 and CX3CR1 in ApoE
-/-
 mice results in a 90% reduction in atherosclerosis, which is 
related to progressive monocytopaenia (Combadiere et al. 2008; Saederup et al. 2008). 
However, chemokine receptor utilisation during recruitment to atherosclerotic plaques 
differentiates Ly6C
+
 and Ly6C
-
 monocytes. Ly6C
+
 monocytes are recruited to mouse 
atherosclerosis via CCR2, CCR5 and CX3CR1 (Swirski et al. 2009). Conversely, Ly6C
-
 
monocytes are recruited less frequently and through CCR5. 
 
In human atherosclerosis, patients with coronary artery disease have increased numbers of 
circulating CD14
+
 CD16
+
 monocytes compared to controls (Wildgruber et al. 2009). 
Furthermore, these patients have raised levels of serum TNFα (Schlitt et al. 2004). There is, 
however, data to the contrary with the finding that inflammatory genes and surface markers 
were down-regulated in monocytes of patients with coronary atherosclerosis (Schirmer et al. 
2009). Of relevance, CD14
+
 CD16
+
 monocytes have also been shown to exhibit pro-
inflammatory and pro-atherosclerotic activity in a population of elderly human subjects. 
These activated monocytes exhibited increased interaction with endothelium and had higher 
expression of chemokine receptors (Merino et al. 2011). Other studies have suggested that the 
bone marrow is the source of these monocytes (Kuwana et al. 2003; Kamari et al. 2011). 
 
1.5.5 Macrophage Differentiation in Atherosclerosis 
Early work relating to the effect of the colony stimulating factors (CSFs) on macrophage 
phenotype was undertaken by Hamilton and colleagues (Hamilton 1993; Hamilton 2008). A 
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variety of groups have generated data using monocytes differentiated in vitro, via exposure to 
either M-CSF or GM-CSF (Hashimoto et al. 1999; Hamilton 2008). In vitro differentiation 
with M-CSF results in a macrophage phenotype close to that of M2 (Martinez et al. 2006). 
GM-CSF plays a role in the induction of a pro-inflammatory macrophage phenotype that 
resembles M1 polarisation, proficiently producing inflammatory cytokines such as TNFα and 
IL6, and being involved in tissue destruction (Martinez et al. 2006). 
 
In further murine studies, both M-CSF and GM-CSF have been shown to be important in 
plaque development. Smith et al studied ApoE
-/-
 mice crossbred with the osteopetrotic 
mutation of the M-CSF gene. These mice were fed a low-fat chow diet with the double 
mutants exhibiting significantly smaller proximal aortic lesions, at an earlier stage of 
progression and with fewer macrophages as compared with their control ApoE
-/-
 littermates 
(Smith et al. 1995). The production of GM-CSF from smooth muscle cells leads to the 
activation of monocytes during atherogenesis (Stojakovic et al. 2007). In another study using 
the hypercholesterolaemic ApoE
-/-
 mouse, animals on a high-fat diet were injected with doses 
of 10 µg/kg GM-CSF or G-CSF daily for 5 days on alternating weeks for a total of 20 doses 
during an 8 week period, finding that both G-CSF and GM-CSF treatment resulted in 
increased atherosclerotic lesion extent (Haghighat et al. 2007). LDLR-null mice have been 
employed in a study which combined 5-bromo-2‘-deoxyuridine pulse labelling with en face 
immunoconfocal microscopy to demonstrate that systemic injection of GM-CSF markedly 
increased intimal cell proliferation, whilst functional GM-CSF blockade inhibited 
proliferation (Zhu et al. 2009).  
 
In a key study, Waldo and colleagues examined human macrophages differentiated in vitro 
for 7 days with either M-CSF or GM-CSF (Waldo et al. 2008). They characterised gene 
expression, surface phenotype, cytokine production and lipid handling in these two 
macrophage groups. With regards to gene expression, they demonstrated differential 
expression of genes of inflammation (Table 1) and cholesterol homeostasis between the two 
groups, including that GM-CSF macrophages exhibited a ten-fold increased gene expression 
of PPARγ. M-CSF differentiated macrophages spontaneously accumulated cholesterol when 
incubated with unmodified low density lipoprotein (LDL), whilst GM-CSF differentiated 
macrophages took up similar levels only when exposed to protein kinase C. Macrophages 
differentiated with M-CSF were shown by immunofluoresence to express CD14 (CD68
+
 
CD14
+
), whilst GM-CSF differentiated macrophages were CD68
+
 CD14
-
. Interestingly, 
human coronary plaque samples were shown to contain predominantly CD68
+ 
CD14
+
 (Waldo 
et al. 2008). 
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1.5.6 Priming of Macrophages in the Atherosclerotic Plaque 
Macrophages are M1-primed by exposure to interferon (IFN)-γ (Mantovani et al. 2004). The 
key role of IFNγ (McLaren and Ramji 2009) has been confirmed in experimental 
atherosclerosis whereby ApoE
-/- IFNγ receptor-/- mice displayed a substantial reduction in 
lesion size compared to ApoE
-/-
 (Gupta et al. 1997). This reduction was manifest alongside a 
reduced level of macrophages and T lymphocytes within the lesions. Furthermore, murine 
cardiac allografts sited in IFNγ-/- recipients had reduced transplant atherosclerosis (Raisanen-
Sokolowski et al. 1998). 
 
Alternative M2 polarisation has originally been described as the result of exposure to 
interleukin (IL4) (Loke et al. 2002; Gordon and Taylor 2005; Martinez et al. 2006; Bouhlel et 
al. 2007). M2 macrophages have a notable role in catabasis, the process inflammation 
resolution which when fails results in progression of atherosclerosis (Tabas 2010). 
 
Wound healing macrophages, concerned primarily with tissue repair, are similar to the 
alternatively activated (M2) macrophages which have been described above. Wound healing 
macrophages establish their phenotype upon exposure to IL4 and/or IL13 from Th2 cells and 
granulocytes. IL4 is an early innate signal released during tissue injury, stimulating 
macrophage arginase to convert arginine to ornithine which is a step in extra-cellular matrix 
collagen production (Kreider et al. 2007). This ornithine is a precursor for polyamines which 
have an effect on cytokine production, affording wound healing macrophages regulatory 
capabilities (Cordeiro-da-Silva et al. 2004). 
 
Regulatory macrophages, with anti-inflammatory activity, are most reliably defined and 
identified through IL10 levels or IL10/IL12 ratio (as they also downregulate IL12 (Gerber and 
Mosser 2001)). These develop in response to a large number of stimuli, including IL10 
produced by regulatory T cells, TGFβ (Fadok et al. 1998), and glucocorticoids. The latter 
attenuate macrophage-mediated inflammation through inhibition of pro-inflammatory 
cytokine gene transcription (Sternberg 2006), nonetheless capacity for phagocytosis does not 
appear to be impaired by glucocorticoids (Liu et al. 1999). Unlike wound-healing 
macrophages, regulatory macrophages do not contribute to the production of extracellular 
matrix. 
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1.5.7 Macrophage Activation Pathways in Atherosclerosis 
Following the priming stage, activation of macrophages is reliant upon ligation of pattern 
recognition receptors (PRR) (Mackaness 1964; Gordon 2003), namely nucleotide-binding 
oligomerisation domain (NOD)-like receptors (NLRs) and TLRs. 
 
1.5.8 Toll-Like Receptor Signalling 
TLRs are the most well-characterised PRRs, of which at least ten have been identified in 
humans (Yan and Hansson 2007). TLRs may be found on the cell surface, as in the case of 
TLRs 1, 2, 4, 5 and 6, or reside intracellularly (Medzhitov et al. 1997; Medzhitov 2001). 
TLRs are key activators of monocytes and macrophages. 
 
Upon exposure to ligand, TLRs couple to signalling adaptors to induces two major 
downstream signalling pathways: the nuclear factor kappa B (NFκB) (Figure 6) and the 
interferon response factor (IRF) pathways. MyD88 is a universal adapter protein that carries 
signalling through all TLRs, except TLR3, leading to the activation of NFκB. MyD88-
dependent signalling relies on recruitment of Mal (MyD88-adaptor like), which leads to the 
recruitment of the IL1 receptor-associated kinase (IRAK). Phosphorylation of IRAK signals 
to tumour-necrosis-factor-receptor-associated factor 6 (TRAF6). The subsequent nuclear 
translocation of NFκB and translation of inflammatory cytokines is driven by phosphorylation 
of the IκB kinase (IKK) complex upon activation of TRAF6. MyD88-independent signalling 
is via TRAM (TRIF-related adaptor molecule) and TRIF (TIR-domain-containing adaptor 
protein inducing IFNβ), and can activate both NFκB and IRF, inducing interferon synthesis. 
The importance of IL1/TLR signalling in atherosclerosis has been further highlighted by work 
implicating IRAK4 kinase in modified LDL-medicated experimental atherosclerosis (Kim et 
al. 2011). 
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Figure 6 The interaction between TLR and inflammasome signalling 
The interaction between innate signalling, through TLRs, and inflammasome signalling in the 
transcription and translation of the pro-inflammatory cytokine IL1. Oxidised LDL is a ligand 
for TLR, resulting in IL1 RNA transcription. Inflammasomes (which may be activated by 
cholesterol crystals (Duewell et al. 2010)) initiate intracellular pathways which result in the 
post-translational modification and, ultimately the secretion of IL1 protein. Therefore, a 
connection between TLR and inflammasome pathways in the innate inflammatory process in 
atherosclerosis is alluded to. 
 
The most characterised recognition system is the one sensing LPS. Serum LPS-binding 
protein (LBP) transfers LPS to CD14, which delivers it to the co-receptor MD2 (Wright et al. 
1990; Tobias et al. 1993). The availability of all members of the complex dictates the 
sensitivity of recognition of endotoxin at extremely low concentrations. Cells that do not 
express CD14, such as endothelial cells, are relatively unresponsive compared to CD14
+
 
monocytes (Wright et al. 1990; Tobias et al. 1993). CD14 acts as a co-receptor (along with 
TLR4 and MD2) for the detection of bacterial LPS. CD14, however, can only bind LPS in the 
presence of LBP. TLR2 may also be activated via scavenger co-receptors, including CD36 
(Hoebe et al. 2005). 
 
1.5.9 Toll-Like Receptor Agonists 
Initially, ligands binding to PRRs such as TLRs on/in innate immune cells were believed to 
be of a pathogenic aetiology; molecules or small molecular motifs derived from, conserved 
within or associated with groups of microorganisms (such as bacterial LPS). These have been 
nominated pathogen associated molecular patterns (PAMPs). More recently, such ligands 
have been classified as danger associated molecular patterns (DAMPs) encompassing a wider 
definition which embodies the existence of endogenous danger signals. The concept that 
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oxidation reactions involving lipids, proteins and DNA produce non-microbial ‗oxidation-
specific epitopes‘ has emerged (Miller et al. 2011). Of particular interest is that host-derived 
oxidation-specific epitopes represent endogenous DAMPs, are recognised by PRRs and are 
capable of driving the inflammation seen in atherosclerosis (Miller et al. 2011). 
 
DAMPs that may bind TLRs are numerous, some of which have been proposed as 
endogenous culprits in atherosclerosis. Examples of endogenous ligands to TLR2 include 
necrotic cell products (Li et al. 2001), apolipoprotein CIII (Kawakami et al. 2008), serum 
amyloid A (Cheng et al. 2008), versican (Kim et al. 2009). Hyaluronan fragment (Scheibner 
et al. 2006), biglycan (Schaefer et al. 2005), oxLDL (Xu et al. 2001; Holvoet et al. 2006) and 
heat shock proteins (Asea et al. 2002) have been shown to act through both TLR2 and TLR4. 
Long surfactant protein A (Guillot et al. 2002), tenascin C (Midwood et al. 2009), fibrinogen 
(Smiley et al. 2001), fibronectin EDA (Okamura et al. 2001), heparan sulphate (Kodaira et al. 
2000), β-defensin 2 (Biragyn et al. 2002), amyloid β peptide (Stewart et al. 2010b) and 
minimally modified LDL (mmLDL) (Miller et al. 2005) act via TLR4 alone. TLR3 detects 
mRNA (Kariko et al. 2004; Cole et al. 2011), whilst TLR7 and TLR9 detect nucleic acid-
containing immune complexes (Leadbetter et al. 2002; Boule et al. 2004). TLRs 5, 6 and 8 are 
yet to have endogenous ligands allocated to them (Cole et al. 2010). 
 
Although both mmLDL and oxLDL are seen as ligands to TLR4, the pathways by which 
recognition occurs differ. The recognition of mmLDL is similar to that of LPS and involves 
CD14 and MD2 (Miller et al. 2003), whilst oxLDL initiates inflammatory responses through a 
TLR4/TLR6 heterodimer in association with CD36 but independently of CD14 (Stewart et al. 
2010a). A lipidic component of LDL, namely oxPAPC, has been shown as capable of 
inducing IL8 transcription via TLR4 in a manner which is independent of both CD14 and 
CD36 (Walton et al. 2003b). Further work, however, has seen oxPAPC inhibiting TLR4-
dependent IL8 induction, along with inhibition of E-selectin and CCL2, whilst IL1β and 
TNFα signalling remained unhindered (Walton et al. 2003a). 
 
1.5.10 Toll-Like Receptor Expression in Atherosclerosis 
TLRs are differentially expressed by the various cell types in atherosclerosis, with TLR2 and 
TLR4 found on monocytes, macrophages, foam cells and myeloid DCs, as well as smooth 
muscle cells and B lymphocytes (Cole et al. 2010). Human and mouse atherosclerosis is 
characterised by an increased expression of TLR1, TLR2 and TLR4 (and to some extent 
TLR5), mainly by macrophages and endothelial cells (Xu et al. 2001; Edfeldt et al. 2002). In 
mouse atherosclerosis, TLR4 expression is exclusively by macrophages (Xu et al. 2001). 
There has been shown to be co-localisation of p65 (an NFκB family member) with both TLR2 
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and TLR4 in macrophages in atherosclerosis (Edfeldt et al. 2002). This supports the role of 
TLRs not only in atherosclerotic lesion size, but also lesion stability. The differential 
expression of the various TLRs by monocyte subsets and macrophage subtypes remains 
largely unknown at present, however there is some data to support the relative transcription of 
TLR5 being higher in M2 polarised human macrophages as compared with M1 (Martinez et 
al. 2006). 
 
The circulating monocytes of ApoE
-/-
 mice with advanced atherosclerosis have increased 
TLR2 and TLR4 expression (Schoneveld et al. 2008). This is also the case for monocytes 
from patients with arterial disease when comparison is made with controls subjects (Methe et 
al. 2005; Geng et al. 2006; Shiraki et al. 2006; Kuwahata et al. 2009). Interestingly, enhanced 
TLR signalling is restricted to patients with acute coronary syndromes (Liuzzo et al. 2001a; 
Ashida et al. 2005; Versteeg et al. 2008).  
 
1.5.11 Role of Toll-Like Receptors in Atherosclerosis 
When recognising ligands, the majority of TLRs associate the signalling adaptor MyD88 to 
initiate an intracellular signalling cascade. MyD88 becomes engaged through the sensing of 
mmLDL in a TLR-dependent and TLR-independent manner (Miller et al. 2003; Bae et al. 
2009). Studies involving the MyD88 knockout mouse have shown that serum cholesterol 
levels are related to the activation of innate immune signalling pathways. More specifically, 
removing the MyD88 pathway led to a reduction in aortic atherosclerosis (by approximately 
60%) and a decrease in macrophage recruitment to the artery wall (by approximately 75%), 
associated with reduced chemokine levels (Bjorkbacka et al. 2004; Michelsen et al. 2004). In 
a functional human atherosclerosis study, a significant reduction of pro-inflammatory 
cytokines and MMPs was found after MyD88 inhibition (Monaco et al. 2009). 
 
The role of TLR2 and TLR4 has been extensively studied in models of atherosclerosis. The 
first indication of a role for TLR4 in atherosclerosis came from the finding that C3H/HeJ 
mice – that hold a missense mutation of TLR4‘s cytoplasmic component – are resistant to 
atherosclerosis (Ishida et al. 1991; Nishina et al. 1993). In accordance, specific deletion of 
TLR4 in ApoE
-/-
 mice resulted in a 24% reduction in whole aortic atherosclerotic lesion area 
and significantly attenuated macrophage infiltration within these lesions (Michelsen et al. 
2004). TLR2 deletion in LDLR
-/-
 mice limits lesion area by between a third and two-thirds 
(Michelsen et al. 2004; Mullick et al. 2005; Liu et al. 2008; Madan and Amar 2008), reducing 
intra-lesion inflammation as evidenced by a reduction in total infiltrating macrophage 
numbers (Liu et al. 2008; Madan and Amar 2008), and attenuates macrophage to smooth 
muscle cell ratio and extent of apoptosis (Madan and Amar 2008).  
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Both TLR2 and TLR4 are known to be important in post-vascular injury neo-intimal lesion 
formation (Vink et al. 2002; Schoneveld et al. 2005). In a hypercholesterolaemic rabbit model 
of atherosclerosis, carotid artery liposomal transfection of TLR2 and TLR4 cDNA revealed 
that upregulation of either TLR alone did not significantly affect carotid atherosclerosis. 
Interestingly, transfection of both TLR2 and TLR4 together resulted in a synergistic 
acceleration of atherosclerosis (Shinohara et al. 2007). 
 
A different picture came from bone marrow chimera studies. Bone marrow transplantation 
from TLR2
-/- 
to LDLR
-/-
 mice was unable to prevent diet-induced atherosclerotic lesions 
(Mullick et al. 2005). Bone marrow transfer from C3H/HeJ to ApoE knockouts did not alter 
atherosclerosis susceptibility (Shi et al. 2000). Synthetic TLR2 ligand administered 
dramatically increases atherosclerosis in LDLR
-/-
 mice, with TLR2 deficient bone marrow 
transfer into this model preventing TLR2 ligand-induced atheroma (Mullick et al. 2005). Such 
studies raise the question of whether TLR2 signalling in myeloid cells is relevant in 
atherosclerosis, as compared with TLR2 expression by cells resident in the arterial wall. 
Importantly, it supports the role of endogenous TLR2 ligand action on myeloid cells in 
atherosclerosis, with exogenous agonists activating TLR2 on cells of a non-myeloid lineage. 
 
Oxidised phospholipids, oxLDL, saturated fatty acids, and lipoprotein A triggered in vitro 
apoptosis in macrophages, under conditions of endoplasmic reticulum stress, via a mechanism 
requiring both CD36 and TLR2 (Seimon et al. 2010). Subsequent in vivo work with LDLR
-/-
 
mice transplanted with TLR2
-/-
 TLR4
-/- 
bone marrow revealed a reduction in both macrophage 
apoptosis and atherosclerotic plaque necrosis as compared with LDLR
-/-
 mice transplanted 
with wild-type
 
bone marrow, offering insight into the contribution of TLR signalling in 
advanced atherosclerosis (Seimon et al. 2010). 
 
Functional studies on human carotid endarterectomy specimens have shown sustained TLR2 
activation in cells isolated from human atheromata (Monaco et al. 2009). TLR2 and MyD88 
play a key role in NFκB activation, and in the production of inflammatory mediators CCL2, 
IL6, IL8, MMPs 1, 2, 3 and 9 (Monaco et al. 2009). Conversely TLR4, and its downstream 
signalling adaptor TRAM, were shown not to be rate-limiting for cytokine production in this 
context. This adds weight to the role of some (but not all) TLRs in plaque vulnerability. 
 
Recent work has elucidated a protective role for TLR3 in the vessel wall (Cole et al. 2011). In 
a perivascular collar induced injury mouse model, the double stranded RNA analogue 
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poly(I:C) reduced neointima formation in a TLR3-dependent manner, with an increase in 
atherosclerosis with TLR3 deficiency in the context of ApoE knockout (Cole et al. 2011). 
 
Importantly, TLR2, TLR4 and TLR9 ligands promote lipid uptake by macrophages and, 
hence, foam cell formation (Oiknine and Aviram 1992; Funk et al. 1993; Lee et al. 2008; Kim 
et al. 2009). Differentiated macrophages exhibit macropinocytosis (fluid phase uptake of 
lipids) which is dependent upon TLR4 (Choi et al. 2009). 
 
Furthermore, and as alluded to above, TLR ligation may influence atherosclerosis through 
alterations in MMP and TIMP expression. The effect of LPS on human blood monocytes has 
been investigated and MMP3 is upregulated (Bar-Or et al. 2003), whilst MMPs 1, 2, 7, 10 and 
14 and TIMPs 1, 2 and 3 are not upregulated by LPS (Welgus et al. 1990; Bar-Or et al. 2003). 
Controversially, two separate studies have found upregulation (Ardans et al. 2002) and no 
upregulation (Bar-Or et al. 2003) of MMP9 in human blood monocytes stimulated with LPS. 
In human macrophages (from various sites) meanwhile, MMPs 2, 3, 8, 9 and 14, and TIMP1 
have all been upregulated by LPS (Shapiro et al. 1990; Welgus et al. 1990; Saren et al. 1996; 
Fabunmi et al. 1998; Herman et al. 2001). 
 
1.5.12 NOD-Like Receptors and Inflammasomes and Atherogenesis 
NLRs are PRRs that sense intra-cellular microbial and non-microbial signals, in a similar 
fashion to the extra-cellular detection of these entities by most TLRs. NLRs have the capacity 
to form large cytoplasmic complexes known as ―inflammasomes‖ (Martinon et al. 2009) 
through the assembly of NLRs, caspase and apoptosis-associated speck-like protein 
containing a caspase recruitment domain (ASC). ASC acts to link the NLR and caspase, the 
latter of which are usually caspase 1 and 11 (Wang et al. 1998). The inflammasome acts as a 
scaffold for the activation of caspase 1 as its central effector molecule (Mariathasan and 
Monack 2007). Upon activation, inflammasome caspase 1 proteolytically activates pro-
inflammatory cytokines, notably the conversion of pro-IL1β and pro-IL18 to IL1β and IL18, 
respectively. 
 
It is largely agreed that inflammasome activation resulting in active IL1β release requires two 
separate signals (Burns et al. 2003). A priming signal may be triggered by TLR activation, 
with resultant NFκB production leading to pro-IL1β synthesis, as well as inflammasome 
components such as caspase 11 (Mariathasan and Monack 2007). Recognition of 
peptidoglycan by NOD1 and NOD2 can also trigger activation of NFκB signal transduction 
through Rip2 kinase (Yan and Hansson 2007). The second signal, which activates the caspase 
1 of a complete inflammasome, allowing the conversion of available pro-IL1β to IL1β 
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includes activation by ATP of the P2X7 purinergic receptor with potassium efflux. The second 
signal may also be achieved by PAMPs such as bacterial toxins and viral DNA, or other 
DAMPs including oxidative stress, large particles and ultraviolet light (Martinon et al. 2009). 
 
Inflammasomes have been described in a number of inflammatory conditions (Martinon et al. 
2009) and evidence for their role in atherosclerosis is emerging. The NLRP3 inflammasome is 
currently the most characterised inflammasome (Figure 6). Recent work has shown that 
cholesterol crystals activate the NLRP3 inflammasome, which in turn results in cleavage and 
secretion of IL1 family cytokines (Duewell et al. 2010). Furthermore, LDLR-deficient mice 
transplanted with NLRP3-deficient bone marrow and fed a high-cholesterol diet had markedly 
decreased early atherosclerosis and inflammasome-dependent IL18 levels (Duewell et al. 
2010). LDLR
-/-
 mice bone-marrow transplanted with ASC-deficient or IL-1α/β-deficient bone 
marrow and fed on a high-cholesterol diet had consistent and marked reductions in both 
atherosclerosis and IL18 production (Duewell et al. 2010). Furthermore, ASC deficiency also 
attenuates neointimal formation after vascular injury via reduced expression of IL1β and 
IL18, with ASC
-/-
 bone marrow chimeras also exhibiting significantly reduced neointimal 
formation (Yajima et al. 2008). These findings taken together suggest that crystalline 
cholesterol acts as an endogenous danger signal, its deposition in arteries being an early cause 
rather than a late consequence of inflammation.  
 
Both IL1 and IL18 signal through MyD88, and their absence in experimental mouse 
atherosclerosis also has the effect of limiting atherosclerosis development (Elhage et al. 2003; 
Kirii et al. 2003). Devlin et al showed that IL1ra knockout mice on a cholesterol/chocolate 
diet, exhibited a 3-fold decrease in non-high-density lipoprotein (HDL) cholesterol and a 
trend toward increased foam cell lesion area compared to controls (Devlin et al. 2002). 
Complementing this experiment they showed, conversely, that increased IL1ra expression 
(using an IL1ra transgenic/LDLR
-/-
 mouse on a cholesterol-saturated fat diet) resulted in a 
40% increase in non-HDL cholesterol levels. Thus concluding that under certain conditions, 
chronic IL1ra depletion or over-expression could have an important effect on lipid 
metabolism. 
 
This was also verified in human atherosclerotic arteries (Dewberry et al. 2000), although 
more recently, IL1ra administration has been shown to have lesser effect on inflammatory 
molecule production when compared to TLR inhibition in the context of human 
atherosclerosis (Monaco et al. 2009). 
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1.5.13 Macrophage Deactivation Pathways in Atherosclerosis 
PPARγ has recently been highlighted as an important determinant of macrophage phenotype 
and function (Figure 7), which may explain the favourable effect of PPARγ modulation in 
experimental atherosclerosis (Nakaya et al. 2009; Ishii et al.). PPARγ is a ligand-activated 
nuclear receptor involved in reverse cholesterol transport and other metabolic cellular 
activities (Gordon and Martinez 2010). Its anti-inflammatory properties occur through 
negative interference with nuclear factor κB (NFκB), signal transducer and activator of 
transcription (STAT), and activating protein 1 (AP1) pathways (Chinetti et al. 2000). PPARγ 
is strongly induced by IL4 (Bouhlel et al. 2007; Odegaard et al. 2007). PPARγ upregulation 
may also be stimulated by oxidised LDL, with PPARγ being highly expressed in the foam 
cells of atherosclerotic lesions, and ligand activation of PPARγ promoting oxidised LDL 
uptake and foam cell formation (Tontonoz et al. 1998). 
 
The functional relationship between PPARγ and the wound healing M2-type macrophage 
phenotype (Straus and Glass 2007; Heilbronn and Campbell 2008) has been proposed through 
the positive correlation between PPARγ expression levels and the M2 markers CD206 (Coste 
et al. 2003), CD36 scavenger receptor (Tontonoz et al. 1998), IL10 (Kim et al. 2005) and 
alternative activated macrophage associated CC-chemokine 1 (AMAC1; CCL18) (Bouhlel et 
al. 2007). Primary human monocytes differentiated in vitro with IL4 in the presence of 
PPARγ agonist (termed M2γ macrophages) resulted in increased CD206 and reduced CD163 
expression, above and beyond that which was seen with IL4 alone (Bouhlel et al. 2007) 
(Figure 7). M2γ culture supernatant exerted a greater anti-inflammatory effect on M1 
macrophages as compared with M2 culture supernatant (Bouhlel et al. 2007). Subsequent 
work has shown that M2γ macrophages have down-regulation of the nuclear liver x receptor α 
with resultant enhanced phagocytosis but reduced cholesterol handling (Chinetti-Gbaguidi et 
al. 2011). PPARγ also limits MMP9 through inhibition of NFκB activation (Hetzel et al. 
2003). 
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Figure 7 The influence of PPARγ on macrophage phenotype 
Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated nuclear receptor 
with potent anti-inflammatory properties that modulates the immune inflammatory response. 
It has been observed in human atherosclerotic lesions and is involved in macrophage 
cholesterol homeostasis, cellular differentiation, lipid storage, insulin modulation, 
macrophage lipid homeostasis and anti-inflammatory activities. Molecules such as oxidised 
low density lipoprotein (oxLDL) or fatty acids may stimulate inflammatory mediators such as 
9- and 13- hydroxyoctadecadienoic acid (HODE) generated via the 12,15 lipoxygenase 
pathway. These are ligands for PPARγ. IL4 is a cytokine that can stimulate PPARγ. PPARγ 
activation is also associated with the expression of M2 macrophage markers such as the 
mannose receptor (MR) also known as CD206 (Bouhlel et al. 2007). AMAC1, alternative 
activated macrophage associated CC-chemokine 1; AP1, activator protein 1; CD, cluster of 
differentiation; IL, interleukin; NFκB, nuclear factor kappa B; SR, scavenger receptor; STAT, 
signal transducer and activator of transcription. 
 
However, in the clinical arena, PPARγ agnonists have been shown to have complex and 
opposing effects on circulating levels of pro- and anti-inflammatory molecules (Marx et al. 
2003; Moulin et al. 2005; Glatz et al. 2010; Halvorsen et al. 2010). Furthermore, macrophages 
have been observed adhering to areas of intimal thickening in PPARγ-dependent manner 
(Fernandez 2008). 
 
Therefore, monocyte-macrophage dichotomy is affected by the macro- and micro-
environment, resulting in significant impact on the development and outcome of 
atherosclerotic disease. Rapid advances are occurring in the fields of atherosclerosis 
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inflammation and innate immunity, particularly the sensing of endogenous danger signals, 
foam cell generation, failure of egression, and the classical polarisation of leukocytes able to 
produce inflammatory mediators and matrix degrading enzymes. This work would benefit 
from being complemented by further research in the field of immunoregulation and adaptive 
immunity, with a clinical focus on dampening such host-detrimental responses. 
 
Inflammatory monocyte levels are elevated during hypercholesterolemia and are 
preferentially recruited to atherosclerotic plaques. During disease progression, alternative 
activation of macrophages induced by M2 stimuli may have a resolving effect on disease. 
Activation of the immune system by endogenous lipid components of a lesion are now 
considered to be mediated by stimulation of the TLR and inflammasome pathways. Lipids 
and inflammation have been highlighted as cooperating in macrophage behaviour in 
atherosclerosis. Oxidised LDL is seen to signal through TLR (Miller et al. 2003; Miller et al. 
2005; Stewart et al. 2010b), cholesterol crystals signalling through NLR (Duewell et al. 
2010), and oxPAPC signalling via NRF2 (Kadl et al. 2010). The convergence of these 
pathways gives rise to the activation of resident monocyte-macrophages leading to cytokine 
and chemokine production. Moreover, TLR activation might have a role in biasing 
macrophage polarisation towards an M1 phenotype, together with Th1 lymphocytes present in 
the plaque. These exciting new findings highlight a wealth of novel potential therapeutic and 
diagnostic targets that may be exploited in the future treatment of cardiovascular disease. 
 
1.6 IMAGING IN ATHEROSCLEROSIS 
Imaging of atherosclerotic cardiovascular disease has certainly evolved from the time when 
only advanced plaques could be observed. Prospects in current imaging of atherosclerosis 
include: early detection of disease; stratifying individuals in accordance with their risk of 
developing signs, symptoms or complications of atherosclerotic lesions; assessing outcomes 
of novel treatment; and furthering our understanding of atherosclerosis biology (Sanz and 
Fayad 2008). Of particular interest is cellular and molecular imaging. It is important to 
consider the distinction between actively and passively targeted imaging. 
 
It is noteworthy that with regards common imaging modalities, there is an inverse relationship 
between spatial resolution and sensitivity for contrast agent detection (Table 3) (Rudd et al. 
2009). 
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Imaging Modality Spatial Resolution 
Sensitivity for Contrast Agent 
Detection 
Contrast Enhanced Ultrasound (CEUS) < 1 mm single microbubble (1 – 10 µm) 
Computed Tomography (CT) < 1 mm > millimolar 
Magnetic Resonance Imaging (MRI) ~ 1 mm > micromolar 
Positron Emission Tomography (PET) ~ 3 mm < nanomolar 
Single Positron Emission Computed 
Tomography (SPECT) 
> 4 mm < nanomolar 
Table 3 The inverse relationship between the relative spatial resolution and 
sensitivity for contrast agent detection of common imaging techniques 
Modified from Inflammation Imaging in Atherosclerosis (Rudd et al. 2009). Ultrasound 
spatial resolution approximately 0.2 mm based upon a 7.3 MHz transducer for normal B-
mode. 
 
As can be seen from Table 3, none of the imaging techniques tend not to offer both high 
spatial resolution and contrast sensitivity. To overcome these limitations, there is the concept 
of integrated, hybrid or multimodal imaging, which combines multiple imaging modalities in 
a single platform and uses one machine for more than one type of imaging (Sanz and Fayad 
2008). A typical example of this is positron emission tomography / computed tomography 
(PET/CT), which harnesses the contrast sensitivity of PET for functional assessment and the 
spatial resolution of CT for structural and anatomical aspects. The acquired images are then 
overlaid, employing fixed points as landmarks for accurate positioning. An exception to this 
generalisation, however, is CEUS, which has both high spatial resolution and good contrast 
sensitivity, coupled with excellent temporal resolution so allowing for the undertaking of 
dynamic investigations. 
 
The features of an ideal imaging test, therefore, are: 
 Accuracy; 
 Reproducibility; and 
 Generalisability (also termed applicability or external validity) 
 
Molecular imaging has facilitated the development of platforms that can transport contrast 
agents to specific biological targets in atherosclerosis. ―Theranostics‖ is the concept that, in 
the future, molecular diagnostics may be coupled with therapeutic agents, such that 
therapeutic delivery and diagnosis is simultaneous, targeted and limited in systemic toxicity 
(Rudd et al. 2009). 
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1.7 SYSTEMS BIOLOGY – THE ‘-OMIC’ DISCIPLINES 
1.7.1 The Complex Biology of Atherosclerosis 
As described above in Section 1.4, atherosclerosis is a multi-stage entity characterised by the 
interaction between multiple biological processes. These centre upon inflammation, but also 
include: matrix degradation; angiogenesis; intra-plaque haemorrhage; oxidative stress; lipid 
metabolism; apoptosis; and autophagy (Narula and Strauss 2007). This being by no means an 
exhaustive list offers insight into the complexity (both within each process and between 
processes) of the biology of atherosclerosis development, its progression and the 
complications which can result from destabilisation of an atherosclerotic plaque. 
 
1.7.2 The Utility of Effective Atherosclerosis Research 
Effective atherosclerosis research has the facility to: elucidate the detail of the mechanisms 
responsible for atherosclerosis destabilisation; uncover targets for functional imaging to risk 
stratify atherosclerosis in terms of its likelihood to cause complications in a particular 
individual at a particular time (including the response to therapies initiated to lower risk); 
discover biomarkers or biomarker ‗patterns‘ for high risk atherosclerosis; and contribute to 
the development of targeted plaque stabilising therapies. Furthermore, as atherosclerosis is a 
systemic condition, affecting the arterial tree throughout the body, an understanding of the 
focal atherosclerosis in the one arterial territory is important as it may be relevant to our 
understanding of atherosclerosis in other arterial territories. 
 
Reflecting its share of the global burden of morbidity and mortality, the research of 
atherosclerosis has been increasing steadily over the past two decades (Figure 8). This was 
particularly the case since the late 1990s with the formal acknowledgement that 
atherosclerosis is an active process driven by inflammation (Ross 1999) – as opposed to the 
passive accumulation of lipid in an arterial wall. 
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Figure 8 The rise of atherosclerosis research 
A graph charting the year-on-year (non-cumulative) number of Pubmed indexed publications 
for the search term “atherosclerosis” in the two decades from 1990 to 2010. In 1990 there 
was just over 1,000 publications in a 12 month period, with approximately three times as 
many (2,771) in a twelve-year period in 2000, with a peak of 6,299 in 2010. Cumulatively, 
that represents 68,300 publications. 
 
With various campaigns relating to atherosclerosis and the rise in research has come 
heightened awareness and knowledge, but also an increase in expectation among both the 
public and the scientific community. Critically, assertions have been made as regards the 
challenge presented in the assimilation and interpretation of such data, particularly by 
practicing clinicians (Fraser and Dunstan 2010). One of the numerous reasons for the quantity 
of publications is the use of low throughput laboratory techniques by focal research groups 
working in isolation. This results in the duplication of process and, often, data and 
publications based upon small numbers of samples. Such an approach, however, is essential 
particularly for (but not exclusively in) the validation of findings and is often driven by a very 
narrow experimental hypothesis. In this sense, traditional laboratory methodologies are 
reductionist in philosophy, understanding the complex processes underlying atherosclerosis 
by deconstructing them into constituent components or pathways. 
 
1.7.3 A Systems Biology Approach 
Systems biology is a term which describes a holistic and integrative approach to the 
understanding of physiology and pathology. By adopting a stance which is opposing (yet 
complimentary) to conventional research techniques, it offers an overview and – in many 
cases – looks at the ‗net‘ biological effect imposed by a disease or non-disease state. To 
expand on this requires a reminder of the synthetic ‗workflow‘ of a cell (Figure 9). What is 
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shown is a simplification of a single pathway in a single cell of a particular cell type. In 
reality, there are multiple interacting pathways in multiple cells of different types, with 
microenvironmental conditions asserting alterations at multiple levels on multiple pathways. 
 
 
Figure 9 The synthetic ‘workflow’ of a cell 
A combination of extrinsic and intrinsic signals act to activate or inhibit transcription factors 
within a cell. These transcription factors modulate the generation of ribonucleic acid (RNA) 
from deoxyribonucleic acid (DNA). Messenger RNA (mRNA) locates to a ribosome where 
amino acids are assembled in accordance with the mRNA‟s code to produce proteins. During 
transcription, in addition to mRNA, mircoRNAs are generated (an average of 22 nucleotides 
in length) which can alter gene transcription. Once a protein is synthesised, it may be subject 
to post-translational modifications (such as phosphorylation, methylation or cleavage). Both 
modified and unmodified proteins are subject to metabolism, resulting in metabolites (a term 
usually reserved for molecules less than 1 kiloDalton in size). These biological entities may 
be found within different „compartments‟ of atherosclerotic environment: the cell nucleus; 
cytoplasm; extracellular matrix; and some components are released (passively or actively) 
into the bloodstream. 
 
1.7.4 The Variety of Disciplines which Constitute Systems Biology 
The ‗Omics‘ is the collective term for the disciplines which employ high-throughput 
techniques to provide an overview of a state or process ongoing in an organism by way of a 
‗top-down‘ approach (Figure 10). This includes (most commonly) the status of DNA, 
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transcription, translation, metabolism (Figure 11), although other disciplines are interested 
specifically in lipids (lipidomics) and carbohydrates (glycomics) to name but a couple. 
 
 
Figure 10 A ‘top-down’ approach to biology 
 
 
Component      Process  Major Discipline Scale (Techniques) Increasing Maturity Increasing Complexity 
    of Discipline of Discipline 
DNA  Genomics Small scale (PCR) 
       Gene expression / Transcription   
RNA  Transcriptomics Large scale (microarray) 
       Translation    Small scale (WB, IHC, ELISA) 
Protein  Proteomics Intermediate scale (MAP) 
       Metabolism   Large scale (MS) 
Metabolites  Metabolomics Large scale (NMR, MS) 
 
Figure 11 Summary of the key disciplines in systems biology 
It is noteworthy that the increasing complexity results from the incremental rise in the number 
of biological analytes when moving from DNA to metabolites. ELISA, enzyme-linked 
immunosorbent assay; IHC, immunohistochemistry; MAP, multi-analyte profiling; MS, mass 
spectrometry; NMR, nuclear magnetic resonance; PCR, polymerase chain reaction; WB, 
Western blotting. 
 
The investigation in the ‗omic‘ disciplines may be hypothesis-driven or non-hypothesis-
driven, the former being studies on small to intermediate scale and the later being a large 
scale examination of the genome, transcriptome, proteome or metabolome requiring complex 
(often multivariate) statistical analysis. The proteome also includes the secreted proteome, or 
‗secretome‘. The use of these techniques in surgical research is growing. 
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1.8 BIOMARKERS IN CAROTID ATHEROSCLEROSIS 
Biomarkers relate to different stages of disease development: screening biomarkers assess 
patients with no apparent disease; diagnostic biomarkers for those suspected of having 
disease; and prognostic biomarkers for individuals with overt disease (Gerszten and Wang 
2008). There are a number of diagnostic and prognostic biomarkers available, with the latter 
holding the possibility of use as surrogate endpoints in trials. 
 
Prevention of cardiovascular events will impact on public-health burden, but there are no 
widely accepted screening biomarkers as the value and appropriate use of proposed screening 
biomarkers remains a source of debate (Wilson 2004). Putative screening biomarkers may be 
classified according to the known roles of the molecules: inflammation (C-reactive protein, 
interleukin-6, lipoprotein-associated phospholipase A2); thombosis and haemostasis 
(fibrinogen, plasminogen-activator inhibitor 1); neurohormonal activation (renin, brain 
natriuretic peptide); insulin resistance (insulin, haemoglobin A1C); and endothelial 
dysfunction (homocysteine; urinary albumin) (Gerszten and Wang 2008). 
 
Looking at data from the well known Framingham Study, when ten biomarkers were 
combined into a ‗multimarker score‘, those with high scores had a twofold higher risk of 
major cardiovascular events and a fourfold higher risk of death than individuals with low 
scores (Wang et al. 2006). Despite this, compared to a risk score based upon conventional risk 
factors alone, the multimarker score was associated with a moderate increase in the receiver 
operating characteristic (ROC) area under the curve (AUC) (an objective assessment of a 
screening test‘s sensitivity and specificity) (Ware 2006). 
 
1.8.1 Lysozyme 
Carotid atheroma can be detected by duplex ultrasound but more sophisticated techniques, 
still under investigation, are required to assess plaque vulnerability. A simple blood test using 
a soluble biomarker of vascular atheroma would have considerable clinical utility and some 
possible advantages over other technically demanding and costly approaches. A proteomic 
study originally identified arterial plasma lysozyme as being a putative biomarker in coronary 
atherosclerosis and pilot study has detected elevated levels of plasma lysozyme in the arterial 
blood of patients with coronary artery disease (Abdul-Salam et al. 2010). As a constituent of 
macrophages (Unanue et al. 1976) it has biological plausibility as a marker of atheroma and a 
chapter in this thesis (Chapter 7) explores plasma lysozyme in patients with carotid 
atherosclerosis. 
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1.9 AIMS  
Stroke is a condition which is related to significant morbidity and mortality, and stroke 
prevention is a global priority. Ischaemic stroke related to the extracranial circulation 
comprises approximately 20% of all strokes. Of these, only 15% experience prior symptoms, 
with the remaining 85% considered asymptomatic before their stroke. It is the selection for 
preventative intervention of these asymptomatic individuals, with atherosclerotic stenosis at 
their carotid bifurcation that I would like to place as the focus of this research. I would like to 
explore in whom, how and why carotid atherosclerosis develops and changes from being a 
chronic pathology to an acute pathology. 
 
This work aims to: 
 
 Investigate the effectiveness of functional imaging techniques (PET / CT and 
microbubble contrast enhanced ultrasound) to probe carotid plaques for features, such 
as inflammation and intra-plaque neovascularisation, which have been implicated in 
plaque vulnerability; 
 Explore the differences in the molecular and cellular microenvironment between 
symptomatic and asymptomatic carotid atherosclerosis using histology and multi-
analyte profiling; 
 Determine the relationship between imaging signal and plaque biological features; 
 Understand the utility of systems biology research (transcriptomics, proteomics, 
lipidomics and metabolomics) in revealing differences between unstable and stable 
atherosclerosis; and 
 Look at putative biomarkers of atherosclerosis – lysozyme – in the context of carotid 
atherosclerosis and plaque vulnerability. 
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2 ASSESSMENT OF CAROTID 
ATHEROSCLEROSIS BY  
11C-PK11195 POSITRON 
EMISSION TOMOGRAPHY / 
COMPUTED TOMOGRAPHY 
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2.1 INTRODUCTION 
Different imaging techniques are currently under evaluation for detecting inflammatory cells 
in atherosclerotic plaques amongst which positron emission tomography (PET) has emerged 
as a promising modality due to its high sensitivity (Rudd et al. 2009). The 
11
C-labeled PET 
tracer PK11195 is a specific ligand of the translocator protein (18 kDa) (TSPO; Figure 12), 
formerly known as peripheral benzodiazepine receptor (PBR), a protein that is highly 
expressed in activated cells of the mononuclear phagocyte lineage (Veenman and Gavish 
2006). TSPO is expressed in large numbers on macrophages, in the range of 250,000 binding 
sites per cell (Zavala et al. 1984; Canat et al. 1993a). PK11195 is a PET ligand which binds 
with high affinity to the PBR (Jones et al. 2002), and has been used to detect 
neuroinflammation (Banati et al. 1999; Banati et al. 2000; James et al. 2006). 
 
Recently, specific in vitro binding of 
3
H-PK11195 to macrophages has been shown in human 
carotid endarterectomy samples (Fujimura et al. 2008b; Bird et al. 2010), with tritiated 
3
H-
PK11195 binding shown to parallel that of the pan-macrophage marker CD68 in intensity and 
distribution (Fujimura et al. 2008a). In an atherosclerosis mouse model, uptake of PK11195 to 
inflamed plaque is greater than uptake to non inflamed plaque (Laitinen et al. 2009). A pilot 
study in patients with large vessel vasculitis has demonstrated that 
11
C-PK11195 
PET/computed tomography angiography (PET/CTA) can be used to assess vascular 
inflammation in vivo in humans (Lamare et al. 2010; Pugliese et al. 2010). 
 
 
Figure 12 Schematic showing the TSPO location on the outer mitochondrial 
membrane of activated cells of the mononuclear lineage and downstream 
signalling 
ANT, adenine nucleotide translocator; IMM, inner mitochondrial membrane; OMM, outer 
mitochondrial membrane; PAP7, peripheral benzodiazepine receptor associated protein 7; 
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PRAX1, peripheral benzodiazepine receptor associated protein 1; scc, side chain cleavage; 
TSPO, translocator protein 18kDa; VDAC, voltage-dependent ion channel. 
 
By detecting TSPO, PK11195 PET/CT may represent a means to quantify intraplaque 
inflammation and assess the vulnerable atherosclerotic plaque in vivo. 
 
2.2 METHODS 
2.2.1 Study Approvals 
The study protocol received research ethics committee approval (09/H0707/2) and all patients 
gave written informed consent. Radiation exposure was licensed by the UK Administration of 
Radioactive Substances Advisory Committee (ARSAC; RPC 262-425 (24111)). 
 
2.2.2 Patients 
Twenty-three asymptomatic and 9 symptomatic patients with a carotid stenosis >50% 
(confirmed by duplex ultrasonography using velocity criteria) (Oates et al. 2009) were 
recruited from a vascular tertiary referral centre serving a hyper-acute stroke unit. 
Asymptomatic subjects were identified through screening carotid ultrasonography of patients 
with cardiovascular risk factors and/or arterial disease in other territories such as coronary or 
lower limb. Exclusion criteria were age less than 40 years or more than 85 years, 
contraindications to iodinated contrast agents (including known intolerance to contrast agents 
or a glomerular filtration rate <60 mL/min/1.73 m
2
) or a positive pregnancy test in women of 
child-bearing potential. Patients were defined as symptomatic if they had unilateral amaurosis 
fugax, clinical features consistent with a cortical TIA, or a completed hemispheric stroke in 
the carotid territory of interest in the preceding three months.  
 
2.2.3 11C-PK11195 Radiotracer Synthesis 
11
C-PK11195 was prepared according to a previously published protocol (Tomasi et al. 2008). 
11
C-methyl iodide was incubated with 1.0 mg of desmethyl-PK11195 (ABX, Radeberg, 
Germany) and 1.0 mg of powdered potassium hydroxide in 200 µl of dimethyl sulfoxide for 
1.5 min at 90°C. The crude product was purified on a semi-preparative Phenomenex Ultracarb 
7µ octadecylsilane (ODS) 250 x 10 mm column using 70% ethanol, 30% water as the high-
performance liquid chromatography (HPLC) solvent. After evaporation of the HPLC solvent, 
the purified product was formulated in 0.9% saline with 5% ethanol and filtered through a 
0.22 µm sterile filter. Measurement of concentration and radiochemical purity of 
11
C-
PK11195 batches was performed by HPLC using an analytical Luna C8 150 x 4.6 mm 
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column (Phenomenex), a UV detector set at 277 nm, and a radioactivity detector in series. 
Radiochemical purity was .99.5%. 
 
2.2.4 PET/CT Scanning Protocol 
Imaging was performed using a 16-slice PET/CT scanner (Discovery RX, GE Healthcare, 
Milwaukee, Wisconsin) with a 15 cm field of view. After acquisition of the localiser, a low-
dose CT scan was acquired in helical mode for attenuation correction with the following 
parameters: 
 
 120 kV 
 20 mAs 
 8 x 2.5 mm slice thickness 
 pitch of 1.675 
 0.5 s rotation time 
 
A line passing 2 cm below the carina was used as lower limit of the PET field of view, which 
thus encompassed the aortic arch, common carotid arteries, and carotid bifurcations. After 
injection of 6.85 MBq/kg of 
11
C-PK11195, PET emission data were acquired over 60 min in 
list mode format and rebinned into 18 temporal frames: 
 
 30 s background 
 1 x 15 s 
 1 x 5 s 
 1 x 10 s 
 1 x 30 s, 
 4 x 60 s 
 7 x 300 s 
 2 x 600 s 
 
After the PET scan, CT angiography was performed with the same field of view as the PET 
scan. A bolus of 70 ml of contrast (Ultravist 370, Schering, Berlin, Germany) was injected at 
a rate of 3.5 ml/s into an antecubital vein. A bolus tracking technique was used to synchronise 
the arrival of contrast in the ascending aorta with the CT angiography scan. The CT 
angiography acquisition parameters were: 
 
 120 kV 
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 180 mAs 
 16 x 0.625 mm slice thickness 
 pitch of 1.0 
 0.5 s rotation time 
 
Using these parameters, scan times for CT angiography were in the range of 12 to 16 s. The 
effective dose of CT (including localiser, attenuation correction, and CT angiography) was 
estimated from the product of the dose-length product and an organ-weighting factor for the 
chest (0.014 mSv x mGy
-1
 x cm
-1
) as proposed by the European Working Group for 
Guidelines on Quality Criteria in CT (Bongartz et al. 2004; Hausleiter et al. 2009). 
 
2.2.5 Image Reconstruction 
All PET emission scans were normalised and corrected for randoms, dead time, scatter and 
attenuation. Correction for radiotracer decay was deferred to the post-processing of the 
images. The 18 frames of the dynamic emission scans were reconstructed using the 3D re-
projection algorithm (3DRP) (Kinahan and Rogers 1989) (with the ramp and Colsher filters 
set to Nyquist frequency) and using an ordered subset expectation maximisation (OSEM) 
algorithm with 2 iterations and 21 subsets. The matrix size was 256 x 256 x 47 for both 
reconstructions. 
 
Reconstruction parameters for CT angiography were 0.625 mm slice thickness, 0.625 mm 
increment, 30 cm wide reconstruction field-of-view, window width of 300 Hounsfield units 
(HU) and window level of 30 HU. 
 
Images were transferred to a dedicated workstation (Advantage Workstation 4.2, GE 
Healthcare) for visual assessment. In case of misalignment between the CT and the PET 
datasets, images were manually re-aligned using the vertebrae and the sternum as anatomical 
landmarks. A 25 min static frame was created by addition of OSEM PET dynamic frames 5 
min after tracer injection. CT images were reduced to a matrix size of 256 x 256 x 47 to 
match the size of the reconstructed PET images, and superimposed to the PET images to help 
defining the regions of interest (ROI).  
 
2.2.6 Measurement of 11C-PK11195 Uptake 
Quantitative measurement of 
11
C-PK11195 uptake was performed using dedicated software 
(MATLAB, The MathWorks Inc.). After PET and CT images were resliced to obtain 
magnified cross-sections of the carotid artery, ROIs were placed on the CT images 
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encompassing the carotid plaque and superimposed on the PET images. To quantify plaque 
tracer uptake, standardised uptake values (SUV) were calculated as the average radioactivity 
concentration in each volume of interest (in Bq/mL) divided by total injected activity per 
body weight (in Bq/g). A background SUV was obtained in a venous structure (superior vena 
cava, subclavian or internal jugular vein) and plaque target-to-background ratios (TBR) were 
calculated as the ratio of plaque SUV over venous blood SUV (Kropholler et al. 2009). 
 
2.2.7 CT Assessment of Carotid Stenosis and Plaque Composition 
CT analysis was performed from axial source images and multiplanar reformations. The 
amount of plaque calcification (PC) was semi-quantitatively determined from carotid cross-
sections according to a previously reported scale:(Rominger et al. 2009) A score of 0 was 
assigned when PC was absent, 1 was assigned for small PCs covering <10% of the vessel 
circumference, 2 was assigned if the PC involved 10-25% of the vessel circumference, 3 if 
26-50%, and 4 if >50% of the vessel circumference were involved (Figure 13). 
 
 
Figure 13 Semiquantitative plaque calcification scoring system. 
A score of 0 was assigned when plaque calcification (PC) was absent, 1 for small PCs 
covering <10% of the vessel circumference, 2 if the PC involved 10-25% of the vessel 
circumference, 3 if 26-50%, and 4 if >50% of the vessel circumference were involved. 
 
Additionally, all plaque cross-sections were analyzed to identify areas of low attenuation at 
fixed window settings (width 700 HU, level 200 HU). In at least 5 planes, a circular or 
elliptical ROI (≥2mm2) was placed within the plaque, at sufficient distance from calcifications 
or areas contaminated with contrast material to avoid beam-hardening artefacts. CT 
attenuation was measured as the mean CT density (in HU) in the region of interest with the 
lowest attenuation. 
 
The severity of stenosis was determined according to the NASCET criteria (NASCET 1991). 
In brief, on cross-sections strictly perpendicular to the axis of the vessel, the minimal luminal 
diameter (MLD) was measured using an electronic calliper and compared to the reference 
Chapter 2 
 72 
diameter (RD) in a more distally located nondiseased segment. The degree of stenosis was 
calculated as (RD-MLD)/RD. 
 
2.2.8 Ex Vivo Plaque Processing 
Eight patients (5 asymptomatic, 3 symptomatic) underwent carotid endarterectomy within 
9±11 days of the PET/CT study. The diseased intimal arterial segments were immediately 
snap frozen in liquid nitrogen and stored at -80 °C for batch analysis. Frozen samples were 
embedded in optimum cutting temperature compound (TissueTek, Qiagen) and adjacent 12 
µm cryosections were used for autoradiography, immunohistochemistry and 
immunofluorescence. 
 
2.2.9 Autoradiography 
TSPOs were labelled with 
3
H-PK11195 (specific activity 86.4 Ci/mmol; 1 mCi/mL, 
PerkinElmer Inc) for autoradiography. Nonspecific binding was determined in the presence of 
excess nonradioactive PK11195 (1 μmol). Slides were apposed to 3H-sensitive film for 5 
months. Calibration standards were included in the cassette (
3
H-microscales 0 – 16 nCi/mg 
and 3 – 110 nCi/mg; GE Lifesciences, UK). Films were developed using an automatic film 
processor (Amersham Hyperprocessor, GE Lifesciences, UK) under safelight conditions. 
Quantitative analysis was performed using a computerised image-analysis system (MCID, 
Interfocus, Cambridge, UK). Optical density readings, corrected for background, were made 
and values standardised against the linear portion of a curve generated using 
3
H-microscale 
standards and expressed as nCi/mg. Specific binding values were determined by subtracting 
non-specific binding values from total binding values. 
 
2.2.10 Immunohistochemistry 
Tissue sections processed for immunohistochemistry were fixed in ice-cold 70% ethanol for 
10 min, followed by 10 min incubation in 0.3% H2O2 and 30 min incubation in 10% normal 
goat serum to block non-specific labelling. Adjacent tissue sections were thereafter incubated 
with primary antibodies raised against either TSPO (rabbit anti-TSPO, RnD Systems, 1:100) 
or CD68 (mouse anti-CD68, Dako, 1:100) overnight at 4C. Secondary labelling was 
performed using species-specific kits with horseradish peroxidase (HRP)-conjugated 
secondary antibodies (Envision) and incubation for 30 min at room temperature. The substrate 
of 3,3‘-diaminobenzidine (DAB; 0.7 mg/mL, Sigma) was used as a chromogen. Plaque 
sections were counterstained in hematoxylin, dehydrated and mounted in DPX mounting 
media (Merck). The slides were rinsed with phosphate buffered saline between each step 
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during the process. Images of TSPO and CD68 labelled tissue sections were captured using a 
Motic camera and software connected to a Nikon microscope.  
 
2.2.11 Confocal Fluorescence Microscopy 
Selected sections were double-labelled for TSPO and CD68 to evaluate co-expression. 
Following incubation with primary antibodies overnight at 4°C, the sections were incubated 
with fluorescence secondary antibodies (ALEXA546 anti-rabbit and ALEXA488 anti-mouse, 
Invitrogen, 1:1000) for 1 h at room temperature. Finally, the tissue sections were mounted in 
Vectashield mounting media with DAPI (Vector Labs). The fluorescent slides were imaged 
using a Nikon/Perkin-Elmer spinning disc confocal microscopy system. 
 
2.2.12 Statistical Analysis 
Statistical analysis was performed with SPSS 16.0.1 (SPSS, Inc, Chicago, Illinois). 
Continuous variables are expressed as mean ± standard deviation (SD) or median (with range) 
where appropriate. Categorical variables are expressed as frequencies (percentages). The 
Mann Whitney test was used for comparison of continuous values and the χ square or Fisher‘s 
exact test for comparison of categorical data. Agreement between CTA and Duplex 
ultrasound for the measurement of stenosis severity was determined with linear correlation 
and Bland-Altman limits of agreement (Bland and Altman 1986). Receiver operating 
characteristics (ROC) analysis was used to determine optimal cut-offs for CTA and PET 
derived parameters to predict ischemic events and their respective diagnostic accuracies. 
Pearson‘s method was used to assess the correlation between 11C-PK11195 PET TBR and 3H-
PK11195 plaque autoradiography. Binary logistic regression was employed to determine the 
association of CTA and PET derived parameters with the occurrence of ischemic events. A p 
value < 0.05 was considered statistically significant. 
 
2.3 RESULTS 
2.3.1 Patients 
Thirty-four patients were enrolled in the study and 32 successfully underwent the PET/CTA 
scan (9 symptomatic and 23 asymptomatic patients). In 2 patients the scans were unsuccessful 
due to failed tracer production (n=1) or technical problems (n=1). The patient baseline 
characteristics are shown in Table 4. In the symptomatic group the index cerebrovascular 
events were amaurosis fugax (n=4), hemispheric TIA (n=4), and hemispheric stroke (n=1). 
The interval between index event and PET/CTA scan was 20 ± 21 days (range 5 to 75 days). 
Effective radiation dose was 3.2 ± 1.2 mSv and 2.1 ± 0.5 mSv for CTA and PET respectively, 
and 5.3 ± 1.7 mSv for the combined PET/CTA study. 
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All patients 
(n=32) 
Symptomatic 
(n=9) 
Asymptomatic 
(n=23) 
P 
Value 
Age, years 70±9 68±6 70±10 0.57 
Female gender (%) 11 (34%) 4 (44%) 7 (30%) 0.68 
Body mass index (kg/m
2
) 26.1±4.5 24.1±3.7 26.8±4.6 0.22 
Previous history of stroke or 
transient ischaemic attack 
(%) 
17 (53%) 9 (100%) 8 (35%) 0.001 
Carotid endarterectomy (%) 8 (25%) 3 (33%) 5 (22%) 0.65 
Cardiovascular risk factors (%) 
 Smoking 21 (66%) 6 (67%) 15 (65%) >0.99 
 Arterial hypertension 22 (69%) 5 (56%) 17 (74%) 0.41 
 Dyslipidemia 23 (72%) 7 (78%) 16 (70%) >0.99 
 Diabetes mellitus 7 (22%) 2 (22%) 5 (22%) >0.99 
 Positive family history 11 (34%) 2 (22%) 9 (39%) 0.44 
Pharmacotherapy (%) 
 Aspirin 25 (78%) 7 (78%) 18 (78%) >0.99 
 Statin 31 (97%) 8 (89%) 23 (100%) 0.28 
 
Angiotensin converting 
enzyme inhibitors / 
angiotensin II receptor 
blocker 
14 (44%) 4 (44%) 10 (43%) >0.99 
 Beta-receptor antagonists 8 (25%) 2 (22%) 6 (26%) >0.99 
 Calcium channel blocker 11 (34%) 1 (11%) 10 (43%) 0.11 
Table 4 Characteristics of the symptomatic and asymptomatic patient groups 
There were no statistically significant differences in the demographic cardiovascular risk 
factors or pharmacotherapeutic parameters when comparing patients with symptomatic to 
those with asymptomatic carotid stenosis. Data are given as mean ± standard deviations 
unless otherwise indicated. 
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2.3.2 PET/CTA Imaging 
A total of 36 carotid stenoses were available for image analysis (4 asymptomatic subjects had 
bilateral stenoses). There was no significant difference in the severity of carotid stenoses on 
CT angiography between symptomatic and asymptomatic patients (77±16% versus 68±16%, 
p=ns) (Table 5). An excellent agreement was found between CTA- and ultrasound-derived 
stenosis severity (r=0.93, P<0.001; limits of agreement -15% to 10%) with only a slight 
underestimation with CTA by 3% compared to ultrasound. 
 
 All stenoses 
 
(n=36) 
Symptomatic 
stenoses 
(n=9) 
Asymptomatic 
stenoses 
(n=27) 
P 
Value 
Carotid stenosis by duplex 
ultrasonography (%) 
70±17 77±16 68±16 ns 
Plaque standardised uptake 
value for 
11
C-PK11195 
0.62±0.10 0.69±0.08 0.60±0.10 0.02 
Plaque target-to-background 
for 
11
C-PK11195 
0.91±0.16 1.06±0.20 0.86±0.11 0.008 
CT plaque attenuation 76±44 46±31 86±44 0.008 
Plaque calcification score  2.4±1.3 2.6±1.7 2.4±1.2 0.61 
Table 5 
11
C-PK11195 PET / CT imaging results 
 
11
C-PK11195 SUV and TBR were higher in the carotid plaques of symptomatic compared to 
asymptomatic patients (Table 5) (Figure 14, Figure 15, Figure 16, Figure 17). No differences 
were noted for SUV values in venous blood (0.66±0.10 versus 0.70±0.09, p=ns). On CTA the 
mean PC score was comparable in both patient groups (Table 5). However, carotid plaques of 
symptomatic patients had areas of lower attenuation compared to asymptomatic plaques 
(46±31 versus 86±44 HU, p=0.008). There was no significant correlation between 
11
C-
PK11195 TBR and either CT plaque attenuation (r=-0.11, p=0.54) or PC score (r=0.23, 
p=0.89). Figure 17 shows the distribution of 
11
C-PK11195 TBR and CT plaque attenuation 
amongst symptomatic and asymptomatic patients. 
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Figure 14 
11
C-PK11195 PET / CT imaging of an asymptomatic carotid atheroma 
11
C-PK11195 PET/CT axial (A, D and G), coronal (B, E and H) and saggital (C, F and I) 
images, respectively, of an 81 year old female patient with a 50% right-sided internal carotid 
artery stenosis. Anatomy is demonstrated by CT angiography (A, B and C), ligand uptake by 
PET (D, E and F), with these merged (G, H and I). No uptake is seen in at the right carotid 
bifurcation (white arrow). 
 
 
Figure 15 
11
C-PK11195 PET / CT imaging of symptomatic carotid atherosclerosis 
CT angiography (A), 
11
C-PK11195 PET (B) and PET/CT fusion (C) in a 52 year old patient 
with right amaurosis fugax 2 weeks prior to the PET/CT scan. The white arrows denote a 
focal area of 
11
C-PK11195 uptake at the carotid bifurcation. 
 
A B C 
D E F 
G H I 
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Figure 16 
11
C-PK11195 PET / CT imaging of a symptomatic carotid atheroma – 
close-up 
Magnified saggital images of the left carotid bifurcation of a 66 year old male with a 90% 
stenosis. A. Computed tomography angiography revealing the stenosis (white arrows). B. 
PET image showing increased uptake (white arrows). C. Merged images locating the 
increased uptake to the area of stenosing plaque (white arrows). 
 
 
Figure 17 Quantification 
11
C-PK11195 PET / CT imaging parameters 
Distribution of 
11
C-PK11195 TBR (A) and CT plaque attenuation (B) values in symptomatic 
and asymptomatic plaques. Each box plot shows median (thick lines), quartiles (upper and 
lower box boundaries), and extreme values (whiskers) within a category. 
A B C 
A B 
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Features associated with the presence of cerebrovascular events on logistic regression analysis 
were: 
11
C-PK11195 TBR (p=0.01) and CT plaque attenuation (p=0.04) (Figure 18). ROC 
analysis revealed an optimal cut-off to discriminate between symptomatic and asymptomatic 
patients at 0.92 for 
11
C-PK11195 TBR and at 40 HU for CT plaque attenuation. Sensitivity, 
specificity, negative and positive predictive values for TBR, CT plaque attenuation, one 
feature positive, and two features positive plaques are shown in Figure 19. 
 
 
Figure 18 Axial co-registration of 
11
C-PK11195 PET and CT images 
CT angiography and co-registered PET/CT cross-sections at 3 mm intervals illustrate 
differences in plaque composition and 
11
C-PK11195 uptake on PET/CT among symptomatic 
(Patient A) and asymptomatic (Patient B) patients. In patient A, areas of low attenuation 
(23.5 HU) can be seen (white arrows, first column) in close vicinity with foci of increased 
11
C-PK11195 uptake (block arrows, second column). In contrast, in patient B, plaque CT 
attenuation was higher (76.2) indicating a predominance of fibrotic tissue (column 3), and no 
11
C-PK11195 uptake was noted (column 4). 
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Figure 19 Discriminatory value of carotid plaque 
11
C-PK11195 PET / CT 
Sensitivity (Sens), specificity (Spec), negative (NPV) and positive predictive value (PPV) to 
identify patients with cerebrovascular events. 
 
2.3.3 Ex Vivo Analysis 
Autoradiography, immunohistochemistry and immunofluorescence. Mean 
3
H-PK11195 
specific binding on autoradiography was 60.6±16.0%, with no significant difference between 
plaque sections from symptomatic (n=3) or asymptomatic (n=5) patients. 
 
TSPO
+
 and CD68
+
 cells were observed in all tissue specimens, and both markers were seen in 
corresponding areas on adjacent plaque sections (Figure 20 C-F). TSPO expression by 
macrophages was confirmed by double immunofluorescence and confocal microscopy 
(Figure 20 G-J). There was no significant difference in the presence of TSPO
+
 CD68
+
 cells 
between the symptomatic or asymptomatic group. TSPO
+
 and CD68
+
 cells were located in 
areas of high 
3
H-PK11195 specific binding on autoradiography (Figure 20 A-F). 
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Figure 20 
3
H-PK11195 autoradiography, CD68 and TSPO immunohistochemistry 
and double immunofluorescence confocal microscopy 
Representative autoradiography, immunohistochemistry and immunofluorescence microscopy 
results in endarterectomy samples. 
3
H-PK11195 total binding to atherosclerotic plaques in 
vitro (A). The non-specific binding of 
3
H-PK11195 was assessed by blockage with excess 
unlabelled PK11195 (B). Tissue sections were immunohistochemically labelled for 
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macrophages (CD68; C) and TSPO (D). The arrows in C and D show the location of the area 
captured at higher magnification in E and F, respectively. Areas with high specific binding of 
3
H-PK11195 had a high density of TSPO+ and CD68+ cells (arrows in A, C and D). Double 
immunofluorescence labelling and spinning disc confocal microscopy for DAPI (G, blue); 
CD68 (H, green) and TSPO (I, red) confirms expression of TSPO by macrophages in carotid 
atherosclerosis (J, merged, white arrowheads). Scale bars: C and D 800 μm; E and F 40 μm; 
G, H, I and J 20 μm. 
 
TBR on 
11
C-PK11195 PET significantly correlated with specific binding by 
3
H-PK11195 
autoradiography (r=0.77, p=0.025) (Figure 21). 
 
 
Figure 21 In vivo and in vitro PK11195 
Correlation of in vivo 
11
C-PK11195 target-to-background ratio with average ex vivo plaque 
PBR density (measured as average 
3
H-PK11195 specific binding). 
 
2.4 DISCUSSION 
It has been demonstrated that 
11
C-PK11195 PET allows the noninvasive detection and 
quantification of intraplaque inflammation in patients with carotid stenoses. Moreover, the 
combination of 
11
C-PK11195 PET with contrast-enhanced CTA provides an integrated 
assessment of plaque structure, composition and biological activity and allows the distinction 
between recently symptomatic vulnerable plaques and asymptomatic plaques with a high 
positive predictive value. Focal 
11
C-PK11195 uptake did not correlate with either the presence 
of low attenuation plaques or the PC score. This is in line with prior reports obtained with 
18
F-
fluorodeoxyglucose (FDG) PET/CT (Ben-Haim et al. 2004) and indicates that information 
obtained with these two modalities is complementary and enhances the diagnostic 
performance of the hybrid technique to detect potentially vulnerable plaques. The absence of 
either increased 
11
C-PK11195 TBR >0.92 or low CT attenuation areas <40 HU was associated 
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with asymptomatic plaques, whereas all plaques positive for both features were found in 
patients with an ipsilateral event. 
 
TSPOs were discovered in the 1970‘s as benzodiazepine binding sites outside the central 
nervous system (Braestrup and Squires 1977). Subsequent studies have shown a high TSPO 
density in circulating human phagocyte populations, particularly in monocytes and 
polymorphonuclear neutrophils, with up to 750,000 binding sites per cell (Canat et al. 1993a). 
TSPO expression is higher in mature monocytic cell lines compared to promonocytic or 
promyelocytic lines and its density increases by a factor of 2 to 3 after in vitro monocyte 
activation with IFNγ or phorbol 12-myristate 13-acetate. Stimulated human monocytes can 
express more than 2,000,000 binding sites for PK11195 and this increase is paralleled by an 
enhanced expression in CD11a and CD11b surface antigens and augmented production of 
IL1, IL8, and TNF, indicating that TSPO over-expression is a marker of activated phagocytes 
(Canat et al. 1993b). PK11195 is a selective TSPO ligand which binds specifically to 
macrophages in specimens of human carotid atherosclerotic plaque (Fujimura et al. 2008b; 
Bird et al. 2010). 
11
C-PK11195 PET/CTA has been shown to allow in vivo detection and 
quantification of vascular inflammation in patients with large vessel vasculitides and can 
distinguish symptomatic from asymptomatic patients in the context of vasculitis (Pugliese et 
al. 2010). 
 
The present study builds on these existing data and further extends the use of 
11
C-PK11195 
PET/CTA imaging onto patients with atherosclerotic disease. These results, if confirmed by 
larger prospective studies, would suggest that 
11
C-PK11195 PET/CTA may be used in 
asymptomatic patients with carotid stenoses to improve their risk stratification and allow 
clinicians to identify patients at risk for ischemic cerebrovascular events. 
 
The PET tracer FDG, a biological glucose analogue, has been extensively evaluated for 
measuring intraplaque inflammation in atherosclerotic lesions (Rudd et al. 2002; Tawakol et 
al. 2006). However, since FDG is taken up by any metabolically active tissue, concerns have 
been raised about the specificity of this tracer for imaging inflammatory cells. Indeed, micro-
autoradiography studies in aortic sections of ApoE
-/-
 mice have shown that 
14
C-FDG uptake 
correlates poorly with fat content and selective macrophage staining with anti-CD68 (Matter 
et al. 2006). Davies and colleagues reported that in vivo FDG microPET SUV in 
atherosclerotic lesions of rabbit aorta were not correlated with macrophage density (r=0.16, 
p=0.57) and there was no significant difference in FDG uptake seen between rabbits with 
highly inflamed aortic walls, those with low levels of inflammation or controls (Davies et al. 
2010b). Conversely, a high degree of specific binding to macrophages of atherosclerotic 
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plaques has been observed with 
3
H-PK11195 in autoradiographic studies which is confirmed 
by the ex vivo results of the present study (Fujimura et al. 2008b). However, no definite 
conclusion on the relative specificity of the aforementioned tracers can be drawn until a direct 
head-to-head comparison is performed. 
 
One of the strengths of this work compared to prior PET/CT studies (Rudd et al. 2007; Rudd 
et al. 2008) was the use of contrast-enhanced CTA with a high-end CT device. This facilitated 
delineation of the atherosclerotic plaque thereby improving co-registration with the PET 
signal, and allowed concurrent evaluation of plaque composition. Measurement of CT 
attenuation within carotid plaques has been shown to identify lipid-rich cores, fibrous tissue 
and areas of calcifications on histology (de Weert et al. 2006). The presence of low 
attenuation plaques has previously been identified as an important predictor for plaque rupture 
and thrombotic events in the coronary vasculature (Motoyama et al. 2009). In this work, a cut-
off at 40 HU was identified to provide the best statistical discrimination between symptomatic 
and asymptomatic plaques, indicating that the presence of lipid-rich areas was a significant 
determinant of plaque vulnerability. A similar cut-off (30 HU) has been found to be a good 
discriminator between rupture-prone and stable plaques in the coronary circulation 
(Motoyama et al. 2009). PCs were not associated with ischemic events in this study, which is 
contrary to prior reports where calcified plaques were up to 21 times less likely to be 
symptomatic (Nandalur et al. 2005). 
 
2.4.1 Clinical Implications 
The management of carotid atherosclerotic disease includes risk factor modification, medical 
treatment, carotid endarterectomy, and recently also percutaneous transluminal angioplasty 
and stenting. The choice of intervention is tailored based upon the individual‘s risk of 
suffering an ischemic cerebrovascular event. Whereas carotid endarterectomy has been 
demonstrated to improve prognosis in symptomatic patients, its role is less clearly established 
in asymptomatic patients where the potential benefit has to be weighed against the risk of 
perioperative mortality and morbidity (Biller et al. 1998). To date, the decision to perform 
CEA in asymptomatic patients has been largely based upon the severity of the stenosis. 
Nonetheless, significant proportion of plaque ruptures occur in stenoses of low and 
intermediate severity (Falk et al. 1995; Topol and Nissen 1995; Nicolaides et al. 2005). 
Recently, other plaque features such as plaque composition, morphology and biological 
activity have been proposed as important determinants of the risk of rupture, calling for 
effective imaging techniques with the potential to identify vulnerable plaque characteristics 
(Naghavi et al. 2003). 
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11
C-PK11195 PET/CT may facilitate the monitoring of response to plaque stabilising 
therapeutic agents, identifying those individuals whose plaques may not be safely managed by 
pharmacotherapeutics alone. It is noteworthy; however, that macrophage activation was 
evident, detectable and significantly different between symptomatic and asymptomatic groups 
despite the patients studied being on best medical therapy, including a statin in 97% of 
individuals. 
 
2.4.2 Limitations 
This work is a proof of principle study. The relatively small number of patients is therefore 
acknowledged. This precluded the use of multivariate models to test for independent 
characteristics associated with ischemic events and warrants larger prospective trials to 
confirm these findings. The fact that more asymptomatic than symptomatic individuals were 
scanned was related to the logistic challenge posed by the imaging facility being located at a 
site different to the hyperacute stroke and vascular units – Hammersmith Hospital and 
Charing Cross Hospital, respectively. It was difficult to transport patients who had suffered 
disabling strokes, particularly in the narrow time window between symptoms and carotid 
endarterectomy practiced by our unit, and that notice was necessary to book the PET/CT 
scanner and produce the radiopharmaceutical. 
 
The proximity of the blood pool and limited thickness of the arterial wall can result in 
spillover and partial volume effects. However, this should affect asymptomatic and 
symptomatic patients to the same extent, and is unlikely to account for any of the differences 
observed between the two groups. Additionally, care was taken to restrict the ROIs to the 
plaque and avoid the residual vessel lumen. Correction for spillover and the quantification of 
receptor kinetics should overcome these potentially confounding factors and further 
quantitative studies are indicated. 
 
The short physical half-life of 
11
C-labeled compounds mandates an onsite cyclotron facility, 
thus limiting its clinical applicability. However, the introduction of new 
18
F-labeled TSPO 
ligands, which are currently under pre-clinical investigation and have shown high affinity 
across species in the brain, may overcome some of these limitations (Briard et al. 2009). 
 
Finally, the added radiation exposure from PET and CT remains an important concern, 
particularly if repeated studies are performed to assess inflammatory activity before and after 
treatment. The total effective radiation dose in the patients in this study was well below 10 
mSv, which is comparable to a standard cardiac FDG scan (Einstein et al. 2007). 
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2.4.3 Conclusions 
Imaging intraplaque inflammation in vivo with 
11
C-PK11195 and PET combined with 
contrast-enhanced CT angiography is feasible and can distinguish between recently 
symptomatic and asymptomatic plaques. The information obtained from both modalities is 
complementary and allows a comprehensive assessment of plaque composition and 
inflammatory activity. Plaques with low CT attenuation and increased 
11
C-PK11195 uptake 
seem to be those at highest risk of thromboembolic events.  
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3.1 INTRODUCTION TO CONTRAST ENHANCED ULTRASOUND IN 
CAROTID ARTERIAL DISEASE 
3.1.1 Microbubbles, Non-Linear Behaviour and Mechanical Index 
Microbubble-based contrast agents are injected intravenously to enhance ultrasound scans, 
and are comprised of 1 to 10 µm diameter albumin or lipid shells filled with air or high 
molecular weight gas. Their small size allows them to recirculate, whereas larger bubbles are 
retained in the pulmonary circulation.  
 
The discovery that gas filled bubbles can act as ultrasound contrast agents was initially made 
because the density change from blood to intrabubble gas causes reflection of sound waves, 
just as the density change from air to cliff-face creates an audible ―echo‖. However, modern 
ultrasonic methods of distinguishing microbubble from native tissue rely on the fact that 
ultrasound waves cause microbubbles to compress and expand, whereas tissue is virtually 
incompressible (Cosgrove 2006). By fortunate coincidence, the resonance frequency for 
microbubbles (the frequency at which compression and expansion occurs most readily) is 
within the range of frequencies used for clinical ultrasound. Sound waves of very low energy, 
therefore, will return detectable signal from microbubbles, provided the transmitted wave is 
around the microbubble resonance frequency. Native tissue, however, will not respond to 
such low energy waves. 
 
When exposed to ultrasound, microbubbles behave in a highly non-linear fashion, i.e. they 
respond differently to different portions of the incident acoustic wave. A typical acoustic 
wave generated by a diagnostic ultrasound scanner is made of a few cycles of a sinusoidal 
wave at a centre frequency of 1 to 10 MHz. Positive pressure compresses a microbubble, 
while negative pressure dilates it. When a microbubble expands while exposed to negative 
pressures, its radius can increase by as much as several hundred percent. On the other hand, as 
a microbubble contracts in response to positive pressures, the decrease in its radius is limited 
due to the gas inside the microbubble rapidly stiffening, making it less compressible. As a 
result, when a microbubble is exposed to ultrasound, its radius oscillates in a non-symmetric 
fashion: the microbubble behaves non-linearly. 
 
The mechanical index (MI) is defined as the peak rarefactional pressure (negative pressure) 
divided by the square root of the ultrasound frequency. It can also be defined as the peak 
rarefactional pressure multiplied by the square root of the ultrasound period. Typical MI used 
for conventional B-mode imaging is high enough to destroy most microbubbles (Villarraga et 
al. 1997; Walker et al. 1997). Triggered imaging techniques have been used in radiology to 
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image flow in the parenchyma of abdominal organs (Heckemann et al. 2000; Kim et al. 2000; 
Wilson et al. 2000). With the more recent development of non-linear imaging techniques 
which take advantage of the highly non-linear behavior of the microbubbles, it is now 
possible to image ultrasound contrast agents non-destructively in real time. Real-time low 
mechanical index (MI < 0.1) harmonic imaging is currently the preferred imaging mode in 
radiological applications of contrast-enhanced ultrasound. Another benefit of imaging 
ultrasound contrast agent at a low MI is that it prevents non-linear propagation in tissue from 
occurring, thereby increasing the contrast-to-tissue ratio when a harmonic imaging technique 
is used. 
 
Unlike most contrast agents used for computed tomography (CT) and magnetic resonance 
imaging (MRI), microbubbles remain within the vascular space and are hence well suited to 
study the vasculature. By improving visualisation of the lumen, contrast enhanced ultrasound 
(CEUS) can improve current carotid structural scans. Furthermore, CEUS may be able to add 
extra information on plaque characteristics, such as neovascularisation, deemed to elucidate 
plaque instability. In addition, manufacturing microbubbles targeted to specific vascular 
endothelial ligands, CEUS may have the ability to probe plaque biology. 
 
Unlike most contrast agents used for computed tomography (CT) and magnetic resonance 
imaging (MRI), microbubbles remain within the vascular space and can hence be used to 
study the vasculature. By improving visualisation of the lumen, contrast enhanced ultrasound 
(CEUS) can improve current carotid structural scans. Furthermore, CEUS may be able to add 
extra information on plaque characteristics, such as neovascularisation, deemed to elucidate 
plaque instability. In addition, manufacturing microbubbles targeted to specific vascular 
endothelial ligands, CEUS may have the ability to probe plaque biology. 
 
3.1.2 The Current Carotid Ultrasound Examination 
With the publication of the results of the European Carotid Surgery Trial (ECST) (ECST 
1991) and the North American Symptomatic Carotid Endarterectomy Trial (NASCET) 
(NASCET 1991), the importance of accurate assessment of the degree of internal carotid 
artery diameter reduction has been highlighted. There has been extensive work undertaken in 
the generation of reliable and reproducible criteria for the calculation of internal carotid artery 
stenosis using unenhanced duplex ultrasonography. This is based on largely velocity criteria, 
is standardised and been used in the creation of national and international society consensus 
documents (Nicolaides et al. 1996; Sidhu and Allan 1997; Filis et al. 2002; Grant et al. 2003; 
Oates et al. 2009). Duplex ultrasonography is likely to remain the first line imaging modality 
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in this context (Sidhu and Allan 1997); as such, much work has been undertaken in its 
refinement. 
 
3.1.3 The Need to Improve the Current Ultrasound Assessment 
Traditionally, stroke risk stratification has revolved around the degree of internal carotid 
artery luminal narrowing, and the presence of recent focal neurological symptoms pertaining 
to the ipsilateral cerebral hemisphere. However, it has become apparent that the degree of 
stenosis alone is a relatively poor predictor of future stroke in asymptomatic patients. Indeed, 
the Asymptomatic Carotid Surgery Trial (ACST) (Halliday et al. 2004; Halliday et al. 2010), 
Asymptomatic Catrotid Atherosclerosis Study (ACAS) (ACAS 1995), and the results of a 
recent Cochrane Review on the subject (Chambers and Donnan 2005) highlighted the need to 
identify a subgroup of asymptomatics that would benefit from intervention. 
 
The attempt to define this subgroup has inspired research into imaging modalities which can 
identify, in vivo, plaques at high risk of causing acute cardiovascular events. Histological and 
functional techniques have determined the features of such plaques, including: inflammation; 
extra-cellular matrix degradation; neovascularisation; intra-plaque haemorrhage; and 
apoptosis (Libby et al. 2002; Virmani et al. 2006; Koenig and Khuseyinova 2007). 
 
3.1.4 Imaging Neovascularisation: The Rationale 
Imaging intraplaque neovascularisation may be a means by which ultrasound can identify the 
high-risk plaque. In healthy large vessels, the vasa vasorum runs through adventitia and outer 
media (Geiringer 1951), penetrating intima only in pathology (Doyle and Caplice 2007). 
Recent work has afforded a central role to intraplaque neovascularisation in initiation, 
progression and rupture of atherosclerotic plaques (Chen et al. 1999; de Boer et al. 1999; 
Fleiner et al. 2004; Moreno et al. 2004; Moreno et al. 2006a; Moreno et al. 2006b; Moulton 
2006; Virmani et al. 2006; Langheinrich et al. 2007). In animal models, progression of 
disease can be reduced if neovascularisation is inhibited with angiostatin (Moulton et al. 
2003), and growth enhanced by administration of Vascular Endothelial Growth Factor 
(VEGF) (Celletti et al. 2001). 
 
3.1.5 Contrast Enhanced Ultrasound to Image Neovascularisation 
Limiting the success of MRI in imaging plaque neovascularisation is the ceiling on imaging 
timepoints and the fact that the contrast agent leaks from the vascular space. CEUS does not 
suffer from these limitations and allows quantification of vessels measuring less than 100 µm 
in diameter (Leen et al. 2004). Unlike CT or MRI contrast agents, microbubbles remain 
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within the vasculature and act as ‗surrogate red blood cells‘; hence they are true intravascular 
tracers which can be imaged in real time (Granada and Feinstein 2008). Combined with high 
temporal and spatial resolution of ultrasound, CEUS is well placed to study 
neovascularisation. 
 
Hitherto, three groups have correlated CEUS imaging results with histological plaque 
neovascularisation. Feinstein reported a moderate correlation value of 0.64 (Shah et al. 2007); 
Coli reported an increase in neovascularisation in patients demonstrating extensive 
enhancement (Coli et al. 2008); Giannoni et al. reported diffuse contrast uptake in plaques 
from symptomatic patients (Giannoni et al. 2009), all of whom had increased number of 
microvessels confirmed on histology. The latter group described the common presence of 
small vessels within plaque underlying ulcerations (Vicenzini et al. 2007). Up until this point, 
these three groups used subjective visual assessment made by human readers to ascribe binary 
or discreet scores to the imaging findings – quantification can be improved by generating 
time-signal intensity curves and using automated image analysis to produce a continuous 
variable. This approach has been demonstrated by Xiong and colleagues who studied 104 
carotid stenoses, revealing that plaque enhanced intensity and the intensity normalised against 
carotid luminal intensity were both significantly greater in symptomatic versus asymptomatic 
atheromata (Xiong et al. 2009). 
 
An alternative approach is to investigate periadventitial, rather than intra-plaque, vasa 
vasorum. A recent study compared quantified B-flow imaging (BFI) CEUS of periadventitial 
vasa vasorum in patients with atherosclerotic carotid stenosis compared with control carotids, 
showing a significant difference as well as a correlation of BFI with intima-media thickness 
(IMT) (Magnoni et al. 2009). 
 
Future work will have to address current unanswered questions about how best to quantify 
microbubble signal, particularly how normalisation can account for administered contrast 
dose and pharmacokinetic factors. Acquisition techniques and methods of image analysis 
need to be standardised, including in motion correction. Work with flow phantoms may help 
with these issues. Validation of the technique against a standardised clinical score, such as the 
modified Rankin (Bonita and Beaglehole 1988; van Swieten et al. 1988), Barthel (Wade and 
Collin 1988) or Frenchay (Holbrook and Skilbeck 1983), is required. Alternatively, 
comparison with a standardised plaque histological score can be undertaken, such as that 
produced by the American Heart Association in 1995 (Stary et al. 1995a; Stary et al. 1995b), 
or a modification (Virmani et al. 2000). 
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3.1.6 Microbubbles to Improve Structural Imaging of Plaque 
Further to potentially providing information on neovascularisation as a biological feature of 
the atherosclerotic plaque, CEUS has been shown to increase accuracy, sensitivity and 
specificity of the structural disease assessment (Sidhu et al. 2006). The concept of ―Doppler-
rescue‖ has emerged, whereby contrast is introduced during an US examination at the point of 
failure to obtain diagnostic images with unenhanced scanning. It should be stated that in 
experienced hands, ―Doppler-rescue‖ is rarely required and this, generally, would indicate the 
need for alternative imaging. This should also be considered against the recent advances in 
imaging technology. Furthermore, CEUS has been shown to be of use in the depiction of 
unsuspected wall irregularities, ulceration, and dissection (Kono et al. 2004), as well as 
improve the resolution of IMT (Vicenzini et al. 2009). 
 
3.1.7 Potential Problems with Contrast Enhanced Ultrasound 
A small number of microbubbles will be destroyed by the incoming ultrasound wave, and 
when this occurs capillary damage may ensue. This in turn recruits vascular endothelial 
growth factor (VEGF)-producing inflammatory cells, stimulating neovascularisation (Yoshida 
et al. 2005). This phenomenon may be a deterrent in the use of CEUS in diagnostics due to 
the theoretical risk of potentiating plaque instability by promoting angiogenesis. However, at 
the low mechanical index employed for CEUS, very few microbubbles will be affected and 
this is therefore a theoretical risk. 
 
The undesirable effects that have been associated with SonoVue®, the most commonly used 
microbubble in the UK, were in general, non-serious, transient and resolved spontaneously 
without residual effects. In clinical trials, the most frequently reported adverse reactions were 
headache (2.3%), injection site pain (1.4%), and injection site bruising, burning and 
paraesthesia (1.7%) (Bracco 2005). Fatal adverse events (AEs) have occurred following the 
administration of microbubbles. In the case of SonoVue®, approximately 160,000 doses have 
been administered and 3 deaths have been temporally related, although causal relationship 
was uncertain. This fatal AE rate is an order of magnitude higher than for MRI and CT 
contrast agents, probably reflecting the comorbidities of the recipients (microbubbles are 
commonly used in high-risk patients for echocardiography) (Dijkmans et al. 2005). 
 
It is important to consider the cost related to the use of ultrasound contrast agents. Although 
not formal health economic assessment has been undertaken for the use of microbubbles in 
carotid arterial disease, the technique has been described as being cost-effective in the context 
of gastrointestinal imaging (Wilson et al. 2009). 
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3.2 METHODS 
3.2.1 Study Approvals 
The study protocol received research ethics committee approval (08/H0706/106) and all 
patients gave written informed consent. The study was further registered as a clinical trial 
(EudraCT 2008-005900-25) and with the Medicines and Healthcare products Regulatory 
Agency (MHRA; 19174/0268/001-0001). 
 
3.2.2 Equipment and Settings 
Equipment details and settings are detailed in Table 6. 
 
Ultrasound machine Phillips iU22 
Probe Linear 12-5 MHz 
B-mode gain 85% 
Contrast gain 85% 
Time gain curve Vertical central / unadjusted 
B-mode mechanical index 0.06 
Contrast mechanical index 0.06 
Dynamic contrast mode Non-linear / pulse inversion 
Late phase contrast mode Non-linear / power modulation 
Intermediate power ‗flash‘ frame mechanical index 0.34 
Depth 4.0 cm 
Frame rate 12 Hz 
Persistence Medium 
Contrast agent SonoVue 
Contrast injection volume 2.0 mL x 2 
Dynamic contrast ultrasound recording time 2 minutes 
Late phase time post contrast injection 6 minutes 
Frame acquisition rate 6 per second 
Table 6 Contrast enhanced ultrasound imaging and acquisition parameters 
 
3.2.3 Study Subjects 
Between December 2008 and May 2009, subjects aged 18 years or over who presented to the 
vascular clinic for a carotid duplex ultrasound scan and whose scan showed an atherosclerotic 
plaque of > 30% stenosis by velocity criteria were recruited. We excluded subjects who 
experienced myocardial infarction or unstable angina (as defined by the European Society of 
Cardiology (Bassand et al. 2007; Thygesen et al. 2007)) in the 14 days prior to the study, 
those with New York Heart Association III or IV heart failure, or prosthetic heart valves, 
these being contraindications to contrast administration. 
 
Plaques were defined as symptomatic if symptoms consistent with stroke, transient ischaemic 
attack (TIA) or amaurosis fugax had occurred within 12 months of entry into the study, in the 
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neurovascular territory of the plaque studied. Plaques were defined as asymptomatic if no 
such events had ever occurred within their neurovascular territory. 
 
3.2.4 Unenhanced Duplex Ultrasonography and Gray-Scale Median Score 
The ultrasound examination was performed with the subject in the supine position. Luminal 
stenosis was measured in the sagittal plane using the velocity criteria which approximates the 
NASCET criteria (NASCET 1991; Sidhu and Allan 1997; Oates et al. 2009). This 
measurement was made by a clinical vascular scientist (with a minimum of 5 years experience 
in carotid ultrasound) as part of the subjects‘ routine care. The Gray-scale median score was 
calculated using the QLAB (Philips; Bothel, WA) quantification software as previously 
described, with the luminal blood and carotid wall adventia as reference points for 
normalisation (Sabetai et al. 2000). 
 
3.2.5 Contrast Agent, Preparation and Administration 
The contrast agent used was SonoVue™ (Bracco spa, Milan, Italy) which consists of a 
phospholipid shell containing the inert gas sulphur hexafluoride. The agent is prepared 
immediately prior to the examination by mixing 25 mg of the lyophilisate powder with 5 mL 
of saline. 2 mL of this preparation was injected as an intravenous bolus into an antecubital 
vein. Subjects were observed for 30 minutes following administration of the contrast agent 
and verbally asked about the occurrence of adverse events. 
 
3.2.6 Dynamic Contrast Enhanced Ultrasound 
The carotid bifurcation was imaged in longitudinal projection. The transducer was kept 
parallel to the vessel so that the near and far wall adventitia were imaged at right angles. 
CEUS was performed after a bolus injection of SonoVue. With contrast non-linear imaging 
mode, a mechanical index (MI) of 0.06 was used to achieve optimum visualisation of the 
plaque vascularity with minimal artefact. Continuous real-time (6 Hz) recording was 
employed. 
 
Digital Imaging and Communications in Medicine (DICOM) cineloops during the early wash-
in, the peak of the injection, and the wash-out phase over 30 to 120 seconds were collected 
and saved for quantitative analysis. Preliminary data showed that two minutes of acquisition 
provides a more complete curve than one minute. Using the fundamental B mode image, a 
single region of interest (ROI) was drawn on the outline of the plaque. The ROI is 
automatically mapped to the same position on the contrast image and QLAB calculates the 
signal intensity of each pixel within the ROI. The mean signal intensity is then automatically 
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calculated. The transfer function of the injection dose and delivery (wash-in and wash-out) 
will be deconvolved to avoid user biased results by using a ROI (of the same volume as that 
of the plaque) placed centrally in the carotid lumen away from the plaque region. ―Native‖ 
raw image data was collected for precise quantification of the intensity corresponding to 
blood volume (peak enhancement, Ip, Figure 22) in both plaque and lumen. Curves are 
constructed of the contrast intensity data for the plaque and lumen ROIs as a function of time 
using the QLAB quantification software (Figure 23). The specific haemodynamics of the 
plaque neovascularisation will be calculated as normalised peak enhancement of the wash-in 
curve. 
 
 
Figure 22 Dynamic contrast enhanced ultrasound time-intensity curve and 
parameters 
The intensities at the „wash in‟ and peak phases lie more closely on the curve than at the 
„wash out‟ phase. Ip, peak intensity; tp, time to peak; WIT, wash in time. From (Averkiou et al. 
2010). 
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Figure 23 Dynamic contrast enhanced ultrasound image analysis and 
quantification 
In longitudinal section. A. Contrast mode, with regions of interest drawn over the plaque 
(red) and the lumen (yellow, for normalisation). The regions of interest are similar in size. B. 
Fundamental B-mode image for the same time-point. This allows the anatomy to be seen. C. 
The process is repeated over all the acquired frames from the point of contrast injection to 
two minutes post-injection. D. Time-intensity curves. These plot the intensity of contrast 
within the plaque (red) and lumen (yellow) for each acquired frame for the time from contrast 
injection to peak intensity. The vertical white line identifies the point plotted for the images 
shown in A and B. 
 
3.2.7 Late Phase Contrast Enhanced Ultrasound 
Late-phase contrast enhanced ultrasound (LP-CEUS) utilises flash-imaging at intermediate 
mechanical index (MI: 0.34) of the carotid bifurcation and internal carotid artery, using a non-
linear imaging (power modulation) contrast mode, 6 minutes following bolus intravenous 
contrast injection. Six flash frames were acquired in less than 1 second in the axial orientation 
at the level of greatest stenosis. Plaque and lumen ROIs are drawn on QLAB to generate to 
A B 
C 
D 
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mean signal intensities from which a normalised peak plaque signal intensity at 6 minutes can 
be calculated (Figure 24). 
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Figure 24 Late phase contrast enhanced ultrasound image analysis 
In transverse section. A. Contrast mode at six minutes from the point of contrast injection, 
flash-imaging at intermediate mechanical index (MI: 0.34). B. Fundamental B-mode image 
for the same time-point. This allows the anatomy to be seen and, in this case the identification 
of an area of plaque calcification. C. Image as seen in A, with region of interest (ROI) drawn 
around the plaque. The area of calcification, as identified in B, is excluded from the ROI so 
as to prevent a false high contrast value. D. Image as seen in B, with plaque ROI drawn. 
A B 
C D 
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3.2.8 Blinding and Standardisation of Contrast Enhanced Ultrasound Image 
Acquisition and Data Processing 
Both scanning and image analysis were performed blinded to the patients‘ clinical 
information (including symptomatic status). 
 
Steps were taken in order to standardise the CEUS image acquisition. These included the use 
of a 3-way tap in the administration of contrast into the end of the cannula (not though the 
filter/valve at the top of the cannula, as this may interfere with the microbubble integrity), 
using a large intra-venous cannula of at least 20 gauge, and asking patients to avoid foods and 
drinks containing caffeine for 12 hours prior to imaging. Tea, coffee, chocolate and colas may 
theoretically cause vasoconstriction, although this is unlikely owing to the described 
immaturity of the microvessels under investigation (Dunmore et al. 2007). 
 
QLAB software (Philips, Bothel, WA) was used to quantify echo intensity of the plaque from 
the acquired cine-loop. For LP-CEUS, a single ROI was drawn on the outline of the plaque on 
the contrast enhanced image, with the B mode image displayed alongside as reference. Areas 
of calcium causing signal artefact (formally defined as areas confirmed through quantification 
as being of aberrant signal >1 order of magnitude above the signal quantified from the 
remainder of the plaque) were not included in the plaque ROI analysed. The mean signal 
intensity was automatically calculated. A second ROI was drawn around the residual lumen to 
calculate mean signal intensity in the lumen. The raw linear data was log transformed, and the 
signal intensity of the plaque was normalised against the lumen signal intensity to account for 
patient factors such as volume of distribution and cardiac output. Intra-observer variability by 
Cohen‘s kappa for this analysis was 0.88, representing substantial agreement. 
 
3.2.9 Statistical Analysis 
The number of subjects enrolled in the study provided 90% power to detect effect sizes 
(difference/standard deviation) of 1.1 with a 5% type-I error rate. Sample size calculations 
were performed using PASS (NCSS, Kaysville, Utah). 
 
The raw linear data generated from QLAB was found to be log-normally distributed, and 
therefore was log transformed for statistical analysis. The signal intensity of the plaque was 
normalised by dividing the plaque signal intensity by the lumen signal intensity (because the 
data was log transformed, normalisation required subtracting the lumen signal intensity from 
the plaque signal intensity). The normalised signal was compared between the two groups 
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(symptomatic and asymptomatic) using the t-test, assuming unequal variances (GraphPad 
Prism 5.01, GraphPad Software, San Diego, CA). Within the symptomatic group, plaques in 
the territory of a stroke were compared to those in the territory of a TIA. Within the 
asymptomatic group, plaques from subjects who had never had a cerebrovascular event were 
compared to those who had a history of such an event affecting the contralateral hemisphere. 
These comparisons were made using the t-test. Pearson correlation was used to investigate 
both the relationship between gray scale median and LP-CEUS signal, and the relationship 
between LP-CEUS signal and luminal stenosis. Baseline frequencies between the two groups 
were compared using Fisher‘s exact test or t-tests where appropriate. The possible 
relationship between subject characteristics and LP-CEUS was assessed using analysis of 
variance (ANOVA) with the characteristic as a covariate (SAS 9.1.3, SAS Institute Inc., Cary, 
NC). Sensitivity and Specificity of LP-CEUS for correctly identifying plaques as 
symptomatic or asymptomatic were derived by using receiver operating characteristic (ROC) 
curve analysis. Cut-off values were chosen which minimised the difference between 
sensitivity and specificity. A p value of 0.05 was used to determine significance for all 
statistical tests. Multivariate logistic regression analysis was performed using Stata 11 
(Statacorp LP, TX). 
 
3.3 RESULTS 
3.3.1 Patient Numbers and Characteristics 
Thirty-seven patients were enrolled, with a mean age of 69.9 years (+/- 8.5 years standard 
deviation). 27 (73%) were male, with a mean age of 69.7 years (range 58-86) and 10 (27%) 
were female, with a mean age of 70.3 years (range 49-86) with no significant difference in the 
ages of men and women. In total, 16 patients were recruited into the symptomatic group and 
21 into the asymptomatic group. Of the symptomatic group, the time from cardiovascular 
event to LP-CEUS assessment was less than 30 days for 10 patients (63%), and less than 50 
days for 14 patients (88%). With regard to the cerebrovascular events, 6 patients (37.5%) had 
had a stroke, 8 (50%) had had a TIA, and 2 (12.5%) had had amaurosis fugax. Of the 
asymptomatic group, 7 (33%) had previously been diagnosed with TIA or stroke which 
affected the hemisphere contralateral to the plaque which was studied. The remaining 14 
(67%) of the asymptomatic group had never been diagnosed with TIA, stroke or amaurosis 
fugax. There was no significant difference between the symptomatic and asymptomatic 
groups in age, gender, or history of diabetes mellitus, hypertension, statin use and smoking 
(Table 7). 
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Characteristic Symptomatic 
(n=16; 43%) 
Asymptomatic 
(n=21; 57%) 
p Value 
Age (years) 71 +/- 9.9 69 +/- 7.5 0.65 
Male Sex 11 (69%) 16 (76%) 0.72 
Diabetes Mellitus 3 (19%) 3 (14%) 1.00 
Statin Use 15 (94%) 16 (71%) 0.24 
Hypertension 12 (75%) 17 (81%) 0.70 
Smoking History 11 (69%) 13 (62%) 0.74 
Table 7 Characteristics of the symptomatic and asymptomatic patient groups 
This table shows that there were no statistically significant differences in the demographic or 
clinical parameters when comparing patients with symptomatic to those with asymptomatic 
carotid stenosis. Data are numbers of patients, with percentages in parentheses, with the 
exception of age, were data are means +/- standard deviations. 
 
3.4 DYNAMIC CONTRAST ENHANCED ULTRASOUND 
Thirty-five of the 37 patients (95%) who underwent carotid plaque assessment by D-CEUS 
had images acquired which were of sufficient quality to allow for accurate intensity 
quantification. Of the two patients whose images were not analysed, one was from the 
symptomatic group and the other from the asymptomatic. The peak plaque echo intensity, 
normalised for the carotid artery luminal intensity, was higher in symptomatic than 
asymptomatic plaques (Figure 25) 
 
Figure 25 Normalised plaque peak dynamic echo intensity 
A. The peak carotid plaque intensity during D-CEUS, when normalised for luminal intensity, 
was higher in symptomatic than asymptomatic patients. Mean and standard error of mean 
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shown. n=35, ***p<0.0001.  B. Receiver operator characteristic curve analysis area under 
the curve for D-CEUS is 0.94. 
 
3.5 LATE PHASE CONTRAST ENHANCED ULTRASOUND 
3.5.1 Relationship between Late Phase Signal and Symptomatology 
The LP-CEUS examination was well tolerated by all patients and of the 37 patients enrolled, 
all produced evaluable LP-CEUS data. Percentage luminal stenosis ranged from 30-99% and 
whilst the mean stenosis in the symptomatic group was greater than in the asymptomatic 
group, the difference between the two groups did not achieve statistical significance (p=0.06) 
(Table 8). Given the standard deviation observed in this study and the sample size, a 
difference of 20.5% in stenosis would have been required to provide 90% power to detect a 
difference between the two groups. 
 
Variable 
Symptomatic 
(n=16) 
Asymptomatic 
(n=21) 
Difference 
(Symptomatic – 
Asymptomatic) 
p Value 
Luminal 
Stenosis 
79% 
(69%-89%) 
67% 
(58%-75%) 
12% 
(–0.4% to 25%) 
0.06 
LP-CEUS 
0.39 
(-0.11 to 0.89) 
-0.69 
(-1.04 to -0.34) 
1.08 
(0.49 to 1.66) 
0.0008 
GSM 
17 
(13 to 20) 
29 
(21 to 37) 
–12 
(–3 to –21) 
0.009 
Table 8 Ultrasound features of carotid plaque in patients with and without 
symptoms 
This table summarises the unenhanced carotid duplex and LP-CEUS results from 37 patients. 
Data is expressed as mean (95% confidence interval). GSM, Gray-scale median. 
 
At 6 minutes, when late phase flash imaging is performed, there are very few microbubbles 
within the circulation in the lumen of the carotid artery. A logarithmic scale is used. When 
there is signal maintained within the plaque at 6 minutes, this tends to exceed the signal from 
the lumen, as such a positive value for normalised late phase signal is obtained. Where there 
is little signal within the plaque at 6 minutes, the signal from the lumen tends to exceed that 
from the plaque, such that a negative value for normalised late phase signal is recorded. 
 
The LP-CEUS normalised plaque intensity was significantly greater in the symptomatic group 
0.3899 (95% CI: -0.1056 to 0.8854) than the asymptomatic group -0.6869 (95% CI: -1.036 to 
-0.3380), (p=0.0005) (Figure 26A). However, there was overlap in signal intensity between 
the two groups. Of note, the lowest signal intensity from the symptomatic group was derived 
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from the patient who had the longest event to scan time (of nearly 1 year). For this patient, the 
signal fell below the mean of the asymptomatic group. 
 
Receiver operator characteristic analysis revealed a sensitivity and specificity of 75% and 
86%, respectively, for a LP-CEUS normalised peak intensity cut off > 0.00 (Figure 26B). 
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Figure 26 Normalised plaque late phase intensity 
A. The carotid plaque intensity during LP-CEUS, when normalised for luminal intensity, was 
higher in symptomatic than asymptomatic patients. Mean and standard error of mean shown. 
n=37, ***p=0.0005.  B. Receiver operator characteristic curve analysis area under the curve 
for LP-CEUS is 0.88. 
 
3.5.2 Relationship between Late Phase Signal and Time Since Symptoms  
Of the symptomatic group, the time from cardiovascular event to LP-CEUS assessment was 
less than 30 days for 10 subjects (63%), and less than 50 days for 14 subjects (88%). With 
regard to the cerebrovascular events, 6 subjects (37.5%) had had a stroke, 8 (50%) had had a 
TIA, and 2 (12.5%) had had amaurosis fugax. Of the asymptomatic group, 7 (33%) had 
previously been diagnosed with TIA or stroke which affected the hemisphere contralateral to 
the plaque which was studied. The remaining 14 (67%) of the asymptomatic group had never 
been diagnosed with TIA, stroke or amaurosis fugax. 
 
Figure 27 demonstrates the relationship between normalised LP-CEUS signal and the time 
since symptoms. There is a weak but significant correlation, however this is likely to be 
driven by a single outlying point representing a patient who experienced symptoms 
approaching 1 year prior to scanning. 
A 
B 
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Figure 27 Normalised plaque late phase and declines with time since symptoms 
For symptomatic plaques, the carotid plaque intensity during L-CEUS, when normalised for 
luminal intensity, was seen to be inversely related to time since symptoms. n=16, r=0.1811, 
p=0.0339. 
 
3.5.3 Relationship between Late Phase Signal and Gray-Scale Median Score 
There was a significant difference between the two groups with regard to GSM (Figure 28). 
The asymptomatic group had a higher GSM score than the symptomatic group (asymptomatic 
mean 29.01 (95% CI: 32.844 to 25.176), symptomatic mean 16.95 (95% CI: 18.544 to 
15.356) (p=0.0124)). There was a moderate (rho=–0.44, p=0.016) inverse correlation between 
normalised plaque intensity and GSM score, demonstrating the tendency for plaques with 
greater normalised plaque intensity to have a lower GSM score. 
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Figure 28 Gray-scale median score 
A. The carotid plaque gray-scale median (GSM) score, was lower in symptomatic than 
asymptomatic patients. Mean and standard error of mean shown. *p=0.0124.  B. Receiver 
operator characteristic curve analysis area under the curve for GSM is 0.79. 
 
A B 
Chapter 3 
 104 
3.5.4 Relationship between Late Phase Signal and Stenosis 
There was no correlation between normalised LP-CEUS plaque intensity and percentage 
luminal stenosis (p=0.27). 
 
3.5.5 Relationship between Late Phase Signal and Patient Characteristics 
There was no evidence of a relationship between diabetes, smoking history, or statin dose 
with LP-CEUS signal, nor of differential LP-CEUS signal between those patients in the 
symptomatic group with TIA versus CVA. Within the asymptomatic group, there was no 
significant difference in LP-CEUS signal between those patients who had never had a 
cerebrovascular event and those who had a history of such an event affecting the contralateral 
hemisphere. 
 
3.5.6 Relationship between Late Phase Signal and Dynamic Signal  
Figure 29 demonstrates the relationship between normalised LP-CEUS signal and the 
normalised peak intensity on dynamic CEUS. As only a trend towards moderate correlation is 
seen between the two, combining the parameters was initially undertaken to observe whether 
this improved the capacity of CEUS to discriminate on the basis of symptomatic status. To 
account for the differences in magnitude between the LP-CEUS and D-CEUS signals, LP-
CEUS signal was multiplied by a factor of 50 before summing with D-CEUS signal. The 
resultant CEUS ‗score‘ discriminated symptomatic from asymptomatic carotid stenosis, at a 
cut off of -25, with improved sensitivity (90%) and specificity (88%) (Figure 30). 
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Figure 29 There is a trend towards positive correlation between normalised plaque 
late phase and dynamic peak signals 
There is a trend towards moderate correlation between normalised D-CEUS and LP-CEUS 
plaque signals. n=29, Pearson r=0.3753, p=0.0571. 
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Figure 30 Combined LP-CEUS and D-CEUS score 
A. As only a trend towards moderate correlation is seen between LP-CEUS and D-CEUS, 
combining these to determine a CEUS „score‟ was undertaken. At a cut off of -25, there was a 
sensitivity of 90% and a specificity of 88% to separate symptomatic from asymptomatic 
carotid plaque. Mean and standard error of mean shown. n=27, ***p=0.0002.  B. Receiver 
operator characteristic curve analysis area under the curve for the CEUS „score‟ is 0.95. 
 
3.5.7 Multivariate Logistic Regression Analysis 
To determine whether any covariates were significantly related, a coefficient correlation 
matrix was generated, based on 27 patients (Table 9). This identified that both LP-CEUS and 
D-CEUS as significant co-variates in the context of symptomatic status. LP-CEUS and D-
CEUS were entered into a multi-variate logistic regression model (Table 10). 
A 
B 
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 Age Gender Statin use Creatinine Degree of 
stenosis 
Symptomatic 
status 
D-CEUS 
Age 1.0000       
p        
Gender -0.1220 1.0000      
p 0.5443       
Statin use 0.1665 -0.0088 1.0000     
p 0.4065 0.9652      
Creatinine 0.4436 0.2737 -0.0142 1.0000    
p 0.0205 0.1672 0.9441     
Degree of 
stenosis 
0.1033 0.0805 0.3658 0.0325 1.0000   
p 0.6082 0.6898 0.0606 0.8723    
Symptomatic 
status 
0.2006 0.1037 0.1040 0.1118 0.2338 1.0000  
p 0.3157 0.6067 0.6059 0.5788 0.2406   
D-CEUS -0.1686 0.1858 0.0550    0.0789 0.2644 0.6372 1.0000 
p 0.4005 0.3534 0.7852 0.6958 0.1825 0.0004  
LP-CEUS -0.0262 0.1186 -0.1645 0.0912 -0.0074 0.6147 0.4935 
p 0.8967 0.5557 0.4122 0.6510 0.9710 0.0006 0.0089 
Table 9 Correlation coefficient matrix 
This matrix shows D-CEUS and LP-CEUS as significant (and correlated) covariates – 
highlighted in bold – in the context of symptomatic status that would warrant their inclusion 
in a multivariate model. 
 
 Coefficient 
Standard 
Error 
z P>|z| 95% Confidence Interval 
D-CEUS 0.2860495 0.1438309 1.99 0.047 0.0041461 – 0.5679528 
LP-CEUS 4.598986 2.625238 1.75 0.080 -0.5463852 – 9.744357 
Constant 6.597783 3.448486 1.91 0.056 -0.161125 – 13.35669 
Table 10 Multivariate logistic regression model for symptomatic status 
 
After adjustment for both D-CEUS and LP-CEUS, there is still borderline significant 
evidence to suggest that both measurements are independently associated with symptomatic 
status. Given the correlation between the D-CEUS and LP-CEUS in this dataset, the p-values 
are likely to be overestimated and the association be stronger than presented in this model. 
Based on this data: 
 
Odds of being symptomatic = 
6.6 + 0.3 (Log normalised D-CEUS signal) + 4.6 (Log normalised LP-CEUS signal) 
 
3.6 DISCUSSION 
3.6.1 Contrast Enhanced Ultrasound as Compared to Functional and Structural 
Imaging Modalities 
Imaging techniques to identify biological features of the plaque in vivo could improve risk 
stratification, facilitating clinicians‘ treatment decisions and monitoring response to plaque-
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stabilising therapies. To this end, imaging intraplaque inflammation, neovascularisation, 
haemorrhage and apoptosis have been attempted with some success using MRI and/or nuclear 
medicine. However, high prevalence of carotid disease and expense associated with these 
techniques preclude them from replacing ultrasound as first line investigation (Rudd et al. 
2002; Kerwin et al. 2003; Trivedi et al. 2003; Cappendijk et al. 2004; Kietselaer et al. 2004). 
 
Using (non-contrast enhanced) ultrasound to identify plaque constituents has been attempted 
with ―Gray-Scale Median‖ (GSM) evaluation. Studies in which patients were imaged prior to 
surgical endarterectomy have consistently demonstrated that plaques which are echolucent on 
ultrasound, with a low GSM, have high lipid, haemorrhage and macrophage on histology. 
Conversely, echogenic plaques, with a high GSM, have a higher fibrous content (El-
Barghouty et al. 1996b; Gronholdt et al. 1997; Gronholdt et al. 1998; Gronholdt et al. 2002). 
GSM is also associated with clinical findings:  evidence of cerebral infarction on CT is more 
common in the presence of echolucent plaques rather than echogenic, regardless of 
symptomatic status (el-Barghouty et al. 1995; el-Barghouty et al. 1996a). Echogenicity on 
ultrasound has also been shown to predict ipsilateral ischaemic stroke; patients with 
echolucent plaques are at increased risk compared to those with echorich plaques (Hayward et 
al. 1995; Polak et al. 1998; Gronholdt et al. 2001; Mathiesen et al. 2001). However, hazard 
ratios for development of stroke that are associated with differing echogenicity scores are not 
sufficiently great to warrant translation into clinical practice. Furthermore, studies 
investigating the use of GSM in selection for carotid artery stenting (CAS) have had 
conflicting results. The Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) study 
revealed that high echolucency increases risk of stroke as a complication of CAS (Biasi et al. 
2004). Subsequently, Reiter and colleagues showed no such relationship between plaque 
echolucency and stroke risk with CAS (Reiter et al. 2006). 
 
3.6.2 Dynamic Contrast Enhanced Ultrasound 
Dynamic contrast enhanced ultrasound (D-CEUS) peak plaque intensity, normalised against 
the peak luminal intensity, is significantly higher in symptomatic plaques as compared with 
asymptomatic plaques. This approach, employing time-intensity curves, has been used by 
Xiong and colleagues who studied 104 carotid stenoses, revealing that plaque enhanced 
intensity and the intensity normalised against carotid luminal intensity were both significantly 
greater in symptomatic versus asymptomatic atheromata (Xiong et al. 2009). 
 
Moreover, we have shown that in symptomatic individuals D-CEUS signal declines with time 
since symptoms. This is in keeping with evidence that remodelling of the plaque occurs 
following stroke (Peeters et al. 2009). 
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3.6.3 Late Phase Contrast Enhanced Ultrasound 
This study has demonstrated that the late phase CEUS (LP-CEUS) signal intensity of the 
carotid plaque is greater in plaques deemed responsible for cerebrovascular events compared 
to asymptomatic plaques. These results imply that once the majority of microbubbles have 
been cleared from the circulation, they are still present within the carotid plaque in sufficient 
numbers to be detected and quantified by this novel ultrasound technique. The results also 
imply that more microbubbles are retained within those plaques deemed responsible for a 
cerebrovascular event, compared to asymptomatic plaques.  
 
This finding may merely represent the fact that symptomatic plaques have more intraplaque 
blood volume than asymptomatic plaques, and thus contain more circulating microbubbles in 
the late phase, just as they do with dynamic contrast enhanced ultrasound (D-CEUS) (Xiong 
et al. 2009). But this is unlikely because, during the dynamic phase, the signal from the lumen 
is approximately two orders of magnitude greater than the signal from the plaque. Were the 
late phase plaque signal purely a result of circulating microbubbles, it should only represent a 
small fraction of the late phase lumen signal. The fact that the late phase signals of plaque and 
lumen are of similar magnitude, implies that microbubbles have accumulated within the 
plaque. 
 
It is hypothesised that the microbubbles may be retained on the endothelium or may leave the 
microvessel and enter the plaque parenchyma; and retained in isolation or within 
phagocytosing macrophages. It is likely that a number of interrelated endothelial processes 
are responsible for this microbubble accumulation: endothelial activation; endothelial 
permeability and leakage (of the microbubbles themselves or of inflammatory cells containing 
them); and endothelial charge changes. 
 
Biological plausibility of this theory is provided by preclinical work demonstrating that 
microbubbles are passively targeted to tissue with activated endothelium and/or inflammation 
(Lindner et al. 2000a; Lindner et al. 2000b; Tsutsui et al. 2004b). Lipid microbubbles, such as 
SonoVue, adhere through opsonisation by serum compliment. In contrast, albumin-shelled 
microbubbles adhere through leukocyte β2-integrin Mac-1 (CD11b/CD18) (Lindner et al. 
2000a). 
 
A potential explanation for the retention of microbubbles by the endothelium is that there are 
charge changes when the endothelium is activated. Furthermore, a role for the negatively 
charged endothelial glycocalyx has been postulated. Glycocalyx has emerged as a potential 
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orchestrator of vascular homeostasis (Broekhuizen et al. 2009) with cytokine ‗scavenging‘ 
(Lortat-Jacob et al. 2002) and mechanosensing (Florian et al. 2003) functions. With regards 
the latter, the ‗state‘ of the endothelial gycocalyx, i.e. the presence of hyaluronan and sialic 
acid which cover cytokine binding sites on selectins, actively determines whether and to what 
extent cytokines will be able to induce localised vessel wall inflammation (Mulivor and 
Lipowsky 2002; Varki 2008). It is thought that when endothelium becomes activated or 
inflamed, it sheds its overlying matrix, including the negative glycocalyx, resulting in a 
charge change to more positive. It has been observed that endotoxin administration in rats 
induced microvascular dysfunction in conjunction with immediate glycocalyx degradation, 
suggesting a role for Toll-like receptors (TLRs) in glycocalyx perturbation (Marechal et al. 
2008; Broekhuizen et al. 2009). Furthermore, in a human study, it was shown that a controlled 
inflammatory challenge leads to instantaneous shedding of glycocalyx constituents and 
leucocyte activation, pointing towards glycocalyx as a protective shield against inflammatory 
stimuli (Nieuwdorp et al. 2009). As SonoVue is negatively charged, this may be one 
mechanism through which microbubbles are retained in LP-CEUS. It can be stained for using 
anti-heparan sulphate antibodies, and may be enzymatically removed from endothelial cells 
using heparinise III. 
 
It is thought that by detecting retained untargeted microbubbles, LP-CEUS has the potential 
to detect inflammation and/or endothelial activation within human carotid plaque in vivo. This 
is the first study demonstrating microbubbles passively targeting atherosclerotic carotid 
plaque in humans. This finding may have important clinical consequences for patients at high 
risk of plaque rupture and consequent stroke, because ex vivo analysis of atherosclerotic 
plaques has demonstrated that plaques causing rupture are characterised by an abundance of 
macrophages and an inflammatory infiltrate (Moreno et al. 1994; van der Wal et al. 1994; 
Boyle 1997; Schaar et al. 2004; Virmani et al. 2006). The fact that the signal intensity derived 
from the symptomatic group overlaps with the asymptomatic group implies LP-CEUS may 
have the potential to identify asymptomatic patients who are at high risk of cerebrovascular 
events who might benefit from intensive medical treatment or surgical intervention. 
Histological validation studies will be required to determine whether features of the plaque 
which pertain to inflammation or endothelial dysfunction correlate with the LP-CEUS signal. 
Such studies may also shed light on the mechanism by which non-targeted microbubbles 
adhere to the plaque, which is currently unclear. Prospective studies will subsequently be 
required to investigate the natural history of the LP-CEUS signal, whether it predicts the 
clinical outcome, and if so over how long a time frame. 
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As expected from previous studies, GSM score was greater in asymptomatic compared to 
symptomatic plaques (Grogan et al. 2005). Although the strength of the correlation was only 
moderate, the LP-CEUS signal was inversely associated with GSM score. Such a correlation 
is expected as plaques with a low GSM score have high lipid, haemorrhage and macrophage 
content (El-Barghouty et al. 1996b; Gronholdt et al. 1997; Gronholdt et al. 1998; Gronholdt et 
al. 2002), and would therefore be expected to retain more microbubbles. 
 
Several studies hitherto have used CEUS to assess the carotid plaque, but these have used the 
contrast as a blood pool agent and acquired data during the dynamic phase (D-CEUS) in order 
to detect intraplaque angiogenesis (Shah et al. 2007; Coli et al. 2008; Giannoni et al. 2009; 
Xiong et al. 2009). In the majority of these studies, visual assessment of the post processed 
data was used (Shah et al. 2007; Coli et al. 2008; Giannoni et al. 2009). In only one study was 
the signal quantified with image analysis software, and the results used to perform a ROC 
analysis (Xiong et al. 2009). The ROC analysis of the present study compares favourably to 
that generated from the aforementioned D-CEUS study (Sensitivity and specificity 75% and 
86% respectively for the present study, compared to 74% and 75% respectively for the D-
CEUS study). Such comparisons between the two techniques are premature at this stage, as 
both techniques are in their infancy. However, LP-CEUS offers distinct advantages over D-
CEUS: the examination is technically much easier to perform, and because image acquisition 
lasts less than 1 second, motion artefacts do not cause a problem.  
 
3.6.4 Limitations of Late Phase Contrast Enhanced Ultrasound 
The symptomatic and asymptomatic groups were both heterogeneous. The symptomatic 
group was comprised of patients with TIA, stroke or amaurosis fugax. Recent evidence 
suggests that plaques deemed responsible for stroke heal differently than those deemed 
responsible for TIA in the post event period (Peeters et al. 2009). The asymptomatic group 
was comprised of patients who had never had a cerebrovascular event, and those who had had 
an event affecting the contralateral hemisphere. MRI studies with iron oxide particles show 
that plaques which are contraleral to symptomatic plaques have greater inflammation than 
plaques from patients who have never had cerebrovascular event (Tang et al. 2007), reflecting 
the systemic nature of atherosclerosis. Although no evidence of a difference in LP-CEUS 
signal was detected between these subgroups, the study was not powered for this purpose and 
such differences cannot be excluded. A larger study would be required to definitively address 
the relationship between LP-CEUS and these characteristics. Furthermore, numbers were too 
small to allow for a comprehensive multivariate logistic regression analysis. 
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The symptomatic group was also heterogeneous with regards to the time from cerebrovascular 
event to LP-CEUS assessment. Because the plaque heals following stroke (Peeters et al. 
2009), had the inclusion criteria for the symptomatic group been more stringent, and 
stipulated an event to scan time of less than 2 weeks, the ROC analysis may have yielded 
improved sensitivity and specificity. 
 
The non-linear pulse sequence used was not designed for this indication and represents a 
crude means of detecting the very low concentration of microbubbles expected to be present 
in the plaque in the late phase. To accurately quantify the degree of microbubble retention and 
correlate the signal with histological features of the plaque, improved non-linear pulse 
sequences developed specifically for this purpose are required. 
 
Contrast modes for three-dimensional ultrasound are not currently available. Because the late 
phase technique destroys retained bubbles, this study was limited to assessing one single slice 
of the plaque. The assumption that the single slice is representative of the entire plaque is no 
doubt incorrect.  
 
As with the majority of modalities which measure signal intensity, the late phase signal in the 
plaque requires normalisation to avoid variation from factors which affect the overall intensity 
of the image. To mitigate these sources of variation, the plaque signal was divided by the 
lumen signal. However, this quantification method will be sensitive to factors which affect 
luminal signal. Furthermore, the kinetics of those microbubbles flowing within the vascular 
space probably differ from those of microbubbles retained in the plaque, and so this method 
will also be sensitive to the time point at which LP-CEUS is performed. Further studies are 
required to investigate the most appropriate method to normalise the signal. 
 
3.6.5 Conclusion 
By quantifying microbubble retention within the carotid plaque, LP-CEUS is able to show 
differences between groups of plaques within the neurovascular territory of recent 
cerebrovascular events and asymptomatic plaques; it thus has promise as a tissue specific 
marker of inflammation. This technique may be useful in helping to identify those 
asymptomatic patients who might benefit from intensive medical or surgical therapy, or as a 
biomarker to investigate pharmacodynamic effects of experimental molecules. 
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4 MULTI-ANALYTE 
PROFILING IN CAROTID 
ATHEROSCLEROSIS 
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4.1 INTRODUCTION 
As described in Section 1.5, atherosclerosis shares features with diseases caused by chronic 
inflammation (Full et al. 2009). Inflammation is intrinsically linked with disease activity, as 
the numbers of monocyte-macrophages infiltrating the plaque (Davies et al. 1993) and their 
location at plaque rupture-sensitive sites (such as the fibrous cap and erosion sites (van der 
Wal et al. 1994; Virmani et al. 2003)) is related to plaque vulnerability. Moreover, 
lymphocyte numbers and their activation markers relate to plaque activity (van der Wal et al. 
1994). Macrophage differentiation is acknowledged as being critical for the development of 
atherosclerosis (Gleissner et al. 2010). 
 
Genetic ablation or intervention studies in mouse models of atherosclerosis have mapped the 
cellular components of the inflammatory infiltrates in the plaques and the soluble mediators 
necessary for their recruitment and activation (Weber et al. 2008). There is less knowledge on 
human atherosclerotic disease, and even less on the mechanisms that make the human plaque 
prone to complications. Our group has previously demonstrated the effectiveness of isolation 
of viable cells from CEA specimens. This system reflects the complex cellular interactions 
occurring in vivo. The mixed cell population contains macrophages, lymphocytes and smooth 
muscle cells, and displays spontaneous cytokine, chemokine and matrix metalloproteinase 
(MMP) production (Monaco et al. 2004; Monaco et al. 2009; Cole et al. 2011). Inflammatory 
molecule production has been shown to be dependent upon toll-like receptor (TLR) 2 
signalling (Monaco et al. 2009), and the nuclear factor κB (NFκB) pathway via myeloid 
primary differentiation response gene 88 (MyD88) (Monaco et al. 2004). 
 
The number, phenotype and fate of infiltrating cells within the plaque is highly dependent on 
soluble mediators such as cytokines and chemokines contained within the milieu of the 
plaque. As instability in atherosclerosis is determined by the balance of cytokines, 
chemokines and other relevant mediators, this micro-environment is determined by the 
complex interaction between cell types within tissue (Hamilton 2008). The characterisation of 
soluble mediators may yield quantitative and functional information on the plaque 
inflammatory milieu. Such characterisation may identify targets for plaque stabilising 
therapies, as well as risk stratification through both functional imaging and biomarkers. 
Moreover, the investigation of soluble mediators has the potential to identify blood-borne 
biomarkers, whether individual or as part of a bio-molecular signature. This study aimed to 
map the components of this milieu for the first time and to study the clustering and 
relationships between such mediators with the aim to understand the specific ―cocktail‖ of 
mediators associated with the high-risk plaque. 
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4.2 METHODS 
4.2.1 Ethical Approval and Regulation, Sample and Data Collection, and Definition 
of Symptomatic Status 
This investigation into factors influencing carotid artheromatous plaque instability received 
research ethics committee approval (08/H0706/129 and Riverside Research Ethics Committee 
RREC 2989). Informed consent was obtained from all patients enrolled. Diseased intimal 
arterial segments were collected from consenting patients undergoing carotid endarterectomy 
surgery at Charing Cross Hospital, London, for both asymptomatic and symptomatic carotid 
stenosis, and anonymised according to the rules set out in the Human Tissue Act (2004). A 
patient was considered symptomatic if the patient had experienced, within the last 6 months, 
focal neurological symptoms pertaining to the ipsilateral carotid territory (stroke, transient 
ischemic attack or amaurosis fugax). The symptomatic status was confirmed by the neuro-
vascular multi-disciplinary team. Demographic, clinical and pharmacotherapeutic data was 
compiled for all patients. 
 
4.2.2 Carotid Atheromatous Plaque Processing Protocol 
In order that a number of laboratory techniques may be employed upon the carotid plaques 
obtained at carotid endarterectomy, a protocol was devised to permit the plaque to be process 
in a manner that would allow for this. Primarily, the plaque is divided symmetrically, 
longitudinally through the point of greatest stenosis. Half of the plaque is then committed to 
the plaque digestion and atheroma cell culture pathway. The other half is axially cut into 
between 3 and 5 parts (depending upon the size of the plaque), equal in size. The top, middle 
and bottom parts are used for histological assessment of the upstream, middle and 
downstream areas of the plaque (Figure 31). 
 
The protocol described also prescribed that the plaque be placed in red cell lysis buffer prior 
to being divided. This is to allow for the removal of any red blood cells. However, if the 
plaque is cut and the sections placed in lysis buffer, this may inadvertently lyse any 
inflammatory cells within the plaque. 
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Figure 31 Carotid plaque processing protocol 
This protocol allows the representative undertaking of atheroma cell culture and 
immunohistochemistry. D, downstream; M, middle; RCLB, red cell lysis buffer; U, upstream. 
 
4.3 CAROTID PLAQUE HISTOLOGY 
Histological analysis of carotid plaque sections was required to explore the biological features 
of the plaque related to patient symptomatic status, production of soluble analytes and 
findings on functional imaging (Chapter 5). The histology comprised, generally, 
immunohistochemistry and picrosirius red staining. 
 
Immunofluorescent staining was not undertaken when semi-automated quantification was 
required as atherosclerotic plaques contain a considerable amount of lipid, which is 
autofluorescent and therefore may interfere with accurate quantification and interpretation 
following this technique. 
 
4.3.1 Tissue Embedding 
The plaque regions are placed within optimised cutting temperature (OCT) embedding matrix 
(Lamb) upon 3mm thick cork discs (Lamb). This is rapidly frozen using Frostbite (Surgipath) 
before inverting into a bath of 100% isopropanol surrounded by dry ice to snap freeze. 
 
4.3.2 Cryosectioning 
Cryosectioning was undertaken using a Leica CM1900 UV cryostat (Leica Microsystems) at -
25 ± 1 °C. 5µm sections were transferred three to a slide. 
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4.3.3 Carotid Plaque Immunohistochemistry 
Cryosections from each of the three regions (top, middle and bottom) were 
immunohistochemically stained for the macrophage marker CD68 (PG-M1, Dako, 1:500) and 
the endothelial cell marker CD31 (for intraplaque neovascularisation; JC70A, Dako, 1:1000) 
by the avidin-biotin complex technique with 3,3'-diaminobenzidine visualisation. 
 
In general, immunohistochemical staining involved the following steps: 
 
 Blocking of endogenous peroxidase activity 
 Primary antibody application 
 Secondary antibody application 
 Substrate preparation and development 
 Counterstaining 
 
The immunohistochemistry (IHC) method used is based on the Standard Operating 
Procedures implemented within Charing Cross Hospital Department of Histopathology, and 
recommendations made by Vector Laboratories Limited, Novocastra Laboratories Limited 
and Dako Limited for use of their products in immunohistochemical investigations. 
 
Frozen tissue sections were initially ‗fixed‘ in acetone at room temperature for 10 minutes.  
 
4.3.4 Blocking 
Background staining (specific or non-specific) could cause false positivity. Endogenous 
peroxidase activity in erythrocytes, leucocytes and other cells may result in heavy non-
specific background staining when using a horseradish peroxidase (HRP) conjugated 
antibody. This could lead to false positives or masking of the actual staining (false negative). 
Such activity was blocked by immersing the sections in a 2% solution of Sigma 30% 
hydrogen peroxide (EC label 23-1-765-0) in 300mL of BDH methanol for 10 minutes. The 
sections were then rinsed in running tap water for approximately 2 minutes. 
 
A further cause of non-specific background staining is non-immunological binding of the 
specific immune sera by hydrophobic and electrostatic forces to certain sites within the tissue 
sections. This was reduced by blocking these sites with normal serum.  
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4.3.5 Avidin-Biotin Complex Immunohistochemistry Technique 
The general IHC protocol employed used the avidin-biotin complex (ABC) peroxidase 
technique. This technique involved three layers. The first layer was the primary antibody 
(study marker). The second layer was the biotinylated secondary antibody. Biotin is a low 
molecular weight vitamin which can be conjugated to a variety of biological molecules 
including antibodies. The third layer was a complex of avidin-biotin peroxidase. Avidin is a 
large glycoprotein which can be labelled with peroxidase or fluorescein (chromogen), and has 
a very high affinity to biotin. Due to the very high affinity of avidin-biotin interaction, the 
binding of the primary antibody to the target antigen (first layer) will be amplified at the 
second and third layers, hence increasing the sensitivity of the method (and reducing the 
amount of primary antibody needed). 
 
4.3.6 Diaminobenzidine Visualisation 
In order to visualise the antibody/antigen complex, a chromogen, peroxidase substrate 
diaminobenzidine (DAB) SK-4100 (Vector Laboratories) was added. DAB produced a brown 
precipitate which is insoluble in alcohol in the presence of hydrogen peroxide. Since 
peroxidise is found in the avidin-biotin complex, addition of DAB to sections results in 
production of this precipitate. 
 
Five millilitres of distilled water, 2 drops of buffer stock solution, 4 drops DAB stock solution 
and 2 drops hydrogen peroxidase were mixed and added to each slide for 5 minutes. The 
reaction was stopped by immersion of the slide in running water. Surgipath Harris‘s 
haematoxylin, followed by 0.3% acid was then applied and this differentiates the 
haematoxylin counterstain. The antigenic sites were thus stained dark brown due to the DAB 
precipitate and the cell nuclei blue from the haematoxylin. 
 
4.3.7 Picro-sirius Red Staining 
Picrosirius red staining was employed to visualise collagen, particularly in the context of the 
fibrous cap. This would facilitate accurate measurement of fibrous cap thickness. Picro-sirius 
red stain was made by combining sirius red F3B (0.5g) with saturated aqueous picric acid 
(500mL). Slides were placed in picro-sirius red solution for 1 hour, prior to washing in two 
changes of acidified (acetic acid) water (Puchtler et al. 1973; Junqueira et al. 1979). 
 
Chapter 4 
 118 
4.3.8 Dehydration, Mounting and Coverslip Application 
The slides were then subjected to serial 70% and 90% alcohol baths and finally completely 
dehydrated with 99% IMS. The alcohol was removed using xylene and the sections were 
mounted in Pertex mountant with 50 x 35mm glass coverslips on a Leica Auto-coverslipper. 
 
4.3.9 Histology Quality Control 
All histology was supervised and checked for quality by Dr Ann Sandison, Consultant 
Histopathologist and Honorary Clinical Senior Lecturer and Dr Federico Roncaroli, Reader in 
Neuropathology and Honorary Consultant Histopathologist. 
 
4.3.10 Image Acquisition and Analysis 
Cap thickness was measured from sections stained with picro-sirius red using an Olympus 
BH2 microscope (Olympus Corporation), with Jenoptik digital camera and linked ProgRes® 
CapturePro (version 2.5) image acquisition software (Jenoptik Laser, Optik, Systeme GmbH). 
 
To reduce selection bias when quantifying immunohistochemical staining, whole plaque 
sections were imaged at x4 magnification using a motorised stage microscope (Eclipse 50i, 
Nikon) – camera (QImaging) system (Figure 32). Semi-automated image analysis was 
undertaken using Vision software (version 5.0, Clemex Technologies Incorporated, 
Longueuil, Quebec, Canada) (Figure 33). This is a ‗routine‘ and ‗bitplane‘ based system for 
automated image analysis in accordance with user-defined parameters. The percentage area of 
immunopositivity by colour thresholding was determined, with the average across the 9 slides 
calculated, for each of CD68 and CD31. 
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Figure 32 Image acquisition of stained histological sections comparing conventional 
and motorised stage microscope - camera setups 
Cryosectioned tissue immunohistochemically stained for the endothelial marker CD31 as a 
marker of neovascularisation. Immunopositivity is indicated by dark brown.  A. Conventional 
image acquisition of „representative‟ or „randomly selected‟ images. A magnification of x2.5 
would be required to obtain as large a field of view as possible.  B. This image is made up of 
35 individual images, each representing a single field of view through a x4 microscope 
objective. A shading correction has been applied to ensure the staining intensity is uniform on 
the image regardless of whether we are looking at the centre or the edge of the field of view.  
C. Magnification of the high resolution images obtained on the motorised stage microscope 
acquisition system allows visualisation of microvessels in axial (*) and longitudinal section 
(#), as well as the luminal endothelium (arrowheads). 
 
A 
B 
C 
* 
# 
# 
# 
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Figure 33 Image analysis for quantification of histological staining 
Clemex Vision is a system for automated image analysis. This is a „routine‟-based system 
whereby the user produces a protocol for analysis which is saved, and may be opened and 
reproduced for subsequent analyses, to reduce variability between runs of analysis. It works 
by producing a „bitplane‟ (shown as a red overlay on the image being analysed) in 
accordance with the user-defined parameters. Quantification is based upon calculations 
related to bitplane-highlighted regions of the image. In this image, a colour threshold has 
been set using the tools on the right, and this produced the red bitplane overlay on the image 
on the left. This is then used for calculation for calculation of percentage area 
immunopositivity. 
 
4.4 CAROTID PLAQUE ENZYMATIC DIGESTION AND CULTURE 
Carotid atherosclerotic plaque specimens were dissociated via an enzymatic mixture in order 
to obtain a single cell suspension for culture as previously described, characterised and 
validated (Monaco et al. 2004) (Figure 34). 
 
Supernatants were removed after 24 hours and stored at -80°C for single-batch analysis. 
Multi-analyte profiling using a Luminex 100 platform was used to quantify supernatant 
protein levels of cytokine and chemokine (Milliplex, Millipore Corporation, Mo), matrix 
metalloproteinase (MMP) and tissue inhibitor or metalloproteinase (TIMP) (Fluorokine, R&D 
Systems, Abingdon, UK). Each supernatant sample was analysed in duplicate. Viability was 
monitored with the use of 3-(4,5-dimethyl-2-yl)-2,5-diphenyltetrazolium (MTT) (Sigma, UK) 
(Mosmann 1983). 
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4.4.1 Plaque Enzymatic Digestion 
Atheromatous plaque enzymatic digestion was undertaken entirely within a class II laminar 
flow cabinet. Diseased intimal arterial segments were isolated under a Wild-Heerbrugg M8 
dissecting microscope (Heerbrugg, Switzerland). Adherent thrombi were removed, and tissue 
fragments were incubated in collagenase type I (400 U/mL), elastase type III (5 U/mL) and 
DNAse (300 U/mL), with 1 mg/mL soybean trypsin inhibitor (SBTI; Sigma, UK), polymixin 
B (2.5 mg/mL; Sigma, UK) and 2 mM CaCl2, in RPMI 1640 (BioWhittaker, UK) with 10% 
foetal bovine serum (Biosera, UK) in a shaker at 37°C. Cells were recovered every 20 
minutes by filtering through an 80 mm Nylon mesh (Falcon, UK), and fresh enzymatic 
mixture was added, in order to avoid activation by collagen fragments, according to previous 
studies (Figure 34). 
 
Every step of the digestion and culture protocol has been carried out in lipopolysaccharide 
(LPS)-free conditions: polymixin has been added to the enzymatic mixture (a potential source 
of LPS contamination); LPS content in all media, reagents, and supernatants from 
experiments was assessed via the Limulus Amebocyte assay (Sigma, UK) and has 
consistently been demonstrated as below detection limits. 
 
 
Figure 34 Carotid atheroma cell culture work-flow 
Carotid plaque specimens were enzymatically digested using a collagenase / elastase / 
DNAse mixture as previously described and validated (Monaco et al. 2004). Previous work 
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has demonstrated by flow cytometry that the macrophage is the predominant cell type in this 
mixed cell culture system. The cells obtained were cultured at a uniform concentration of 
1x10
6
 cells/mL for 24 hours prior to supernatant collection. The supernatant from 67 
atheroma cell cultures was batch analysed for the quantification of a total of 45 protein 
analytes across four panels on a Luminex 100 platform. 
 
4.4.2 Plaque Cell Culture 
Cell fractions were pooled, and cultured at 1x10
6
 cells/mL in RPMI 1640 containing 10% 
FCS and 10% human serum (BioWhittaker, UK). Viability was monitored using MTT (3-
(4,5-dimethyl-2-yl)-2,5-diphenyltetrazolium; Sigma, UK). The cells were cultured in the 
wells of a 96 well plate. This increased the cell density and allowed the culture to reach near-
confluence. This is known to facilitate the production and release of cytokines and 
chemokines into the culture supernatant. 
 
4.4.3 Storage of Culture Supernatant 
At the 24 hours, the culture supernatant was aspirated and stored in multiple aliquots in a        
-80ºC freezer. 
 
4.5 MULTI-ANALYTE PROFILING 
4.5.1 Principles of Multi-Analyte Profiling 
Multi-analyte profiling (MAP) requires systems such as Luminex that are capable of 
performing a variety of bioassays, including immunoassays, on the surface of fluorescent-
coded beads known as microspheres. Luminex employs proprietary techniques to internally 
colour-code microspheres with two fluorescent dyes. Through precise concentrations of these 
dyes, up to 100 distinctly coloured bead sets can be created, each of which is coated with a 
specific capture antibody. 
 
After an analyte from a test sample is captured by the bead, a biotinylated detection antibody 
is introduced. The reaction mixture is then incubated with streptavidin-phycoerythrin (PE) 
conjugate, the reporter molecule, to complete the reaction on the surface of each microsphere. 
The microspheres are allowed to pass rapidly through a laser which excites the internal dyes 
marking the microsphere set. A second laser excites PE, the fluorescent dye on the reporter 
molecule. 
 
Finally, high-speed digital-signal processors identify each individual microsphere and 
quantify the result of its bioassay based on fluorescent reporter signals, termed the mean 
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fluorescent intensity (MFI). The capability of adding multiple conjugated beads to each 
sample results in the ability to obtain multiple results from each sample. 
 
Multi-analyte profiling was undertaken using human multiplex panels: Milliplex (Millipore 
Corporation, Missouri, USA); and Fluorokine (R&D Systems, Abindgon, UK). The choice of 
panel was determined by the availability of analytes on the panels produced by each 
manufacturer. 
 
Prior to use in the assay, all reagents were allowed to warm to room temperature (20-25°C). 
Samples which were frozen were initially defrosted on ice before being allowed to equilibrate 
to room temperature. The assay is run in duplicate. 
 
4.5.2 Milliplex Multi-Analyte Profiling 
Initially, the 96-well filter plate is wet by pipetting 200 μL of assay buffer into each well. The 
plate is then sealed and allowed to mix on a plate shaker for 10 minutes at room temperature. 
The assay buffer is removed by vacuum manifold. Twenty-five microlitres of each standard, 
quality control solution and background (assay buffer) were placed in the appropriate wells. 
Twenty-five microlitres of assay buffer is further added to each of the sample wells. Twenty-
five microlitres of the relevant culture medium is added to the standard, quality control and 
background wells. Twenty-five microlitres of the samples are added to the appropriate wells. 
Twenty-five microlitres of the bead mixture is then added to each well. The plate is sealed, 
covered with a light opaque lid and incubated with agitation on a plate shaker for 1 hour at 
room temperature. 
 
At this point the fluid is gently removed by vacuum manifold. The plate is washed twice with 
200 μL per well of wash buffer, removing the wash buffer by vacuum filtration between each 
wash. Twenty-five microlitres of detection antibodies are then added into each well. The plate 
is sealed, covered with a light opaque lid and incubated with agitation on a plate shaker for 30 
minutes at room temperature. 
 
Twenty-five microlitres of streptavidin-phycoerythrin is added to each well. The plate is 
sealed, covered with a light opaque lid and incubated with agitation on a plate shaker for 30 
minutes at room temperature, before the contents are gently removed by vacuum. The plate is 
washed twice with 200 μL per well of wash buffer, removing the wash buffer by vacuum 
filtration between each wash. One hundred and fifty microlitres of sheath fluid is then added 
to all wells and the beads resuspended on a plate shaker for 5 minutes. 
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4.5.3 Fluorokine Multi-Analyte Profiling 
Initially, the 96-well filter plate is wet by pipetting 100 μL of wash buffer into each well, 
which is then removed by vacuum manifold. Fifty microlitres of resuspended bead mixture is 
then added to each well. Fifty microlitres of each sample, standard and background (diluted 
calibrator diluent) were placed in the appropriate wells. The plate is securely covered with a 
foil plate sealer, and incubated with agitation on a plate shaker for 2 hours at room 
temperature. 
 
At this point the fluid is gently removed by vacuum manifold. The plate is washed three times 
with 100 μL per well of wash buffer, removing the wash buffer by vacuum filtration between 
each wash. Fifty microlitres of the diluted biotin detection antibody cocktail is then added into 
each well. The plate is securely covered with a foil plate sealer, and incubated with agitation 
on a plate shaker for 1 hour at room temperature. 
 
The fluid is gently removed by vacuum manifold and the plate is washed three times with 100 
μL per well of wash buffer. Fifty microlitres of diluted streptavidin-phycoerythrin is added to 
each well. The plate is securely covered with a foil plate sealer, and incubated with agitation 
on a plate shaker for 30 minutes at room temperature. 
 
The fluid is gently removed by vacuum manifold and the plate is washed three times with 100 
μL per well of wash buffer. One hundred microlitres of wash buffer is then added to all wells 
and the beads resuspended on a plate shaker for 2 minutes. 
 
4.5.4 Multi-Analyte Profiling Plate Analysis 
The plate is run on a Luminex 100 analyser. STarStation version 2.0 (Applied Cytometry, 
Sheffield, UK) was used for data acquisition (Figure 34). 
 
4.5.5 Cytokines and Chemokines 
The candidate molecules explored in the Milliplex cytokine and chemokine panels used, are 
outlined in Table 11. Plaque culture supernatants were used undiluted for this assay. 
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Cytokine  Role 
IL1α Pleotropic cytokine, polymorphism of its gene known to be associated with rheumatoid arthritis 
IL1β Produced as a pro-protein by activated macrophages and activated by caspase 1 
IL2 Leukocytotrophic cytokine involved in T cell proliferation 
IL4 Promotes T cell differentiation to TH2 lymphocytes 
IL5 Produced by TH2 and mast cells, and stimulates B cell growth and immunoglobulin secretion. IL5 is 
often co-secreted with IL3, IL4 and GM-CSF owing to the proximity of the genes on chromosome 5 in 
humans 
IL6 Secreted by T calls, macrophages and vascular smooth muscle cells, and is upstream of C-reactive 
protein production through liver stimulation of the acute phase response 
IL10 Anti-inflammatory molecule produced primarily by monocytes and downregulates expression of TH1 
cytokines and macrophage co-stimulatory molecules, can block NFκB activity and induce TNFβ 
IL11 
(AGIF) 
Involved in haemato- and lymphopoeisis 
IL12 (p40) Produced by dendritic cells and macrophages, and stimulate T cell growth and production of IFNγ and 
TNFα. IL12 is also known to be anti-angiogenic, through IFNγ and IP10 IL12 (p70) 
IL15 Pro-inflammatory cytokine sectreted by monocytes which shares structural similarities to IL2 
IL17 Pro-inflammatory cytokine family, which induces the synthesis of a number of pro-inflammatory 
cytokines and chemokines by T cells, and has been linked to rheumatoid arthritis 
IL29 Type III interferon involved in the innate immune response to viral infection 
GM-CSF Macrophage differentiation 
TNFα Pro-inflammatory 
TNFβ Lymphotoxin produced by T cells induced by IL10 
IFNα2 Involved in the innate immune response to viral infection and acts upon dendritic cells 
IFNγ Involved in innate and adaptive immunity with a number of functions including: increased antigen 
presentation of macrophages; activation and increase of lysosome activity in macrophages; 
suppression of TH2 activity; increased expression of MHC I; promotes adhesion and binding for 
leukocyte migration; promotes natural killer cell activity; activates antigen presenting cells; and 
promotes TH1 differentiation 
VEGF Pro-angiogenic 
sCD40L Is a member of the TNF molecule superfamily and expressed primarily by T cells 
M-CSF Influences haematopoietic stem cells to differentiate into macrophages 
  
Chemokine Role 
CCL2 
(MCP1) 
Monocyte, dendritic and T cell recruitment 
CCL5 (RANTES) Chemotactic for T cells, eosinophils and basophils, and leukocyte recruitment to areas of inflammation 
CCL14a 
(HCC1) 
Antibodies used in the assay were raised against the mature propeptide 1-74 which is a low-affinity 
agonist of CCR1 and which is converted to a high-affinity agonist of CCR1 and CCR5 on proteolytic 
processing by serine proteases 
CCL19 
(MCP3) 
Binds to CCR7 and chemotracts dendritic cells, as well as T and B cells 
CCL20 
(MIP3α) 
Strongly chemoattractant for lymphocytes, is induced by IFNγ and TNF, and down-regulated by IL10. 
Linked to IL17 and TH17 
CXCL6 Chemoattractant for neutrophilic granulocytes through interaction with CXCR1 and CXCR2 
CXCL7 Released in large amounts from platelets upon their activation, stimulating mitogenesis, extracellular 
matrix synthesis, glucose metabolism and production of plasminogen activator. Antibodies used in the 
assay were raised against the mature 76-AA chemokine 
CXCL9 
(MIG) 
T cell chemoattractant, which is induced by IFNγ and closely related to CXCL10 and CXCL11 
CXCL10 (IP10) Secreted in response to IFNγ and chemotracts monocytes, macrophages, T, dendritic and natural killer 
cells 
CXCL11 
(I-TAC) 
Inducible by interferons 
CX3CL1 
(Fractalkine) 
Soluble fractalkine chemotracts T cells and monocytes whilst cell-bound fractalkine promotes 
leukocyte adhesion to activated endothelial cells. 
XCL1 
(Lymphotaxin) 
Small cytokine which attracts T cells 
Table 11 Candidate cytokines and chemokines for exploration using multi-analyte 
profiling and their roles 
 
Chapter 4 
 126 
4.5.6 Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases 
The candidate molecules explored in the MMP and TIMP Fluorokine panels, are outlined in 
Table 12. These MMPs and TIMPs were quantified on two different panels owing to 
interference between the two molecular groups if run together. MMP concentrations of 
greater than 66 ng/mL will interfere with the correct running of the TIMP assays. Plaque 
culture supernatants are diluted 1:4 for the MMP panel and 1:10 for the TIMP panel. 
 
MMP Role 
MMP1 Interstitial collagenase and has been implicated in arthritis 
MMP2 Gelatinase A degrading type IV collagen which is a major structural component of the basement 
membrane, and has involved in vascularisation and the inflammatory response 
MMP3 Stromelysin which is thought to be involved in the progression of atherosclerosis 
MMP7 Matrilysin 
MMP8 Neutophil collagenase, stored in secondary granules within neutrophils and is involved in the 
degradation of type I, II and III collagen  
MMP9 Gelatinase B degrades type IV and V collagen 
MMP12 Macrophage elastase degrades both soluble and insoluble elastin 
MMP13 Collagenase 3 which cleaves collagen type II more efficiently than it does collagen type I and III 
  
TIMP Role 
TIMP1 Inhibitory against most MMPs, is pro-proliferative and anti-apoptotic, and is inducible in response to 
cytokines 
TIMP2 Interacts with MMP 2 and MMP14, and is able to directly suppress the proliferation of endothelial 
cells hence may suppress a tissue response to angiogenic factors 
TIMP3  
TIMP4 Interacts with MMP2 
Table 12 Candidate matrix metalloproteinases and tissue inhibitors of 
metalloproteinases for exploration using multi-analyte profiling and their 
roles 
 
4.5.7 Multi-Analyte Profiling Assay Sensitivity 
The working MAP assay sensitivity was considered to be the lowest concentration on the 
standard curve. For the cytokine and chemokine panel this was 3.2 pg/mL. For the MMP and 
TIMP panels, these vary according to the analyte and are described in Table 13. 
 
MMP Sensitivity (pg/mL)  TIMP Sensitivity (pg/mL) 
MMP1 10.70  TIMP1 15.50 
MMP2 95.34  TIMP2 57.61 
MMP3 16.05  TIMP3 155.01 
MMP7 102.19  TIMP4 6.17 
MMP8 91.91    
MMP9 60.36    
MMP12 15.09    
MMP13 86.42    
Table 13 Multi-analyte profiling assay sensitivity for MMP and TIMP analysis 
The working MAP assay sensitivity was considered to be the lowest concentration on the 
standard curve. 
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4.5.8 Statistical Analysis 
Data was analyzed with Prism (version 5.02, GraphPad Software, Calif). Data was not 
normally distributed, therefore non-parametric methods were employed. A p-value
 
of 0.05 
was considered statistically significant. All tests
 
used were 2-tailed. 
 
4.5.9 Pathway Analysis 
Analyte differences between symptomatic and asymptomatic groups were converted to ratios. 
The resulting data sets were analyzed using Ingenuity Pathway Analysis (Ingenuity Systems, 
version 7.6). A 1.5-fold cut-off value was set to identify proteins whose expression was 
significantly increased or decreased, creating a highly interconnected protein network. 
Biological functions and processes were attributed to predefined canonical pathways by 
mapping the proteins in the network to functions in the Ingenuity ontology. A right-tailed 
Fisher‘s exact test was performed to determine the significance (p-value) of any over-
representation of proteins to a function compared to the result expected by a random set of 
proteins. 
 
4.6 RESULTS 
Sixty-seven patients (32 asymptomatic, 35 symptomatic) underwent carotid endarterectomy 
and consented to the use of their plaque tissue. There was a higher proportion of patients with 
a formal diagnosis of hypertension in the asymptomatic group compared with the 
symptomatic group (84% versus 66%; p=0.0329). The groups were otherwise well matched 
for demographic, clinical and pharmacotherapeutic parameters, as well as degree of carotid 
luminal stenosis (Table 14). There were no statistically significant relationships between these 
parameters and analyte levels, including no significant correlation between analyte levels and 
time from symptoms in the symptomatic group. 
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 Asymptomatic Symptomatic 
 n = 32 n = 35 
Age (years) 70 (60 – 78) 70 (67 – 74) 
Male gender 26 (81%) 23 (72%) 
Family history of arterial disease 9 (28%) 6 (19%) 
Smoking 18 (56%) 17 (53%) 
Hypertension 27 (84%) * 21 (66%) 
Diabetes mellitus 4 (13%) 11 (34%) 
Dyslipidaemia 20 (63%) 24 (75%) 
Serum Cholesterol 3.6 (3.4 – 4.5) 3.7 (3.3 – 4.4) 
Aspirin 24 (75%) 27 (77%) 
Statin 28 (88%) 33 (94%) 
ACEi or A2RA 20 (63%) 20 (57%) 
Plaque carotid luminal stenosis 81 (75 – 90) 88 (80 – 93) 
Time from symptoms to carotid 
endarterectomy (days) 
N.A. 20 (12 – 41) 
Table 14 Subject characteristics 
Demographic and clinical information relating to the patients from which the 67 studied 
arterial intimal segments were obtained. Data are presented as median (inter-quartile range), 
or number (%). There were significantly more patients with hypertension in the asymptomatic 
group compared to the symptomatic group (*p=0.0329; Fisher‟s exact test). ACEi, 
angiotensin converting enzyme inhibitor; A2RA, angiotensin 2 receptor antagonist; N.A., not 
applicable. 
 
4.6.1 Histological Analysis 
The minimum thickness of the fibrous cap was significantly less when analysing carotid 
plaque sections where collagen was stained with picro-sirius red (Figure 35). 
Immunohistochemistry confirmed that macrophage abundance (CD68, Figure 36A) and 
neovascularisation (CD31, Figure 36B) were significantly higher in sections from 
symptomatic compared with asymptomatic plaques. Furthermore, there was a significant 
positive correlation between CD68 and CD31 immunopositivity amongst matched pairs of 
sections (Figure 36C). 
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Figure 35 Plaque cap thickness on picro-sirius red staining 
A. A representative section of carotid plaque stained with picro-sirius red, showing clear 
distinction between necrotic core and fibrous cap, thus facilitating measurement of the cap at 
its thinnest point. This example section also illustrates thrombus on the plaque surface in the 
context of this symptomatic plaque.  B. Minimum cap thickness was measured, showing 
significantly thinner fibrous caps in symptomatic plaques (n=35 plaques; Mann Whitney test, 
bar denotes median). 
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Figure 36 CD68 and CD31 percentage area immunopositivity 
A. CD68 percentage area immunopositivity measured carotid plaque sections revealed 
macrophage abundance as being significantly higher in symptomatic compared with 
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asymptomatic (n=452 sections, Mann Whitney test, bar denotes median).  B. CD31 
immunopositivity was also significantly higher amongst symptomatic plaques (n=476 
sections, Mann Whitney test, bar denotes median).  C. There was a significant positive 
correlation between CD68 and CD31 immunopositivity (n=339 paired sections; Spearman 
r=0.3683; p<0.0001). 
 
4.6.2 Analyte Detection by Multi-Analyte Profiling 
The viable cell number obtained from carotid plaque enzymatic digestion was 11 ± 8.5 x10
6
 
(mean ± standard deviation). We were able to detect 41 of the 45 analytes (Table 15 and 
Table 16). There was a predominance of myeloid-derived over lymphoid-derived cytokines in 
keeping with the predominance of macrophages in the culture system, as previously published 
(Monaco et al. 2004; Monaco et al. 2009). The results are summarised in Table 15 and Table 
16 and illustrated in Figure 37, Figure 38 and Figure 39. 
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Cytokine 
Detected 
(n = 67) 
Asymptomatic (n = 32) Symptomatic (n = 35) Symptomatic versus 
Asymptomatic 
(p value, Mann 
Whitney Test) 
Median (pg/mL) 
Inter-Quartile 
Range (pg/mL) 
Median (pg/mL) 
Inter-Quartile 
Range (pg/mL) 
GM-CSF 64 69.25 21.93 - 241.4 246.7 95.15 - 433.1 p = 0.0061 
IFNα2 26 3.200 3.200 - 7.749 3.200 3.200 - 9.488 p = NS 
IFNγ 8 3.200 3.200 - 3.200 3.200 3.200 - 3.200 p = NS 
IL1α 45 3.395 3.200 - 36.46 16.62 6.132 - 45.03 p = 0.0225 
IL1β 58 16.58 4.031 - 67.61 72.89 20.36 - 263.0 p = 0.0037 
IL2 2 3.200 3.200 - 3.200 3.200 3.200 - 3.200 p = NS 
IL4 38 3.447 3.200 - 10.17 7.343 3.200 - 9.010 p = NS 
IL5 1 - - 3.200 3.200 - 3.200 - 
IL6 67 1790 579.2 – 4180 8398 1463 - 9892 p = 0.0118 
IL10 63 62.21 13.70 - 274.0 225.9 47.99 - 572.3 p = 0.0263 
IL11 0 - - - - - 
IL12 (p40) 38 6.939 3.200 - 29.76 9.607 3.200 - 18.66 p = NS 
IL12 (p70) 3 3.200 3.200 - 3.200 3.200 3.200 - 3.200 p = NS 
IL15 2 3.200 3.200 - 3.200 3.200 3.200 - 3.200 p = NS 
IL17 1 - - 3.200 3.200 - 3.200 - 
IL29 0 - - - - - 
M-CSF 63 330.9 180.1 - 586.7 552.1 329.4 - 846.4 P = 0.0082 
sCD40L 26 13.92 4.766 - 25.00 31.57 14.54 - 71.29 p = 0.0162 
TNFα 65 148.1 61.67 - 319.5 436.3 147.7 - 1032 p = 0.0063 
TNFβ 0 - - - - - 
VEGF 51 35.68 3.200 - 62.74 38.29 16.00 - 67.23 p = NS 
       
Chemokine 
Detected 
(n = 67) 
Asymptomatic (n = 32) Symptomatic (n = 35) Symptomatic versus 
Asymptomatic 
(p value, Mann 
Whitney Test) 
Median (pg/mL) 
Inter-Quartile 
Range (pg/mL) 
Median (pg/mL) 
Inter-Quartile 
Range (pg/mL) 
CCL2 67 318.3 121.3 - 1050 1180 369.4 - 3757 p = 0.0162 
CCL5 65 43.81 26.85 - 83.11 120.5 56.44 - 203.4 p = 0.0002 
CCL14a 67 34.53 25.44 - 66.13 62.36 29.64 - 86.34 p = NS 
CCL19 0 - - - - - 
CCL20 45 9.770 9.770 - 25.27 53.10 14.62 - 100.7 p = 0.0003 
CXCL6 9 9.770 9.770 - 9.770 9.770 9.770 - 9.770 p = NS 
CXCL7 67 118.9 64.24 - 271.9 178.7 97.31 - 386.5 p = NS 
CXCL9 51 80.60 48.83 - 224.9 252.7 112.2 - 400.0 p = 0.0011 
CXCL10 60 13.92 4.766 - 25.00 31.57 14.54 - 71.29 p = 0.0162 
CXCL11 6 1.950 1.950 - 1.950 1.950 1.950 - 1.950 p = NS 
CX3CL1 59 16.00 9.607 - 20.74 16.00 9.607 - 18.37 p = NS 
XCL1 38 19.53 19.53 - 19.53 19.53 19.53 - 19.53 p = NS 
Table 15 Analyte detection – cytokines and chemokines 
Cells were isolated from carotid atherosclerotic plaques as a mixed cell suspension and 
cultured at 1x10
6
 cells/mL for 24 hours, at which point the supernatant was aspirated. In this 
unstimulated system, the cells displayed a spontaneous cytokine and chemokine production. 
All samples were analysed in duplicate and data are given to 4 significant figures. IL, 
interleukin; GM-CSF, granulocyte macrophage colony-stimulating factor; TNF, tumor 
necrosis factor; IFN, interferon; VEGF, vascular endothelial growth factor; sCD40L, soluble 
cluster of differentiation 40 ligand; M-CSF, macrophage colony-stimulating factor; CX3CL1, 
fractalkine; CCL2, monocyte chemotactic protein 1 (MCP1); CCL5, regulated upon 
activation, normal T cell expressed and secreted (RANTES); CXCL6, granulocyte 
chemotactic protein 2 (GCP2); CXCL7, neutrophil activating protein 2 (NAP2); CXCL9, 
monokine induced by interferon gamma (MIG); CXCL10, interferon-inducible protein 10 
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(IP10); CXCL11, interferon-inducible T cell alpha chemoattractant (I-TAC); CCL14a, 
hemofiltrate CC chemokine 1 (HCC1); CCL19, inflammatory protein 3β (MIP3β); CCL20, 
macrophage inflammatory protein 3α (MIP3α); XCL1, lymphotactin; NS, non-significant. 
 
 
Matrix 
Metallo-
proteinase 
Detected 
(n =67) 
Asymptomatic (n = 32) Symptomatic (n = 35) Symptomatic versus 
Asymptomatic 
(p value, Mann 
Whitney Test) 
Median 
(pg/mL) 
Inter-Quartile 
Range (pg/mL) 
Median 
(pg/mL) 
Inter-Quartile 
Range (pg/mL) 
MMP1 64 625.0 182.3 - 2007 1753 433.4 - 8569 p = 0.0366 
MMP2 58 679.3 511.2 – 1284 892.7 496.8 - 1291 p = NS 
MMP3 36 16.05 16.05 - 131.2 118.2 16.05 - 341.9 p = 0.0076 
MMP7 37 255.5 102.2 - 1016 686.8 102.2 - 2129 p = NS 
MMP8 47 404.0 91.91 - 1067 616.6 378.0 - 1903 p = 0.0464 
MMP9 66 3456 1309 - 8011 8391 3799 - 22050 p = 0.0039 
MMP12 67 480.3 257.4 - 1322 666.7 272.3 - 1278 p = NS 
MMP13 3 86.42 86.42 - 86.42 86.42 86.42 - 86.42 p = NS 
       
Tissue 
Inhibitor of 
Metallo-
proteinase 
Detected 
(n =67) 
Asymptomatic (n = 32) Symptomatic (n = 35) Symptomatic versus 
Asymptomatic 
(p value, Mann 
Whitney Test) 
Median 
(pg/mL) 
Inter-Quartile 
Range (pg/mL) 
Median 
(pg/mL) 
Inter-Quartile 
Range (pg/mL) 
TIMP1 67 4451 2936 - 9697 4014 2201 - 9970 p = NS 
TIMP2 67 5829 3829 - 131400 42560 3870 - 119500 p = NS 
TIMP3 9 155.0 155.0 - 155.0 155.0 155.0 - 155.0 p = NS 
TIMP4 3 - - 6.170 6.170 - 6.170 - 
Table 16 Analyte detection – MMPs and TIMPs 
Cells were isolated from carotid atherosclerotic plaques as a mixed cell suspension and 
cultured at 1x10
6
 cells/mL for 24 hours, at which point the supernatant was aspirated. In this 
unstimulated system, the cells displayed a spontaneous matrix metalloproteinase (MMP) and 
tissue inhibitor of metalloproteinases (TIMP) production. All samples were analysed in 
duplicate and data are given to 4 significant figures. NS, non-significant. 
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Figure 37 Plaque culture supernatant levels of cytokines in distinguishing 
symptomatic from asymptomatic plaques 
Cells were isolated from carotid atherosclerotic plaques as a mixed cell suspension and 
cultured at 1x10
6
 cells/mL for 24 hours in the absence of any stimulus. Supernatants were 
collected, aliquoted and frozen at -80°C for single batch analysis. Multi-analyte profiling was 
accomplished on a Luminex 100 platform. Levels of cytokine production in vitro were 
significantly higher in atheroma cells from symptomatic versus asymptomatic plaques for the 
following mediators: A. Granulocyte macrophage colony-stimulating factor (GM-CSF); B. 
Tumor necrosis factor α (TNFα); C. Interleukin (IL) 1α; D. IL1β; E. IL6; F. IL10; G. Soluble 
CD40 ligand (sCD40L); H. Macrophage colony-stimulating factor (M-CSF). Each dot 
represents a single donor; medians are shown as dark horizontal lines; ** p < 0.005; * p < 
0.05 (Mann Whitney test; n = 67). 
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Figure 38 Plaque culture supernatant levels of chemokines in distinguishing 
symptomatic from asymptomatic plaques 
Cells were isolated from carotid atherosclerotic plaques as a mixed cell suspension and 
cultured at 1x10
6
 cells/mL for 24 hours in the absence of any stimulus. Supernatants were 
collected, aliquoted and frozen at -80°C for single batch analysis. Multi-analyte profiling was 
accomplished on a Luminex 100 platform. Levels of chemokine production in vitro were 
significantly higher in atheroma cells from symptomatic versus asymptomatic plaques for the 
following mediators: A. CCL2 (monocyte chemotactic protein 1; MCP1); B. CCL5 (regulated 
upon activation, normal T cell expressed and secreted; RANTES); C. CXCL9 (monokine 
induced by interferon gamma; MIG); D. CXCL10 (interferon-inducible protein 10; IP10); E. 
CCL20 (macrophage inflammatory protein 3α; MIP3α). Each dot represents a single donor; 
medians are shown as dark horizontal lines; *** p < 0.0005; ** p < 0.005; * p < 0.05 (Mann 
Whitney test; n = 67). 
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Figure 39 Plaque culture supernatant levels of matrix metalloproteinases in 
distinguishing symptomatic from asymptomatic plaques 
Cells were isolated from carotid atherosclerotic plaques as a mixed cell suspension and 
cultured at 1x10
6
 cells/mL for 24 hours in the absence of any stimulus. Supernatants were 
collected, aliquoted and frozen at -80°C for single batch analysis. Multi-analyte profiling was 
accomplished on a Luminex 100 platform. Levels of matrix metalloproteinase (MMP) 
production in vitro were significantly higher in atheroma cells from symptomatic versus 
asymptomatic plaques for the following mediators: A. MMP1; B. MMP3; C. MMP8; D. 
MMP9. Each dot represents a single donor; medians are shown as dark horizontal lines; ** p 
< 0.005; * p < 0.05 (Mann Whitney test; n = 67). 
 
4.6.3 Cytokines 
In the atheroma cell culture system, there was a significantly higher production of classical 
pro-inflammatory cytokines from symptomatic compared with asymptomatic atherosclerosis. 
Levels of tumor necrosis factor (TNF)-α (median 436.6 pg/mL versus 148.1 pg/mL; 
p=0.0063), interleukin (IL)-1 (16.62 pg/mL versus 3.395 pg/mL; p=0.0225), IL1 (72.89 
pg/mL versus 16.58 pg/mL; p=0.0037), IL6 (8398 pg/mL versus 1790 pg/mL; p=0.0118) and 
soluble CD40 ligand (31.57 pg/mL versus 13.92 pg/mL; p=0.0162) were significantly higher 
in the symptomatic than asymptomatic supernatant. Interestingly, IL10 production was also 
higher in symptomatic atheroma cell culture (225.9 pg/mL versus 62.21 pg/mL; p=0.0263). 
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4.6.4 Chemokines 
CCL2 (monocyte chemotactic protein, MCP1; 1180 pg/mL versus 318.3 pg/mL; p=0.0162) 
and CCL5 (regulated on activation normal T cell expression and secreted, RANTES; 120.5 
pg/mL versus 43.81 pg/mL; p=0.0002) production was higher in symptomatic atheroma 
culture. 
 
CXCL9 (monokine induced by interferon gamma, MIG; 252.7 pg/mL versus 80.60 pg/mL; 
p=0.0011) and CXCL10 (interferon-inducible protein 10, IP10; 31.57 pg/mL versus 13.92 
pg/mL; p=0.0162) were higher from symptomatic plaques. Both these chemokines are known 
to be induced by interferon γ (IFNγ). Of note, IFNγ was detected in 8 of the 67 cultures 
(Table 15) and no difference was demonstrated on the basis of symptomatic status. 
 
CCL20, also known as liver and activation-regulated chemokine (LARC) or macrophage 
inflammatory protein-3α (MIP-3α), was significantly higher in the symptomatic group than 
asymptomatic (53.10 pg/mL versus 9.770 pg/mL; p=0.0003).  
 
4.6.5 Colony Stimulating Factors 
Levels of production of both granulocyte-macrophage colony-stimulating factor (GM-CSF; 
246.7 pg/mL versus 69.25 pg/mL; p=0.0061) and macrophage colony-stimulating factor (M-
CSF; 552.1 pg/mL versus 330.9 pg/mL; p=0.0082) were significantly higher in cultures 
obtained from symptomatic patients. 
 
4.6.6 Matrix Metalloproteinases 
MMP1 (1753 pg/mL versus 625.0 pg/mL; p=0.0366), MMP3 (118.2 pg/mL versus 16.05 
pg/mL; p=0.0076), MMP8 (616.6 pg/mL versus 404.0 pg/mL; p=0.0464) and MMP9 (8391 
pg/mL versus 3456 pg/mL; p=0.0039) levels were significantly higher in symptomatic than 
asymptomatic plaques. 
 
4.6.7 Tissue Inhibitors of Metalloproteinases 
There was no significant difference in the production of TIMP1 (4014 pg/mL versus 4451 
pg/mL; p=NS), TIMP2 (42560 pg/mL vs 5829 pg/mL; p=NS), TIMP3 (155.0 pg/mL versus 
155.0 pg/mL; p=NS) and TIMP4 (6.170 pg/mL versus 6.170 pg/mL; p=NS) between 
symptomatic and asymptomatic atherosclerosis. 
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4.6.8 Analyte Inter-Relationships and Pathway Analysis 
The inter-relationship between analytes were computed statistically and via the use of 
Ingenuity pathways. The statistical analysis revealed significant relationship between analytes 
(Figure 40), for example the concentrations of classical pro-inflammatory cytokines TNFα, 
IL1α and IL1β were positively correlated to the IFNγ–dependent chemokine CXCL10 
(p<0.001), colony stimulating factors GM-CSF (p>0.001) and M-CSF (p<0.001) and also, of 
note, to IL10 production (p>0.001). Moreover, the pro-inflammatory cytokines displayed 
positive correlation with levels of the catabolic enzymes MMP1 (p<0.001), MMP3 (p<0.001) 
and MMP9 (p≤0.005). 
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Figure 40 Analyte inter-relationships 
Cells were isolated from carotid atherosclerotic plaques as a mixed cell suspension and 
cultured at 1x10
6
 cells/mL for 24 hours, at which point the supernatant was aspirated. In this 
unstimulated system, the cells displayed a spontaneous protein production. All samples were 
analysed in duplicate. The inter-relationship of cytokines, chemokine, matrix 
metalloproteinase (MMP) and tissue inhibitor of metalloproteinases (TIMP) was assessed 
with Spearman correlations. Statistically significant (p<0.05) positive correlations are 
displayed in green and negative correlations highlighted in red. IL, interleukin; GM-CSF, 
granulocyte macrophage colony-stimulating factor; TNF, tumor necrosis factor; IFN, 
interferon; VEGF, vascular endothelial growth factor; sCD40L, soluble cluster of 
differentiation 40 ligand; M-CSF, macrophage colony-stimulating factor; CX3CL1, 
fractalkine; CCL2, monocyte chemotactic protein 1 (MCP1); CCL5, regulated upon 
activation, normal T cell expressed and secreted (RANTES); CXCL6, granulocyte 
chemotactic protein 2 (GCP2); CXCL7, neutrophil activating protein 2 (NAP2); CXCL9, 
monokine induced by interferon gamma (MIG); CXCL10, interferon-inducible protein 10 
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(IP10); CXCL11, interferon-inducible T cell alpha chemoattractant (I-TAC); CCL14a, 
hemofiltrate CC chemokine 1 (HCC1); CCL19, inflammatory protein 3β (MIP3β); CCL20, 
macrophage inflammatory protein 3α (MIP3α); XCL1, lymphotactin; NS, non-significant. 
 
 
Bioinformatic analysis identified detected soluble analytes within seven networks (Table 17). 
A merge of networks 2 and 3 is shown in Figure 41. The canonical pathways associated with 
differences between data sets obtained from symptomatic and asymptomatic patients are 
shown in Figure 42. The most statistically significant of the canonical pathways raised in 
Ingenuity were: role of cytokines in mediating communication between immune cells 
(p=9.64x10
-26
); altered T and B cell signalling in rheumatoid arthritis (p=5.46x10
-23
); 
communication between innate and adaptive immune cells (p=1.27x10
-22
); role of 
hypercytokinemia / hyperchemokinaemia in the pathogenesis of influenza (p=1.88x10
-22
); role 
of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis (p=2.37x10
-17
); 
atherosclerosis signalling (p=4.58x10
-16
); and T helper cell differentiation (p=5.37x10
-14
). 
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No. Molecules in Network Key Functions 
1 
C1q, Casein, collagen, Collagen type I,  Collagen type III, Collagen type IV, 
Collagen(s), Cyclooxygenase, Eotaxin, ERK1/2, Fcer1, Fibrin, Fibrinogen, Gelatinase, 
Igfbp, Integrin, Laminin, MMP2, MMP3, MMP7, MMP8, MMP9, MMP12, MMP13, 
MMP1 (includes EG:4312), PPBP, Secretase gamma, STAT1/3/5 dimer, Tenascin, Tgf 
beta, Timp, TIMP2, TIMP3, TIMP4, Trypsin 
Post-Translational 
Modification, Connective 
Tissue Disorders, Genetic 
Disorder 
2 
Angiotensin II receptor type 1, C/ebp, CCL20, Cebp, CX3CL1, CXCL6, CXCL9, 
CXCL10, CXCL11, Elastase, ETS, Ferritin, Ggt, HLA-DR, Ifn, IFN alpha/beta, Ifn 
gamma, IFN TYPE 1, IL23, IL-1R, IL1/IL6/TNF, IL12B, JUN/JUNB/JUND, LTA, MHC 
CLASS I (family), NFkB (complex), NfkB-RelA, Pro-inflammatory Cytokine, 
REL/RELA/RELB, SAA, sphingomyelinase, TH1 Cytokine, Tlr, Tnf, Tnf receptor 
Cell-To-Cell Signaling and 
Interaction, Infection 
Mechanism, Infectious 
Disease 
3 
Akt, Ap1, CCL2, CCL5, CD3, CD80/CD86, Collagen Alpha1, CSF1, CSF2, 
Cytochrome p450, Ikb, Ikk (family), IL1, IL2, IL17A (includes EG:3605), IL1A, JINK1/2, 
Lfa-1, MAP2K1/2, Mek, N-cor, NFAT (complex), Nfat (family), NFkB (family), NfkB1-
RelA, p70 S6k, Pak, Pde4, Pdgf, Rap1, Rxr, Sphk, TCR, VitaminD3-VDR-RXR, XCL1 
Antigen Presentation, Cell-
To-Cell Signaling and 
Interaction, Hematological 
System Development and 
Function 
4 
Angiotensin II receptor type 1, C1R, CCL1, CCL8, CCL9, CCL20, CCL21, CCL22, 
CCR2, CHEMOKINE, Ck2, CX3CL1, CXCL1, CXCL5, CXCL6, CXCL9, CXCL11, 
CXCL16, IKK (complex), IL-1R, KLF1, LTBR, MAP4K4, Neurotrophin, NFkB 
(complex), NFKBIE, PELI1, PELI3, PTPN2, RNASE2, S100B, spermine, TFPI, TLR8 
(includes EG:51311), TNFRSF6B 
Cellular Movement, 
Hematological System 
Development and 
Function, Immune Cell 
Trafficking 
5 
Adaptor protein 1, Alp, Arginase, Calpain, Caspase, Caspase 3/7, Cpla2, Creb, Cyclin 
A, Cyclin E, Cytochrome c, Growth hormone, Histone h3, Histone h4, HLA Class I, 
Hsp27, Hsp70, Hsp90, IFNA2, IFNG, IL1B, IRG, LDL, Mlc, Nos, PLA2, Ptger, Rb, 
RNA polymerase II, Rsk, Smad, Sod, TNF, Tni, VEGFA 
Lipid Metabolism, Small 
Molecule Biochemistry, 
Cardiovascular System 
Development and Function 
6 
ALT, Fc gamma receptor, Fcgr3, Gm-csf, GOT, HISTONE, HLA-DQ, IFN Beta, Ifnar, 
Iga, Ige, IgG, IgG1, IgG2a, Igm, IL5, IL10, IL15, IL-2R, IL12 (complex), Il12 receptor, 
Il8r, Immunoglobulin, Interferon alpha, JAK, Laminin1, Ldh, MHC Class I (complex), 
MHC Class II (complex), PI3K (complex), PLC gamma, STAT5a/b, TH2 Cytokine, 
TLR2/TLR4, VAV 
Cellular Development, 
Hematological System 
Development and 
Function, Hematopoiesis 
7 
ADCY, Alpha tubulin, CCL14, ERK, Estrogen Receptor, F Actin, Focal adhesion 
kinase, FSH, G protein, G protein alphai, Gsk3, hCG, Hemoglobin, IL4, IL6, IL12 
(family), Insulin, Jnk, Lh, Mapk, Mmp, NGF, P110, P38 MAPK, p85 (pik3r), PDGF BB, 
Pka, Pkc(s), Pld, Rac, Ras, Ras homolog, Shc, STAT, Vegf 
Cardiovascular System 
Development and 
Function, Tissue 
Morphology, Cell-To-Cell 
Signaling and Interaction 
Table 17 Biological networks in human carotid atherosclerosis 
The seven networks into which bioinformatic analysis placed detected soluble analytes. The 
molecules and key functions of the networks are shown. Detected analytes are highlighted in 
bold. CSF1, colony stimulating factor 1 (M-CSF); CSF2, colony stimulating factor 2 (GM-
CSF); LTA, lymphotaxin α (tumor necrosis factor β); PPBP, pro-platelet basic protein 
(CXCL7). 
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Figure 41 Network analysis 
The inter-relationship between cytokines, chemokines and matrix metalloproteinases as constructed through application of a bioinformatic approach with 
Ingenuity Pathway Analysis. Key canonical pathways (CP) are highlighted at the periphery of the network. 
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Figure 42 Key canonical pathways in human carotid atherosclerosis 
The bars relate to the top Y axis show the –log(p-value), reflecting the likelihood that a 
specific canonical pathway and the data are related by chance. The points related to the 
lower Y axis show the ratio of analytes we have detected by multi-analyte profiling divided by 
the total number of molecules known to make up that pathway. HIF1α, hypoxia inducible 
factor 1α; IL, interleukin; IRF, interferon regulatory factor; LXR/RXR, liver X receptor / 
retinoid X receptor; MSP, macrophage-stimulating protein; NFκB, nuclear factor κB; RON, 
receptor d'origine nantais; TREM1, triggering receptor expressed on myeloid cells 1. 
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4.7 DISCUSSION 
The aim of this study was to characterise the inflammatory microenvironment of the high-risk 
plaque with a combination of multianalyte profiling and pathway analysis. It was identified 
that the recently unstable human carotid plaque contains a pro-inflammatory 
microenvironment that may favour the recruitment of Th1 lymphocytes and monocytes and 
the generation of M1-polarised macrophages (Figure 43). 
 
 
Figure 43 A schematic summarising the soluble analytes with differential protein 
production between symptomatic and asymptomatic carotid 
atherosclerosis, reflecting a predominance of pro-inflammatory M1-
macrophage polarisation 
 
In this study, bioinformatic analysis showed inflammatory cell recruitment featured as one of 
the hallmarks of human atherosclerosis instability, with cell-to-cell signalling and interaction, 
and immune cell trafficking, with leukocyte extravasation signalling emerging as a top 
canonical pathways. In particular, unstable atherosclerosis was associated with an increased 
production of CCL2/MCP1 and CCL5/RANTES. CCR2-/- in the context of apolipoprotein E 
(apoE)-/- (Boring et al. 1998) and low density lipoprotein receptor (LDLR)-/- (Gu et al. 1998) 
mice independently resulted in markedly decreased lesion formation. In human 
atherosclerosis, CCL2 is elevated in patients with proven coronary artery disease compared 
with individuals with normal angiograms (Martinovic et al. 2005). No association has 
previously been found between CCL2 production and unstable atherosclerosis. CCL5 
expression in atherosclerotic plaques is associated with macrophages, monocytes, smooth 
muscle cells and T lymphocytes (Ahn et al. 2007). CCL5 recognition is promiscuous and 
involves CCR1, CCR3 and CCR5, with the functions of CCR1 and CCR5 now shown to be 
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distinct (Potteaux et al. 2005; Potteaux et al. 2006; Braunersreuther et al. 2007; Quinones et 
al. 2007; Zernecke and Weber 2010). The complexity of the biological role of 
CCL5/RANTES in atherosclerosis is reflected by contradictory results in clinical studies 
(Rothenbacher et al. 2006; Cavusoglu et al. 2007; Kraaijeveld et al. 2007). 
 
Ingenuity pathway analysis also implicated the MSP/RON signalling pathway as important in 
the difference between symptomatic and asymptomatic atherosclerosis (Figure 44). 
 
 
Figure 44 The MSP/RON Pathway 
Ingenuity pathway analysis highlighted the MSP/RON pathway (known to play a role in 
inflammation and the response to tissue injury) as being important in the difference between 
symptomatic and asymptomatic atherosclerosis. MSP‟s inactive precursor Pro-MSP is 
produced in the liver and is activated by proteolytic cleavage in the context of tissue injury. 
RON is expressed by monocytes and macrophages. When MSP binds RON, RON kinase and 
second messenger pathways are activated (Correll et al. 1997; Nanney et al. 1998; 
Danilkovitch and Leonard 1999). DAMP, danger-associated molecular pattern; IL, 
interleukin; M-CSF, macrophage colony stimulating factor; MSP, macrophage-stimulating 
protein; PAMP, pathogen-associated molecular pattern; RON, receptor d'origine nantais; 
TNF, tumour necrosis factor. 
 
T lymphocytes are also recruited to atherosclerotic lesions, with IFNγ-producing Th1 
lymphocytes particularly implicated in their pathogenesis. Deletion of IFNγ and its receptors 
have a profound effect on atherosclerotic plaque development (Koga et al. 2007a; Koga et al. 
2007b). Activation of the chemokine receptor CXCR3 by IFNγ-inducible proteins CXCL9 
and CXCL10 is required for the recruitment of CXCR3-positive Th1 in atherosclerosis (Mach 
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et al. 1999). A murine CXCL10-/- apoE-/- double knockout exhibited reduced aortic 
atherosclerosis, with reduced CD4+ and CXCR3+ T cells, and increased IL10 and 
transforming growth factor (TGF)-β1 expression (Heller et al. 2006), highlighting the 
importance of CXCL10/CXCR3 signalling in regulating T cell responses in atherosclerosis. 
Human carotid atheroma-associated endothelial cells, smooth muscle cells and macrophages 
all express CXCL10, with CXCL9 expressed by endothelial cells and macrophages (Mach et 
al. 1999). CXCL10 levels are higher in individuals with coronary artery disease than in 
controls (Rothenbacher et al. 2006). It has been shown for the first time that production of the 
IFNγ–inducible CXCR3 ligands CXCL9 and CXCL10 is significantly higher in symptomatic 
than asymptomatic atherosclerosis, underlining the importance of the recruitment of Th1 
lymphocytes in carotid instability. Interestingly, CD40L – also increased in unstable 
atherosclerosis in this study – has previously been found to have an additive effect together 
with IFNγ in inducing CXCL10 production (Mach et al. 1999). Communication between 
innate and adaptive immune cells, highlighted as a significant canonical pathway in 
symptomatic plaques, also concurs with the positive correlation of CXCL10 with each of 
IL1α, IL1β and TNFα. Pattern recognition receptors as inducers of the innate immune 
signalling supports the findings from previous work in this context (Monaco et al. 2004; 
Monaco et al. 2009). 
 
It was not possible to consistently detect IFNγ production by plaques cells, however 
expression of IFNγ-inducible chemokines could represent an IFNγ ‗signature‘ that marks the 
high-risk carotid plaque. It is likely that IFNγ production is strictly confined to the early 
instability phase and only its late effectors are detectable at the time of carotid 
endarterectomy. In support of these observations, circulating monocytes isolated from patients 
with unstable angina exhibit signatures of IFNγ activation, when compared to chronic stable 
angina (Liuzzo et al. 2001b). 
 
CCL20 interacts with CCR6 and is responsible for the chemotraction of immature dendritic 
cells, and effector/memory T- and B-cells (Schutyser et al. 2003). CCL20 production is 
known to be augmented in a number of human inflammatory conditions (Mosser and Edwards 
2008) including rheumatoid arthritis (Chabaud et al. 2001; Matsui et al. 2001; Chevrel et al. 
2002; Page et al. 2002) similarities to which have been drawn by the pathway analysis 
performed in this work. This study is the first to show CCL20 production in atherosclerosis 
and also that CCL20 production is significantly higher in plaques responsible for recent 
cerebrovascular events. In a murine model of rheumatoid arthritis, CCR6 expression was 
shown on IL17-producing Th17 lymphocytes, as well as CCL20 production by Th17 cells 
(Hirota et al. 2007). Th17 cells, which are distinct from Th1 and Th2 (Harrington et al. 2005), 
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have been demonstrated in mouse (Smith et al. 2010; Xie et al. 2010) and human 
atherosclerosis (Eid et al. 2009; Taleb et al. 2009). The expression of CCL20 may therefore 
relate to Th17 recruitment to the lesions, as supported by the identification of IL17 signalling 
as a key canonical pathway by bioinformatic analysis. It is yet unclear, however, whether 
IL17 has a detrimental or protective role in atherosclerosis (Eid et al. 2009; Taleb et al. 2009; 
Taleb et al. 2010). Importantly, CCL20 is also up-regulated by IFNγ (Martinez et al. 2006; 
Mosser and Edwards 2008). In support of this, the production of CXCL10 and CCL20 was 
confirmed to be positively correlated. 
 
A recent review by Gordon and Martinez, proposed a sequential four-stage paradigm of 
macrophage activation: differentiation; priming (also termed polarisation); activation; and 
resolution (Gordon and Martinez 2010). Macrophages are plastic and capable of modifying 
their behaviour upon microenvironmental cues, undergoing so-called classic (or M1) 
‗activation‘ in response to bacterial motifs (e.g. LPS) and IFNγ, a type of priming that mirrors 
Th1 lymphocyte polarisation. They produce pro-inflammatory cytokines such as IL1, IL12 
and TNFα (Mantovani et al. 2004). Alternative (or M2) macrophage polarisation was first 
identified upon exposure to IL4 (Gordon and Martinez 2010). M2 macrophages are 
heterogenous and can be generated by different inflammatory and opsonic signals: IL4/IL13, 
immune complexes, TGFβ and IL10. Lipids are also known to affect macrophage activation 
patterns (Gordon and Martinez 2010; Kadl et al. 2010). Interestingly, M2 macrophages 
accumulate first in murine atherosclerosis, while lesion progression correlates with 
predominance of M1 over M2 macrophages (Khallou-Laschet et al. 2010). Both IFNγ and 
TLR4 – the LPS receptor – are implicated in M1 polarisation (Martinez et al. 2008) and their 
genetic deletion reduces atherosclerosis development (Michelsen et al. 2004). 
 
The chemokine data presented here pointing toward an IFNγ signature is also supported by a 
significant elevation of cytokines typically produced by classically primed macrophages, 
namely TNF, IL6, IL1 and IL1, in unstable plaques. Elevated plasma TNF levels have 
been found to be predictive of recurrent coronary events following myocardial infarction 
(Ridker et al. 2000). Similarly, IL6 plasma levels are higher in patients with unstable than 
stable angina (Biasucci et al. 1996). The analytes seen to be more abundant in atherosclerosis 
responsible for recent symptoms comply largely with the cytokine and chemokine signature 
for M1 polarisation described by Martinez et al in study of transcriptional profiling in human 
monocyte-to-macrophage polarisation (Martinez et al. 2006). LPS- and IFNγ-differentiated 
M1 macrophages had increased gene expression of TNF (21 fold), IL6 (7 fold), CXCL10 (59 
fold), CXCL9 (58 fold), CCL5 (19 fold) and CCL20 (7 fold), than IL4-differentiated M2 
macrophages (Martinez et al. 2006). A similar pattern has been observed when comparing 
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murine macrophages, with increased TNFα, IL1α, IL1β, IL6, M-CSF, CCL2, CCL5, CXCL9 
and CXCL10 gene expression in M1 over M2 macrophages (Kadl et al. 2010). M1 
predominance is supported by identification of IL12 signalling and production in 
macrophages as a key canonical pathway in symptomatic human atherosclerosis. The 
increased production of IL12 by symptomatics in the atheroma culture system employed did 
not reach statistical significance, in part due to IL12 protein detection in under half of 
supernatants. 
 
The differentiation of monocytes to macrophages is essential in atherosclerotic lesion 
development; M-CSF-deficient mice are atherosclerosis resistant (Smith et al. 1995). Growth 
factors have a role in conditioning preferential paths of macrophage activation and M-CSF 
alone may drive the acquisition of M2 properties (Martinez et al. 2006). GM-CSF-
differentiated macrophages recapitulate many features of classically activated macrophages, 
including production of inflammatory cytokines such as TNFα and IL6, and their involvement 
in tissue destruction (Martinez et al. 2006). In this study, both M-CSF and GM-CSF are 
increased in unstable plaque pointing to an important role for macrophage differentiation in 
plaque instability, implicating a toll of GM-CSF for the first time in this process. In the 
context of rheumatoid arthritis, a mechanism of interaction between macrophages and 
neighbouring cells has been proposed, whereby macrophages release IL1 and TNFα which 
stimulate M-CSF and GM-CSF from these neighbouring cells (Hamilton 1993). Indeed, levels 
of production of GM-CSF in this study significantly correlated with those of IL1α, IL1β and 
TNFα, supporting the possibility that similar mechanisms might be at play in atherosclerosis. 
 
IL10 is anti-atherogenic (Mallat et al. 1999a), and is associated with regulatory T cells(Taleb 
et al. 2008) and a specific subset of M2c or regulatory macrophages (Mosser and Edwards 
2008). In apoE-/- mice, IL10 was more abundant in plaques with a vulnerable phenotype 
(Cheng et al. 2007). Intra-plaque haemorrhage is a promoter of lesion progression (Virmani et 
al. 2005) and carotid plaque-responsible symptomatology (Takaya et al. 2006). In human 
coronary atheroma, CD163+ macrophages have been detected at sites of haemorrhage (Boyle 
et al. 2009) and linked to an IL10 positive feedback loop. Hence the increased IL10 observed 
in the symptomatic group may reflect the presence of such CD163+ macrophages in regions 
of haemorrhage or plaque remodelling.  
 
There is an inextricable link between inflammation and matrix degradation in atherosclerosis 
(Galis et al. 1994a). Production of MMPs 1, 3, 8 and 9 is significantly higher within 
symptomatic compared with asymptomatic plaques. Moreover, the top network identified by 
pathway analysis is pertinent to matrix degradation. Previous studies have observed that 
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MMPs 1, 3, 8 and 9 co-localise with macrophages (Galis et al. 1994b; Pasterkamp et al. 2000) 
and are related to unstable atherosclerosis (Loftus et al. 2000; Molloy et al. 2004). In keeping 
with this data, recent work has confirmed the association of MMPs 8 and 9 with an 
inflammatory human carotid atherosclerosis phenotype (Sluijter et al. 2006; Newby et al. 
2009). Interestingly, MMP1, 3 and 9 concentrations were found to positively correlate with 
GM-CSF, TNFα, IL1α, IL1β, IL6, IL10, CCL2, CCL5, CCL20 and CXCL10 protein 
production. 
 
To date, macrophage polarisation data is concentrated largely on the murine system (Gordon 
2003), with studies showing both conservation (Gordon and Taylor 2005) and discrepancy 
(Raes et al. 2005; Scotton et al. 2005; Martinez et al. 2006; Mantovani et al. 2009) in 
macrophage heterogeneity between mice and humans. It has been proposed that macrophage 
polarisation and activation have a role in atherosclerosis (Mantovani et al. 2009). However, 
previous studies on macrophage polarisation have focused on experimental animal 
atherosclerosis or gene expression of monocytes differentiated in vitro, including using M-
CSF and GM-CSF (Hashimoto et al. 1999). Cell phenotypes generated in vitro might not 
reflect cells that have matured within atherosclerotic plaques in vivo, with exposure to a 
complex cytokine and growth factor microenvironment (Johnson and Newby 2009). This 
underlines the utility of employing an unstimulated mixed atheroma-derived cell culture 
representative of in vivo conditions. Of note, differences in cytokine, chemokine and MMP 
expression were evident despite 61 of the 67 patients in this study being subject to long-term 
statin therapy (Tang et al. 2009). This suggests that tailored therapies targeting inflammation 
may deliver an advantage as compared to standard treatment in terms of modulating 
inflammation. 
 
4.7.1 Limitations of the Study 
It would have been of considerable interest to demonstrate the TIMP3
low
 MMP14
high
 
phenotype of the highly invasive foam-cell macrophages as previously described (Johnson et 
al. 2008). With regards to TIMP3, only 9 out of the 67 samples had detectable levels. 
Furthermore MMP14 (membrane type-1 MMP), being membrane bound, is not amenable to 
analysis. This highlights the limitations of the atheroma cell culture and supernatant analysis 
system employed in this study. 
 
The utilisation of mixed cell type culture has the intrinsic limitation of not allowing the 
precise identification of which cell type is ultimately responsible for the production of which 
cytokine(s). Tissue size and hence number of cells extracted are important limiting factors. 
Moreover, a high amount of cell loss and death are observed with further isolation attempts. 
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Additional technological development is necessary prior to enabling cell isolation and single 
cell type analyses. 
 
4.7.2 Conclusions 
This data demonstrate that symptomatic human atherosclerotic carotid disease is associated 
with a cytokine and chemokine pattern consistent with the predominance of pro-inflammatory 
M1-type macrophage polarisation. Furthermore, IFNγ signatures are observed, including the 
novel finding of CCL20 with its significant elevation in symptomatic atherosclerosis. The role 
of anti-inflammatory and anti-atherogenic cytokines such as IL10 are highlighted in 
attempting to offer regulation in the plaque microenvironment. This study has implications for 
future therapeutic and diagnostic applications for high-risk atherosclerosis. 
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5 THE RELATIONSHIP 
BETWEEN LATE-PHASE 
CONTRAST ENHANCED 
ULTRASOUND AND 
ATHEROSCLEROTIC 
PLAQUE BIOLOGICAL 
FEATURES 
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5.1 INTRODUCTION 
Inflammation, angiogenesis and matrix degradation – determined by the balance between 
matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) – are 
among the key features which contribute to plaque vulnerability (Ross 1999; Narula and 
Strauss 2007).  
 
Therefore, functional imaging modalities are being developed to visualise these biological 
features in vivo as a means of stroke prediction. Methods of assessing plaque inflammation 
based on magnetic resonance imaging (MRI) are expensive and not appropriate for a 
screening test given the prevalence of asymptomatic carotid atherosclerosis. Likewise 
computed tomography, positron emission tomography (PET) and single photon emission 
computed tomography (as well as being expensive) also rely on ionising radiation (Rudd et al. 
2009). 
 
Contrast enhanced ultrasound (CEUS), in its dynamic phase (the period immediately 
following contrast administration), has been studied as a translational modality for assessing 
carotid atherosclerosis. Dynamic CEUS can assess the carotid vasa vasorum and plaque 
neovascularisation, relating findings to histological evaluation of angiogenesis (Giannoni et 
al. 2009), and cardiovascular disease and past cardiovascular events (Staub et al. 2010). 
 
Previously, animal studies have linked microbubble persistence in the microcirculation at 12 
to 30 minutes with adhesion to and phagocytosis by leukocytes (Lindner et al. 2000a; Lindner 
et al. 2000b). Late-phase- (LP-) CEUS at 6 minutes post-contrast injection has been used to 
quantify retention of microbubble contrast within human carotid plaques in vivo, this being 
able to distinguish asymptomatic from atherosclerosis responsible for recent focal 
neurological symptoms pertaining to the ipsilateral anterior cerebral circulation (Chapter 3). It 
is hypothesised that, at this 6 minute timepoint, microbubbles are adhering to activated intra-
plaque microvascular endothelium, hence it is proposed that LP-CEUS is identifying 
inflammation within atherosclerosis. 
 
The biological characteristics of human atherosclerosis which are represented by changes in 
LP-CEUS signal have not previously been examined. The aim of this study is to investigate 
whether LP-CEUS reflects key plaque biological features. 
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5.2 METHODS 
5.2.1 Study Subjects 
Consecutive patients who were due to undergo carotid endarterectomy for primary 
atherosclerotic stenosis of the carotid bifurcation from the vascular surgery clinics of a 
tertiary referral centre were recruited. Exclusion criteria were as outlined in Section 3.2.3. 
 
Between December 2008 and May 2009, a total of 31 subjects were enrolled (mean age 70.5 
years ± 9.0 [standard deviation]), of these 24 (77%) were male. The carotid plaques from 
sixteen (52%) patients were symptomatic; a plaque was considered symptomatic if symptoms 
consistent with stroke, transient ischemic attack or amaurosis fugax had occurred in the 
neurovascular territory of the plaque studied in the 12 months prior to the study. The 
symptomatic status was decided by a neurovascular multi-disciplinary team. For the 
symptomatic group, the median time from symptoms to LP-CEUS scan was 21.0 days (inter-
quartile range 11.3 – 40.8). The median time from LP-CEUS scan to carotid endarterectomy 
surgery was 1 day (inter-quartile range 1 – 1). 
 
5.2.2 Conventional Ultrasound, Late-Phase Contrast Enhanced Ultrasound and 
Analysis 
Measurement of carotid stenosis by unenhanced duplex ultrasonography was undertaken as 
described in Section 3.2.4. LP-CEUS was subsequently performed as per Section 3.2.7 and 
analysed using QLAB software (Philips, Bothel, WA) as detained in Section 3.2.8. On the 
logarithmic scale, a plaque contrast signal greater than luminal signal resulted in a normalised 
signal >0 and where the plaque signal was less than the luminal signal, normalised LP-CEUS 
was <0. According to receiver operating characteristic curve analysis, a normalised plaque LP 
echo intensity of 0 was the optimum cut-off point to distinguish symptomatic from 
asymptomatic plaques. The subjects were grouped according to a normalised plaque LP-
CEUS intensity cut-off of 0. 
 
5.2.3 Carotid Endarterectomy Specimen Processing 
Where possible, fresh specimens were divided symmetrically along their long axis, allowing 
for representative undertaking of both immunohistochemistry and atheroma cell culture 
(Section 4.2.2) (n=19). Where there was insufficient material to undertake both techniques 
(n=12), specimens were assigned to either histology alone (n=10) or atheroma cell culture 
alone (n=2). 
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5.2.4 Histology 
Atheroma specimens (n=29) were axially divided into three regions representing the 
proximal, middle and distal plaque regions. Three 7 µm cryosections from each of the three 
regions were immunohistochemically stained for the macrophage marker CD68 (PG-M1, 
Dako, 1:500) and the endothelial cell marker CD31 (JC70A, Dako, 1:1000) by the ABC 
technique with DAB visualisation. Whole plaque sections were imaged at x4 magnification 
using a motorised stage microscope (Eclipse 50i, Nikon) – camera (QImaging) system. Semi-
automated image analysis was undertaken using Vision software (version 5.0, Clemex). The 
percentage area of immunopositivity by colour thresholding was determined, with the average 
across the 9 slides calculated, for each of CD68 and CD31. Plaque minimum cap thickness 
was calculated for 17 plaques (Section 4.3). 
 
This study adheres to the recommendations made for the performance, reporting and 
interpretation of imaging-pathological correlation studies (Lovett et al. 2005). 
 
5.2.5 Atheroma Cell Culture and Multi-Analyte Profiling 
Fresh diseased intimal arterial segments (n=21) were enzymatically digested and cultured 
(Section 4.4) and supernatant subject to multi-analyte profiling (Section 4.5). 
 
5.2.6 Statistical Analysis 
Data was analysed with Prism (version 5.02, GraphPad Software, California). Where data was 
not normally distributed, groups were compared by Mann-Whitney test. Normally distributed 
data was compared using unpaired t test and relationships assessed by Pearson‘s correlation. 
All tests
 
used were 2-tailed and a p-value
 
less than 0.05 was considered statistically 
significant. No post-test was used. 
 
5.3 RESULTS 
Fifteen (48%) subjects had a LP-CEUS signal <0, and 16 (52%) had 0. The characteristics of 
the groups are shown in Table 18. The groups were well matched in terms of degree of carotid 
luminal stenosis under investigation, demographic and clinical parameters, and statin use. 
Both groups had a median 1 day interval between LP-CEUS evaluation and carotid 
endarterectomy surgery. There were significantly more symptomatic stenoses in the LP-
CEUS 0 group (p=0.001). There was no significant difference in venous plasma C-reactive 
protein between the two groups. 
Chapter 5 
 155 
 
 
LP-CEUS signal <0 
(n = 15) 
LP-CEUS signal 0 
(n = 16) 
P 
value 
Symptomatic 3 (1 CVA, 1 TIA, 
1 Am Fu) 
13 (4 CVA, 7 TIA, 
2 Am Fu) 
0.001 
Time from symptoms to LP-
CEUS scan (days) 
19 (15.0 – 44.0) 21 (9.0 – 40.5) 0.893 
Luminal stenosis (%) 75.0 (65.0 – 90.0) 84.5 (80.0 – 91.5) 0.233 
Age (years) 70 ± 9.2 71 ± 9.1 0.794 
Male sex 12 12 1.000 
Diabetes mellitus 2 2 1.000 
Statin use 13 15 0.600 
Antiplatelet use 13 14 1.000 
Hypertension 11 13 0.685 
Smoking history 9 11 0.716 
Venous plasma C-reactive 
protein (mg/L) 
4.3 (1.3 – 9.0) 1.6 (1.3 – 3.7) 0.237 
Time from LP-CEUS scan to 
carotid endarterectomy 
surgery (days) 
1 (1 – 1) 1 (1 – 1) 0.977 
Table 18 Characteristics of the high and low LP-CEUS signal groups 
Demographic and clinical information relating to the 31 patients included in the study. 
Parametric data are presented as mean ± standard deviation, and non-normally distributed 
data shown as median (inter-quartile range). Am Fu, amaurosis fugax; CVA, cerebrovascular 
accident; TIA, transient ischemic attack. 
 
5.3.1 Histological Analysis 
CD68 and CD31 average percentage area immunopositivity, as well as plaque minimum cap 
thickness data were normally distributed. CD68 average percentage area immunopositivity 
was significantly higher in subjects where normalised plaque late-phase intensity was 0 
versus <0 (n=29, mean 11.80 versus 6.684, p=0.004, Table 19, Figure 45A, Figure 46). There 
was a significant positive correlation between normalised LP-CEUS signal and CD68 
percentage area immunopositivity (n=29, r=0.4661, p=0.011, Figure 45B). CD31 average 
percentage area immunopositivity was significantly higher in subjects where normalised 
plaque late-phase intensity was 0 versus <0 (n=29, mean 9.445 versus 4.819, p=0.025, Table 
19, Figure 45C). There was no significant correlation between normalised LP-CEUS signal 
and CD31 percentage area immunopositivity (n=29, r=0.1800, p=0.3501, Figure 45D). 
Regarding minimum cap thickness, there was a trend towards there being thinner caps where 
normalised plaque late-phase intensity was 0 (n=17, mean 187.1µm versus 341.8µm, 
p=0.0771, Figure 45E), however there was a significant negative correlation between these 
parameters (n=17, r=-0.51475, p=0.0345, Figure 45F). 
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Average % Area Immunopositivity 
± Standard Deviation P value 
(unpaired t test) LP-CEUS signal <0 
(n = 14) 
LP-CEUS signal 0 
(n = 15) 
CD68 6.684 ± 3.558 11.80 ± 4.947 0.004 
CD31 4.819 ± 3.300 9.445 ± 6.520 0.025 
Table 19 Analysis of immunohistochemistry 
29 specimen were immunohistochemically stained for the macrophage marker CD68 
(inflammation) and the endothelial marker CD31 (angiogenesis). Whole sections were 
imaged using a motorised stage microscope-camera system, with semi-automated image 
analysis to quantify percentage area immunopositivity of staining. The average percentage 
area immunopositivity from 9 sections for each stain was determined. Data are given to 4 
significant figures and P values to 3 decimal places. CD, cluster of differentiation. 
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Figure 45 The relationship between normalised plaque late phase echo intensity 
and CD68, CD31 and minimum plaque cap thickness 
CD68 (A) and CD31 (C) average percentage area immunopositivity were significantly higher 
in subjects (n=29) where normalised plaque late-phase intensity was 0 versus <0. There 
was a trend towards a reduced minimum plaque cap thickness where normalised plaque late-
phase intensity was 0, although this did not reach statistical significance (E, n=17, 
p=0.0771). Normalised signal was not significantly correlated to CD31 percentage area 
staining (D, n=29, r=0.1800, p=0.3501), but was positively correlated with CD68 
immunopositivity (B, n=29, r=0.4661, p=0.011) and negatively correlated with minimum cap 
thickness (F, n=17, r=-0.51475, p=0.0345). Bar denotes mean; CD, cluster of differentiation. 
A B 
C D 
E F 
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Figure 46 LP-CEUS and B-mode ultrasound comparison with plaque CD68 
imunohistochemistry 
Image panel of representative axial late-phase contrast enhanced ultrasound (LP-CEUS) 
images (A and D) with corresponding B-mode ultrasound images (B and E) and CD68 
immunohistochemistry (C and F) for plaques with LP-CEUS signal <0 (A-C) and >0 (D-F). 
The lumen is delineated by a solid line and the plaque by a dashed line. In A and B, plaque 
calcification is evident and reflected in the histology by calcium clefts (asterisks). In A, there 
is more luminal than plaque late-phase enhancement, and there is scant staining of 
macrophages in C. In D, there is more plaque than luminal late-phase enhancement, with 
areas of focal intense staining for CD68 (arrowheads). 
 
5.3.2 Multi-Analyte Profiling 
There was detection of 11/18 cytokines, 4/4 chemokines, 7/8 MMPs and 4/4 TIMPs. Data for 
detected analytes is summarised in Table 20 and Table 21). IL6, MMP1 and MMP3 were 
significantly higher in the LP-CEUS 0 versus the <0 group (IL6 median 5797 versus 764.0, 
p=0.030; MMP1 median 2173 versus 480.7, p=0.043; MMP3 median 184.7 versus 16.05, 
p=0.024, Figure 47). There was a trend towards increased production of IL1β (p=0.101), 
CCL2 (p=0.082) and CCL5 (p=0.102), with a trend towards reduced TIMP1 production 
(p=0.070), from plaques above the 0 cut-off. 
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Cytokine 
or 
Chemokine 
LP-CEUS signal <0 
(n = 9) 
LP-CEUS signal 0 
(n = 12) P value 
(Mann-Whitney 
Test) Median 
(pg/mL) 
Inter-Quartile 
Range (pg/mL) 
Median 
(pg/mL) 
Inter-Quartile 
Range (pg/mL) 
IL1α 3.200 3.200 – 5.626 12.28 3.200 – 23.40 0.205 
IL1β 4.778 3.200 – 24.96 69.46 12.70 – 292.6 0.101 
IL4 3.200 3.200 – 7.764 3.200 3.200 – 3.572 0.563 
IL6 764.0 360.8 – 2736 5797 1613 – 9765 0.030 
IL10 54.03 9.567 – 87.01 148.0 30.61 – 545.0 0.337 
IL12 (p40) 3.200 3.200 – 12.87 3.200 3.200 – 3.200 0.476 
GM-CSF 49.96 22.37 – 114.7 175.3 42.76 – 428.0 0.127 
TNFα 191.2 77.45 – 239.2 540.3 112.2 – 930.2 0.127 
IFNα2 3.200 3.200 – 4.143 3.200 3.200 – 3.200 0.351 
VEGF 16.00 3.200 – 35.68 16.00 3.200 – 28.85 0.942 
sCD40L 3.200 3.200 – 8.323 3.200 3.200 – 6.405 0.924 
CX3CL1 16.00 12.80 – 20.16 16.00 13.60 – 16.00 0.557 
CCL2 162.5 107.9 – 536.9 783.4 244.2 – 1427 0.082 
CCL5 33.34 18.75 – 61.75 107.8 35.90 – 187.4 0.102 
CXCL10 6.698 3.913 – 22.87 16.00 4.075 – 24.85 0.519 
Table 20 Analysis of cytokine and chemokine multi-analyte profiling 
Cells were isolated from carotid atherosclerotic plaques as a mixed cell suspension and 
cultured at 1x10
6
 cells/mL for 24 hours, at which point the supernatant was aspirated. In this 
unstimulated system, the cells displayed a spontaneous cytokine and chemokine production. 
All samples were analysed in duplicate, data are given to 4 significant figures and P values to 
3 decimal places. IL, interleukin; GM-CSF, granulocyte macrophage colony-stimulating 
factor; TNF, tumour necrosis factor; IFN, interferon; VEGF, vascular endothelial growth 
factor; sCD40L, soluble cluster of differentiation 40 ligand; CX3CL1, fractalkine; CCL2, 
monocyte chemotactic protein 1 (MCP1); CCL5, regulated upon activation, normal T cell 
expressed and secreted (RANTES); CXCL10, interferon-inducible protein 10 (IP10). 
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Matrix 
Metalloproteinase 
or 
Tissue Inhibitor of 
Metalloproteinase 
LP-CEUS signal <0 
(n = 9) 
LP-CEUS signal 0 
(n = 12) 
P value 
(Mann-
Whitney 
Test) Median (pg/mL) 
Inter-Quartile 
Range (pg/mL) 
Median (pg/mL) 
Inter-Quartile 
Range (pg/mL) 
MMP1 480.7 134.8 – 1901 2173 669.1 – 7865 0.043 
MMP2 671.6 480.8 – 899.8 702.8 478.8 – 1026 0.749 
MMP3 16.05 16.05 – 51.71 184.7 29.70 – 477.3 0.024 
MMP7 102.2 102.2 – 877.3 652.9 102.2 – 3008 0.205 
MMP8 461.1 91.91 – 1986 419.6 91.91 – 1885 0.942 
MMP9 3799 2801 – 7861 8527 3971 – 16840 0.155 
MMP12 468.5 279.3 – 806.5 1174 502.9 – 1569 0.127 
TIMP1 7901 3645 – 16680 3694 1273 – 4128 0.070 
TIMP2 110200 104200 – 253300 124500 42800 – 180400 0.749 
TIMP3 155.0 155.0 – 155.0 155.0 155.0 – 155.0 0.115 
TIMP4 6.170 6.170 – 6.170 6.170 6.170 – 6.170 0.185 
Table 21 Analysis of matrix metalloproteinase and tissue inhibitor of 
metalloproteinase multi-analyte profiling 
Cells were isolated from carotid atherosclerotic plaques as a mixed cell suspension and 
cultured at 1x10
6
 cells/mL for 24 hours, at which point the supernatant was aspirated. In this 
unstimulated system, the cells displayed a spontaneous matrix metalloproteinase (MMP) and 
tissue inhibitor of metalloproteinases (TIMP) production. All samples were analysed in 
duplicate, data are given to 4 significant figures and P values to 3 decimal places. 
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Figure 47 IL6, MMP1 and MMP3 production is significantly higher from plaques 
with a LP-CEUS signal 0 
IL6 (A), MMP1 (B) and MMP3 (C) production in atheroma cell culture, as determined by 
multi-analyte profiling, were significantly higher in subjects (n=21) where normalised plaque 
late-phase intensity was 0 versus <0. Bar denotes median; CD, cluster of differentiation. 
 
5.4 DISCUSSION 
These results show that human atherosclerotic plaques with a normalised LP-CEUS signal 0 
have significantly more inflammation (CD68, IL6), angiogenesis (CD31) and matrix 
degradation (MMP1, MMP3) than plaques with a normalised LP-CEUS signal <0. 
Inflammation, angiogenesis and matrix degradation are key biological features involved in the 
initiation, progression and complications of atherosclerosis (Narula and Strauss 2007). 
 
IL6 plasma levels are significantly higher in patients with unstable as compared with stable 
angina (Biasucci et al. 1996). Previous studies have observed that MMPs 1 and 3 co-localise 
with macrophages (Galis et al. 1994b; Pasterkamp et al. 2000) and are related to unstable 
atherosclerosis (Loftus et al. 2000; Molloy et al. 2004). Furthermore, it is possible that this 
pattern of inflammation and matrix degradation in the context of vulnerable atherosclerosis is 
B C 
A 
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attributable to pro-inflammatory M1 macrophage polarisation (Martinez et al. 2006; Waldo et 
al. 2008; Mantovani et al. 2009). 
 
Studies have shown that carotid plaques retrieved at endarterectomy have many more 
microvessels and transcripts known to promote neovascularisation when they originate from 
symptomatic, compared to asymptomatic patients (McCarthy et al. 1999a; Mofidi et al. 2001; 
Tureyen et al. 2006; Dunmore et al. 2007). High-risk plaques, in addition, have been shown to 
contain abnormal, immature or ‗incompetent‘ vessels that may precipitate plaque instability 
through their acting as sites of vascular leakage and so inflammation (McCarthy et al. 1999a; 
McCarthy et al. 1999b; Dunmore et al. 2007). With regards to dynamic CEUS, the peak 
intensity achieved following the administration of contrast relates to microvascular volume 
(Averkiou et al. 2010). 
 
This clinical study supports previous pre-clinical investigation showing that non-targeted 
microbubbles are passively retained within tissue where there is inflammation, endothelial 
activation, or both (Lindner et al. 2000a; Lindner et al. 2000b; Tsutsui et al. 2004b). It is 
hypothesised that the microbubbles adhere to endothelium or may leave the microvessel and 
enter the plaque parenchyma, are retained in isolation or within phagocytosing macrophages. 
It is likely that a number of interrelated endothelial processes are responsible for this 
microbubble accumulation: endothelial activation; endothelial permeability and leakage (of 
the microbubbles themselves or of inflammatory cells containing them); and endothelial 
charge changes, although this is an area of ongoing study. 
 
A number of other methods have been proposed for the risk stratification in carotid 
atherosclerosis. These include transcranial Doppler (Markus et al. 2010) and the presence of 
sub-clinical cerebral ischemia using computed tomography (Kakkos et al. 2009) or magnetic 
resonance imaging (Romero et al. 2009). However, these modalities are not carotid-specific, 
and may be reflecting silent embolisation from another source, for example of cardiac origin. 
Fluorodeoxyglucose (FDG) PET studies have shown that in vivo FDG signal corresponded to 
in vitro active plaque inflammation (Graebe et al. 2009). This approach, however, is limited 
by non-specificity and the use of tracers targeted to specific ligands has been proposed and is 
currently being examined in the clinical setting. Ultrasmall super-paramagnetic iron oxide 
(USPIO) MRI relies on USPIO being internalised by circulating monocytes, some of which 
enter the inflamed carotid as macrophages. The USPIO is detected by MRI in carotid plaques 
where there exists inflammation. Studies have shown that there is a larger signal drop 
(suggesting more USPIO uptake) in symptomatic as compared with asymptomatic carotid 
plaques (Howarth et al. 2009). 
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These findings were made in the context of a study group where more than 90% were taking 
statins. This shows that despite statin use, there is ongoing production of inflammatory 
mediators and that the presence of inflammation is still detectable through imaging. 
 
5.4.1 Study Limitations 
The limitations of this work include the numbers of subjects enrolled and the potential for 
sampling error. Ultrasound is a planar imaging technique and LP-CEUS at a single level in 
the plaque (at the point of greatest stenosis) was compared with nine immunohistochemically 
stained sections taken at points throughout the plaque and atheroma cell culture data 
representative of at least half the plaque. Such may be overcome through the use of 3- or 4-
dimensional volumetric ultrasound acquisition technology. These probes are under 
investigation by our group, however, the spatial resolution is, at present, not adequate for their 
use in the context of LP-CEUS. 
 
5.4.2 Conclusion 
This chapter demonstrates that LP-CEUS reflects the biological features of inflammation, 
angiogenesis and matrix degradation, which are key to plaque rupture. These findings support 
the further study of LP-CEUS as a tissue-specific marker of inflammation with potential 
utility in risk stratification of carotid atherosclerosis. 
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6.1 INTRODUCTION 
In order to look at the utility of the ‗omic‘ disciplines in exploring the biology of 
atherosclerosis, carotid atherosclerotic plaques were examined using four systems biology 
approaches: 
 
 Transcriptomics 
 Proteomics 
 Lipidomics 
 Metabonomics 
 
 
6.2 TRANSCRIPTOMICS 
Transcriptomics (epigenomics, gene expression or transcription profiling are synonyms) looks 
at RNA and is therefore a means of identifying which genes are ‗activated‘ or transcribed. As 
a patient‘s genotype is the same regardless of which somatic cell is looked at, genomics is 
patient-specific. On the other hand, gene transcription varies within individuals from tissue to 
tissue and under different circumstances, such that they will have a unique genotype but a 
number of transcriptomic profiles. 
 
A further challenge with transcriptomics is that, whilst the genome is relatively stable and 
DNA is relatively robust, RNA is less so and subject to degradation. RNA quality is looked at 
prior to a transcriptomic study and this is achieved by calculation of the RNA integrity 
number (RIN) from a number of parameters obtained by electrophoresis of the RNA (Figure 
49). 
 
Following RNA extraction from samples, double stranded complementary DNA (cDNA) is 
synthesised. This is a stable copy of the RNA which can be used for gene profiling. The 
cDNA is labelled, hybridised and quantified producing a gene expression pattern (Archacki 
and Wang 2006). Microarrays allow the comparison of global expression changes in 
thousands of genes. Results can be validated using real time PCR (Hiltunen et al. 2002; 
Archacki et al. 2003; Randi et al. 2003; Archacki and Wang 2004; Fu et al. 2008). These 
techniques have led to the identification of unique subsets of genes associated with specific 
diseases and disease processes (Archacki and Wang 2004). 
 
There have been several studies validating the technique of gene expression profiling in 
normal and atherosclerotic tissue (Hiltunen et al. 2002; Archacki et al. 2003; Randi et al. 
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2003; Tabibiazar et al. 2005; Bijnens et al. 2006; Fu et al. 2008). Seo and colleagues 
generated gene expression data from human aortas with varying degrees of atherosclerosis to 
create genomic phenotypes which may allow prediction of disease states from any given 
sample of aorta (Seo et al. 2004). Microarray analysis has also demonstrated that 97% genes 
are unaffected when atherosclerotic samples were taken during surgery compared to post 
mortem samples. Differentially expressed genes were shown to be involved in basal cell 
metabolism and hypoxia at mRNA level, but these changes were not reflected in protein 
expression (Sluimer et al. 2007). 
 
Further to the assessment of presence or absence of atherosclerosis (i.e. atherosclerotic 
‗burden‘) is examination of the transcriptional profile of plaque instability. Papaspyridonos 
and colleagues examined total RNA from stable and unstable areas from 3 human carotid 
plaques, identifying the differential expression of 170 genes between these areas of which 
four varied by greater than fivefold: retinoic acid receptor responder; junctional adhesion 
molecule; haemoglobin scavenger receptor CD163; and ganglioside activator protein GM2A 
(Papaspyridonos et al. 2006) (Table 22). 
 
RIN may be artificially lowered in circumstances were degraded RNA exists, for example in 
the mural thrombus of an aneurysm or – in the context of atherosclerosis – the necrotic core 
of a plaque. This is one reason for why transcriptome-wide analysis of human atherosclerotic 
tissue has not been readily performed (Table 22). 
 
One way round the challenges inherent to transcriptomics of human atherosclerosis tissue is 
by profiling peripheral blood in the context of atherosclerotic disease. This has the further 
inherent utility for direct discovery of biomarkers. An example of this was a study which used 
arrays to expression profile peripheral blood from 10 patients with carotid stenosis and 10 
matched controls. Of the 14,000 transcripts represented on the arrays, 82 genes were found to 
be differentially expressed between these two groups (Rossi et al. 2010). Fourteen of the 82 
differentially expressed genes were selected as candidate genes and subsequently confirmed 
by PCR on separate validation groups of 40 patients with carotid stenosis and 40 controls. 
These genes were largely involved in immune activities and oxygen transport (Rossi et al. 
2010) A summary of this and other studies pertaining to transcriptomic studies in human 
atherosclerosis to date can be seen in Table 22. 
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Study Reference Methodology Sample Source Results Genes of Interest 
(Rossi et al. 
2010) 
Carotid stenosis 
versus healthy 
individuals 
Plasma from 40 patients 
with carotid stenosis and 
40 healthy controls 
82 genes 
differentially 
expressed 
Immune activities and oxygen 
transport 
(Fu et al. 2008) Peripheral arterial 
disease as 
classified by the 
American Heart 
Association 
30 whole femoral arteries 
from live subjects: 14 
advanced; 11 
intermediate; 
5 normal 
 
366 genes 
differentially 
regulated in 
intermediate and 
447 in advanced  
Immune and inflammatory 
genes enriched especially Toll-
like receptor signalling and 
natural killer cell-mediated 
cytotoxicity 
(Papaspyridonos 
et al. 2006) 
Plaque instability 3 human carotid plaques 170 genes 
differentially 
expressed 
Retinoic acid receptor 
responder, junctional adhesion 
molecule, haemoglobin 
scavenger receptor CD163, 
ganglioside activator protein 
GM2A 
(Sluimer et al. 
2007) 
Advanced 
atherosclerotic 
plaques. Surgery 
versus autopsy 
samples 
26 carotid segments taken 
at autopsy from 11 donors. 
11 samples from live 
donors 
97.2% genes have 
similar expression 
levels in advanced 
lesions 
Differentially expressed genes 
involved in basal cell 
metabolism and hypoxia driven 
pathways 
(Tabibiazar et al. 
2005) 
3 cohorts of 5 mice 
with varying 
disease 
susceptibility and 
diet compared to 
human data sets to 
identify shared 
genes 
Entire aortas from 
euthanized mice. Once 
data sets were identified, 
they were compared with 
those of 40 coronary artery 
samples from 17 
transplant patients 
Established 
‘classifier gene set’ 
which can 
distinguish 
specimens with 
atherosclerotic 
disease state 
Gene subset was found to be 
equivalent in human subjects 
when grading human coronary 
disease 
(Seo et al. 2004) Human aorta 
samples with 
varying degrees of 
atherosclerosis 
Cadaveric whole aortas. 
Severity assessed as mild 
proximally with increasing 
severity distally 
Identified gene 
expression 
‘signatures’. A set of 
208 genes relating 
to disease severity 
Multiple, including apoE, 
osteopontin, OLR1. Cell cycle 
regulation and inflammatory 
response 
(Randi et al. 
2003) 
Comparison of 
coronary plaques in 
stable and unstable 
angina 
8 coronary plaques from 
live subjects 
Examination of 
genes using data 
sets for 
inflammation, 
adhesion and 
haemostasis 
Lymphocyte adhesion 
molecule (MadCAM) in all 
plaques. Anticoagulant protein 
S and TF increased. COX1, 
IL7, MCP1 and MCP2 
decreased in unstable plaques 
(Archacki et al. 
2003) 
Differential gene 
expression in 
human coronary 
artery disease. 
Atherosclerosis 
versus normal  
9 severe and 6 non-
atherosclerotic human 
coronary arteries from 
explanted hearts 
Established gene 
profiling as reliable 
tool for analysis of 
atherosclerosis.  56 
genes differentially 
expressed 
Altered gene expression of 
inflammation, cell 
necrosis/apoptosis, altered cell 
migration, matrix degradation 
genes 
(Hiltunen et al. 
2002) 
Human arterial 
samples from 
varying locations 
from aorta to lower 
limb 
12 arterial samples 
obtained after amputation 
of limb or from organ 
donors 
75 differentially 
expressed genes 
previously unknown 
to be associated 
with atherosclerosis 
Sub-group for cell signalling 
and proliferation selected for 
further analysis; receptors for 
signalling in activated 
macrophages, angiogenic and 
vasculoprotective 
(Faber et al. 
2001) 
Comparison of 
human stable and 
ruptured plaques. 
American Heart 
Association 
classification 
20 human arterial plaques 
from varying locations (10 
stable, 10 ruptured) 
3,000 clones 
upregulated and 
2000 downregulated 
in ruptured plaques  
SSH6 and Perilipin (SSH1 
SSH11) expressed in ruptured 
plaques in the cytoplasm of 
cells surrounding cholesterol 
clefts and in foam cells 
Table 22 Summary of transcriptomic studies in human atherosclerosis 
ApoE, apolipoprotein E; COX, cyclooxygenase, IL, interleukin; MCP, monocyte chemotactic 
protein; ORL, oxidised low density lipoprotein receptor; SSH, suppression subtractive 
hybridisation; TF, tissue factor. 
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Contemporary microarrays, including the Affymetrix Human Exon 1.0 ST array used in this 
study, have multiple probes per exon. In the case of the Affymetrix Human Exon 1.0 ST, 
there are approximately four probes per exon, equating to roughly 40 probes per gene. This 
allows for two complementary levels of analysis: gene expression and alternative splicing. 
Multiple probes per exon enable ‗exon-level‘ analysis, allowing the distinction between 
different isoforms of a gene, with detection of specific alterations in exon usage that may 
contribute to disease aetiology. ‗Gene-level‘ expression analysis, in which multiple probes on 
different exons are summarised into an expression value of all transcripts from the same gene, 
is also possible. 
 
6.2.1 Transcriptomic Aims 
The primary aim of the transcriptomic section of this chapter was to assess the utility of 
transcriptomics to distinguish between stenosing plaque and intimal thickening, highlighting 
differentially expressed and differentially spliced genes. A secondary aim was to determine 
whether transcriptomics was able to separate stable from unstable atherosclerosis. 
 
6.3 TRANSCRIPTOMIC METHODOLOGY 
6.3.1 Sample Selection, RNA Extraction and Processing 
Eighteen carotid endarterectomy specimens were initially identified for this experiment. 
These were each ‗chipped‘ into two areas where possible to give samples relating to stenosing 
atheroma and areas of intimal thickening (Figure 48). Regions of stenosing atherosclerosis 
from symptomatic plaques were considered to be unstable, whilst all areas of intimal 
thickening and the stenosing atherosclerosis from asymptomatic plaques were considered 
stable (Figure 48). 
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Figure 48 Carotid endarterectomy specimen processing for transcriptomic 
profiling 
Where possible each of the eighteen carotid endarterectomy specimens were processed to 
yield samples of stenosing atheroma and intimal thickening for further analysis. Regions of 
stenosing atherosclerosis from symptomatic plaques were considered to be unstable, whilst 
all areas of intimal thickening and the stenosing atherosclerosis from asymptomatic plaques 
were considered stable. 
 
In total from the initial 18 endarterectomy specimens, RNA was extracted from 44 samples 
(27 samples of stenosing atheroma and 17 samples from intimal thickening). Total RNA was 
extracted using a commercially available kit in accordance with the manufacturer‘s 
instructions (miRNAeasy, Qiagen). Extracted RNA was assessed by both Nanodrop and 
Agilent 2100 bioanalyser (Figure 50, Table 23). There was a weak but significant correlation 
between the results of Nanodrop assessment and the RNA integrity number (RIN) as seen in 
Figure 50. 
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Figure 49 Agilent bioanalyser output for assessment of RNA quality 
The Agilent 2100 bioanalyser offers an indirect assessment of mRNA quality by informing 
about ribosomal RNA. Up to 12 samples undergo electrophoresis per „chip‟ (A) before lane is 
represented individually in graph form (B and C). B demonstrates a sample with an RNA 
integrity number (RIN) of 5.2, where 18S and 28S ribosomal RNA peaks are clearly seen and 
labelled. C shows the graph for a sample with a RIN of 1.0, and 18S and 28S ribosomal RNA 
peaks are not visible. 
C 
A B 
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Sample Number 
Nanodrop 
260nm / 280nm Ratio 
Agilent Bioanalyser 
RNA Integrity 
Number 
V0012 SP 2.05 3.9 
V0012 SP 1.85 2.9 
V0012 IT 1.77 3.3 
V0162 SP 1.56 3.0 
V0162 SP 1.34 2.8 
V0162 SP 1.23 3.7 
V0162 IT 1.45 2.9 
V0162 SP 1.29 3.4 
V1299 IT 2.06 2.5 
V1299 SP 1.80 2.4 
V1299 SP 1.94 3.8 
V1355 IT 1.44 2.4 
V1355 SP 1.65 2.4 
V1376 IT 1.86 3.2 
V1376 SP 1.79 2.3 
V1377 SP 1.96 2.4 
V1377 SP 2.03 3.1 
V1420 IT 2.01 2.6 
V1420 SP 2.00 3.9 
V1236 IT 2.03 3.4 
V1236 SP 2.06 5.0 
V1388 IT 2.04 2.9 
V1388 SP 2.20 2.4 
V1241 IT 1.76 2.3 
V1241 SP 1.41 2.5 
V1465 IT 2.11 3.0 
V1465 SP 1.95 2.7 
V1468 IT 2.01 5.2 
V1468 SP 1.86 3.0 
V1139 IT 1.29 2.4 
V1139 SP 1.35 2.2 
V1139 SP 1.64 1.0 
V1470 IT 1.28 1.5 
V1470 SP 1.14 1.2 
V1471 IT 1.51 2.3 
V1471 SP 1.66 2.4 
V1477 IT 1.99 4.5 
V1477 SP 1.32 2.4 
V1477 SP 1.97 4.5 
V1476 IT 1.55 2.4 
V1476 SP 1.31 2.4 
V1486 IT 1.49 2.5 
V1486 SP 1.37 2.5 
V1486 SP 1.43 2.4 
Table 23 Extracted RNA assessed by Nanodrop and Agilent bioanalyser 
Eighteen carotid endarterectomy specimens yielded 44 samples – 27 stenosing plaque (SP) 
and 17 intimal thickening (IT). 260nm / 280nm ratio was determined by Nanodrop and RNA 
integrity number by Agilent bioanalyser. The samples highlighted in bold are those which 
were selected to proceed to transcriptomic analysis. 
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Figure 50 Relationship between Nanodrop and Agilent bioanalyser data 
Linear regression, r
2
 = 0.2373, p = 0.0008, n = 44 samples from 18 carotid endarterectomy 
specimens. 
 
Of the 44 available samples, 19 (highlighted in Table 23) were selected for Affymetrix Exon 
Array 1.0ST based on RNA quality, of which 2 did not pass the preliminary quality control 
process. Results were obtained from 17 samples: 7 paired samples (5 from symptomatic and 2 
asymptomatic patients) and 3 unpaired samples (1 stenosing atheroma and 1 intimal 
thickening from a symptomatic patients, and 1 intimal thickening from an asymptomatic 
individual) (Table 24). 
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Table 24 Characteristics of the individuals included in the transcriptomic study 
Demographic, clinical and pharmacotherapeutic information relating to the subjects included 
in the study. F, female; IT, intimal thickening; M, male; SP, stenosing plaque. 
 
6.3.2 Transcriptomic Data Analysis 
Initial quality control analysis was undertaken using Expression Console (Version 1.1, 
Affymetrix) to examine the spread of signal intensities across samples following 
normalisation. Subsequent analysis was performed using Genomics Suite (Version 6.5, 
Partek, St Louis, Missouri, USA). Only ‗core‘ probe sets were used for the analysis, thus 
employing only the highest quality annotation data from RefSeq and GenBank. Clustering 
and separation of sample groups was examined using unsupervised statistical methods: 
hierarchical clustering and principal components analysis (PCA). The primary aim was 
investigated by paired samples T-test to compare levels of gene expression and differential 
splicing between the seven stenosing plaque / intimal thickening sample pairs. 
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V0012 
IT & 
SP 
1 76 F 0 0 1 0 1 - - 
90-
95 
1 1 22 
V1236 
IT & 
SP 
0 85 M 0 1 1 0 1 169 - 85 1 1 - 
V1299 
IT & 
SP 
1 79 M 0 0 1 0 0 103 82 
90-
95 
1 0 2 
V1376 
IT & 
SP 
1 60 M 1 0 0 1 1 72 0.6 90 1 1 29 
V1377 IT 1 73 M 0 0 1 1 1 95 0.8 - 1 1 3 
V1388 IT 0 66 F 0 0 1 0 0 63 1.9 80 1 0 - 
V1420 SP 1 51 M 0 0 1 0 1 74 0.9 
55-
65 
0 0 3 
V1465 
IT & 
SP 
0 67 M 0 0 1 1 0 101 1 
75-
80 
0 1 - 
V1468 
IT & 
SP 
1 55 M 0 0 0 0 0 79 1.1 
80-
90 
0 1 2 
V1477 
IT & 
SP 
1 54 M 0 0 1 0 0 73 5.8 
60-
75 
1 1 63 
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6.4 TRANSCRIPTOMIC RESULTS 
6.4.1 Initial Analysis 
Quality control analysis confirmed that the normalised expression signal was comparable 
across the 17 analysed samples (Figure 51). 
 
 
Figure 51 Relative Log expression signal 
The spread of the 17 sample intensities are plotted following normalisation. 
 
Initial analysis showed that there was no clustering of samples based upon which carotid 
endarterectomy specimen the samples were from (Figure 52). 
 
 
Figure 52 Sample pairs derived from the same carotid endarterectomy specimen 
were not seen to cluster 
Paired samples from the same carotid endarterectomy specimen are shown in the same 
colour (7 pairs). There are three unpaired samples (Patient Number 3, 4 and 6). 
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6.4.2 Stenosing Plaque and Intimal Thickening 
Analysing the seven stenosing plaque / intimal thickening sample pairs, hierarchical 
clustering analysis (unsupervised) was able to separate all but a single sample into two groups 
(Figure 53). 
 
 
Figure 53 Hierarchical clustering analysis of stenosing plaque and intimal 
thickening paired samples 
Hierarchical clustering (unsupervised) analysis was able to separate all but a single sample 
into two groups. The first separation is made upon stenosing plaque (1) or intimal thickening 
(0). The subsequent breakdown is according to sample pairs labelled 1, 2, 5, 7, 8, 9 and 10. 
Upregulated genes are shown in blue and downregulated genes in red. 
 
Principal components analysis (PCA) represented 39.3% of the data variation on 2 principal 
components (PCs) (Figure 54) and 48.8% of the data variation on 3 PCs (Figure 55). A clear 
separation between the stenosing plaque and intimal thickening samples was observed. 
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Figure 54 Separation of stenosing plaque and intimal thickening on 2-dimensional 
principal components analysis 
39.3% of the data variation was represented by two principal components. Clustering of 
intimal thickening (red, 0) and stenosing plaque (blue, 1) tissue transcriptomic data was seen, 
with a good separation observed between the two groups. Ellipses represent 2 standard 
deviations. 
 
  
Figure 55 Separation of stenosing plaque and intimal thickening on 3-dimensional 
principal components analysis 
48.4% of the data variation was represented by three principal components. Clustering of 
intimal thickening (red, 0) and stenosing plaque (blue, 1) tissue transcriptomic data was seen, 
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with a good separation observed between the two groups. Ellipsoids represent 2 standard 
deviations. 
 
Differential expression analysis was performed based on the Genbank RNA transcript ‗core‘ 
geneset of 22,011 genes. 2,988 (14%) genes were seen to display significant (p<0.05) 
differential expression between the intimal thickening and stenosing plaque paired samples. 
Differential splicing analyses was also performed based on the Genbank RNA transcript 
‗core‘ 232,487 probe sets. 1,912 (11%) genes were seen to display significant (p<0.05) 
differential splicing between the two paired sample groups. Common amongst both the 
differentially expressed and differentially spliced gene lists was the interferon regulatory 
factor 5 (IRF5) (Figure 56). 
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Figure 56 Differential expression and splicing of interferon regulatory factor 5 
(IRF5) comparing stenosing atherosclerosis and intimal thickening 
A. Interferon regulatory factor 5 (IRF5) expression is significantly higher in stenosing plaque 
(SP, blue) compared with intimal thickening (IT, red) (paired T-test, p = 0.0008).  B. IRF5 
was seen to be differentially spliced in SP (blue) compared with IT (red) (paired T-test, p = 
A B 
C 
D 
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0.0015).  C. The IRF5 gene organisation. Its location is on chromosome 7q32. Modified from 
(Cunninghame Graham et al. 2007; Malarstig et al. 2008).  D. In the core probe set, 12 
probes are allocated to IRF5. Comparing SP (blue) with IT (red), there appears to be no 
difference as regards exon splicing of the 5‟ end of the IRF5 gene, whilst difference in 
splicing is seen to be located on the 3‟ end, with a consistent difference in all five of the 3‟ 
end probes. 
 
6.4.3 Stable and Unstable Atherosclerosis 
A clear separation on PCA was also observed between the stable and unstable atherosclerosis 
(Figure 57). 
 
 
Figure 57 Separation of stable and unstable atherosclerosis on 3-dimensional 
principal components analysis 
Clustering of unstable atherosclerosis (defined as stenosing plaque from symptomatic 
patients; red, 0) and stable atherosclerosis (defined as all areas of intimal thickening, or 
stenosing plaque from asymptomatic patients; blue, 1) tissue transcriptomic data was seen, 
with a good separation observed between the two groups. Ellipsoids represent 2 standard 
deviations. 
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6.5 TRANSCRIPTOMICS DISCUSSION 
Based upon the ‗core‘ probe set analysis, transcriptional profiling analysis hierarchical 
clustering, and two- and three-dimensional PCA were able to demonstrate good clustering of 
intimal thickening and stenosing plaque samples, with a clear separation between these two 
tissue types. Furthermore, when samples were separated based on stable and unstable 
atherosclerosis, clustering and separation was again observed. This highlights the utility of 
transcriptomics coupled to unsupervised statistical analysis to separate samples in accordance 
with biologically and clinically relevant parameters. 
 
A difference in both expression and splicing of IRF5 in the context of advanced 
atherosclerosis may contribute to the explanation for why there is an increase in inflammatory 
cytokines in advanced atherosclerosis (Sections 1.5 and 4). This finding remains to be 
validated using probes specific for the different gene isoforms. It is further worth 
investigating whether the 3‘ end of the IRF5 gene has known (or yet to be discovered) 
functional domains. This finding may be a step towards completing the picture which sees 
pattern recognition receptor activation resulting in pro-inflammatory cytokine production 
(Watters et al. 2007; Kawai and Akira 2010) (Figure 58). This systems biology approach, 
generally regarded as non-hypothesis driven, has been powerful in the generation of 
hypotheses to be further addressed experimentally. 
 
Macrophage Cell Membrane 
Pattern Recognition Receptors 
TLR5 TLR2 TLR4 
TIRAP TRAM 
MyD88 
IRAK4 
IRAK1, 
IRAK2 
TRAF6 
IRF5 MAPKs NFκB 
Nuclear Membrane 
IRF3 
Inflammatory Cytokines 
 
Figure 58 Interferon regulatory factor 5 in the pattern recognition receptor 
pathway 
Interferon regulatory factor 5 (IRF5) in the pattern recognition receptor pathway (PRR). 
IRF5 is a nuclear transcription factor signalling downstream of PRRs, including Toll-like 
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receptors (TLRs) 2, 4 and 5 (Modified from (Watters et al. 2007; Kawai and Akira 2010)). 
IRF5 promotes the transcription of inflammatory cytokines and has recently been implicated 
in the M1 polarisation of human macrophages in vitro (Krausgruber et al. 2011). IRAK, 
interleukin 1 receptor-associated kinase; MAPK, mitogen-activated protein kinase; MyD88, 
myeloid differentiation primary response gene 88; NFκB, nuclear factor κB; TIRAP, Toll-
interleukin 1 receptor domain containing adaptor protein; TRAF, tumour necrosis factor 
receptor associated factor; TRAM, TRIF related adaptor molecule. 
 
Furthermore, this finding concurs with the recent publication from the Kennedy Institute at 
Imperial College London that IRF5 promotes the transcription of inflammatory cytokines and 
has recently been implicated in Th1 and Th17 responses, and M1 polarisation of human 
macrophages in vitro (Krausgruber et al. 2011). 
 
IRF5 has been intimately implicated in TLR signalling, with a target gene profile including 
the cytokines and chemokines IL6, CCL2 and CCL5 (Kozyrev and Alarcon-Riquelme 2007) 
which were seen to be upregulated in advanced atherosclerosis in Chapter 4. Several single 
nucleotide polymorphisms (SNPs) of IRF5 have been found to be associated with systemic 
lupus erythematosus (SLE) (Sigurdsson et al. 2005; Graham et al. 2006; Cunninghame 
Graham et al. 2007; Malarstig et al. 2008). In the context of SLE, SNPs have been shown to 
be responsible for IRF5 transcript variants with differences at both the 5‘(Graham et al. 2006; 
Graham et al. 2007) and 3‘ (Cunninghame Graham et al. 2007) ends. 
 
A study has compared IRF5 gene expression in 99 carotid endarterectomy specimens obtained 
from the Biobank of Karolinska Endarterectomies (BIKE) – with or without macroscopic 
signs of plaque rupture and superimposed thrombus – with eight control iliac artery samples 
from organ donors without macroscopic or microscopic signs of atherosclerosis (Malarstig et 
al. 2008). IRF5 mRNA expression was significantly increased in atherosclerotic compared 
with control tissue, however it is noted that in this study intimal disease was compared with 
control artery comprising intima, media and adventitia. Furthermore, the location within the 
plaque where the tissue was sampled for mRNA extraction is not declared. In this study, 
modification of IRF5 expression is explained by gene SNPs (Malarstig et al. 2008), a factor 
which does not explain the differential expression seen in this thesis chapter as samples were 
paired from the same individual. 
 
Four distinct alternative spliced IRF5 isoforms have been identified in human primary 
plasmacytoid dendritic cells, with and additional two in human primary peripheral blood 
mononuclear cells (Mancl et al. 2005). Three of these isoforms have distinct insertion/deletion 
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patterns in exon 6 at the 3‘ end (Mancl et al. 2005). This study of human mononuclear cells of 
the innate immune system revealed distinct cell type-specific expression and dissimilar 
functions in interferon induction of the spliced isoforms (Mancl et al. 2005). 
 
In the future it will be increasingly important to collate transcriptomic data from multiple 
studies in order to improve data sets and to make them freely available (Bijnens et al. 2006). 
The ultimate aim would be the identification of classification gene sets which would offer 
insight into the potential diagnostic and therapeutic strategies in atherosclerotic disease 
(Tabibiazar et al. 2005). 
 
 
6.6 PROTEOMICS 
The proteome is defined as all proteins expressed in a cell, tissue or organism (Bagnato et al. 
2007). Proteomics, the analysis of a proteome, can detect proteins that are associated with a 
disease by measuring their levels of expression between control and disease states (You et al. 
2003). Two dimensional electrophoresis (2DE) combined with protein identification by mass 
spectrometry allows for the analysis of hundreds to thousands of proteins at a time, including 
post-translational modifications (Martinez-Pinna et al. 2010). Proteomic studies have been 
carried out on both human artery carotid plaques and on atherosclerotic plasma samples 
(Martinez-Pinna et al. 2010). A recent review has looked into the proteomics of 
atherosclerosis (Didangelos et al. 2009). This included two relevant studies where proteomics 
was undertaken on human carotid atherosclerosis. Martin-Ventura et al. looked at 25 CEA 
specimens, comparing these to 36 control endarteries (Martin-Ventura et al. 2004). The 
endartery segments were used to condition protein-free medium, which was subsequently 
separated by 2-dimensional electrophoresis (DE) and subject to matrix-assisted laser 
desorption/ionisation- time of flight (MALDI-TOF) mass spectrometry. The main finding of 
this study was that heat shock protein (HSP)-27 secretion was significantly less in carotid 
atherosclerosis, and was barely detectable in the secretome of complicated plaques 
(determined histologically by the presence of rupture, intra-plaque haemorrhage and an 
important proportion of inflammatory cells). 
 
You et al. took a proteomic approach to coronary atherosclerosis in ten diseased and seven 
normal individuals (You et al. 2003). 2D electrophoresis plates were directly visualised to 
compare diseased and normal specimens. Protein sequencing using mass spectrometry was 
performed on a protein spot which was shown to have higher levels of expression in the 
diseased sample. Proteomics identified that ferritin light chain was increased by 1.9 fold in 
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coronary artery disease. The mRNA expression level of ferritin light chain was investigated 
using PCR, but ferritin light chain was increased to a lesser extent than protein, highlighting 
the discrepancy often seen between mRNA and protein differences of the same analyte. 
 
Lepedda et al. compared 19 histologically stable with 29 histologically unstable carotid 
plaques (Lepedda et al. 2009). Their criteria for plaque instability included the presence of a 
thin or fissured fibrous cap covering a foamy or necrotic core, and the presence of overt 
haemorrhage, ulceration or thrombosis. The CEA specimens were finely minced and 
extracted proteins were separated by 2DE, revealing 57 distinct spots representing 33 
different proteins. MALDI-TOF MS. Compared to the stable plaques, unstable ones showed 
reduced abundance of the protective enzymes superoxide dismutase (SOD)-3, glutathione S-
transferase (GST), HSP27, HSP20, annexin A10 and Rho guanosine 5'-diphosphate 
dissociation inhibitor (GDI). 
 
Our group has undertaken proteomic analysis of smooth muscle cells (SMCs), which are key 
players in atherosclerosis (Full 2010). Carotid endarterectomies were collected from ten 
consenting patients (six symptomatic, four asymptomatic) and enzymatically digested as 
described in Section 4.4.1. SMCs were isolated from the resultant mixed cell population by 
negative selection using immunomagnetic beads (magnetic cell sorting, MACS, Miltenyi 
Biotech Ltd, Surrey, UK). Commercially available aortic medial SMCs from six healthy 
donors were purchased (Promocell, Heidelberg, Germany) as a non-diseased comparator. The 
cells were consistently used at passage number three. 2DE with digital image analysis 
(SameSpots, Non-linear Dynamics) and tandem mass spectrometry was used to detect 
changes in the proteome of atherosclerotic SMC. 2D gel image analysis revealed 29 proteins 
with a statistically significant difference in expression between medial and plaque SMC 
(P<0.05). Plaque SMC had decreased levels of mitochondrial protein ATP synthase subunit-
beta but an increase in the oxidised form of peroxiredoxin-4, suggesting decreased 
mitochondrial function, possibly due to oxidative stress.  Furthermore, differences in protein 
expression between SMC from symptomatic and asymptomatic patients were also found.  
Plaque SMC from symptomatic patients exhibited decreased levels of the anti-inflammatory 
protein Annexin I (P<0.05), compatible with pro-inflammatory behaviour. This data 
demonstrates that plaque-derived SMC are exposed to higher levels of oxidative stress 
compared to control SMC. Differences between SMC from symptomatic and asymptomatic 
patients appear to reflect pro-inflammatory changes associated with plaque instability. 
 
Early proteomic studies in atherosclerosis failed to identify inflammatory cytokines which are 
involved in plaque inflammation raising the possibility that the extraction technique was poor 
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at identifying components which existed at low levels (Bagnato et al. 2007). Extraction of 
protein in samples and enriching for low abundant analytes (depleting potentially ‗masking‘ 
high abundant entities such as albumin and haemoglobin) has previously been undertaken 
effectively in proteomics of aortic aneurysm tissue (Didangelos et al. 2010). Three human 
aortic samples were prepared with a phosphatase inhibitor mixture to inhibit proteinase 
activity and 25mM EDTA to inhibit metalloproteinases. Biochemical subfractionation 
comprised decellularisation to enrich scarce extracellular proteins, solubilisation and 
deglycosylation of extracellular membrane proteins and relative estimation of protein 
abundance before proteomic analysis. One dimensional electrophoresis was performed. Gel 
bands were excised in identical parallel positions across the lanes enabling each portion to be 
analysed separately by mass spectrometry (Didangelos et al. 2010). This is pertinent to 
atherosclerosis research, where the level of complexity is high, as individual components can 
be analysed separately and low level components can be unmasked. Proteomic and 
metabonomic studies in human atherosclerosis are summarised in Table 25. 
 
Study Reference Methodology Sample Technique Results Analytes of Interest 
(Chen et al. 
2010) 
Plasma 
metabonomics for 
biomarkers of 
atherosclerosis 
Plasma from 16 
subjects with stable 
atherosclerosis and 
28 normal subjects 
Development of 
atherosclerosis 
directly perturbed fatty 
acid metabolism 
Palmitate was proposed as a 
phenotypic biomarker for the 
diagnosis of atherosclerosis 
(Mayr et al. 
2009) 
Proteomics, 
metabonomics and 
immunomics on 
human atherosclerotic 
plaques 
Human carotid 
atherosclerotic 
plaques from live 
subjects 
Immunoglobilins are 
present within micro-
particles derived from 
plaque macrophages  
Anti-A antibodies (IgG, IgA, 
IgE), anti-carbohydrate 
antibodies and antibodies to 
oxidised LDL detected in 
plaques 
(Bagnato et al. 
2007) 
Proteomics of human 
coronary 
atherosclerotic 
plaques 
35 archival coronary 
vessels from 28 
explanted hearts. 
Artery and plaque 
analysed separately  
Distinct expression of 
806 proteins. Selected 
4 sub-groups for 
further analysis: 
extracellular; lipid 
binding; inflammatory; 
and apoptotic-cell 
Periostin (cell migration),  
PEDF (expressed when cells 
are exposed to oxidised LDL), 
MFG-E8 (phagocytosis ligand), 
annexin1 (expressed by 
macrophages of foam cell 
phenotype, linked to apoptosis 
and phagocytosis) 
(You et al. 2003) Proteomics of 
coronary 
atherosclerosis 
10 diseased and 7 
normal coronary 
arteries from 
explanted hearts 
Increased expression 
of ferritin light chain  
May contribute to coronary 
artery disease by modulating 
oxidation of lipids within the 
vessel wall through generation 
of reactive oxygen species 
Table 25 Summary of proteomic and metabolite profiling studies in human 
atherosclerosis 
Ig, immunoglobulin; LDL, low density lipoprotein; MFG-E8, milk fat globule epidermal 
growth factor 8; PEDF, Pigment epithelium-derived factor. 
 
6.7 PROTEOMICS METHODOLOGY 
6.7.1 Study Design 
Formal ethical approval (08/H0706/129) was obtained and all patients gave written fully 
informed consent for their participation in the study. This study design attempts to account for 
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biological heterogeneity in human samples: half the patients were male (n=6) and half female 
(n=6); half were symptomatic (n=6) and half asymptomatic (n=6) (Table 26). With regards to 
symptoms, only formal strokes were considered, defined as focal neurological events lasting 
for more than 24 hours pertaining to the anterior circulation of the cerebral hemisphere 
ipsilateral to the index carotid stenosis. As such transient ischaemic attack and amaurosis 
fugax were excluded, as were patients with atrial fibrillation from the symptomatic group 
where atrial thromboembolism may be a source of misdiagnosis. 
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0 62 Male 1 0 1 0 0 1 1 1 
0 70 Male 0 0 1 0 0 1 1 1 
0 71 Male 0 0 1 0 0 1 1 1 
0 80 Female 0 0 1 0 0 1 1 1 
0 65 Female 0 1 1 0 0 1 0 1 
0 69 Female 1 0 1 0 0 1 1 1 
1 71 Male 0 0 1 0 0 1 1 0 
1 76 Male 1 0 1 0 0 1 1 1 
1 71 Male 0 0 1 1 0 1 1 1 
1 84 Female 0 0 1 0 0 1 1 1 
1 78 Female 0 0 1 0 0 1 1 0 
1 71 Female 0 0 1 0 0 1 1 1 
Table 26 Clinical characteristics of symptomatic and asymptomatic patients 
 
6.7.2 Approach to Extraction for Proteomic Analysis 
The proteomic studies described have used whole tissue (Martin-Ventura et al. 2004; Lepedda 
et al. 2009) or whole cell lysates, which are complex and rich in cellular proteins. These mask 
less abundant proteins, including proteins in the extracellular matrix (ECM), thus to date the 
vascular ECM and associated proteins are poorly defined. A novel approach to protein 
extraction has recently been described and employed in the context of human aortic tissue 
(Didangelos et al. 2010). This involves the sequential exposure of tissue to three solvents 
which extract protein from different tissue compartments. The initial salt extraction releases 
proteins and peptides bound loosely to ECM. The sodium dodecyl sulphate (SDS) step 
extracts cellular components. The use of guanidine at a low pH as been shown to solubilise 
vascular proteoglycans (Eisenstein et al. 1975). The salt extract holds particular interest as the 
proteins which are loosely bound to the ECM have the potential to contain putative 
biomarkers which may be translocated from the ECM compartment of the plaque into the 
arterial circulation. 
Chapter 6 
 186 
 
6.7.3 Protein Extraction 
Protein extraction was performed as previously described (Didangelos et al. 2010). Before 
extraction the tissue pieces were partially thawed and weighed. Approximately 150mg of 
tissue per plaque sample was immediately placed in ice-cold phosphate buffered saline (PBS) 
to remove frank blood and plasma contaminants. Commercially available protease and 
phosphatase inhibitor cocktails (Sigma-Aldrich) were included according to the 
manufacturer‘s instructions in order to inhibit broad-range proteinase activity. 25mM EDTA 
was added to ensure inhibition of metalloproteinases. While the tissue samples were 
immersed in the cold saline mixture, they were quickly diced with a scalpel into eight to ten 
smaller pieces. This was done to enhance: 
 
 the initial removal of plasma contaminants; and 
 the effective extraction of extracellular proteins. 
 
The PBS mixture was changed a total of five times (approximately 30 mL total per sample). 
The diced samples were then incubated with 0.5 M NaCl, 10 mM Tris (pH 7.5), plus 
proteinase and phosphatase inhibitor cocktail and 25 mM EDTA. The volume of the buffer 
was adjusted to 10:1 of the tissue weight (i.e. 100 mg in 1 mL) and the samples were mildly 
vortexed for 4 hours at room temperature. The NaCl extracts were then desalted with 
centrifugation using desalting columns (Zeba Spin, Pierce Biotechnology). Following 
desalting the extracts were mixed with 100% acetone (5:1 volume ratio) at -20°C for 16 
hours. Proteins were precipitated with centrifugation (16.000 x g for 45 minutes) and the 
pellets were dried and redissolved in deglycosylation buffer. Deglycosylation (removal of 
glycosaminoglycan side chains) of the salt extract was achieved in a 150 mM NaCl, 50 mM 
sodium acetate (pH 6.8) buffer supplemented with proteinase and phosphatase inhibitors and 
10mM EDTA for 16 hours at 37°C. The deglycosylation enzymes (0.05 U) used (all 
purchased from Sigma-Aldrich) were: 
 
 chondroitinase ABC from Proteus vulgaris (catalyzes the removal of polysaccharides 
containing 1→4-β-D-hexosaminyl and 1→3-β-D-glucuronosyl or 1→3-α-L 
iduronosyl linkages to disaccharides containing 4-deoxy-β-D-gluc-4-enuronosyl 
groups. It acts on chondroitin 4-sulfate, chondroitin 6-sulfate, and dermatan sulfate 
glycosaminoglycan side chains); 
 keratanase from Bacteroides fragillis (cleaves internal 1→4-β-galactose linkages in 
unbranched, repeating poly-N-acetyl-lactosamine and keratan sulphate); and 
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  heparatinase II from Flavobacterium heparinum (cleaves heparan sulphate). 
 
Following, deglycosylation the solutions were clarified again by centrifugation (16.000  x g 
for 10 minutes) in order to ensure that the samples were free of turbidity. Protein 
concentration was estimated by ultraviolet (UV) absorbance at 280 nm using extinction 
coefficient of 1.1 of 0.1% mg/mL solution calculated on the basis of the frequency of tyrosine 
and tryptophan which are the main UV absorbing amino acids at 280 nm in mammalian 
proteins (Zhuang et al. 2003). 
 
6.7.4 Gelatinolytic Zymography 
Gelatinolytic zymograms were used to detect the presence and activity of MMP2 and MMP9 
in the 0.5 M NaCl extracts. Extract aliquots (20 μg of protein) were mixed with non-reducing 
sample buffer containing 100 mM Tris (pH 6.8) 40% glycerol, 0.2% SDS and 0.02% 
bromophenol blue and separated in 10% SDS-PAGE gels containing 0.5 mg/mL gelatin 
(Sigma-Aldrich). Pre-stained protein standards were run alongside the samples to allow 
molecular mass estimation of proteins (All Blue, Precision Plus, Bio-Rad Laboratories). To 
allow in-gel MMP activity, SDS was removed from the gels with three washes in a buffer 
containing 2% Triton X-100, 50 mM Tris (pH 7.4) and 200 mM NaCl for 45 minutes. Gels 
were then incubated for 16 hours to detect MMP9 or 36 hours to detect MMP2 at 37°C in a 
buffer containing 50mM Tris (pH 7.4), 200 mM NaCl and 10mM CaCl2. Finally, gels were 
stained for 60 minutes with Coomassie Brilliant Blue (Sigma-Aldrich) and destained for 2 
hours to visualise the MMPs. 
 
6.7.5 Protein Gel Electrophoresis 
The NaCl extracts were denatured and reduced in sample buffer containing 100 mM Tris (pH 
6.8), 40% glycerol, 0.2% SDS, 2% beta-mercaptoethanol and 0.02% bromophenol blue, and 
boiled at 96°C for 10 minutes. 35 μg of protein per sample was loaded and separated on Bis-
Tris discontinuous 4-12% polyacrylamide gradient gels (NuPage, Invitrogen). Pre-stained 
protein standards were run alongside the samples to allow molecular mass estimation of 
proteins (All Blue, Precision Plus, Bio-Rad Laboratories). Following electrophoresis, gels 
were silver stained (PlusOne Silver Staining Kit, GE Healthcare) (Figure 59). Silver staining 
was used to facilitate subsequent band excision to avoid cross-contamination with fainter gel 
bands, as Coomassie staining will preferably stain the abundant proteins hence fainter gel 
bands could be missed. The gel bands were excised in identical parallel positions across lanes 
and no ―empty‖ gel pieces were left behind (Figure 60). 
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Figure 59 Salt extract protein gel electrophoresis 
Salt extracts from carotid atherosclerotic plaques from male (A) and female (B) patients were 
separated on Bis-Tris discontinuous 4-12% polyacrylamide gradient gels (NuPage, 
Invitrogen) and silver stained. 
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Figure 60 Salt extract protein gel band excision prior to trypsination 
Each of the two proteins gels were fully sectioned into 96 pieces. The gel with separated salt 
extracts from female proteins is shown. Excision in identical parallel positions across lanes 
meant that no “empty” gel pieces were left behind. 
 
6.7.6 Nanoflow Liquid Chromatography Tandem Mass Spectrometry 
Subsequently, all gel bands were subjected to in-gel digestion with trypsin using an 
Investigator ProGest (Genomic Solutions) robotic digestion system. Tryptic peptides from the 
NaCl extract were separated on a nanoflow liquid chromatography (LC) system (Dionex 
UltiMate 3000, UK) and eluted with a 40 minute gradient (10-25% B in 35 minutes, 25-40% 
B in 5 minutes, 90% B in 10 minutes and 2% B in 30 minutes, where A = 2% acetonitrile 
[ACN], 0.1% formic acid in high performance liquid chromatography [HPLC] H2O and B = 
90% ACN, 0.1% formic acid in HPLC H2O). The column (Dionex PepMap C18, 25 cm 
length, 75 μm internal diameter, 3 μm particle size) was coupled to a nanospray source 
(Picoview) using RePlay (Advion). After the direct LC-MS run, the flow was switched and 
the portion stored in the capillary of the RePlay device re-analyzed (‘replay run’) (Waanders et 
al. 2008). Spectra were collected from an ion-trap mass analyzer (LTQ Orbitrap XL, 
ThermoFisher Scientific) using full ion scan mode over the mass-to-charge (m/z) range 450-
1600. Tandem mass spectrometry (MS/MS) was performed on the top six ions in each MS 
scan using the data-dependent acquisition mode with dynamic exclusion enabled. MS/MS 
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peaklists were generated by extract_msn.exe and matched to human database 
(UniProtKB/Swiss-Prot Release 14.6, 20333 protein entries) using SEQUEST v.28 (rev. 13), 
(Bioworks Browser 3.3.1 SP1, ThermoFisher Scientific) and X! Tandem (Version 
2007.01.01.2). Carboxyamidomethylation of cysteine was chosen as fixed modification and 
oxidation of methionine as variable modification. 
 
The mass tolerance was set at 1.5 atomic mass units (AMU) for the precursor ions and at 1.0 
AMU for fragment ions. Two missed cleavages were allowed. Scaffold (version 2.0.5, 
Proteome Software Inc., Portland, OR) was used to calculate the spectral counts and to 
validate MS/MS based peptide and protein identifications (Keller et al. 2002; Nesvizhskii et 
al. 2003). According to the default values in the Scaffold software, the following peptide 
thresholds were applied: X! Tandem: -Log(Expect Scores) > 2.0, SEQUEST: deltaCn > 0.10 
and XCorr > 2.5 (+2), 3.5 (+3) and 3.5 (+4). Peptide identifications were accepted if they 
could be established at greater than 95.0% probability as specified by the Peptide Prophet 
algorithm (Keller et al. 2002). Protein identifications were accepted if they could be 
established at greater than 99.0% probability (Nesvizhskii et al. 2003) with at least two 
independent peptides and a mass accuracy of ≤ 10 parts per million (ppm) of the precursor 
ion. 
 
6.8 SALT EXTRACT PROTEOMICS RESULTS 
There was a highly significant correlation between the number of assigned spectra in the first 
sample and the replay sample (linear regression, r
2
 = 0.9342, p < 0.0001, Figure 61). 
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Figure 61 Comparison of assigned spectra in sample and replay of tandem mass 
spectrometry 
Linear regression, r
2
 = 0.9342, p < 0.0001. 
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Ion trap mass spectrometry of the atherosclerotic plaque salt extract identified 2,470 proteins. 
National Center for Biotechnology Information (NCBI) annotations were applied to all the 
proteins identified, and the proteins were categorised according to sub-categories of biological 
process, cellular compartment, and molecular function (Table 27). 
 
Ontology 
Category 
Process / Compartment / Function 
Number of 
Indentified Proteins 
Biological 
Process 
Biological Adhesion 146 
Biological Regulation 937 
Cell Killing 8 
Cellular Process 1621 
Developmental Process 357 
Establishment of Localisation 370 
Growth 7 
Immune System Process 143 
Localisation 435 
Locomotion 42 
Metabolic Process 1028 
Multi-Organism Process 109 
Multi-Cellular Organismal Process 357 
Pigmentation 4 
Reproduction 44 
Reproductive Process 43 
Response to Stimulus 381 
Rhythmic Process 6 
Viral Reproduction 10 
Cellular 
Compartment 
Golgi Apparatus 106 
Cytoplasm 1099 
Cytoskeleton 296 
Endoplasmic Reticulum 78 
Endosome 40 
Extra-Cellular Region 352 
Intra-Cellular Organelle 1177 
Membrane 662 
Mitochondrion 89 
Nucleus 635 
Organelle Membrane 116 
Organelle Part 631 
Plasma Membrane 378 
Ribosome 43 
Molecular 
Function 
Anti-Oxidant Activity 21 
Auxilliary Transport Protein Activity 1 
Binding 1819 
Catalytic Activity 734 
Chemoattractant Activity 1 
Electron Carrier Activity 20 
Enzyme Regulator Activity 172 
Molecular Function 2005 
Molecular Transducer Activity 146 
Motor Activity 58 
Structural Molecule Activity 157 
Transcription Regulator Activity 124 
Translation Regulator Activity 33 
Transporter Activity 120 
Table 27 Categorisation of the 2470 identified salt extract proteins 
Categorisation is in accordance with National Center for Biotechnology Information (NCBI) 
annotation. 
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6.8.1 Analysis Based Upon Symptomatic Status 
T-test revealed that the average number of spectra relating to 159 proteins were significantly 
different between symptomatic and asymptomatic atherosclerosis (Table 28). Principal 
components analysis revealed a clear separation of the samples based upon symptomatic 
status (Figure 62). 
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Protein Name 
Swiss-Prot 
Accession 
Name 
Molecular Mass 
(kDa) 
Unique 
Peptides (n) 
Unique 
Spectra (n) 
Coverage 
(%) 
Average Spectra (n) 
Average Spectra 
Asymptomatic versus 
Symptomatic 
Asymptomatic Symptomatic 
T-Test 
P-Value 
Fold 
Difference 
Adhesion          
 Integrin beta-1 ITB1_HUMAN 75 1.8 1.8 3.8 5.7 2.0 0.0011 -2.8 
Angiogenesis / Vasculogenesis          
 Thymidine phosphorylase TYPH_HUMAN 51 1.6 1.6 3.9 2.0 3.7 0.018 1.8 
* Cysteine and glycine-rich protein 2 CSRP2_HUMAN 21 6.5 6.8 35.2 14.8 11.3 0.019 -1.3 
* Chloride intracellular channel protein 4 CLIC4_HUMAN 62 0.8 0.8 2.5 5.7 3.8 0.0075 -1.5 
Binding          
 Fatty acid-binding protein, epidermal FABP5_HUMAN 15 0.7 0.7 6.4 0.1 2.2 0.00037 26.0 
* Retinoblastoma-binding protein 6 RBBP6_HUMAN 81 0.6 0.6 1.1 0.3 1.1 0.022 3.3 
* Far upstream element-binding protein 2 FUBP2_HUMAN 20 1.6 1.6 10.4 0.5 1.0 0.048 2.0 
* Coronin-1A COR1A_HUMAN 84 2.4 2.4 3.6 2.6 4.9 0.018 1.9 
 Stress-70 protein, mitochondrial GRP75_HUMAN 74 2.8 2.8 6.0 3.0 4.8 0.024 1.6 
 Serotransferrin TRFE_HUMAN 77 45.7 59.6 55.3 292.9 252.0 0.043 -1.2 
 Vitamin D-binding protein VTDB_HUMAN 68 0.7 0.7 1.8 22.0 18.5 0.018 -1.2 
* Phosphatidylethanolamine-binding protein 1 PEBP1_HUMAN 21 3.2 3.3 25.8 6.4 5.0 0.049 -1.3 
 Insulin-like growth factor-binding protein 7 IBP7_HUMAN 42 4.9 6.5 14.9 17.3 13.4 0.033 -1.3 
 Apolipoprotein D APOD_HUMAN 76 0.5 0.5 0.7 9.4 6.8 0.037 -1.4 
 Methyl-CpG-binding protein 2 MECP2_HUMAN 118 0.8 0.8 1.1 1.6 0.7 0.039 -2.4 
* Non-POU domain-containing octamer-binding 
protein 
NONO_HUMAN 54 0.6 0.6 1.4 1.6 0.3 0.018 -6.3 
Coagulation          
 Prothrombin THRB_HUMAN 50 1.8 1.9 5.4 33.3 55.3 0.018 1.7 
Collagen          
 Collagen alpha-1(XV) chain COFA1_HUMAN 142 3.7 3.7 3.5 5.2 8.1 0.015 1.6 
Cytoskeletal / Cytokinesis 
* Dynein heavy chain 10, axonemal DYH10_HUMAN 202 1.1 1.1 0.7 0.3 1.6 0.025 4.8 
* Neurofilament light polypeptide NFL_HUMAN 29 2.4 2.4 13.3 0.9 2.5 0.0075 2.7 
* Cdc42-interacting protein 4 CIP4_HUMAN 53 7.0 9.4 18.6 0.7 1.8 0.018 2.6 
 Keratin, type I cytoskeletal 18 K1C18_HUMAN 46 0.5 0.5 1.9 1.1 2.8 0.0063 2.6 
 Radixin RADI_HUMAN 51 2.7 2.7 6.3 0.2 0.4 0.024 2.5 
* T-complex protein 1 subunit eta TCPH_HUMAN 124 3.0 3.0 3.5 0.6 1.3 0.017 2.3 
* Septin-9 SEPT9_HUMAN 124 2.8 2.8 2.9 0.9 1.8 0.013 2.0 
 Vasodilator-stimulated phosphoprotein VASP_HUMAN 42 1.0 1.0 3.5 1.1 1.9 0.031 1.8 
* Keratin, type II cytoskeletal 2 epidermal K22E_HUMAN 65 2.7 2.8 5.5 3.2 5.5 0.035 1.7 
* Rootletin CROCC_HUMAN 229 0.7 0.7 0.4 0.6 1.0 0.029 1.7 
 Ezrin EZRI_HUMAN 69 1.3 1.3 2.9 1.7 2.6 0.017 1.6 
* ADP-ribosylation factor 6 ARF6_HUMAN 83 0.9 0.9 1.4 2.3 3.3 0.048 1.5 
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Protein Name 
Swiss-Prot 
Accession 
Name 
Molecular Mass 
(kDa) 
Unique 
Peptides (n) 
Unique 
Spectra (n) 
Coverage 
(%) 
Average Spectra (n) 
Average Spectra 
Asymptomatic versus 
Symptomatic 
Asymptomatic Symptomatic 
T-Test 
P-Value 
Fold 
Difference 
* Actin-related protein 2/3 complex subunit 1B ARC1B_HUMAN 73 0.6 0.6 1.3 5.0 7.2 0.048 1.4 
 Moesin MOES_HUMAN 13 0.9 1.1 9.5 25.8 30.4 0.0026 1.2 
* Talin-1 TLN1_HUMAN 47 11.3 13.5 33.9 154.3 124.5 0.027 -1.2 
* Actin, alpha cardiac muscle 1 ACTC_HUMAN 29 6.3 7.8 29.3 27.1 20.8 0.033 -1.3 
 Calponin-1 CNN1_HUMAN 227 19.3 20.8 11.7 39.9 28.2 0.0074 -1.4 
* Spectrin alpha chain, brain SPTA2_HUMAN 285 14.6 14.8 6.9 28.3 17.3 0.045 -1.6 
* Fermitin family homolog 2 FERM2_HUMAN 38 0.4 0.4 1.6 6.3 3.8 0.032 -1.7 
 Myosin-11 MYH11_HUMAN 33 7.4 7.6 28.0 43.8 26.5 0.0074 -1.7 
* T-complex protein 1 subunit theta TCPQ_HUMAN 19 0.7 0.7 3.6 4.9 2.9 0.017 -1.7 
* Spectrin beta chain, brain 1 SPTB2_HUMAN 275 10.2 10.4 5.2 19.8 11.2 0.016 -1.8 
* Microtubule-associated protein 1B MAP1B_HUMAN 271 4.8 4.8 2.5 11.3 6.3 0.047 -1.8 
 Myosin-10 MYH10_HUMAN 51 1.4 1.4 4.1 26.4 13.8 0.013 -1.9 
* Actin, gamma-enteric smooth muscle ACTH_HUMAN 31 0.6 0.6 2.8 1.4 0.7 0.03 -2.1 
* Vinexin VINEX_HUMAN 88 2.6 2.6 3.8 4.2 1.9 0.0011 -2.2 
* Annexin A11 ANX11_HUMAN 54 1.6 1.6 4.2 3.1 1.3 0.021 -2.3 
* Peptidyl-prolyl cis-trans isomerase H PPIH_HUMAN 59 0.7 0.7 1.8 1.8 0.8 0.017 -2.3 
* Talin-2 TLN2_HUMAN 272 0.5 0.5 0.3 0.8 0.3 0.0014 -2.5 
* Dynein heavy chain 11, axonemal DYH11_HUMAN 521 0.4 0.4 0.1 0.7 0.3 0.048 -2.7 
* Synaptopodin-2 SYNP2_HUMAN 52 0.6 0.6 2.0 1.4 0.5 0.039 -2.8 
 Filamin-C FLNC_HUMAN 291 3.3 3.3 1.9 6.8 2.3 0.00058 -2.9 
 Sorbin and SH3 domain-containing protein 1 SRBS1_HUMAN 143 2.2 2.2 2.0 5.3 1.8 0.0079 -3.0 
 Alpha-adducin ADDA_HUMAN 202 0.6 0.6 0.5 1.4 0.4 0.022 -3.4 
DNA Processing / Repair 
* Dihydropyrimidine dehydrogenase [NADP+] DPYD_HUMAN 111 0.6 0.6 0.8 0.1 1.8 0.0062 22.0 
* Replication factor C subunit 5 RFC5_HUMAN 34 0.9 0.9 3.6 0.3 0.9 0.012 2.8 
* ATP-dependent DNA helicase Q1 RECQ1_HUMAN 73 0.7 0.7 1.3 1.4 0.8 0.048 -1.9 
 High mobility group protein B2 HMGB2_HUMAN 24 1.1 1.3 7.8 2.8 1.3 0.01 -2.2 
* Fanconi anemia group B protein FANCB_HUMAN 98 0.4 0.4 0.7 1.1 0.1 0.044 -13.0 
Energy Metabolism 
* Hexokinase-3 HXK3_HUMAN 99 0.5 0.5 0.8 0.0 1.3 0.042 - 
* 6-phosphofructokinase, liver type K6PL_HUMAN 85 0.8 0.8 1.4 0.6 1.7 0.0036 2.9 
* UTP--glucose-1-phosphate uridylyltransferase UGPA_HUMAN 57 1.2 1.2 3.0 0.8 2.1 0.036 2.5 
* ADP-ribosylation factor 1 ARF1_HUMAN 
(+1) 
21 1.7 1.7 11.6 2.6 4.6 0.00045 1.8 
* L-lactate dehydrogenase A chain LDHA_HUMAN 37 6.3 6.7 21.4 9.8 12.8 0.0061 1.3 
* ATP synthase subunit beta, mitochondrial ATPB_HUMAN 57 4.5 4.8 11.0 8.7 5.9 0.033 -1.5 
Enzyme / Enzyme Regulator 
Chapter 6 
 195 
 
Protein Name 
Swiss-Prot 
Accession 
Name 
Molecular Mass 
(kDa) 
Unique 
Peptides (n) 
Unique 
Spectra (n) 
Coverage 
(%) 
Average Spectra (n) 
Average Spectra 
Asymptomatic versus 
Symptomatic 
Asymptomatic Symptomatic 
T-Test 
P-Value 
Fold 
Difference 
* Aldose 1-epimerase GALM_HUMAN 78 3.1 3.2 5.5 0.2 0.8 0.032 4.5 
* Mitogen-activated protein kinase 13 MK13_HUMAN 42 0.5 0.5 1.2 0.4 1.6 0.032 3.8 
* CMP-N-acetylneuraminate-poly-alpha-2,8-
sialyltransferase 
SIA8D_HUMAN 629 32.8 32.8 7.5 0.3 0.9 0.04 3.7 
 Myeloperoxidase PERM_HUMAN 70 12.8 13.7 26.7 2.2 6.8 0.018 3.2 
* N-acetyl-D-glucosamine kinase NAGK_HUMAN 76 2.3 2.4 4.3 1.1 3.3 0.0024 3.1 
* Phospholipase DDHD2 DDHD2_HUMAN 14 4.9 5.1 43.3 0.4 1.1 0.015 2.6 
 Matrix metalloproteinase-9 MMP9_HUMAN 229 10.8 10.8 7.0 2.7 6.8 0.013 2.6 
* Leukocyte elastase inhibitor ILEU_HUMAN 36 3.6 5.4 15.5 2.9 4.3 0.046 1.5 
 Calpain-1 catalytic subunit CAN1_HUMAN 82 3.9 4.0 4.9 5.9 8.2 0.04 1.4 
 Triosephosphate isomerase TPIS_HUMAN 633 1.5 1.5 0.5 23.8 28.9 0.0089 1.2 
 Alpha-enolase ENOA_HUMAN 270 42.8 50.4 22.1 36.0 42.2 0.027 1.2 
 Purine nucleoside phosphorylase PNPH_HUMAN 18 1.0 1.0 7.9 6.6 5.3 0.028 -1.2 
* UDP-glucose:glycoprotein glucosyltransferase 1 UGGG1_HUMAN 47 1.0 1.0 3.1 1.3 0.8 0.036 -1.7 
* cAMP-dependent protein kinase type I-alpha 
regulatory subunit 
KAP0_HUMAN 43 1.5 1.7 4.4 3.0 1.8 0.023 -1.7 
 Integrin-linked protein kinase ILK_HUMAN 43 1.0 1.0 5.6 6.0 3.0 0.024 -2.0 
* NADH-cytochrome b5 reductase 3 NB5R3_HUMAN 38 0.5 0.5 4.0 1.4 0.7 0.012 -2.1 
 Kallistatin KAIN_HUMAN 49 2.0 2.0 5.5 4.2 1.8 0.011 -2.3 
* Probable 2-oxoglutarate dehydrogenase E1 
component DHKTD1, mitochondrial 
DHTK1_HUMAN 103 0.6 0.6 0.9 1.1 0.4 0.02 -2.6 
* Glutathione S-transferase Mu 3 GSTM3_HUMAN 27 2.7 2.8 13.9 6.3 2.3 0.0015 -2.8 
 Ubiquitin carboxyl-terminal hydrolase isozyme L1 UCHL1_HUMAN 25 1.2 1.4 8.2 2.8 0.9 0.026 -3.1 
* Omega-amidase NIT2 NIT2_HUMAN 236 0.4 0.4 0.3 1.3 0.4 0.03 -3.2 
* Glutathione S-transferase Mu 2 GSTM2_HUMAN 26 0.5 0.5 2.1 1.3 0.3 0.046 -3.8 
GDP / GTP Associated          
 Ras GTPase-activating-like protein IQGAP1 IQGA1_HUMAN 189 22.0 22.5 15.6 49.0 59.7 0.0029 1.2 
* Rab GDP dissociation inhibitor beta GDIB_HUMAN 51 7.6 7.7 19.4 16.3 9.8 0.0044 -1.7 
* Rab GDP dissociation inhibitor alpha GDIA_HUMAN 78 2.7 2.8 4.9 2.9 1.8 0.013 -1.7 
* Rho guanine nucleotide exchange factor 11 ARHGB_HUMAN 168 0.7 0.7 0.9 1.3 0.4 0.043 -3.0 
Glycoprotein          
 Lactotransferrin TRFL_HUMAN 78 5.5 5.9 9.3 3.3 17.7 0.0046 5.4 
 Fibronectin FINC_HUMAN 263 42.0 53.4 23.6 168.7 242.3 0.0084 1.4 
 Serum amyloid P-component SAMP_HUMAN 25 7.9 9.4 29.2 60.0 45.6 0.026 -1.3 
 Beta-2-glycoprotein 1 APOH_HUMAN 38 8.1 9.3 31.6 22.9 13.6 0.000024 -1.7 
* Thrombospondin-3 TSP3_HUMAN 104 1.0 1.0 1.3 1.8 0.9 0.014 -2.0 
Inflammation          
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Protein Name 
Swiss-Prot 
Accession 
Name 
Molecular Mass 
(kDa) 
Unique 
Peptides (n) 
Unique 
Spectra (n) 
Coverage 
(%) 
Average Spectra (n) 
Average Spectra 
Asymptomatic versus 
Symptomatic 
Asymptomatic Symptomatic 
T-Test 
P-Value 
Fold 
Difference 
* Mannan-binding lectin serine protease 2 MASP2_HUMAN 192 13.7 14.3 9.3 0.2 0.9 0.037 5.5 
 Osteopontin OSTP_HUMAN 35 1.8 1.8 6.7 5.5 16.6 0.0093 3.0 
* L-amino-acid oxidase OXLA_HUMAN 63 0.8 0.8 1.3 0.7 2.0 0.0048 3.0 
 Protein S100-A9 S10A9_HUMAN 41 2.7 3.2 9.2 3.8 8.8 0.048 2.3 
 Scavenger receptor cysteine-rich type 1 protein 
M130 
C163A_HUMAN 125 1.4 1.4 1.6 1.3 2.9 0.0051 2.2 
* Ig kappa chain V-IV region (Fragment) KV401_HUMAN 
(+1) 
13 2.0 2.5 19.7 4.2 7.9 0.013 1.9 
* Smad nuclear-interacting protein 1 SNIP1_HUMAN 46 1.1 1.1 4.2 2.9 5.5 0.00091 1.9 
 Suppressor of cytokine signaling 6 SOCS6_HUMAN 60 1.1 1.1 3.2 1.8 2.9 0.037 1.6 
* Ig kappa chain V-III region VG (Fragment) KV309_HUMAN 13 2.7 2.7 24.0 5.4 7.8 0.0071 1.4 
* Ig kappa chain V-III region HAH KV312_HUMAN 81 0.6 0.6 1.4 11.9 15.8 0.015 1.3 
* Ig gamma-3 chain C region IGHG3_HUMAN 30 2.0 2.1 9.7 110.2 140.2 0.014 1.3 
* Ig gamma-2 chain C region IGHG2_HUMAN 43 2.2 2.2 6.6 33.7 37.5 0.046 1.1 
* SAM domain and HD domain-containing protein 1 SAMH1_HUMAN 72 1.6 1.6 3.0 3.2 2.1 0.044 -1.5 
Intracellular Trafficking          
* Sorting nexin-6 SNX6_HUMAN 70 0.8 0.8 2.1 1.8 1.1 0.036 -1.7 
 Early endosome antigen 1 EEA1_HUMAN 515 0.9 0.9 0.3 2.5 1.0 0.025 -2.5 
* Sorting nexin-2 SNX2_HUMAN 58 1.6 1.6 4.0 3.9 1.3 0.0046 -3.1 
* AP-3 complex subunit sigma-1 AP3S1_HUMAN 22 0.4 0.4 2.2 0.8 0.3 0.033 -3.3 
Mitosis          
 Kinesin-like protein KIF15 KIF15_HUMAN 28 2.8 3.4 15.4 0.3 1.7 0.041 6.7 
Neural Cell Differentiation / Migration          
* Glia maturation factor beta GMFB_HUMAN 21 3.1 3.2 18.1 1.1 1.8 0.037 1.6 
* Neuroblast differentiation-associated protein 
AHNAK 
AHNK_HUMAN 41 0.4 0.4 1.4 94.8 68.3 0.04 -1.4 
* Neuron navigator 1 NAV1_HUMAN 162 1.4 1.4 1.4 6.0 3.7 0.025 -1.6 
Other          
* NKAP-like protein NKAPL_HUMAN 48 1.5 1.5 3.7 0.2 1.1 0.0063 6.5 
* Ankyrin repeat domain-containing protein 12 ANR12_HUMAN 43 5.1 5.2 17.3 0.2 0.8 0.03 5.0 
* Niban-like protein 1 NIBL1_HUMAN 13 2.1 2.9 25.2 0.6 2.0 0.048 3.4 
* Neurocalcin-delta NCALD_HUMAN 22 0.5 0.5 3.1 0.3 0.9 0.032 2.8 
 Epididymal secretory protein E1 NPC2_HUMAN 17 1.3 1.3 11.5 1.6 3.3 0.021 2.1 
* Protein FAM49B FA49B_HUMAN 70 9.7 11.1 17.7 1.8 3.6 0.039 2.0 
* Glyoxalase domain-containing protein 4 GLOD4_HUMAN 60 2.5 2.5 5.4 0.9 1.8 0.017 1.9 
* Importin-5 IPO5_HUMAN 35 0.9 0.9 4.0 3.2 4.8 0.017 1.5 
 78 kDa glucose-regulated protein GRP78_HUMAN 72 10.4 11.5 20.0 17.4 21.6 0.02 1.2 
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Protein Name 
Swiss-Prot 
Accession 
Name 
Molecular Mass 
(kDa) 
Unique 
Peptides (n) 
Unique 
Spectra (n) 
Coverage 
(%) 
Average Spectra (n) 
Average Spectra 
Asymptomatic versus 
Symptomatic 
Asymptomatic Symptomatic 
T-Test 
P-Value 
Fold 
Difference 
 Clathrin heavy chain 1 CLH1_HUMAN 17 1.0 1.0 6.6 31.3 23.6 0.037 -1.3 
 Heat shock 70 kDa protein 1 HSP71_HUMAN 37 1.6 1.7 5.6 28.8 21.2 0.039 -1.4 
 Tetranectin TETN_HUMAN 23 5.7 6.5 30.2 17.3 11.8 0.011 -1.5 
* Forkhead-associated domain-containing protein 1 FHAD1_HUMAN 162 1.1 1.1 1.2 4.0 2.5 0.023 -1.6 
* Tumor protein D54 TPD54_HUMAN 22 1.3 1.3 6.3 3.8 2.1 0.043 -1.8 
* Huntingtin-associated protein 1 HAP1_HUMAN 9 1.2 1.2 18.4 1.4 0.8 0.028 -1.9 
* Tetratricopeptide repeat protein 39A TT39A_HUMAN 177 0.8 0.8 0.6 1.8 0.9 0.036 -2.0 
* Layilin LAYN_HUMAN 69 0.3 0.3 0.5 2.3 1.1 0.024 -2.2 
* Secernin-1 SCRN1_HUMAN 46 1.0 1.0 3.3 2.3 0.7 0.0017 -3.4 
* Olfactomedin-like protein 1 OLFL1_HUMAN 46 0.8 0.8 1.8 2.5 0.6 0.0056 -4.3 
* Thioredoxin-like protein 1 TXNL1_HUMAN 32 0.4 0.4 2.5 0.8 0.2 0.037 -4.5 
Platelet 
 CD9 antigen CD9_HUMAN 25 0.6 0.6 2.6 1.3 0.3 0.023 -4.0 
Prohormone 
 Angiotensinogen ANGT_HUMAN 53 2.4 2.4 6.2 4.8 3.1 0.011 -1.6 
Proteosomal 
* Proteasome subunit alpha type-1 PSA1_HUMAN 41 11.5 14.4 33.4 1.9 3.4 0.014 1.8 
* Proteasome subunit beta type-5 PSB5_HUMAN 28 1.7 2.3 8.7 3.8 2.7 0.049 -1.4 
* 26S protease regulatory subunit 7 PRS7_HUMAN 49 1.5 1.5 4.0 2.9 1.8 0.044 -1.7 
* Proteasome subunit beta type-4 PSB4_HUMAN 29 1.0 1.0 4.8 1.9 1.0 0.043 -1.9 
Redox          
* Uncharacterized protein KIAA0467 K0467_HUMAN 32 3.3 3.3 13.7 1.7 4.2 0.028 2.5 
Signalling          
* Mitogen-activated protein kinase 11 MK11_HUMAN 41 0.5 0.5 1.0 0.4 1.5 0.032 3.6 
* 14-3-3 protein eta 1433F_HUMAN 28 4.1 4.1 19.8 9.2 7.3 0.043 -1.3 
* 14-3-3 protein zeta/delta 1433Z_HUMAN 160 0.7 0.7 0.8 9.4 7.5 0.041 -1.3 
* 14-3-3 protein theta 1433T_HUMAN 28 3.0 3.6 15.8 7.9 4.8 0.00003 -1.7 
* Sorbin and SH3 domain-containing protein 2 SRBS2_HUMAN 65 1.0 1.0 2.9 10.4 2.8 0.013 -3.7 
* Ras-related protein Rab-23 RAB23_HUMAN 27 0.5 0.5 2.2 1.3 0.1 0.046 -15.0 
Transcription 
* Midasin MDN1_HUMAN 27 11.2 13.8 49.8 0.9 2.8 0.0089 3.0 
* 40S ribosomal protein S20 RS20_HUMAN 68 12.8 14.8 20.3 0.8 2.1 0.0026 2.8 
* 40S ribosomal protein S16 RS16_HUMAN 16 0.9 0.9 6.7 0.8 1.9 0.005 2.3 
* 60S ribosomal protein L30 RL30_HUMAN 13 1.7 1.7 21.0 2.0 4.4 0.021 2.2 
* Heterogeneous nuclear ribonucleoprotein G HNRPG_HUMAN 40 1.2 1.2 4.3 2.3 3.8 0.031 1.7 
* 60S ribosomal protein L23a RL23A_HUMAN 278 1.1 1.1 0.7 1.8 2.8 0.028 1.6 
 Polymerase I and transcript release factor PTRF_HUMAN 25 2.0 2.1 11.8 15.6 10.4 0.03 -1.5 
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Table 28 Indentified proteins whose abundance within salt extracts is significantly different between symptomatic and asymptomatic carotid 
atherosclerosis 
Proteins identified by proteomic analysis of salt extracts which are significantly different between asymptomatic (n=6) and symptomatic (n=6) carotid 
atherosclerotic plaques. Total spectra (based upon two technical replicates for each sample) are shown separately for each of the two groups, with the T-test 
P-value and the fold difference in total spectra. * Proteins identified for the first time by proteomics in the context of atherosclerosis or the carotid artery 
 
 
Protein Name 
Swiss-Prot 
Accession 
Name 
Molecular Mass 
(kDa) 
Unique 
Peptides (n) 
Unique 
Spectra (n) 
Coverage 
(%) 
Average Spectra (n) 
Average Spectra 
Asymptomatic versus 
Symptomatic 
Asymptomatic Symptomatic 
T-Test 
P-Value 
Fold 
Difference 
* 60S ribosomal protein L10a RL10A_HUMAN 42 0.5 0.5 2.4 4.4 2.3 0.03 -2.0 
* 40S ribosomal protein S21 RS21_HUMAN 76 0.8 0.8 1.5 2.3 1.1 0.028 -2.1 
* Splicing factor 3B subunit 3 SF3B3_HUMAN 136 0.6 0.6 0.6 1.1 0.4 0.02 -2.6 
* Splicing factor, proline- and glutamine-rich SFPQ_HUMAN 37 1.5 1.5 5.5 5.5 1.9 0.0024 -2.9 
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Figure 62 Separation based on proteomic analysis of symptomatic and 
asymptomatic carotid atherosclerosis by 2-dimensional principal 
components analysis 
Excellent separation was observed between symptomatic (red) and asymptomatic (blue) 
samples in principal component (Prin. Comp.) 2. 
 
6.8.2 Analysis Considering Gender 
Analysing males and females separately, from the male carotid plaques there were 1,810 
identified proteins of which 204 were significantly different in quantity considering 
symptomatic status In the female group 1,790 proteins were identified, with 90 significant 
differences Of the significant differences between symptomatic and asymptomatic in the 
gender sub-groups, only 11 proteins were significantly different in common in both male and 
female: 
 
 14-3-3 protein theta 
 Apolipoprotein C-III 
 Beta-2-glycoprotein 1 
 Biliverdin reductase A 
 Fatty acid-binding protein, epidermal 
 Glutathione S-transferase Mu 3 
 Latent-transforming growth factor beta-binding protein 2 
 Neuron navigator 1 
 Ras GTPase-activating-like protein IQGAP1 
 Smad nuclear-interacting protein 1 
 Sorting nexin-2 
 
Chapter 6 
 200 
This prompted a comparison between females and males, at which point 332 significant 
differences were identified. Comparing asymptomatic males and females 221 differences 
emerged, and comparing symptomatic males and females 237 differences were seen. 
 
6.8.3 Gelatinolytic Zymography Results and Validation 
There was a significant difference in MMP9 activity between symptomatic and asymptomatic 
salt extracts (Figure 63A and B). This was also seen when comparing spectral counts between 
symptomatics and asymptomatics (Table 28). The significant correlation between MMP9 by 
zymography and tandem mass spectrometry (Figure 63C) serves to contribute to the 
validation of the dataset obtained through this proteomic analysis. 
 
 
Figure 63 Salt extract gelatinolytic zymography – comparison with MMP9 spectra 
by tandem mass spectrometry 
Total MMP9 levels by gelatine zymography (Males, A; Females, B), quantified by gel 
densitometry, significantly correlated with MMP9 spectral count as detected by tandem mass 
spectrometry (C; Linear regression, r
2
 = 0.5514, p < 0.0001). 
 
6.9 DISCUSSION 
Proteomic analysis of the salt extract fraction from carotid atherosclerotic plaques identified 
2,470 proteins implicated in 33 bio-molecular functions and having their origins previously 
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described in 14 different cellular compartments. There were 159 proteins which, based upon 
the number of assigned spectra, were significantly different between symptomatic and 
asymptomatic atherosclerosis. Of these, 8 did not feature in Pubmed, 119 had not been 
previously published in the context of ―carotid‖, 112 not published in the context of 
―atherosclerosis‖, 132 not published in the context of ―carotid AND atherosclerosis‖, and 108 
not published in the context of ―carotid OR atherosclerosis‖. 
 
Osteopontin levels were significantly higher in the plaques from symptomatic compared with 
asymptomatic plaques in the salt extract. A recent study has confirmed that atherosclerotic 
plaques, in the carotid with validation in the femoral, are a source of biomarkers which make 
be predictive of future adverse cardiovascular events (de Kleijn et al. 2010). In particular, this 
large prospective study identified osteopontin by proteomics as a potential biomarker, 
subsequently confirming a hazard ratio of 3.8 in carotid plaques for the highest quartile 
compared with the lowest quartile for prediction of a composite cardiovascular endpoint. 
Epidermal fatty-acid binding protein (26-fold increased in symptomatic plaque salt extracts in 
this proteomic study) levels were found to be significantly higher in the plasma of patients 
with cardio-metabolic risk factors and also seen to be correlated with carotid intima-media 
thickness (Yeung et al. 2008; Yeung et al. 2009). 
 
In addition to these two differentially abundant proteins which have previously been 
described in the context of atherosclerosis, a number of further novel ‗candidate‘ proteins 
have been nominated as of potential interest. The glycolytic enzyme hexokinase 3 had no 
spectra detected in asymptomatic plaques, resulting in an ‗infinite‘ fold change increase in 
symptomatic plaques. Mannan-binding lectin serine protease 2 showed a 5.5-fold increase in 
symptomatic atherosclerosis. This protein is known to have an important role in the activation 
of the compliment system via mannose-binding lectin. Mannan-binding lectin serine protease 
2, after activation by auto-catalytic cleavage, cleaves C2 and C4 compliment pathway 
components leading to their activation and the subsequent formation of C3 convertase. 
 
L-amino acid oxidase showed a 3-fold increase in symptomatic salt extracts. This protein is 
also known as interleukin 4 induced protein 1 and is considered to play an important role in 
lysosomal antigen processing and presentation. Smad nuclear-interacting protein 1 (SNIP1) 
was 1.9-fold higher in symptomatics than asymptomatics, and down-regulates NFκB 
signalling by competing with RELA for CREBBP/EP300 binding. SNIP1 has further been 
implicated in microRNA biogenesis, with microRNAs emerging as potentially important 
players in atherosclerosis development, progression and stability. SAM domain and HD 
domain-containing protein 1, which is also known as dendritic cell-derived IFNγ-induced 
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protein and monocyte protein 5, was 1.5-fold decreased in symptomatics It is a putative 
nuclease involved in the innate immune response by acting as a negative regulator of the cell-
intrinsic antiviral response. Furthermore, it may play a role in mediating pro-inflammatory 
responses to TNFα signalling. 
 
NKAP-like protein, for which little functional information exists, is 6.5-fold increased in 
symptomatic salt protein extracts. Mitogen-activated protein kinase (MAPK) 11 protein levels 
were 3.6-fold increased in symptomatic. Also known as MAPK p38β or stress-activated 
protein kinase 2, MAPK11 is implicated in a signal transduction pathway that is activated by 
changes in the osmolarity of the extracellular environment, by cytokines, or by environmental 
stress. Furthermore, it preferentially phosphorylates transcription factor ATF2. Monocyte / 
leukocyte elastase inhibitor, which is 1.5-fold increased in symptomatic, regulates the activity 
of the neutrophil proteases elastase, cathepsin G, proteinase-3, chymase, chymotrypsin, and 
kallikrein-3. 
 
Of note, from the ten proteins highlighted in this discussion, two also featured in the list 
which was commonly differentially expressed when comparing symptomatic with 
asymptomatic extracts in the two gender groups: epidermal fatty-acid binding protein; and 
SNIP1. 
 
6.9.1 Gender Differences in Protein Abundance 
The difference between male and female atheromata supports the likely differences 
(biological heterogeneity) between male and female plaques, which also reflect the clinical 
differences. There are notable variations in the clinical behaviour of (particularly) 
asymptomatic plaques, with those in females considered by some as being more stable than 
those in males. This results in a higher number needed to treat (NNT) for significant 
asymptomatic female carotid stenosis (Halliday et al. 2004), which is reflected in the cost-per-
quality-adjusted life year (QALY) for asymptomatic carotid endarterectomy being 
considerably more in young females (€311,133) than in young males (€34,557) (based on 
ACST data) (Henriksson et al. 2008). Gender medicine is an important and emerging field of 
study. 
 
6.9.2 Limitations 
Male and female samples were run on different gels. It is possible, although unlikely, that 
some of the differences seen between males and females could be attributed to them being run 
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on these different gels, and therefore analysed through the mass spectrometry process at 
slightly different times. 
 
Luminex multi-analyte profiling (MAP) is more sensitive than mass spectrometry. This is 
evidenced by the lack of detection of a large number of analytes by mass spectrometry that 
were quantified by MAP. It is important at this point, however, to clarify the distinction that 
MAP of plaque cell culture supernatants detect production of proteins, i.e. the secretome 
(analogous in epidemiological terms to incidence of condition), whilst mass spectrometry of 
plaque tissue compartment fractions looks at the presence of protein at a particular timepoint 
(similar to prevalence). 
 
 
6.10 LIPIDOMICS 
According to the response-to-retention hypothesis, the binding of cholesterol containing 
lipoprotein particles to intimal proteoglycans is the central pathogenic process in 
atherogenesis (Williams and Tabas 1995). Once retained, lipoproteins are oxidised, 
accumulate in foam cells and provoke a cascade of immune-inflammatory processes, which 
drive the formation of atherosclerosis and ultimately define the propensity of the plaque to 
rupture. In most studies, the lipid content in plaques is visualised by oil red O staining. A 
more detailed characterisation, including the detection of single lipid species rather than lipid 
classes, may provide a better classification of atherosclerotic lesions with the goal of 
illuminating biology and discovering clinical biomarkers (Hu et al. 2009; Kim et al. 2010). 
 
New mass spectrometry (MS) technologies allow the identification and quantification of 
hundreds of individual lipid species in complex biological samples and hold great promise to 
transform the profiling of atherosclerotic plaques (Gerszten and Wang 2008; Mayr 2008). For 
example, a recent study demonstrated that atherosclerotic lipids in murine lesions can be 
imaged by multiplex coherent anti-stokes Raman spectroscopy (Kim et al. 2010), however 
this method cannot identify individual lipid species. In another study (Manicke et al. 2009), 
desorption electrospray ionisation (DESI)-MS was used to image and identify 26 distinct lipid 
species in a single human plaque. However, a MS-based analysis comparing different human 
atherosclerotic lesions has not been reported to date. 
 
To reveal a characteristic lipid signature for plaque vulnerability, the latest MS developments 
in lipidomics were harnessed to compare endarterectomy specimens from symptomatic and 
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asymptomatic patients, as well as stable and unstable areas within the same symptomatic 
lesion. 
 
6.11 LIPIDOMICS METHODS 
6.11.1 Clinical Samples 
The study received Research Ethics Committee approval (08/H0706/129) and all patients 
gave their written informed consent. Carotid endarterectomy specimens were briefly rinsed 
with cold PBS to remove superficial blood, snap-frozen in liquid nitrogen and stored at -80°C. 
Eight carotid plaques from symptomatic patients were dissected into ruptured versus non-
ruptured areas before freezing (Figure 64). 
 
 
Figure 64 Macroscopic classification of unstable ruptured regions and stable areas 
within carotid plaques 
Plaques from eight symptomatic patients were processed such that ruptured (lower dashed 
line region) were separated from areas of stable plaque or intimal thickening (upper solid 
line region). 
 
6.11.2 Workflow Overview 
Using QqQ-MS, two analyses were performed: 
 
1. LESA, adapted for analysis of plaque lipids, allowed the direct extraction of 
molecules from tissue sections (Kertesz and Van Berkel 2010; Marshall et al. 2010); 
and 
2. Shotgun lipidomics (Han and Gross 2003) was applied to endarterectomy tissue 
extracts. 
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The different scan options of a QqQ-MS can resolve isobaric lipids from different lipid 
subclasses and detect components, which would otherwise be masked by the presence of 
abundant lipid species. First a full MS scan in positive and negative ion mode was acquired. 
Then precursor ion (PI) and negative loss (NL) scans, characteristic for different lipid classes, 
unambiguously identify certain lipids by their characteristic MS/MS product ions. 
 
6.11.3 Liquid Extraction Surface Analysis (LESA) Coupled to Nano-ESI-MS 
A liquid extraction-based surface sampling device (Kertesz and Van Berkel 2010) was used to 
analyse lipids directly from tissue sections. Frozen human carotid plaque specimens were 
sectioned at 200 μm, without optimal cutting temperature (OCT) compound to avoid 
contamination with polyethylene glycol, using a rotary microtome (Microm HM560 cryostat, 
Thermo Scientific) and placed on electrostatically charged slides (Superfrost Plus, BDH), air 
dried for 15–30 min and analysed directly with a Advion TriVersa NanoMate system (Advion 
BioSciences Incorporated, Ithaca, NY) controlled by Chipsoft software (v8.1.0.928, Advion 
BioSciences) coupled to a triple quadrupole (QqQ)-MS (TSQ Vantage, Thermo Fisher 
Scientific, UK). The solvent extraction volume was 1.5 μL (chloroform/methanol/isopropanol 
1:2:4 containing 7.5 mM ammonium acetate) and the dispensed volume was 1.0 μL. Solvents 
were sprayed through a 4.1-μm nozzle diameter chip (Advion BioSciences) at an ionisation 
voltage of 1.2 kV and a gas pressure of 0.3 psi. The first and third quadrupoles (mass 
resolution 0.7 Th) served as independent mass analysers while the second quadrupole was 
used as collision cell for tandem MS. The temperature of the ion transfer capillary was 
maintained at 150 °C. Full MS spectra and PI scans (argon was used as collision gas with a 
pressure of 1.0 mTorr) for cholesteryl esters (CEs) (PI 369.3) and phosphatidylcholine (PC) 
(PI 184.1) from different plaque sections were acquired over a period of 6 min. 
 
6.11.4 Lipid Extraction 
Lipids were extracted from endarterectomies specimens of greater than 25 mg wet weight 
using an adaptation of the Folch method (Folch et al. 1957). Tissue was pulverised with a 
pestle and mortar, or a ball-grinding method (Mikro Dismembrator, Sartorius). All subsequent 
steps were performed in glass vials that were thoroughly rinsed with water, methanol, and 
chloroform before use. 300 μL water (HPLC grade, Fisher Scientific), 2 mL methanol (HPLC 
grade, Fisher Scientific) and 4 mL chloroform (GLC-pesticide residue grade, Fisher 
Scientific) were added to each sample. The mixture was the vortexed for 10 min and 
centrifuged for 10 min at 3000 rpm. The supernatant was transferred, mixed with 1.2 mL 
water and vortexed for 10 min. After centrifugation at 1000 rpm for 5 min the lower organic 
phase was transferred into a new glass vial and 2 ml of chloroform/methanol/water (3:48:47) 
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was added. To extract any remaining lipids, the upper phase was washed with 2 mL 
chloroform and centrifuged for 5 min at 1000 rpm. The two organic phases were combined 
and split into aliquots corresponding to 50 mg of tissue. The organic solvent was evaporated 
and samples stored at -80°C. 
 
6.11.5 Shotgun Lipidomics 
Aliquots from tissue extracts were reconstituted in 500 μl chloroform/methanol 1:2 and 
further diluted 1:100 with chloroform/methanol/isopropanol 1:2:4 containing 7.5 mM 
ammonium acetate. Just prior to analysis, samples were centrifuged at 12,000 rpm for 2 min 
and analysed with a TriVersa NanoMate coupled to a QqQ-MS as described above. An 
ionisation voltage of 0.95 – 1.40 and a gas pressure of 1.25 psi was used (Graessler et al. 
2009). Full MS spectra were acquired over a 1 min period of signal averaging in the profile 
mode in both positive and negative mode. The intensity of the full MS in positive mode was 
one magnitude higher than the one in negative ion mode. 
 
For NL and PI scans the collision gas pressure (argon) was set at 1.0 mTorr, the collision 
energy was chosen depending on the classes of lipids. Spectra were automatically acquired 
with rolling scan events by a sequence subroutine operated under the Xcalibur software 
(Thermo, version 2.0.7). The different NL and PI scans were set according to previously 
published descriptions (Brugger et al. 1997; Han and Gross 2003; Han and Gross 2005). 
 
The main classes of lipids in positive ion mode were: 
 
 phosphatidylethanolamine (PE) / lyso-PE (lPE); 
 phosphatidylserine (PS) / lyso-PS (lPS); 
 cholesteryl ester (CE); 
 triacylglycerol (TAG); 
 phosphatidylcholine (PC) / lyso-PC (lPC); and 
 sphingomyelin (SM) 
 
The PI scan of the acetate ion of the PC species in the negative ion mode was used for the 
identification of PC-derived fatty acids. The same parent ion scan at 184.1 was used for the 
identification of SMs, but the nitrogen rule allowed a discrimination of these two lipid 
species. SMs with two nitrogen atoms appear at odd mass-to-charge (m/z) values, whereas 
PC-signals occur at even m/z values (Brugger et al. 1997). To further separate PCs from SMs, 
SMs were identified in negative ion mode by precursor ion scan at m/z 168.011. For lipid 
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quantification, 392 pmol of CE 19:0 (Avanti polar lipids, Alabaster, AL) was added to 100 μL 
of each sample as internal standard and analysed for 2 min using a PI scan at m/z 369.3. The 
coefficient of variation for these measurements was <10% in 58% (53%) of the analytes, 10% 
to 20% in 18% (28%) of the analytes, 20% to 40% in 5% (5%) of the analytes, and >40% in 
the remainder for intraday (interday) measurements. For quantification of PC, lPC and SM 
species 52 pmol PC(17:0/17:0), 46.4 pmol/μL lPC(19:0), and 61.2 pmol SM(d18:1/12:0) were 
added per 100 μL sample (all Avanti polar lipids) and analysed for 2 min using a PI scan at 
184.1. 
 
6.11.6 Data Processing 
QqQ-MS data were analyzed with Xcalibur (version 2.0.7, ThermoFisher, USA). Lipid 
identification was based on their characteristic head groups and corresponding fatty acids or 
using the LipidMaps database and Lipid MS Predictor (v1.5) available at 
http://www.lipidmaps.org. For quantification, a peak list was generated and imported into 
LIMSA software (version 1.0) (Haimi et al. 2006) using the following settings: 
 
 linear fit 
 offset = 0 
 peak full width at half maximum (fwhm) = 0.5 
 sensitivity = 0.1 
 
6.11.7 Nomenclature 
We followed the designations and abbreviations recommended by the International Union of 
Pure and Applied Chemistry (IUPAC; http://www.chem.qmul.ac.uk/iupac/lipid). Glycero- 
and glycerophospholipids were named with shorthand notification and numbers separated by 
colons refer to carbon chain length and number of double bonds. The composition of the side 
chains for the glycero- and glycerophospholipids were not assigned and were used randomly 
for glycerolipids. For glycerophospholipids, the unsaturated fatty acid was set on sn-1 
position and the saturated on sn-2. Sphingolipids are presented in the order of long-chain base 
and N-acyl substituent. 
 
6.11.8 Statistical Analysis 
Statistical analysis was performed using the Student‘s t-test or analysis of variance and 
Scheffe‘s post hoc test. A p value of <0.05 was considered significant. Principal components 
analysis (PCA) were performed in Matlab (2009a, The Mathworks Limited). Data were 
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normalised by expressing individual lipid intensities as percentage of accumulative intensities 
in each lipid class. 
 
6.12 LIPIDOMICS RESULTS 
6.12.1 Liquid Extraction Surface Analysis (LESA) 
1.5 μL extraction solution was sufficient to provide a stable spray for over 10 min. The 
signals within the lipid relevant m/z range of 400 – 1000 in the full MS scan (Figure 65A) 
were comparable to the ones obtained from tissue extracts (Figure 65B). 
 
 
Figure 65 Liquid extraction surface analysis (LESA) compared to lipid extracts 
The full MS in positive ion mode (A) and head group specific scans for PC (C, PI 184.1) and 
CE species (E, PI 369.3) from tissue sections of human endarterectomies. Note the similarity 
in peak numbers and signal intensities to tissue extracts (B, D, F). m/z, mass-to-charge. 
 
Also, lipid class specific head group scans showed similar peaks and signal intensities (Figure 
65C-F). Notably, lPC species within the m/z range of 490 – 540 were detected in tissue 
sections as well as extracts, confirming that these degradation products are present in human 
atherosclerotic plaques and not artefacts of the extraction method. 
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6.12.2 Identification of Plaque Lipids 
Six scans were performed in positive ion mode and 14 in negative ion mode. The full MS 
scan between m/z 790 and 930 of endarterectomy samples was dominated by CE, SM, PC and 
TAG species. A comparison was made with lipidomic data from 3 radial artery specimens 
where TAGs accounted for the few prominent signals in the full MS. In total, 150 different 
lipid species were identified, of which 24 lipid species were detected in atherosclerotic 
plaques only (Table 29). 
 
 
Table 29 Lipid species found exclusively in atherosclerotic plaques 
Of the 150 lipid species identified by lipidomics, 24 were found exclusively in carotid 
endarterectomy specimens and not in control radial artery samples. Nomenclature: (carbon 
chain length : number of double bonds); CE, cholesteryl ester; lPC, lysophosphatidylcholine; 
lPS, lysophosphatidylserine; PC, phatidylcholine; PE, phosphatidylethanolamine; PS, 
phosphatidylserine; SM, sphingomyelin; m/z, mass-to-charge. 
 
Additional scans for acylcarnitine, phosphatidylinositol, phosphatidylinositol-phosphates, 
phosphatidylinositol (4,5) bisphosphate, sulfatides, acylCoA, ceramides and cerebrosides did 
not reveal strong signals for these lipid classes in shotgun lipidomics. In contrast, the signal 
intensities of the head group scans for CE differed by two orders of magnitude. For 
quantification, authentic standards were spiked into the samples. The average CE content was 
23.8 mg/g in atherosclerotic plaques but 0.2 mg/g in control radial arteries (Figure 66A). As 
expected, oleic (18:1) and linoleic acid (18:2) were the most common fatty acids. The relative 
distribution of CEs identified in plaque and control arteries is depicted in Figure 66B. 
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Figure 66 Cholesteryl ester species abundance differentially and exclusively found 
within atherosclerotic plaque compared with control artery 
A. Quantification of cholesteryl ester (CE) species in plaque and control radial artery 
samples with CE(19:0) as internal standard.  B. Relative distribution of CE in atherosclerotic 
plaques compared with control arteries. Plaque-specific CE species are highlighted in colour. 
Nomenclature: (carbon chain length : number of double bonds). 
 
6.12.3 Comparison of Carotid Endarterectomy Samples 
The lipid content of carotid endarterectomy samples from closely matched symptomatic and 
asymptomatic patients (n=6 per group, Table 26) was compared. PCA was performed to 
investigate the global variation of the patient samples in the metabolite space (Figure 67). 
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Figure 67 Principal components analysis for lipid profiles of symptomatic and 
asymptomatic patients 
A. The red circles denote symptomatic patients; the blue squares denote asymptomatic 
patients. The first two principal components (PCs) capture 97% of the variance.  B. The 
proportional magnitude of the first 2 PCs based on all measurements. The blue and green 
lines represent the mean value of the weights in symptomatic and asymptomatic plaques. 
Principal component analyses were biased towards cholecteryl esters (CE) with significant 
contributions from sphingomyelin (SMs), but the distance between symptomatic and 
asymptomatic patients was negligible. lPC, lysophosphatidylcholine; PC, phatidylcholine. 
 
Given the heterogeneity of carotid endarterectomy samples, plaques excised from 
symptomatic and asymptomatic patients may share similar features. Thus, in another cohort of 
patients (Table 30), the stable area of the plaque/intimal thickening with no signs of rupture 
was excised from the unstable area, in which there was ulceration of the surface with or 
without thrombosis and/or macroscopic intra-plaque haemorrhage, thereby providing an 
internal control for each sample and minimising the effect of inter-patient variability. 
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Table 30 Clinical characteristics of patients whose plaques were divided into 
ruptured (unstable) and non-ruptured (stable) areas. 
ACEI, angiotensin-converting enzyme inhibitor; ASA, acetyl salicylic acid (aspirin); COPD, 
chronic obstructive pulmonary disease; DM, diabetes mellitus; HTN, hypertension. 
 
The 10 most differentially expressed species from 4 different lipid classes were sufficient to 
separate stable and unstable areas within the same lesion in PCA (Figure 68). No separation 
was obtained with individual lipid classes (Figure 69). 
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Figure 68 Principal components analysis of lipidomic data based upon top 10 
differentially expressed species 
PCA for lipid profiles of ruptured and non-ruptured areas of the same carotid atherosclerotic 
plaques (n=8). The green circles denote non-ruptured areas (S, stable) and the red squares 
ruptured areas (U, unstable) of the same lesion. A separation is seen. 
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Figure 69 Principal components analysis of lipidomic data based upon lipid classes 
PCA for lipid profiles of ruptured and non-ruptured areas of the same carotid atherosclerotic 
plaques (n=8). The green circles denote non-ruptured areas (stable) and the red squares 
ruptured areas (unstable) of the same lesion. No clear separation is observed based upon 
individual lipid classes: CE, cholesteryl esters (A); SM, sphingomyelin (B); lPC, lyso-
phosphatidylcholine (C); or PC, phosphatidyl-choline (D). 
A B 
C D 
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6.12.4 Systems-Wide Analysis of Plaque Lipids 
Lipid expression similarity in plaques from asymptomatic and symptomatic patients as well 
as in stable and unstable areas within the same lesion was inferred using Pearson correlation 
coefficients (PCC) and visualised as networks where nodes correspond to lipids and edges 
link correlated pairs (PCC≥0.70). Clusters of interlinked lipids were identified using an 
unbiased network clustering algorithm (Blondel et al. 2008). This systems-wide analysis 
revealed plaque-specific lipid signatures consisting of 19 lipid species in asymptomatic-
symptomatic lesions (Figure 70A) and 12 lipid species in stable-unstable plaque areas (Figure 
70B). There were 33 common lipid species that were differentially linked in the two networks 
(Figure 70). Unbiased network clustering (Blondel et al. 2008) demonstrated that lipid species 
belonging to the same class are more likely to be linked in the stable-unstable network (for 
example CE22:4, CE22:5 and CE22:6). These connectivity patterns were not observed in the 
asymptomatic-symptomatic network. Thus, the lipid composition as well as their connectivity 
change in atherosclerosis and may allow a differentiation between stable and unstable plaque 
areas. 
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Figure 70 Systems-wide relationships between lipids involved in atherosclerosis 
Lipid-lipid co-expression network where each node represents a lipid and each edge a 
correlation in expression between two lipid pairs. Only lipid pairs with Pearson correlation 
coefficient ≥ 0.70 were included in the network. Lipids and co-expressions specific for the 
asymptomatic-symptomatic phenotype are represented as triangles and red links, respectively 
(A). Lipids and co-expressions specific for stable-unstable network are represented as 
diamonds and blue links, respectively (B). Lipids and co-expressions common to both 
phenotypes are represented as circles and black edges, respectively. Lipid colours correspond 
to unique clusters, computed using an unbiased network clustering algorithm (Blondel et al. 
2008). 
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6.13 LIPIDOMICS DISCUSSION 
While lipids of human atherosclerotic plaques have previously been analysed, target-focused 
measurements restricted to individual lipid classes remain insufficient to reveal the global 
lipid imbalances in atherosclerosis. This study demonstrates the integration of advanced MS 
towards improved characterisation of the lipid composition in atherosclerosis. LESA allowed 
a rapid analysis of plaque lipids from tissue sections without time and labour-intensive sample 
preparation. This was the first time that LESA was used in combination with a QqQ 
instrument for lipid profiling. Notably, LESA provided similar signals and signal intensities 
as shotgun proteomics of chloroform/methanol extracts. For quantification, lipid extracts were 
spiked with class specific internal standards. Since only a single standard per lipid class is 
required, the shotgun lipidomics approach is less expensive compared to other lipid analysis 
techniques. Specificity is achieved by characteristic headgroup scans. In total, 150 lipid 
species were identified in this study, making it the most comprehensive lipid analysis of 
human atherosclerotic lesions to date. 
 
6.13.1 Lipids in Atherosclerosis 
The lipid classes accounting for the major differences between endarterectomy specimens and 
control radial artery tissue were CE, lPC and SM. Cholesterol within the vasculature 
accumulates as CE, either as a droplet in the cytosol or in lysosomes (Shio et al. 1979). 
Infiltrating LDL-particles contain a CE-rich core with linoleic acid (18:2) as the most 
abundant polyunsaturated fatty acid (Mallat et al. 1999b). The intimate relationship of plasma 
lipids, vascular matrix and CE deposits in the arterial wall is well documented (Suarna et al. 
1995; Brown et al. 1997; Witting et al. 1999). Currently, knowledge at the biological level is 
mostly related to the classes of lipids rather than the bioactivity of single lipid species within 
the classes (Hu et al. 2009). Yet, the composition of the classes is likely to be an important 
atherogenic factor, i.e. LDL particles enriched with monounsaturated cholesteryl oleate 
(CE18:1) are typically larger and appear to be more active in binding to arterial 
proteoglycans, thereby favouring retention and subsequent formation of early atherosclerotic 
lesions (Degirolamo et al. 2009). In comparison, LDL particles enriched with polyunsaturated 
cholesteryl linoleate (CE18:2) are thought to be less atherogenic. Consistent with previous 
reports (Rapp et al. 1983), CE(18:2) was the major CE species in atherosclerosis and the 
relative distribution of most CEs was comparable to results obtained by thin layer 
chromatography, providing independent validation of the quantitative accuracy of the 
approach taken in this study. The sensitivity of shotgun lipidomics, however, allowed the 
identification of additional CE species as well as other lipid classes, such as lPCs (a by-
product of LDL oxidation and formed by the enzymes phospholipase A1, phospholipase A2 
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or lecithin:cholesterol acyltransferase) and SMs (an ubiquitous component of cell membranes 
and of the LDL surface). Moreover, a simple, rapid macroscopic method of classification 
based on the definitions of plaque progression and instability (Stary et al. 1995a) was used to 
differentiate ruptured (unstable) versus non-ruptured (stable) segments of the same plaque as 
previously reported (Papaspyridonos et al. 2006; Papaspyridonos et al. 2008). In this 
homogenous cohort, the lipidomics approach was most successful and provided insights in the 
lipid heterogeneity within atherosclerotic lesions. Several lipids were reduced in regions with 
evidence of rupture and one could envisage that leakage of plaque-related lipid products into 
the circulation may constitute a better marker for plaque burden and vulnerability than total 
cholesterol levels and plasma lipoproteins. 
 
6.13.2 Systems-Wide Network Analysis 
The post-genomic shift in paradigm from reductionism to systems-wide network inference 
acknowledges the fact that biological systems are pleiotropic and interconnected (Barabasi 
and Oltvai 2004). Similarly, systemic relationships between lipid classes in atherosclerotic 
lesions are important for understanding genotype-phenotype relationships (Dreze et al. 2009) 
and working towards a lipid signature for risk prediction, early diagnosis, and personalised 
treatment of this disease. Previous studies enabled only a partial analysis of plaque lipids and 
mainly focused on LDL (Carpenter et al. 1994; Carpenter et al. 1995; Brown et al. 1997; 
Upston et al. 2002), cholesterol and its derivatives (Carpenter et al. 1993; Upston et al. 2002). 
There are also publications about individual lipid classes in atherosclerotic plaques, i.e. on 
isoprostanes (Mallat et al. 1999b), lPCs (Thukkani et al. 2003), and oxidised PCs (Davis et al. 
2008), but no comprehensive comparison between diseased arteries across different lipid 
classes has been performed to date. 
 
DESI-MS has recently been applied to atherosclerotic plaque tissue (Manicke et al. 2009). As 
proof-of principle, lipid profiling was performed on a single human plaque in positive and 
negative ion mode and 26 lipid species were identified. The shotgun lipidomic approach used 
in this study identified all of the 26 lipids except SM 22:0. Moreover, 16 of the 26 lipids in 
the former study were present in control arteries and were therefore not plaque-specific. Using 
a network approach, it was demonstrated that homogeneous lipid clusters were identified in 
the stable-unstable network and that sampling differentially expressed species across lipid 
classes improves the separation by PCA. 
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6.13.3 Clinical Relevance 
While lipids of human atherosclerotic plaques have previously been analysed, target-focused 
measurements restricted to individual lipid classes remain insufficient to reveal the global 
lipid imbalances in atherosclerosis. A liquid extraction-based surface sampling device has 
been adapted for the analysis of plaque lipids from tissue sections. For quantification, shotgun 
lipidomics was performed on lipid extracts using the different scan options of a triple 
quadrupole mass spectrometer. In total, 150 lipid species from 9 different classes were 
identified, of which 24 were exclusive to atherosclerotic plaques. A comparison of 28 carotid 
endarterectomy specimens revealed lipid signatures of symptomatic compared with 
asymptomatic lesions, as well as stable and unstable plaque areas. This is the most 
comprehensive analysis of plaque lipids to date and highlights the importance of measuring 
individual lipid species rather than lipid classes to obtain insights into the lipid heterogeneity 
within atherosclerotic lesions. 
 
6.13.4 Study Limitations 
While MS has proven a valuable tool for comparative lipid analysis, minor components like 
signalling molecules (sphingosine-1-phosphate (Levkau 2008) or isoprostanes) remain 
undetected and not all the lipids identified can be reliably quantified due to low abundance. 
Also, modified lipids with alterations in the characteristic head groups as well as free 
cholesterol and other species, which do not readily ionise by ESI, are not detected in this 
analysis. Importantly, LESA only provides a qualitative comparison of plaque lipids. For 
quantification, lipids have to be extracted and spiked with authentic standards. 
 
6.13.5 Conclusions 
This study is the most comprehensive MS analysis of the lipid content in human 
atherosclerotic plaque to date. An in-depth comparison of the lipid composition in different 
atherosclerotic plaques combined with systems-wide network analysis unravelled plaque-
specific lipid signatures. In future, these advanced technologies may be exploited for 
diagnostic purposes or as a platform for drug screening. 
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6.14 INTRODUCTION TO METABOLIC PROFILING 
Metabolic profiling is defined as ―the quantitative measurement of the dynamic 
multiparametric metabolic response of living systems to pathophysiological stimuli or genetic 
modification‖ (Nicholson et al. 1999). Combined with multivariate statistical methods, 
metabolic profiling via high-resolution spectroscopy provides a powerful tool for discovering 
novel biomarkers for disease diagnosis (Brindle et al. 2002) and prognosis (Clayton et al. 
2006) as well as pharmaceutical targets, which could also pave the way for more 
individualised diagnostics and treatment schedules (Nicholson et al. 2005; Clayton et al. 
2006). The potential application spectrum of the metabolic profiling approach is broad, due to 
advances in the analytical platforms employed, for example the introduction of cryoprobes in 
nuclear magnetic resonance (NMR), high resolution mass spectrometers (MS) and ultra 
performance liquid chromatography (UPLC) (Coen et al. 2008). These have enhanced the 
potential coverage of the metabolome. Further, recent statistical developments, allowing data 
integration of different analytical matrices, have provided new insights in gene (Nicholson et 
al. 2002) and enzyme function (Saghatelian et al. 2004; Tagore et al. 2009) studies and could 
potentially lead to cost reduction in the drug development pipeline (Nicholson et al. 2005), for 
example, by improving mechanistic understanding of drug toxicity (Nicholson et al. 2005; 
Clayton et al. 2006). 
 
Screening of biological samples, such as biofluids, cells or tissues is usually performed as a 
first stage towards obtaining biomarker/metabolic pathway information relating to disease. 
This is done in order to obtain a global overview on the low-molecular weight metabolic 
composition and changes due to disease. Therefore, various spectroscopic techniques are 
employed (Nicholson et al. 2005; Martin et al. 2007; Holmes et al. 2008), such as NMR 
spectroscopy (Beckonert et al. 2007; Beckonert et al. 2010), UPLC-MS (De Vos et al. 2007; 
Want et al. 2010), mass spectrometry coupled to gas chromatography (GC-MS) (Lisec et al. 
2006), and less frequently capillary electrophoresis (Hirai et al. 2005). 
 
It has been shown that metabolic profiling of tissue, and/or of the biofluids that interact with 
the tissue of interest, delivers clinically and biologically significant results (Schmidt 2004). 
Consequently, metabolic profiling techniques are now being applied to homogenised or even 
intact tissues, as well as biofluids (Beckonert et al. 2007; Beckonert et al. 2010; Masson et al. 
2010; Want et al. 2010). However, since with this approach the significant parameter of 
spatial distribution of the biomolecules through the tissue is disregarded, new screening 
techniques for untargeted determination of biomolecules in a manner that incorporates the 
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spatial distribution have been considered (Bunch et al. 2004; McDonnell and Heeren 2007; 
Trim et al. 2008b; Trim et al. 2010). 
 
6.14.1 Metabolic Profiling in Atherosclerosis 
There have been two contemporaneous reviews on the subject of metabolic profiling in 
atherosclerosis (Goonewardena et al. 2010; Martinez-Pinna et al. 2010). It is clear from these 
that, to date, there have been a limited number of such studies and that even fewer interrogate 
human samples, in particular human atherosclerosis tissue. 
 
Chen et al. collected plasma from those with stable atherosclerosis and compared it with 
plasma from normal individuals. They found evidence of perturbed fatty acid metabolism in 
atherosclerosis, including differential levels of palmitate, which was confirmed as a 
phenotypic biomarker for the clinical diagnosis of atherosclerosis (Chen et al. 2010). 
Martinez-Pinna et al. identified multiple metabolites which were significantly modified 
associated with insulin resistance, correlating with metabolic syndrome (Martinez-Pinna et al. 
2010) (Table 25). Mayr et al. used a combination of proteomics, metabolomics and 
immunomics to analyse microparticles derived from human atherosclerotic plaques (Mayr et 
al. 2009). They found that immunoglobulins present within the microparticles were derived 
from plaque macrophages. Plaque antibodies were different to circulating antibodies in the 
plasma as they recognise carbohydrate antigens including blood group antigen A. 
 
6.14.2 Objectives 
The objectives of this study were to investigate the utility of metabolic profiling in the context 
of human carotid atherosclerosis in separating plaque tissue responsible for recent focal 
neurological symptoms and tissue from asymptomatic individuals. 
 
6.15 METABOLIC PROFILING METHODOLOGY 
6.15.1 Biological Sample Characteristics and Handling 
Ten patients (five asymptomatic and five recently symptomatic) consented to the collection of 
their atherosclerotic plaque at carotid endarterectomy surgery (Table 31). With regards to 
symptoms, only formal strokes were considered, defined as focal neurological events lasting 
for more than 24 hours pertaining to the anterior circulation of the cerebral hemisphere 
ipsilateral to the index carotid stenosis. As such transient ischaemic attack and amaurosis 
fugax were excluded, as were patients with atrial fibrillation from the symptomatic group 
where atrial thromboembolism may be a source of misdiagnosis. These diseased intimal 
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arterial segments were retrieved, snap frozen in liquid nitrogen and stored at -80°C for batch 
processing. 
 
The endarterectomy specimens were processed as shown in Figure 71. For each specimen, 
two samples were obtained, each of which would have sequential aqueous (polar) and organic 
extraction of metabolites allowing for analysis of two biological replicates per sample. 
 
Table 31 Characteristics of the individuals included in the metabolite profiling 
study 
Demographic, clinical and pharmacotherapeutic information relating to the subjects included 
in the study. F, female; M, male. 
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V1248 0 67 M 1 0 1 0 1 77 15 
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1 1 - 
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V1430 0 91 M 0 0 0 0 0 102 10.2 
75-
80 
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V1445 1 59 M 1 0 1 0 1 66 8.5 95 1 0 3 
V1446 1 78 F 1 0 1 0 0 75 - >95 1 1 6 
V1448 1 75 M 0 1 1 0 0 115 14.7 95 1 1 6 
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Figure 71 Processing of carotid atherosclerotic plaque for metabolic profiling with 
storage of tissue for future mass spectroscopy imaging 
Frozen samples had a central slice of 1 mm in thickness at the point of greatest stenosis 
removed and stored in a labelled well of a 12-well culture plate which was returned to -80°C 
for future mass spectroscopy imaging. The areas of tissue flanking the central area (A and B) 
were cut and weighed to a target mass of 120 mg for each of these two biological replicate 
samples. It was aimed that sample weights should be within ±5% of each other. 
 
6.15.2 Metabolite Extraction – Aqueous (Polar) 
Tissue samples of 120 mg to which was added 1.5 mL methanol : water solution (1:1) 
(methanol HPLC gradient grade, Fisher; water LC-MS grade, Fluka). These samples were 
frozen on dry ice and loaded onto a bead beater (Bertin Technologies, Precellys 24, 1 mm 
zirconium beads, 6500 Hz, 40 seconds, 2 + 2 cycles separated by cooling on dry ice). 
Centrifugation (Biofuge Pico, Heraeus) at 13,000 rpm for 10 minutes, followed by aliquoting 
of supernatant into Eppendorf tubes (300 μL x4). 70 μL of each aqueous sample was 
combined to generate a ‗quality control‘ (QC), which was mixed and split into aliquots (300 
μL x4). Samples were spun on a vacuum concentrator for 160 minutes (Eppendorf 
Concentrator Plus, 45°C, V-AQ mode). Samples were then stored at -40°C for analysis. 
 
6.15.3 Metabolite Extraction – Organic 
Following decanting of supernatant from centrifuged aqueous samples, 1.5 mL 
dichloromethane (DCM, CH2Cl2) : methanol (3:1) (methanol HPLC gradient grade, Fisher; 
DCM HPLC grade, Sigma-Aldrich) was added and the samples were frozen on dry ice and re-
loaded onto the bead beater (2 cycles). Centrifugation at 13,000 rpm for 20 minutes, followed 
by aliquoting of organic phase supernatant into glass tubes (200 μL x4). 50 μL of each 
aqueous sample was combined to generate a QC, which was mixed and split into aliquots 
(200 μL x4). Samples were allowed to evaporate at room temperature in an extractor hood 
overnight. Samples were then stored at -40°C for analysis. 
 
A B 
120 mg 120 mg 
Central slice (1 mm) taken at the point of greatest 
stenosis and stored for MALDI imaging 
Chapter 6 
 224 
6.15.4 Metabolite Profiling 
Both aqueous and organic extracts were subject to metabolic profiling by NMR and UPLC-
MS. 
 
6.15.5 Nuclear Magnetic Resonance 
NMR analyses were run using a Bruker 600 MHz spectrometer. For the aqueous phase 
analysis, extracts were resuspended in deuterium oxide (D2O) and Nuclear Overhauser effect 
spectroscopy (NOESY) and Carr-Purcell-Meiboom-Gill (CPMG) sequences were employed. 
Organic phase extracts were resuspended in Chloroform-D and run with a standard sequence. 
Spectra were subjected to phasing, calibration, baseline correction, alignment and 
normalisation. Principal components analysis (PCA) was performed with unit variance 
scaling in Matlab (The MathWorks Incorporated) programming language using a script 
developed in-house in the Department of Biomolecular Medicine at Imperial College London. 
 
6.15.6 Nuclear Overhauser Effect Spectroscopy – NOESY 
The Overhauser effect is the transfer of spin polarisation from one spin population to another 
via cross-relaxation. In NOESY, the nuclear Overhauser effect between nuclear spins is used 
to establish correlations. Hence the cross-peaks in the resulting two-dimensional spectrum 
connect resonances from spins that are spatially close. 
 
6.15.7 Carr-Purcell-Meiboom-Gill – CPMG 
The Carr-Purcell (CP) sequence is a spin-echo pulse sequence consisting of a 90 
radiofrequency pulse followed by an echo train induced by successive 180 pulses. CP is 
designed to measure the T2 relaxation time in the presence of diffusion and magnetic field 
inhomogeneity. CPMG is an improved modification of the CP sequence. In the CP sequence, 
a constant flip-angle deviation from the nominal 180 results in errors accumulated throughout 
the echo train and in concomitant under-estimation of the T2 relaxation time. In contrast, 
CPMG partially corrects this error in every second echo, due to application of the initial 90 
pulse and the subsequent 180 pulses with a defined phase difference of 90 in the rotating 
frame of reference. As a side effect, all echo signals in the CPMG experiment have the same 
phase, whereas signal phase alternates in successive echoes of the CP sequence. 
 
6.15.8 Ultra Performance Liquid Chromatography Mass Spectrometry – UPLC-MS 
UPLC separation was carried out on an Acquity UPLC system (Waters Ltd) using a HSS T3 
C18 column. The mass spectrometer used was quadrupole-time of flight (Q-TOF) Premier 
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(Waters MS Technologies). Metabolic features were extracted from the UPLC-MS spectra. 
PCA was performed with unit variance scaling using SIMCA-P+ 11.5 (Umetrics) software. 
 
6.15.9 Unit Variance and Pareto Scaling 
Scaling is employed when variables are on different scales. As PCA is scale-dependent, 
scaling can be achieved by applying a scaling weight to each variable. Unit variance (UV) 
applies a scaling weight of 1/standard deviation (SD) for each variable, i.e. dividing each 
variable by its SD, whilst Pareto scaling uses the √(SD) as the scaling factor. 
 
6.16 METABOLIC PROFILING RESULTS 
In terms of time from symptoms to surgery in the symptomatic group, the times were: 3 days; 
6 days; 6 days; 6 days; and 12 days. Spectroscopy by NMR and UPLC-MS generated high 
quality spectra (Figure 72). 
 
 
Figure 72 Representative NMR and UPLC-MS spectra 
NMR (A) and UPLC-MS (B) spectra from analysis of the organic extract of atherosclerotic 
plaque. m/z, mass/charge ratio. 
 
6.16.1 Results of NMR PCA 
PCA from aqueous (Figure 73A) and organic phase (Figure 73B) extracts analysed using 
NMR did not provide clear separation between the symptomatic and asymptomatic groups. 
The organic phase NMR PCA presented a clear group comprising two samples with both their 
biological replicates (Figure 73B). 
 
A B 
m/z m/z 
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Figure 73 Results of NMR PCA 
PCA scores plot of NMR analysis of aqueous extracts (CPMG sequence, A) and organic 
extracts (normal sequence, B). Unit variance scaling was applied to the data. Biological 
replicates are represented by the same marker. Green makers represent samples from the 
asymptomatic patients, red markers samples from symptomatic patients, and blue markers are 
pooled (QC) samples used for stability testing at 0 hours, 24 hours and 72 hours. No clear 
separation was seen, however with regards the organic phase NMR, a clear group 
comprising two samples with both their biological replicates was observed (circled), 
separated in PC t[1]. 
 
Results of UPLC-MS PCA 
PCA from the organic phase positive mode UPLC-MS data provided good separation 
between the two groups (Figure 74). At least one of the two biological replicates was 
represented in the cluster of symptomatic samples. 
A B 
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Figure 74 Results of organic UPLC-MS PCA 
PCA scores plot of the organic phase positive mode UPLC-MS analysis. Data were Pareto 
scaled. Biological replicates are represented by the same marker. Green makers represent 
samples from the asymptomatic patients, red markers samples from symptomatic patients, and 
blue markers are pooled (QC) samples used for stability testing. Tight clustering of the QC 
samples indicate good system stability. There is clustering of symptomatic samples seen 
(circled), with at least one sample from each symptomatic pair located within the 
symptomatic cluster. 
 
6.17 METABOLITE PROFILING DISCUSSION 
Metabolic differences can be seen between symptomatic and asymptomatic patients. It is 
evident that UPLC-MS of the organic extract is able to generate a metabolite ‗signature‘ 
which can separate samples from symptomatic from samples derived from asymptomatic 
atherosclerotic plaques. This finding is in line with the separation seen in the lipidomic study 
and it is plausible that the analytes allowing for separation in this study are the metabolites of 
the lipids which are differentially abundant in the lipidomic analysis (Section 6.12). It has 
been proposed that the integration of metabonomic data with that from other techniques in 
molecular biology, such as those seen in this chapter and other areas of this thesis, is feasible 
(Lindon et al. 2006). Such an integrative approach would be necessary to support or refute 
this suggestion. 
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The times from symptoms to carotid endarterectomy (hence sample collection) are relatively 
short (median 6 days). To this end, when examining time from symptoms on the PCA plots, 
this did not result in any change in interpretation. 
 
It would be useful to localise organic metabolites of differential abundance to particular areas 
within the plaque according to the metabolite mass / charge ratio (m/z). Applications of 
imaging techniques that can deliver chemical profiles related to organ or tissue topography 
have recently been demonstrated for metabolic profiling approaches (Bunch et al. 2004; 
Burrell et al. 2007; Trim et al. 2008a; Trim et al. 2008b). Mass spectrometry imaging (MSI) 
techniques appear to possess what is needed for metabolite in situ screening. There are several 
techniques proposed for MSI. However, matrix-assisted laser desorption/ionisation (MALDI)-
MSI appears to be a dominating presence over the past few years. MALDI-MSI is currently 
under development in the Department of Biomolecular Medicine at Imperial (Figure 75). 
Samples from the plaques analysed in this experiment have been stored for this purpose and 
will be scrutinised by this ‗virtual histology‘ technique once optimised. 
 
 
Figure 75 An example of MALDI mass spectroscopy imaging 
A. Eosin stained aortic heart valve leaflet (12 µm thickness).  B-D. MALDI mass spectroscopy 
images of the same leaflet, showing the localisation of three different metabolites in different 
areas of the leaflet based upon mass / charge ratio. 
A B 
C D 
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7.1 INTRODUCTION 
Arterial plasma of patients with three vessel coronary disease with those with no coronary 
arterial disease on angiography has previously been compared (Abdul-Salam et al. 2010). 
Through the use of surface-enhanced laser desorption/ionisation–time-of-flight mass 
spectrometry (SELDI-TOF MS) proteomics, the level of a 14.7 kDa protein was found to be 
significantly raised. This protein was isolated and identified as the glycoside hydrolase 
enzyme lysozyme. The measurement of arterial plasma lysozyme levels in 197 patients with 
varying degrees of coronary atherosclerosis, using a cutoff value of 1.5 µg/mL, enabled the 
investigators to distinguish patients with one or more significantly involved coronary arteries, 
with 86% sensitivity and 93% specificity (Abdul-Salam et al. 2010). As such, arterial plasma 
lysozyme has emerged as a candidate biomarker of atherosclerotic burden, reflecting the 
amount of stenosing atheroma. 
 
7.1.1 Aim 
This study aimed to assess the utility of plasma lysozyme in the context of carotid 
atherosclerosis. 
 
7.2 METHOD 
7.2.1 Study Subjects 
The study received research ethics committee approval (08/H0707/146). We recruited 
consecutive subjects who were due to undergo carotid endarterectomy for primary 
atherosclerotic stenosis of the carotid bifurcation from the vascular surgery clinics of a 
tertiary referral centre during a 6 month period between February 2009 and August 2009. All 
participants were greater than 18 years of age and gave written informed consent. The 
symptomatic status of the subjects with carotid stenosis was decided by a neurovascular 
multi-disciplinary team; subjects were considered symptomatic if symptoms consistent with 
stroke, TIA or amaurosis fugax had occurred in the neurovascular territory of a carotid 
stenosis in the four months prior to enrolment. 
 
Additionally, age-matched control subjects were enrolled comprising two groups. Patients 
undergoing coronary angiography and found to have entirely normal coronary vessels were 
enrolled to act as arterial plasma controls. Individuals with no evidence of carotid 
atherosclerosis bilaterally on duplex ultrasound assessment volunteered to act as venous 
plasma controls.  
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7.2.2 Sample Collection and Processing 
For subjects undergoing carotid endarterectomy whole arterial blood was collected from a 
radial artery cannula, sited in the arm contralateral to the operated carotid artery for the 
purpose of intra-operative continuous blood pressure monitoring, prior to the administration 
of any drugs. A group of these patients for carotid endarterectomy, along with matched 
control individuals without carotid disease, also had whole venous blood collected by 
venipuncture of a peripheral vein. Patients for coronary angiography had whole arterial blood 
collected from their femoral or radial artery interventional access sheath prior to contrast or 
drug administration – only samples from patients with normal coronary arteries were included 
in this study. Published evidence supports that, in the absence of detectable coronary 
atherosclerosis, subjects have a low likelihood of carotid disease (Craven et al. 1990). 
 
For both arterial and venous samples, 3 ml of whole blood was collected in tubes containing 
5.4 mg K2 EDTA (BD Vacutainer, New Jersey) Samples were transported on ice prior to 
centrifugation for 5 minutes at 1000 x g at 4°C. Aliquots of plasma were stored at -80°C. 
 
Atherosclerotic plaques were collected from the patients undergoing carotid endarterectomy, 
immediately snap frozen in liquid nitrogen and stored at -80°C. 
 
7.2.3 Lysozyme Analysis 
The concentration of lysozyme in plasma and atherosclerotic plaque extracts was measured at 
using Enzyme-Linked Immunosorbent Assay (ELISA, Biomedical Technologies, Stoughton, 
Massachusetts) according to manufacturer‘s instructions. Zymography (EnzChek, Invitrogen 
Ltd, Paisley, UK) was used to quantify enzymatic activity of plaque lysozyme. 
 
7.2.4 Statistical Analysis 
Data was analysed with Prism (version 5.02, GraphPad Software, California). Where data was 
normally distributed, parametric tests were used. Non-parametric statistics were used for data 
which was not normally distributed. All tests
 
used were 2-tailed and a p-value
 
less than 0.05 
was considered statistically significant. 
 
7.3 RESULTS 
A total of 54 subjects with carotid stenosis were enrolled. Of these 54 patients 28 also had 
venous plasma analysis. Venous plasma was analysed from 13 aged-matched controls and 
arterial plasma from 31 individuals with normal coronary angiograms. The characteristics of 
all groups are shown in Table 32. The groups were well matched in terms of sum of carotid 
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stenoses, demographic – particularly the proportion of patients with known ischaemic heart 
disease and peripheral arterial disease – clinical and pharmacotherapeutic parameters. The 
control group had a significantly higher total cholesterol level than the patients with carotid 
stenosis. 
 
Parameter 
Carotid Stenosis 
(n = 54) 
Control Subjects 
Arterial 
(n = 31) 
Venous 
(n = 13) 
Age (years) 
69 
(64.5 – 75) 
57 
(49 – 66) 
60 
(58 – 68.5) 
Male gender 18 (33%) 14 (45%) 4 (31%) 
Ischaemic heart disease 3 (6%) N.A. 1 (8%) 
Peripheral arterial 
disease 
9 (17%) 0 (0%) 0 (0%) 
Hypertension 38 (70%) 3 (10%) 2 (15%) 
Diabetes mellitus 10 (19%) 6 (19%) 2 (15%) 
Smoking history 29 (54%) 7 (23%) 6 (46%) 
Plasma creatinine 
(µmol/L) 
85 
(76 – 102) 
80 
(70 – 94) 
- 
Statin use 50 (93%) 13 (42%) 2 (15%) 
Antiplatelet use 46 (85%) 14 (45%) - 
Symptomatic carotid 
stenosis 
26 (48%) 
(13 CVA, 10 TIA, 3 AmFu) 
N.A. N.A. 
Sum of carotid 
stenoses (%) 
118 
(98 – 136) 
N.A. N.A. 
Plasma C-reactive 
protein (mg/L) 
2.3 
(2.0 – 5.2) 
- - 
Plasma total cholesterol 
(mmol/L) 
4.20 
(3.53 – 4.78) 
5.51 * 
(4.28 – 5.95) 
- 
Table 32 Characteristics of the study groups 
Demographic, clinical and pharmacotherapeutic information relating to the three groups of 
subjects included in the study. Age, sum of stenoses, plasma C-reactive protein, plasma total 
cholesterol, and time from symptoms to plasma collection are presented as median (inter-
quartile range). AmFu, amaurosis fugax; CVA, cerebrovascular accident; N.A., not 
applicable; TIA, transient ischaemic attack. * Mann Whitney test, P = 0.0118. 
 
7.3.1 Plasma Lysozyme 
Plasma lysozyme levels were not normally distributed. Arterial plasma lysozyme levels were 
significantly higher in patients with carotid stenosis than controls with normal coronary 
angiograms (median 6.5 µg/mL versus 1.3 µg/mL, Mann Whitney test p<0.0001, Figure 
76A). Receiver operator characteristic (ROC) curve analysis (Figure 76B) gave an area under 
the curve (AUC) of 0.88 (Table 33). 
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Figure 76 Arterial plasma lysozyme for carotid stenosis versus controls 
A. Distribution of arterial plasma lysozyme levels in patients with carotid stenosis and 
controls. Median levels are shown as bars.  B. Receiver operator characteristic curve 
analysis area under the curve is 0.88. 
 
Plasma Lysozyme 
Area 
under the 
curve 
Lysozyme 
cut off 
(µg/mL) 
Sensitivity 
(%) 
Specificity 
(%) 
Arterial, carotid stenosis versus 
controls 
0.88 4.85 65 97 
Venous, carotid stenosis versus 
controls 
0.88 2.00 79 92 
Arterial, carotid stenosis, 
symptomatic versus asymptomatic 
0.69 12.8 35 96 
Table 33 Receiver operator characteristic analysis results 
Summary of receiver operator characteristic analyses for plasma lysozyme. 
 
Venous plasma lysozyme levels were significantly higher in patients with carotid stenosis 
than the control group (median 3.2 µg/mL versus 1.2 µg/mL, p=0.0001, Mann Whitney test, 
Figure 77A). ROC curve analysis (Figure 77B) gave an AUC of 0.88 (Table 33). There was 
no significant correlation between arterial and venous plasma lysozyme levels (Spearman r=-
0.3110, p=0.1072, Figure 77C). Venous plasma lysozyme levels were on the whole 
approximately half those seen in arterial plasma. 
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Figure 77 Venous plasma lysozyme for carotid stenosis versus controls 
A. Distribution of venous plasma lysozyme levels in patients with carotid stenosis and 
controls. Median levels are shown as bars.  B. Receiver operator characteristic curve 
analysis area under the curve is 0.88.  C. There is no significant relationship between venous 
and arterial plasma lysozyme levels in patients with carotid stenosis. Spearman r=-0.3110, 
p=0.1072. 
 
Arterial plasma lysozyme levels from patients with carotid stenosis were examined for their 
relationship to a number of key clinical, demographic and pharmacotherapeutic parameters 
(Table 34). Arterial plasma lysozyme was identified as being significantly higher in 
symptomatic patients with carotid stenosis than asymptomatic patients (median 10.4 µg/mL 
versus 5.1 µg/mL, p=0.0161, Figure 78A). There were a subgroup of symptomatic patients 
(n=6) seen to have very high arterial plasma lysozyme levels (>30 µg/mL) (Table 35). These 
results were confirmed on repeat analysis. 
A B 
C 
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Parameter n 
Median Arterial 
Plasma 
Lysozyme  
(µg/mL) 
Test Statistics 
Age 54 - 
Spearman r=-0.1324 
p=0.3397 
Gender 
Male 36 7.749 Mann Whitney 
p=0.5819 Female 18 5.832 
Ischaemic heart 
disease 
Yes 13 5.299 Mann Whitney 
p=0.4979 No 41 7.160 
Peripheral arterial 
disease 
Yes 9 4.582 Mann Whitney 
p=0.3777 No 45 8.337 
Hypertension 
Yes 38 6.496 Mann Whitney 
p=0.3018 No 16 7.251 
Diabetes mellitus 
Yes 10 8.240 Mann Whitney 
p=0.2952 No 44 6.469 
Smoking history 
Yes 29 8.337 Mann Whitney 
p=0.5847 No 25 5.414 
Plasma creatinine (µmol/L) 54 - 
Spearman r=0.1941 
p=0.1596 
Statin use 
Yes 50 6.496 Mann Whitney 
p=0.5971 No 4 6.541 
Antiplatelet use 
Yes 46 6.496 Mann Whitney 
p=0.6006 No 8 6.875 
Sum of carotid stenoses (%) 54 - 
Spearman r=0.02712 
p=0.8532 
Plasma C-reactive protein (mg/L) 54 - 
Spearman r=0.04632 
p=0.7394 
Plasma total cholesterol (mmol/L) 54 - 
Spearman r=-0.1097 
p=0.6100 
Symptomatic 
Yes 26 10.39 Mann Whitney 
p=0.0161 No 28 5.149 
Time from last symptom to plasma 
collection (days) 
26 - 
Spearman r=0.1544 
p=0.4714 
Table 34 Arterial plasma lysozyme and its relationship with demographic, clinical 
and pharmacotherapeutic parameters 
There was a significant difference in arterial plasma lysozyme level between symptomatic and 
asymptomatic patients with carotid stenosis. No significant relationship was observed when 
assessing arterial plasma lysozyme level against other parameters. 
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Figure 78 Arterial plasma lysozyme levels and symptomatic status 
A. Distribution of arterial plasma lysozyme levels in patients with asymptomatic and 
symptomatic carotid stenosis. Median levels are shown as bars.  A subgroup of symptomatic 
patients (n=6) displayed very high arterial plasma lysozyme levels (>30 µg/mL).  B. Receiver 
operator characteristic curve analysis area under the curve is 0.69.  C. There was no 
significant difference in the plasma C-reactive protein levels of these patients. Median levels 
are shown as bars. 
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Parameter Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 
Arterial Plasma 
Lysozyme  (µg/mL) 
421.55 75.15 71.38 43.80 38.51 36.26 
Age (years) 63 58 65 66 63 78 
Gender Male Male Male Male Male Male 
Ischaemic heart 
disease 
0 0 1 0 0 0 
Peripheral arterial 
disease 
1 0 0 0 0 0 
Hypertension 0 0 1 1 1 1 
Diabetes mellitus 1 0 1 0 0 0 
Smoking history 1 1 0 0 1 1 
Plasma creatinine 
(µmol/L) 
78 103 92 98 77 1501 
Statin use 1 1 1 1 1 1 
Antiplatelet use 1 0 1 1 1 0 
Carotid symptoms 
CVA 
(right hemi-
paresis) 
CVA 
(right hemi-
paresis) 
CVA 
(right hemi-
paresis) 
CVA 
(dysphasia, 
dysphagia) 
TIA 
(right hemi-
paresis) 
TIA 
(left hemi-
paresis) 
Sum of carotid 
stenoses (%) 
88 128 149 120 121 113 
Symptomatic carotid 
stenosis (%) 
Left 
(50) 
Left 
(85-90) 
Left 
(77) 
Left 
(90) 
Left 
(95-99) 
Right 
(90-95) 
Plasma C-reactive 
protein (mg/L) 
2 2 2 2 2 50 
Table 35 Characteristics of the six patients with high arterial plasma lysozyme 
levels 
Six patients had arterial plasma lysozyme levels of >30 µg/mL. All of these patients were 
symptomatic, male and were on statin therapy. CVA, cerebrovascular accident; TIA, transient 
ischaemic attack. 
 
There was no significant relationship between the other parameters examined and arterial 
plasma lysozyme level, including time since symptoms in the symptomatic subgroup, sum of 
carotid stenoses, statin use and self-reported history of ischaemic heart disease or peripheral 
arterial disease. 
 
ROC curve analysis (Figure 78B) gave an AUC of 0.69 (Table 33). Comparing symptomatic 
and asymptomatic carotid stenosis, there was no significant difference in plasma C-reactive 
protein (CRP) levels (Figure 78C). 
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7.3.2 Carotid Atherosclerotic Plaque Lysozyme 
Lysozyme concentration within seven carotid plaques was quantified (Table 36). Per unit wet 
weight, lysozyme ranged from 0.02 to 0.22 µg/mg (median 0.06 µg/mg). Per unit protein, this 
equated to 0.62 to 4.30 µg/mg (median 1.3 µg/mg). In all cases, plaque lysozyme activity was 
below the assay detection limit. 
 
Symptomatic 
Status 
Wet Weight 
(g) 
Lysozyme per unit 
Wet Weight 
(µg/g) 
Lysozyme per unit 
Protein (µg/mg) 
Lysozyme 
Activity 
(U/mL) 
Symptomatic 0.1257 62 1.278 0.000 
Symptomatic 0.1558 129 2.953 0.000 
Symptomatic 0.2206 51 1.209 0.000 
Symptomatic 0.2960 32 1.139 0.000 
Symptomatic 0.4402 22 0.622 0.000 
Asymptomatic 0.0572 152 3.083 0.000 
Asymptomatic 0.0832 216 4.298 0.000 
Table 36 Carotid atherosclerotic plaque lysozyme analysis 
Summary of results obtained from the analysis of carotid atherosclerotic plaque for lysozyme 
levels and enzymatic activity. 
 
7.4 DISCUSSION 
These results demonstrate that lysozyme levels in both arterial and venous plasma are 
significantly elevated in patients with carotid stenosis compared with control individuals. It 
has been shown for the first time that arterial plasma lysozyme levels are significantly higher 
in those with symptomatic compared with asymptomatic atherosclerosis. Furthermore, the 
presence of significant quantities of lysozyme within human atherosclerotic plaque has been 
confirmed, and shown to be inactive. 
 
It is known that risk of cardiovascular and cerebrovascular events is determined not only by 
extent of disease, but by disease activity (Falk et al. 1995; Topol and Nissen 1995; Nicolaides 
et al. 2005). 
 
In keeping with the finding in patients with coronary arterial disease (Abdul-Salam et al. 
2010), there was no significant correlation between arterial and venous plasma lysozyme 
levels. 
 
Previous work has demonstrated that, in the context of atherosclerosis, circulating lysozyme 
is largely inactive (Abdul-Salam et al. 2010). The finding in this study that lysozyme is found 
in carotid atherosclerotic tissue in significant concentration but that this lysosyme is inactive 
supports the hypothesis that the discriminatory arterial plasma lysozyme seen in individuals 
with arterial disease originates from such plaque. Naito and colleagues have previously 
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reported that whilst circulating monocytes enclose active lysozyme, in a rabbit model of 
atherosclerosis plaque-derived foam cells contain inactivated lysozyme (Naito et al. 1997). It 
has been postulated that foam cell myeloperoxidase catalyzes the production of hypochlorous 
acid which inactivates lysozyme (Schaffner et al. 1980; Naito et al. 1997; Heinecke 1999). In 
both experimental and human atherosclerosis, monocyte-macrophage and foam cell numbers 
are related to the development and destabilisation of atherosclerosis. It is noteworthy to 
mention at this point that the proteomic analysis of the salt extract of atherosclerotic plaques 
identified that myeloperoxidase levels were significantly higher in symptomatic than 
asymptomatic carotids (Table 28). This supports the inactivation of lysozyme by macrophages 
in symptomatic atherosclerosis which has been proposed (Abdul-Salam et al. 2010). 
 
Low density lipoprotein (LDL)-associated lysozyme has recently been linked to the 
atherogenic properties of LDL found in type 2 diabetes and the metabolic syndrome 
(Pettersson et al. 2010). Patients with diabetes have also been shown to have increased levels 
of leukocyte-associated lysozyme than those without diabetes in the context of both acute 
myocardial infarction and unstable angina (Chavan et al. 2007). Importantly, the proportion of 
patients with known ischaemic heart disease and diabetes among the study population was not 
significantly different between those who were symptomatic and asymptomatic. There was no 
significant effect of statin use on lysozyme levels. 
 
The fact that there was not significant relationship between total carotid stenosis and 
lysozyme levels may be explained by the fact that the all patients with carotid stenosis had a 
considerable burden of disease (median 118% combined stenosis). 
 
A number of circulating biomarkers of atherosclerosis have been investigated, including CRP 
(CCGC 2011), matrix metalloproteinases, and pregnancy-associated plasma protein A 
(Alsheikh-Ali et al. 2010). To date, these have not been adopted into routine clinical practice. 
CRP levels were not significantly different between symptomatic and asymptomatic patients 
in this study. A circulating marker of atherosclerosis is eagerly sought. CRP has shown 
considerable promise but has not entered the clinical arena in this context. The data presented 
suggests that lysozyme is more sensitive than CRP in detecting unstable plaque. However, the 
specificity of lysozyme in identifying unstable plaque may be an important benefit. 
 
The fact that there was no significant relationship between arterial plasma lysozyme and time 
from symptoms to sample collection may reflect the global instability of atherosclerosis 
across all arterial territories in individuals who have experienced a cerebrovascular event. 
 
Chapter 7 
 240 
The reason for very high arterial lysozyme levels in symptomatic individuals may be 
explained by higher macrophage numbers in symptomatic plaques or greater release of 
lysozyme into the arterial circulation by ruptured plaques. It is hypothesised that circulating 
fragments from unstable plaques may be collected from the arterial line and be reflected as 
high lysozyme levels. 
 
When patients with coronary arterial disease were studied (Abdul-Salam et al. 2010) there 
were no patients with the levels measured in this study. Although the patients in previous 
study had chronic stable without acute coronary events, it is unlikely that none of these had 
unstable disease. 
 
Large scale studies are ongoing investigating the utility of lysozyme in coronary 
atherosclerosis. It is hoped that the results from this and the present study will support the use 
of plasma lysozyme as part of a multi-modal atherosclerosis risk stratification strategy, in 
terms of both extent and vulnerability of disease. This would facilitate the prioritisation, 
investigation and treatment of individuals with cardiovascular and cerebrovascular risk 
factors. 
 
7.4.1 Limitations 
Meaningful comparison between venous and plaque samples from symptomatic and 
asymptomatic individuals was precluded due to the small number of samples analysed in 
these groups. 
 
7.4.2 Conclusions 
This study demonstrates that arterial and venous plasma lysozyme levels are significantly 
higher in patients with carotid stenosis. Among the symptomatic group, there is a subgroup of 
patients with dramatically raised levels in their arterial plasma. The potential of arterial 
plasma lysozyme as a specific test for instability in atherosclerosis, either alone or as part of a 
multi-modal approach to risk stratification, warrants further investigation. 
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8 FINAL DISCUSSION 
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Risk stratification in patients with carotid stenosis is a clinical challenge and priority, as it 
bears implications for treatment or the timing of treatment. To date our risk stratification 
strategy has (formally and informally) considered age, life expectancy and quality of life, but 
has otherwise focused on structural features of the plaque. Time frame is important in that we 
need to explore when a stroke may occur in relation to a patient‘s life expectancy. For this 
reason, demographic and clinical parameters are considered, i.e. is this carotid stenosis likely 
to be responsible for a stroke in this individual‘s lifetime? ACST showed that half of patients 
with significant carotid stenosis aged 75 years or older die within five years from unrelated 
causes, hence the benefits of carotid intervention were lost (Halliday et al. 2004). 
 
Plaque density, assessed by echogenicity on duplex ultrasound, has been shown to predict 
ipsilateral ischaemic stroke (Polak et al. 1998; Gronholdt et al. 2001; Mathiesen et al. 2001), 
however hazard ratios have not been sufficient to warrant translation into clinical practice. 
The mainstay structural predictor is degree of luminal stenosis as reported by the landmark 
European (ECST 1991) and North American (NASCET 1991) trials, but it is important to 
remember that these studied symptomatic individuals. 
 
Therefore, even after the application of evidence-based current best practice, there remains a 
cohort of young individuals with significant asymptomatic carotid stenosis who face a 
‗number needed to treat‘ of 16 to prevent a stroke over 5 years; this prophylactic procedure 
itself carries a risk of stroke of up to 5%. Functional imaging and biomarkers offer the 
opportunity to explore plaque biology non-invasively, in vivo, and facilitate the selection of 
high-risk asymptomatic carotid stenoses warranting intervention. This need to risk stratify 
carotid atherosclerosis is ‗bilateral‘: not only is there a desire to highlight high risk 
asymptomatic disease, but robust risk stratification could allow identification of symptomatic 
stenosis which is unlikely to be responsible for future cerebrovascular events. This approach 
facilitates informed decision making to benefit individual patients, but also has health 
economic implications when considering the allocation of health resources and reducing the 
overall burden of stroke and atherosclerosis in other arterial territories. With regards the latter, 
it has emerged that features of carotid atherosclerosis vulnerability are associated with global 
cardiovascular risk (Staub et al. 2010). 
 
There has been a recent strong interest in functional imaging to investigate the biology of 
atherosclerosis. The results of the work on CEUS and PET/CTA have shown that functional 
imaging reflects plaque biological attributes. With regards PET/CTA, the ability to 
discriminate between symptomatic and asymptomatic atherosclerosis was enhanced when the 
functional parameter (PET) was combined with the structural aspects (CT). This underlines 
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the opportunities that a multi-modal or hybrid approach to imaging can offer (Sanz and Fayad 
2008; Rudd et al. 2009). From a practical point of view it is unlikely that PET/CT will be 
translational into large-scale clinical use, owing to issues of acceptability, radiation dose, 
timing with regards radio-isotope half-life necessitating on-site cyclotron facility with clinical 
grade radio-pharmaceutical capabilities, and the costs thereof. There is the opportunity, 
however, that PET/CT may be harnessed as a research tool for the in vivo examination of 
plaque biology. The development of bespoke tracers targeted to ligands of interest would 
allow assessment of the in vivo discriminatory and predictive power of that ligand for future 
cerebrovascular events, both alone and when combined with the structural components of the 
imaging. An example of this would be determination of M1 burden using a CCR7 (Martinez 
et al. 2006) targeting compound, or even assessment of M1:M2 balance by combining this 
with CD206 quantification. 
 
Such targeting is possible in the context of CEUS (Leong-Poi et al. 2005). However, it has 
been demonstrated that LP-CEUS employing untargeted microbubbles is able to reflect key 
biological features related to plaque vulnerability, namely inflammation (Owen et al. 2010), 
angiogenesis and matrix degradation. D-CEUS, an assessment of microvascular volume, may 
also be undertaken alongside LP-CEUS to complete the ‗CEUS score‘ and offer greater 
discrimination between symptomatic and asymptomatic atherosclerosis. CEUS is a 
refinement of the current carotid duplex ultrasound assessment, building on a modality of 
investigation which is acceptable to patients and uses existing imaging infrastructure. Duplex 
assessment of stenosis, based upon velocity criteria (Oates et al. 2009), with or without 
measurement of plaque echolucency, provides the structural part of the hybrid structural-
functional examination. CEUS is being developed for potential clinical use through 
prospective study to see whether CEUS measurements can predict future cerebrovascular 
events (Section 9.1). 
 
Targets for imaging, as well as informing about pathogenesis and therapeutic strategies, are 
elucidated though the study of cellular and molecular biology. The activation of the innate 
immune system is central to atherosclerosis development, progression, rupture and the 
resulting sequelae. Considering the multi-step paradigm of macrophage activation recently 
proposed (Gordon and Martinez 2010) and the theory of a ‗spectrum‘ of activation (Mosser 
and Edwards 2008), macrophage phenotype may be polarised to towards injurious and pro-
inflammatory (‗classical‘; M1) or resolving, healing and regulatory (‗alternative‘; M2). The 
path of activation is determined by exposure to cytokines and chemokines 
microenvironmental. Examination of this microenvironment in human atherosclerosis with 
the aim of determining the predominant macrophage phenotype had not been previously 
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undertaken. In addition to showing a cytokine, chemokine and MMP pattern consistent with 
there being more M1 than M2-type macrophages in symptomatic compared with 
asymptomatic, the differentially abundant analytes feature in the ‗differentiation‘, ‗priming‘ 
and ‗resolution‘ stages of the paradigm (Figure 5). The novel finding of CCL20 in 
atherosclerotic plaque and, in the context of an M1-type cytokine ‗signature‘ pointed towards 
Th17/IL17 signalling, a feature of other inflammatory conditions (Hirota et al. 2007), a 
hypothesis which was supported by the listing of IL17 signalling as a key canonical pathway 
by bioinformatic analysis undertaken. 
 
Ingenuity pathway analysis also highlighted ‗Role of Pattern Recognition Receptors in 
Recognition of Bacteria and Viruses‘ and ‗Activation of IRF by Cytosolic Pattern 
Recognition Receptors‘. This is in line with important studies which link danger-associated 
molecular pattern (DAMP) activation of pattern-recognition receptors (PRRs), including 
TLRs and NLRs and the inflammasome pathway in generation of pro-inflammatory cytokines 
(Duewell et al. 2010). Furthermore exon-level transcriptomic analysis has shown that 
stenosing atherosclerosis, as compared with intimal thickening, has differential expression 
and splicing of IRF5, a transcription factor downstream of TLRs (Watters et al. 2007; Kawai 
and Akira 2010) and which has been shown to be important in human M1 macrophage 
polarisation (Krausgruber et al. 2011). The increased expression of IRF5 in stenosing plaque 
compared with intimal thickening also supports an interferon-gene expression signature in 
advanced atherosclerosis (Mancl et al. 2005; Cunninghame Graham et al. 2007), which was 
seen in the multi-analyte profiling analysis of symptomatic atheroma cell culture supernatants. 
 
The concept of atherosclerosis as a passive accumulation of lipid in the arterial wall is 
considered outdated and has been superseded by an acute acknowledgement of the role played 
by inflammation in this most active of conditions (Ross 1999). Lipids, including cholesterol 
crystals, have been shown to activate PRRs (Duewell et al. 2010) and hence been implicated 
as endogenous ligands triggering the innate immune response. The finding by lipidomic 
analysis that the lipid profile of undiseased artery differs from that of atherosclerosis, and that 
stable and unstable areas of atherosclerosis may be separated by principal components 
analysis (PCA) is in keeping with lipids contributing to the pro-inflammatory drive within the 
plaque. Cholesteryl esters (CEs), a lipid class which contributed to the difference between the 
lipid profiles with advancing arterial disease, are a manifestation of vascular cholesterol found 
as lysosomal or cytosolic droplets (Shio et al. 1979) as would be seen in the foam cell 
macrophage phenotype. The importance of the lipidic compartment of atherosclerosis is once 
again seen in the results of the metabolic profiling, with PCA of the organic fraction showing 
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clustering of symptomatic plaques and separation of this cluster from asymptomatic 
atherosclerosis. 
 
In addition to the results of multi-analyte profiling (‗secretomics‘), transcriptomics, 
lipidomics and metabonomics, proteomics identified almost 2,500 proteins, 159 of which 
differed significantly between symptomatic and asymptomatic atherosclerosis, and a large 
proportion of these found to be new to carotid atherosclerosis research. Interestingly, 
comparing male and females showed a greater degree of difference in protein abundance than 
based upon symptomatic status. The latter may contribute to the difference in clinical 
behaviour between carotid plaques in male and female individuals (Halliday et al. 2004). The 
utility of a systems biology approach, at multiple levels in the biological synthetic pathway, 
with human atherosclerosis tissue as the research substrate has been shown in separating early 
from advanced, and stable from unstable atherosclerosis. The role of bioinformatics in the 
analysis and interpretation of the large amount of data generated is evident. Furthermore, 
systems biology, as an exploratory tool, has been useful in the generation of hypotheses for 
further investigation. Beyond analyte identification and validation of findings, the ‗omics‘ 
have been able to generate putative biomarkers of atherosclerosis burden for confirmation in 
clinical studies (Abdul-Salam et al. 2010). 
 
Lysosyme, initially identified by MALDI-TOF mass spectrometry in plasma samples from 
patients with angiographically proven coronary artery disease, was measured in patients with 
carotid stenosis. The lysozyme measured is thought to be inactivated by foam cell 
myeloperoxidase (Schaffner et al. 1980), hence reflecting inflammation. Proteomic analysis 
revealed that myeloperoxidase levels were significantly higher in the salt extracts of 
symptomatic compared with asymptomatic atherosclerosis. Both arterial and venous plasma 
lysozyme levels were greater in patients with carotid stenosis than controls, and arterial 
plasma lysozyme was able to distinguish based on symptomatic status. Arterial plasma 
lysozyme ROC AUC for symptomatic status was 0.69 and was driven by a sub-group of 
symptomatic patients with very high levels. Although it is hoped that a single circulating 
biomarker will be sufficient to identify high risk individuals, it is more likely that a panel of 
uncorrelated molecules (Gerszten and Wang 2008). Similarly, the approach to risk 
stratification should be holistic, accounting for clinical factors, imaging features and 
circulating biomarkers, as well as patient choice and perception of risk. 
 
These findings support the use of hybrid structural-functional imaging, and the utility and use 
of a systems biology approach in identifying significantly different and biologically relevant 
variations in atherosclerosis tissue, and in hypothesis generation for further study. The data 
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presented concurs with recent reports in the literature which link the lipidic/organic 
component of atherosclerosis with the generation of a pro-inflammatory plaque 
microenvironment prone to lesion development, instability and the complications thereof. The 
importance of innate immunity has been highlighted with the demonstration of a 
predominance of M1 macrophage polarisation and evidence of Th17/IL17 signalling in 
unstable atherosclerosis. It is hoped that this work will contribute to the ongoing refinement 
of multi-factorial risk stratification in carotid atherosclerosis. 
 
 
8.1 CONCLUDING COMMENTS 
 11C-PK11195 PET allowed the non-invasive detection and quantification of intraplaque 
inflammation in patients with carotid stenoses and, when combined with CTA provided an 
integrated assessment of plaque structure, composition and biological activity. 
11
C-
PK11195 PET/CT distinguished between recently symptomatic vulnerable plaques and 
asymptomatic plaques with a high positive predictive value. 
 D-CEUS and LP-CEUS (at a cut-off of zero) was able to distinguish symptomatic and 
asymptomatic plaques. The utility in distinguishing based upon symptomatic status was 
improved by combining both techniques to achieve a carotid CEUS ‗score‘. 
 Atheroma cell culture and supernatant MAP revealed that symptomatic human 
atherosclerotic carotid disease is associated with a cytokine, chemokine pattern consistent 
with the predominance of pro-inflammatory M1-type macrophage polarisation. 
 IFNγ signatures are observed, including the novel finding of CCL20 with its significant 
elevation in symptomatic atherosclerosis. 
 MAP of supernatants from patients who had undergone ipsilateral carotid LP-CEUS 
revealed significantly higher levels of interleukin 6, MMP1 and MMP3, as well as greater 
CD68 (macrophages) and CD31 (neovascularisation) immunopositivity by quantitative 
immunohistochemistry, in those with high (0) compared with low (<0) LP-CEUS signal. 
This suggests that LP-CEUS was able to reflect plaque biological attributes associated 
with unstable atherosclerosis. 
 Transcriptomic analysis was able to able to clearly separate stenosing plaque and intimal 
thickening, as well as unstable and stable atherosclerosis based on messenger RNA profile, 
and was also able to generate a hypothesis based upon the finding of differential 
expression and alternative splicing of IRF5 between stenosing plaque and intimal 
thickening. 
 Proteomic analysis of the salt extract fraction from carotid atherosclerotic plaques 
identified 2,470 proteins implicated in 33 bio-molecular functions and having their origins 
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previously described in 14 different cellular compartments. There were 159 proteins 
which, based upon the number of assigned spectra, were significantly different between 
symptomatic and asymptomatic atherosclerosis. 
 Through lipidomic analysis, 150 lipid species from 9 different classes were identified, of 
which 24 were exclusive to atherosclerotic plaques. A comparison of 28 carotid 
endarterectomy specimens revealed lipid signatures of symptomatic compared with 
asymptomatic lesions, as well as stable and unstable plaque areas. 
 Metabolite profiling by LC-MS analysis of organic plaque extract was able to separate 
symptomatic from asymptomatic atherosclerosis. 
 These findings support the utility and use of a systems biology approach in indentifying 
significantly different and biologically relevant variations in atherosclerosis tissue, and in 
hypothesis generation for further study. 
 The data supports recent reports in the literature which link the lipidic/organic component 
of atherosclerosis with the generation of a pro-inflammatory plaque microenvironment 
prone to lesion development, instability and the complications thereof. 
 Levels of arterial and venous plasma lysozyme (initially identified as a candidate 
biomarker by proteomic analysis) were seen to distinguish individuals with carotid 
atherosclerosis from matched control subjects. Furthermore, arterial plasma lysozyme 
levels were significantly higher in patients with symptomatic than asymptomatic carotid 
stenosis. 
 It is unlikely that, in the near future at least, a single modality will alone be adequate in the 
risk stratification of asymptomatic carotid stenosis. However, it is hoped that a refined 
multi-factorial approach will be developed using clinical, structural and functional 
imaging, and biochemical parameters; this may take the form of an effective and validated 
scoring system. 
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9 FUTURE WORK 
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9.1 FUTURE DIRECTIONS FOR CONTRAST ENHANCED ULTRASOUND 
9.1.1 Contrast Ultrasound for Stroke Prediction (CUSP) 
As part of the ongoing validation of the CEUS in carotid risk stratification, ethical approval 
has been granted and funding obtained for a prospective study in asymptomatic carotid 
stenosis. This will allow exploration of the natural history of the CEUS signal by rescanning 
at annual intervals, including looking at the effect of pharmacotherapies, such as statin 
usage, on signal change. Primarily, evidence as regards the utility of CEUS signal upon 
entry into the study to predict outcomes will be generated. This Contrast Ultrasound for 
Stroke Prediction (CUSP) study (http://www1.imperial.ac.uk/surgeryandcancer/ 
divisionofsurgery/clinical_themes/vascular/research/cusp/) aims to follow asymptomatic 
carotid stenosis patients for up to 2 years (Figure 79). 
 
Recruit 750 patients asymptomatic carotid stenosis
90% power to detect a HR of 2 per 1 SD increase in signal
Optimise image, establish variability and pilot 3D CEUS
Natural history study
Annual scans for 5 years
Hazard ratio study
Single scan and follow
n=200
Primary endpoint: Ipsilateral ischaemic stroke, TIA, amaurosis fugax
Secondary endpoints: MI, all cause mortality
Statistical analysis: Cox proportional hazards, Kaplan Meier survival, 
Bland Altman plots
Parallel 
plaque
laboratory 
analysis
2010
2015
2012
Silent stroke study
Correlate with TCD
n=200n=750
 
Figure 79 Contrast Ultrasound for Stroke Prediction (CUSP) study design 
3D CEUS, 3-dimensional contrast enhanced ultrasound; HR, hazard ratio; MI, myocardial 
infarction; SD, standard deviation; TCD, trans-cranial Doppler; TIA, transient ischaemic 
attack. 
 
The results of the CUSP study will confirm the signal cut off when deciding which 
asymptomatic patients to intervene on. This cut off may then be employed in a randomised 
trial to see if intervening on patients based upon CEUS signal can alter overall morbidity 
and mortality in asymptomatic carotid stenosis. 
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9.1.2 3-Dimensional Contrast Enhanced Ultrasound 
The carotid plaque has been imaged in 3-dimensions (3D) with unenhanced ultrasound 
(Landry et al. 2004; Nanayakkara et al. 2009). The development of contrast modes on high 
frequency 3D transducers offers the opportunity to image carotid plaques in their entirety 
during a single microbubble acquisition. This potentially addresses two issues: out of plane 
motion for which there is no solution in 2-dimensional (2D) CEUS bar the exclusion of 
affected frames; and the false assumption that the single slice imaged by 2D CEUS is 
representative of the entire inhomogeneous plaque. As it is practically impossible to select the 
same plaque slice for imaging over two sessions using 2D CEUS, 3D imaging should improve 
reproducibility and monitoring of therapy. As described in the CUSP study design (Figure 
79), it is planned that 3D CEUS will be piloted. There are a number of platforms and probe 
designs for consideration. The GE Logiq E9 system allows a static 3D acquisition (Figure 
80), hence may be appropriate for LP-CEUS. Philips are developing matrix probes which 
allow real-time simultaneous multiple plane imaging. 
 
 
Figure 80 3-dimensional contrast enhanced ultrasound 
Using a GE Logiq E9 system 2-dimensional contrast enhanced (A) and B mode (B) imaging is 
demonstrated. 3-dimensional contrast enhanced ultrasound represented as multiple 
longitudinal sections 1 mm apart (C) or as a rendered reconstruction (D) of cylindrical 
carotid lumen with plaque shown as a filling defect (arrow). 
 
A 
B 
C D 
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9.1.3 Advances in Microbubble Technology 
Smaller microbubbles may have the facility to more readily enter the vasa vasorum, be 
retained by activated endothelium, and phagocytosed by macrophages. Furthermore, 
microbubbles need to be developed with increased longevity and stability, including stability 
to standard low MI imaging. Current microbubbles are used as blood pool agents because, for 
all intents and purposes, they remain in the vascular space. However, over time they have 
been shown to be passively taken up by macrophages, such as Kupffer cells in the liver, with 
the rate of phagocytosis being a function of their shell‘s constituents (Yanagisawa et al. 
2007). Conjugation of microbubbles with ligands creates the possibility of actively targeting 
to specific molecules accessible from the vascular space. Microbubbles containing sialyl-
Lewis X have been used to bind selectins (Villanueva et al. 2007). Kaufmann et al have 
quantified vascular inflammatory changes occurring at different stages of murine 
atherosclerosis utilising microbubbles targeted to vascular cell adhesion molecule-1 (VCAM-
1) (Kaufmann et al. 2007). Similarly, microbubbles have been surface conjugated with the 
disintegrin echistatin which binds to V- and 51-integrins expressed by the endothelium of 
neovessels (Leong-Poi et al. 2005). These tailored microbubbles have been used to assess 
endogenous and fibroblast growth factor-2-induced therapeutic neovascularisation in a rodent 
model of hindlimb ischaemia. Such molecular imaging with targeted microbubbles offers the 
possibility of early pharmacodynamic readouts for drugs in development, assisting drug 
discovery in the field of vascular inflammation. 
 
9.1.4 Combining Diagnosis and Therapeutic Drug Delivery 
In addition to imaging, microbubbles may have a future role in enhancing selectivity for 
delivery of therapeutics. Ultrasound itself can improve uptake of drugs by causing cavitation 
in the local cell membrane or increasing capillary permeability, but the energy levels required 
to do so exceed safety limits (Tinkov et al. 2008). However, by using ultrasound to destroy 
microbubbles (ultrasound targeted microbubble destruction (UTMD)) the amount of energy 
required to create these local pores is reduced to within acceptable limits. Moreover, if 
microbubbles are loaded with a drug of interest, either on their surface or within the shell, 
UTMD can further improve the selectivity of the drug delivery system (Tsutsui et al. 2004a; 
Tsutsui et al. 2004c; Tinkov et al. 2008). 
 
9.2 FUTURE WORK IN MOLECULAR AND CELLULAR 
CHARACTERISATION OF ATHEROSCLEROSIS 
I hope to be involved in ongoing work within our group in relation to characterising, at a 
molecular and cellular level, advanced and unstable atherosclerosis. To take forward the 
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results generated by multi-analyte profiling, I will be examining mRNA expression in carotid 
plaque tissue from the same CEA specimens as those for atheroma cell culture and Luminex. 
This will employ microfluidic card arrays with TaqMan probes (Applied Biosystems) to 
examine a bespoke panel of 95 transcripts described as distinguishing M1 and M2 
macrophages in humans (Martinez et al. 2006; Krausgruber et al. 2011). These arrays also 
include IRF5 which will allow examination of the role of this transcription factor in the 
context of our MAP findings. It will also serve to contribute to the validation of the 
differential expression of IRF5 in advanced atherosclerosis by exon-level analysis. Further 
validation of the different splice variants using probes specific to the different isoforms will 
also be necessary, as will validation of other key analytes found to be differentially expressed 
or spliced on the candidate list. The transcriptomic data will be subject to Ingenuity Pathway 
Analysis in a fashion similar to the MAP data to highlight the top canonical pathways 
involved in atherosclerosis progression on a broader transcriptional scale. 
 
It is also hoped that the utility of proteomic analysis will be supported by validation of the 
candidate proteins by Western blotting and immunohistochemistry. The analysis of guanidine 
extracts of the plaque extracellular matrix and, subsequently, the complicated SDS extracts 
from in intracellular compartment will allow dissection of the mechanisms underlying plaque 
progression and destabilising in increments of increasing complexity; the SDS extracts are 
likely to require separation on two-dimensional gels prior to analysis in view of the expected 
protein mix. 
 
In addition to optimising and undertaking MALDI-MS imaging to localise metabolites of 
interest within atherosclerotic plaque sections in a process akin to ‗virtual histology‘, data 
generated by LC-MS of the aqueous metabolite extract will also be analysed. Subsequent to 
this there will be a period of metabolite identification. The transition of this technology into 
the arena of biomarkers will be taken by examining biofluids (plasma and urine) in the same 
manner as the plaque tissue metabolite extracts. The analysis to date has informed that, in this 
context, LC-MS appears to have a better ability to discriminate than NMR spectroscopy. 
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